answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
sequence
text
stringlengths
5
72.4k
tokens
sequence
types
sequence
repressor / activator, NF - E1, YY-1, delta, immunoglobulin kappa 3 ' enhancer, immunoglobulin heavy - chain mu E1 site
91080_task2
Sentence: Isolation of a candidate repressor/activator, NF-E1 (YY-1, delta), that binds to the immunoglobulin kappa 3' enhancer and the immunoglobulin heavy-chain mu E1 site. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]
Isolation of a candidate repressor/activator, NF-E1 (YY-1, delta), that binds to the immunoglobulin kappa 3' enhancer and the immunoglobulin heavy-chain mu E1 site.
[ "Isolation", "of", "a", "candidate", "repressor", "/", "activator", ",", "NF", "-", "E1", "(", "YY-1", ",", "delta", ")", ",", "that", "binds", "to", "the", "immunoglobulin", "kappa", "3", "'", "enhancer", "and", "the", "immunoglobulin", "heavy", "-", "chain", "mu", "E1", "site", "." ]
[ "DNA_domain_or_region", "protein_family_or_group", "other_name", "protein_molecule", "DNA_molecule", "protein_N/A", "DNA_family_or_group" ]
incident depression is a Outcome_Mental, hip fracture surgery is a Intervention_Surgical, 139 is a Participant_Sample-size, elderly is a Participant_Age, > 60 years is a Participant_Age, 15-item Geriatric Depression Scale . is a Outcome_Mental, cumulative incidence rate is a Outcome_Mental, depression , anxiety is a Outcome_Mental, pain is a Outcome_Pain, cognitive impairment is a Outcome_Mental, depression as risk factors for incident depression is a Outcome_Mental, postoperative pain is a Outcome_Pain, baseline anxiety is a Outcome_Mental, Incident depression is a Outcome_Mental, hip - fracture is a Participant_Condition
32048_task0
Sentence: Predictors of incident depression after hip fracture surgery . OBJECTIVE Depression after hip fracture surgery is prevalent and associated with increased mortality rates and impaired functional recovery . The incidence of new-onset depressive symptoms in patients initially not depressed after hip fracture surgery and their relationship with functional recovery is unknown . METHODS A cohort of 139 nondepressed elderly patients ( > 60 years ) hospitalized for hip fracture surgery were followed up for six months . Clinically significant depressive symptoms were defined as a score of 7 or more on the 15-item Geriatric Depression Scale . RESULTS The authors found a cumulative incidence rate of 20.5 % adjusted for dropouts . Multiple Cox-regression analyses yielded the presence of subthreshold symptoms of depression , anxiety , pain , and cognitive impairment at baseline , the premorbid level of mobility , and a history of ( treated ) depression as risk factors for incident depression ( p < 0.05 ) . A forward , conditional procedure identified postoperative pain ( hazard ratio [ HR ] = 1.32 , 95 % confidence interval [ CI ] : 1.14-1.53 , Wald chi ( 2 ) = 13.57 , df = 1 , p < 0.001 ) and baseline anxiety ( HR = 1.25 , 95 % CI : 1.08-1.44 , Wald chi ( 2 ) = 8.86 , df = 1 , p = 0.003 ) as the strongest independent risk factors . Incident depression was associated with a less favorable outcome at 3 months follow-up . CONCLUSION This exploratory study identified two treatable baseline characteristics that predicted incident depression in nondepressed patients after hip-fracture surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Outcome_Pain, Participant_Age, Participant_Sample-size, Intervention_Surgical, Outcome_Mental
[ "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Age", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Pain", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O" ]
Predictors of incident depression after hip fracture surgery . OBJECTIVE Depression after hip fracture surgery is prevalent and associated with increased mortality rates and impaired functional recovery . The incidence of new-onset depressive symptoms in patients initially not depressed after hip fracture surgery and their relationship with functional recovery is unknown . METHODS A cohort of 139 nondepressed elderly patients ( > 60 years ) hospitalized for hip fracture surgery were followed up for six months . Clinically significant depressive symptoms were defined as a score of 7 or more on the 15-item Geriatric Depression Scale . RESULTS The authors found a cumulative incidence rate of 20.5 % adjusted for dropouts . Multiple Cox-regression analyses yielded the presence of subthreshold symptoms of depression , anxiety , pain , and cognitive impairment at baseline , the premorbid level of mobility , and a history of ( treated ) depression as risk factors for incident depression ( p < 0.05 ) . A forward , conditional procedure identified postoperative pain ( hazard ratio [ HR ] = 1.32 , 95 % confidence interval [ CI ] : 1.14-1.53 , Wald chi ( 2 ) = 13.57 , df = 1 , p < 0.001 ) and baseline anxiety ( HR = 1.25 , 95 % CI : 1.08-1.44 , Wald chi ( 2 ) = 8.86 , df = 1 , p = 0.003 ) as the strongest independent risk factors . Incident depression was associated with a less favorable outcome at 3 months follow-up . CONCLUSION This exploratory study identified two treatable baseline characteristics that predicted incident depression in nondepressed patients after hip-fracture surgery .
[ "Predictors", "of", "incident", "depression", "after", "hip", "fracture", "surgery", ".", "OBJECTIVE", "Depression", "after", "hip", "fracture", "surgery", "is", "prevalent", "and", "associated", "with", "increased", "mortality", "rates", "and", "impaired", "functional", "recovery", ".", "The", "incidence", "of", "new", "-", "onset", "depressive", "symptoms", "in", "patients", "initially", "not", "depressed", "after", "hip", "fracture", "surgery", "and", "their", "relationship", "with", "functional", "recovery", "is", "unknown", ".", "METHODS", "A", "cohort", "of", "139", "nondepressed", "elderly", "patients", "(", ">", "60", "years", ")", "hospitalized", "for", "hip", "fracture", "surgery", "were", "followed", "up", "for", "six", "months", ".", "Clinically", "significant", "depressive", "symptoms", "were", "defined", "as", "a", "score", "of", "7", "or", "more", "on", "the", "15-item", "Geriatric", "Depression", "Scale", ".", "RESULTS", "The", "authors", "found", "a", "cumulative", "incidence", "rate", "of", "20.5", "%", "adjusted", "for", "dropouts", ".", "Multiple", "Cox", "-", "regression", "analyses", "yielded", "the", "presence", "of", "subthreshold", "symptoms", "of", "depression", ",", "anxiety", ",", "pain", ",", "and", "cognitive", "impairment", "at", "baseline", ",", "the", "premorbid", "level", "of", "mobility", ",", "and", "a", "history", "of", "(", "treated", ")", "depression", "as", "risk", "factors", "for", "incident", "depression", "(", "p", "<", "0.05", ")", ".", "A", "forward", ",", "conditional", "procedure", "identified", "postoperative", "pain", "(", "hazard", "ratio", "[", "HR", "]", "=", "1.32", ",", "95", "%", "confidence", "interval", "[", "CI", "]", ":", "1.14", "-", "1.53", ",", "Wald", "chi", "(", "2", ")", "=", "13.57", ",", "df", "=", "1", ",", "p", "<", "0.001", ")", "and", "baseline", "anxiety", "(", "HR", "=", "1.25", ",", "95", "%", "CI", ":", "1.08", "-", "1.44", ",", "Wald", "chi", "(", "2", ")", "=", "8.86", ",", "df", "=", "1", ",", "p", "=", "0.003", ")", "as", "the", "strongest", "independent", "risk", "factors", ".", "Incident", "depression", "was", "associated", "with", "a", "less", "favorable", "outcome", "at", "3", "months", "follow", "-", "up", ".", "CONCLUSION", "This", "exploratory", "study", "identified", "two", "treatable", "baseline", "characteristics", "that", "predicted", "incident", "depression", "in", "nondepressed", "patients", "after", "hip", "-", "fracture", "surgery", "." ]
[ "Outcome_Mental", "Intervention_Surgical", "Outcome_Pain", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
incident depression is a Outcome_Mental, hip fracture surgery is a Intervention_Surgical, 139 is a Participant_Sample-size, elderly is a Participant_Age, > 60 years is a Participant_Age, 15-item Geriatric Depression Scale . is a Outcome_Mental, cumulative incidence rate is a Outcome_Mental, depression , anxiety is a Outcome_Mental, pain is a Outcome_Pain, cognitive impairment is a Outcome_Mental, depression as risk factors for incident depression is a Outcome_Mental, postoperative pain is a Outcome_Pain, baseline anxiety is a Outcome_Mental, Incident depression is a Outcome_Mental, hip - fracture is a Participant_Condition
32048_task1
Sentence: Predictors of incident depression after hip fracture surgery . OBJECTIVE Depression after hip fracture surgery is prevalent and associated with increased mortality rates and impaired functional recovery . The incidence of new-onset depressive symptoms in patients initially not depressed after hip fracture surgery and their relationship with functional recovery is unknown . METHODS A cohort of 139 nondepressed elderly patients ( > 60 years ) hospitalized for hip fracture surgery were followed up for six months . Clinically significant depressive symptoms were defined as a score of 7 or more on the 15-item Geriatric Depression Scale . RESULTS The authors found a cumulative incidence rate of 20.5 % adjusted for dropouts . Multiple Cox-regression analyses yielded the presence of subthreshold symptoms of depression , anxiety , pain , and cognitive impairment at baseline , the premorbid level of mobility , and a history of ( treated ) depression as risk factors for incident depression ( p < 0.05 ) . A forward , conditional procedure identified postoperative pain ( hazard ratio [ HR ] = 1.32 , 95 % confidence interval [ CI ] : 1.14-1.53 , Wald chi ( 2 ) = 13.57 , df = 1 , p < 0.001 ) and baseline anxiety ( HR = 1.25 , 95 % CI : 1.08-1.44 , Wald chi ( 2 ) = 8.86 , df = 1 , p = 0.003 ) as the strongest independent risk factors . Incident depression was associated with a less favorable outcome at 3 months follow-up . CONCLUSION This exploratory study identified two treatable baseline characteristics that predicted incident depression in nondepressed patients after hip-fracture surgery . Instructions: please typing these entity words according to sentence: incident depression, hip fracture surgery, 139, elderly, > 60 years, 15-item Geriatric Depression Scale ., cumulative incidence rate, depression , anxiety, pain, cognitive impairment, depression as risk factors for incident depression, postoperative pain, baseline anxiety, Incident depression, hip - fracture Options: Participant_Condition, Outcome_Pain, Participant_Age, Participant_Sample-size, Intervention_Surgical, Outcome_Mental
[ "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Age", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Pain", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O" ]
Predictors of incident depression after hip fracture surgery . OBJECTIVE Depression after hip fracture surgery is prevalent and associated with increased mortality rates and impaired functional recovery . The incidence of new-onset depressive symptoms in patients initially not depressed after hip fracture surgery and their relationship with functional recovery is unknown . METHODS A cohort of 139 nondepressed elderly patients ( > 60 years ) hospitalized for hip fracture surgery were followed up for six months . Clinically significant depressive symptoms were defined as a score of 7 or more on the 15-item Geriatric Depression Scale . RESULTS The authors found a cumulative incidence rate of 20.5 % adjusted for dropouts . Multiple Cox-regression analyses yielded the presence of subthreshold symptoms of depression , anxiety , pain , and cognitive impairment at baseline , the premorbid level of mobility , and a history of ( treated ) depression as risk factors for incident depression ( p < 0.05 ) . A forward , conditional procedure identified postoperative pain ( hazard ratio [ HR ] = 1.32 , 95 % confidence interval [ CI ] : 1.14-1.53 , Wald chi ( 2 ) = 13.57 , df = 1 , p < 0.001 ) and baseline anxiety ( HR = 1.25 , 95 % CI : 1.08-1.44 , Wald chi ( 2 ) = 8.86 , df = 1 , p = 0.003 ) as the strongest independent risk factors . Incident depression was associated with a less favorable outcome at 3 months follow-up . CONCLUSION This exploratory study identified two treatable baseline characteristics that predicted incident depression in nondepressed patients after hip-fracture surgery .
[ "Predictors", "of", "incident", "depression", "after", "hip", "fracture", "surgery", ".", "OBJECTIVE", "Depression", "after", "hip", "fracture", "surgery", "is", "prevalent", "and", "associated", "with", "increased", "mortality", "rates", "and", "impaired", "functional", "recovery", ".", "The", "incidence", "of", "new", "-", "onset", "depressive", "symptoms", "in", "patients", "initially", "not", "depressed", "after", "hip", "fracture", "surgery", "and", "their", "relationship", "with", "functional", "recovery", "is", "unknown", ".", "METHODS", "A", "cohort", "of", "139", "nondepressed", "elderly", "patients", "(", ">", "60", "years", ")", "hospitalized", "for", "hip", "fracture", "surgery", "were", "followed", "up", "for", "six", "months", ".", "Clinically", "significant", "depressive", "symptoms", "were", "defined", "as", "a", "score", "of", "7", "or", "more", "on", "the", "15-item", "Geriatric", "Depression", "Scale", ".", "RESULTS", "The", "authors", "found", "a", "cumulative", "incidence", "rate", "of", "20.5", "%", "adjusted", "for", "dropouts", ".", "Multiple", "Cox", "-", "regression", "analyses", "yielded", "the", "presence", "of", "subthreshold", "symptoms", "of", "depression", ",", "anxiety", ",", "pain", ",", "and", "cognitive", "impairment", "at", "baseline", ",", "the", "premorbid", "level", "of", "mobility", ",", "and", "a", "history", "of", "(", "treated", ")", "depression", "as", "risk", "factors", "for", "incident", "depression", "(", "p", "<", "0.05", ")", ".", "A", "forward", ",", "conditional", "procedure", "identified", "postoperative", "pain", "(", "hazard", "ratio", "[", "HR", "]", "=", "1.32", ",", "95", "%", "confidence", "interval", "[", "CI", "]", ":", "1.14", "-", "1.53", ",", "Wald", "chi", "(", "2", ")", "=", "13.57", ",", "df", "=", "1", ",", "p", "<", "0.001", ")", "and", "baseline", "anxiety", "(", "HR", "=", "1.25", ",", "95", "%", "CI", ":", "1.08", "-", "1.44", ",", "Wald", "chi", "(", "2", ")", "=", "8.86", ",", "df", "=", "1", ",", "p", "=", "0.003", ")", "as", "the", "strongest", "independent", "risk", "factors", ".", "Incident", "depression", "was", "associated", "with", "a", "less", "favorable", "outcome", "at", "3", "months", "follow", "-", "up", ".", "CONCLUSION", "This", "exploratory", "study", "identified", "two", "treatable", "baseline", "characteristics", "that", "predicted", "incident", "depression", "in", "nondepressed", "patients", "after", "hip", "-", "fracture", "surgery", "." ]
[ "Outcome_Mental", "Intervention_Surgical", "Outcome_Pain", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
incident depression, hip fracture surgery, 139, elderly, > 60 years, 15-item Geriatric Depression Scale ., cumulative incidence rate, depression , anxiety, pain, cognitive impairment, depression as risk factors for incident depression, postoperative pain, baseline anxiety, Incident depression, hip - fracture
32048_task2
Sentence: Predictors of incident depression after hip fracture surgery . OBJECTIVE Depression after hip fracture surgery is prevalent and associated with increased mortality rates and impaired functional recovery . The incidence of new-onset depressive symptoms in patients initially not depressed after hip fracture surgery and their relationship with functional recovery is unknown . METHODS A cohort of 139 nondepressed elderly patients ( > 60 years ) hospitalized for hip fracture surgery were followed up for six months . Clinically significant depressive symptoms were defined as a score of 7 or more on the 15-item Geriatric Depression Scale . RESULTS The authors found a cumulative incidence rate of 20.5 % adjusted for dropouts . Multiple Cox-regression analyses yielded the presence of subthreshold symptoms of depression , anxiety , pain , and cognitive impairment at baseline , the premorbid level of mobility , and a history of ( treated ) depression as risk factors for incident depression ( p < 0.05 ) . A forward , conditional procedure identified postoperative pain ( hazard ratio [ HR ] = 1.32 , 95 % confidence interval [ CI ] : 1.14-1.53 , Wald chi ( 2 ) = 13.57 , df = 1 , p < 0.001 ) and baseline anxiety ( HR = 1.25 , 95 % CI : 1.08-1.44 , Wald chi ( 2 ) = 8.86 , df = 1 , p = 0.003 ) as the strongest independent risk factors . Incident depression was associated with a less favorable outcome at 3 months follow-up . CONCLUSION This exploratory study identified two treatable baseline characteristics that predicted incident depression in nondepressed patients after hip-fracture surgery . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Age", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Pain", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O" ]
Predictors of incident depression after hip fracture surgery . OBJECTIVE Depression after hip fracture surgery is prevalent and associated with increased mortality rates and impaired functional recovery . The incidence of new-onset depressive symptoms in patients initially not depressed after hip fracture surgery and their relationship with functional recovery is unknown . METHODS A cohort of 139 nondepressed elderly patients ( > 60 years ) hospitalized for hip fracture surgery were followed up for six months . Clinically significant depressive symptoms were defined as a score of 7 or more on the 15-item Geriatric Depression Scale . RESULTS The authors found a cumulative incidence rate of 20.5 % adjusted for dropouts . Multiple Cox-regression analyses yielded the presence of subthreshold symptoms of depression , anxiety , pain , and cognitive impairment at baseline , the premorbid level of mobility , and a history of ( treated ) depression as risk factors for incident depression ( p < 0.05 ) . A forward , conditional procedure identified postoperative pain ( hazard ratio [ HR ] = 1.32 , 95 % confidence interval [ CI ] : 1.14-1.53 , Wald chi ( 2 ) = 13.57 , df = 1 , p < 0.001 ) and baseline anxiety ( HR = 1.25 , 95 % CI : 1.08-1.44 , Wald chi ( 2 ) = 8.86 , df = 1 , p = 0.003 ) as the strongest independent risk factors . Incident depression was associated with a less favorable outcome at 3 months follow-up . CONCLUSION This exploratory study identified two treatable baseline characteristics that predicted incident depression in nondepressed patients after hip-fracture surgery .
[ "Predictors", "of", "incident", "depression", "after", "hip", "fracture", "surgery", ".", "OBJECTIVE", "Depression", "after", "hip", "fracture", "surgery", "is", "prevalent", "and", "associated", "with", "increased", "mortality", "rates", "and", "impaired", "functional", "recovery", ".", "The", "incidence", "of", "new", "-", "onset", "depressive", "symptoms", "in", "patients", "initially", "not", "depressed", "after", "hip", "fracture", "surgery", "and", "their", "relationship", "with", "functional", "recovery", "is", "unknown", ".", "METHODS", "A", "cohort", "of", "139", "nondepressed", "elderly", "patients", "(", ">", "60", "years", ")", "hospitalized", "for", "hip", "fracture", "surgery", "were", "followed", "up", "for", "six", "months", ".", "Clinically", "significant", "depressive", "symptoms", "were", "defined", "as", "a", "score", "of", "7", "or", "more", "on", "the", "15-item", "Geriatric", "Depression", "Scale", ".", "RESULTS", "The", "authors", "found", "a", "cumulative", "incidence", "rate", "of", "20.5", "%", "adjusted", "for", "dropouts", ".", "Multiple", "Cox", "-", "regression", "analyses", "yielded", "the", "presence", "of", "subthreshold", "symptoms", "of", "depression", ",", "anxiety", ",", "pain", ",", "and", "cognitive", "impairment", "at", "baseline", ",", "the", "premorbid", "level", "of", "mobility", ",", "and", "a", "history", "of", "(", "treated", ")", "depression", "as", "risk", "factors", "for", "incident", "depression", "(", "p", "<", "0.05", ")", ".", "A", "forward", ",", "conditional", "procedure", "identified", "postoperative", "pain", "(", "hazard", "ratio", "[", "HR", "]", "=", "1.32", ",", "95", "%", "confidence", "interval", "[", "CI", "]", ":", "1.14", "-", "1.53", ",", "Wald", "chi", "(", "2", ")", "=", "13.57", ",", "df", "=", "1", ",", "p", "<", "0.001", ")", "and", "baseline", "anxiety", "(", "HR", "=", "1.25", ",", "95", "%", "CI", ":", "1.08", "-", "1.44", ",", "Wald", "chi", "(", "2", ")", "=", "8.86", ",", "df", "=", "1", ",", "p", "=", "0.003", ")", "as", "the", "strongest", "independent", "risk", "factors", ".", "Incident", "depression", "was", "associated", "with", "a", "less", "favorable", "outcome", "at", "3", "months", "follow", "-", "up", ".", "CONCLUSION", "This", "exploratory", "study", "identified", "two", "treatable", "baseline", "characteristics", "that", "predicted", "incident", "depression", "in", "nondepressed", "patients", "after", "hip", "-", "fracture", "surgery", "." ]
[ "Outcome_Mental", "Intervention_Surgical", "Outcome_Pain", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
GppNHp is a chemical, RalA is a protein, Sec5 is a protein, GDP - bound RalA is a protein, Sec5 is a protein
1.0alpha7.train.1276_task0
Sentence: Therefore, we will consider the differences between the GppNHp-bound RalA structure complexed with Sec5 and the GDP-bound RalA structure to be primarily caused by the difference in nucleotide state rather than caused by binding of Sec5 to RalA. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: chemical, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]
Therefore, we will consider the differences between the GppNHp-bound RalA structure complexed with Sec5 and the GDP-bound RalA structure to be primarily caused by the difference in nucleotide state rather than caused by binding of Sec5 to RalA.
[ "Therefore", ",", "we", "will", "consider", "the", "differences", "between", "the", " ", "GppNHp", "-", "bound", "RalA", "structure", "complexed", "with", " ", "Sec5", "and", "the", " ", "GDP", "-", "bound", "RalA", "structure", "to", "be", "primarily", "caused", "by", "the", "difference", "in", "nucleotide", "state", "rather", "than", "caused", "by", "binding", "of", " ", "Sec5", "to", " ", "RalA." ]
[ "protein", "chemical" ]
GppNHp is a chemical, RalA is a protein, Sec5 is a protein, GDP - bound RalA is a protein, Sec5 is a protein
1.0alpha7.train.1276_task1
Sentence: Therefore, we will consider the differences between the GppNHp-bound RalA structure complexed with Sec5 and the GDP-bound RalA structure to be primarily caused by the difference in nucleotide state rather than caused by binding of Sec5 to RalA. Instructions: please typing these entity words according to sentence: GppNHp, RalA, Sec5, GDP - bound RalA, Sec5 Options: chemical, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]
Therefore, we will consider the differences between the GppNHp-bound RalA structure complexed with Sec5 and the GDP-bound RalA structure to be primarily caused by the difference in nucleotide state rather than caused by binding of Sec5 to RalA.
[ "Therefore", ",", "we", "will", "consider", "the", "differences", "between", "the", " ", "GppNHp", "-", "bound", "RalA", "structure", "complexed", "with", " ", "Sec5", "and", "the", " ", "GDP", "-", "bound", "RalA", "structure", "to", "be", "primarily", "caused", "by", "the", "difference", "in", "nucleotide", "state", "rather", "than", "caused", "by", "binding", "of", " ", "Sec5", "to", " ", "RalA." ]
[ "protein", "chemical" ]
GppNHp, RalA, Sec5, GDP - bound RalA, Sec5
1.0alpha7.train.1276_task2
Sentence: Therefore, we will consider the differences between the GppNHp-bound RalA structure complexed with Sec5 and the GDP-bound RalA structure to be primarily caused by the difference in nucleotide state rather than caused by binding of Sec5 to RalA. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]
Therefore, we will consider the differences between the GppNHp-bound RalA structure complexed with Sec5 and the GDP-bound RalA structure to be primarily caused by the difference in nucleotide state rather than caused by binding of Sec5 to RalA.
[ "Therefore", ",", "we", "will", "consider", "the", "differences", "between", "the", " ", "GppNHp", "-", "bound", "RalA", "structure", "complexed", "with", " ", "Sec5", "and", "the", " ", "GDP", "-", "bound", "RalA", "structure", "to", "be", "primarily", "caused", "by", "the", "difference", "in", "nucleotide", "state", "rather", "than", "caused", "by", "binding", "of", " ", "Sec5", "to", " ", "RalA." ]
[ "protein", "chemical" ]
neoformación is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma mal diferenciado is a MORFOLOGIA_NEOPLASIA, progresión hepática is a MORFOLOGIA_NEOPLASIA
517_task0
Sentence: Anamnesis Mujer de 75 años sin antecedentes personales de interés, que se encontraba en seguimiento por enfermedad de Paget vulvar. La paciente consulta en diciembre de 2017 por empeoramiento del prurito en la zona vulvo-vaginal. Exploración física Se aprecia neoformación vulvar en introito vaginal, con crecimiento hacia vagina y extensión superficial al resto de la vulva en forma de enfermedad de Paget. Pruebas complementarias Se realiza una tomografía computarizada (TC) en enero de 2018, describiéndose adenopatías de aspecto patológico en la cadena iliaca externa-femoral derecha de al menos 5,5 x 2,6 cm, así como adenopatías inguinales ipsilaterales sospechosas de 2,9 x 1,6 cm. Engrosamiento nodular en cúpula vaginal izquierda y ligero engrosamiento cutáneo en la región vulvar. Se toma biopsia del introito vaginal, mostrándose infiltración por carcinoma compatible con primario vulvar. También se realiza biopsia de las adenopatías inguinales, mostrando infiltrados de células grandes con morfología que corresponde a adenocarcinoma mal diferenciado. El perfil inmunohistoquímico (positividad para CK7, EMA, receptores de andrógenos y CEA; negatividad para CK20, estrógenos, progesterona y GCDFP-15) orienta a origen vulvar. Ante estos hallazgos, se completa con una tomografía por emisión de positrones (PET), donde se objetiva captación en hemivulva derecha, cúpula vaginal izquierda y adenopatías inguinales derechas, en la cadena iliaca externa derecha y en la bifurcación iliaca común derecha. Diagnóstico Enfermedad de Paget vulvar estadio IV por afectación ganglionar. Tratamiento Se inicia tratamiento de primera línea con carboplatino AUC 4 y paclitaxel 135 mg/m2 cada 21 días. Dosis reducidas por fragilidad de la paciente. Evolución La paciente inicia tratamiento en marzo de 2018. Tras tres ciclos, en la TC de reevaluación se objetiva respuesta parcial a nivel ganglionar, manteniéndose dicha respuesta tras otros 3 ciclos más (6 en total). Se decide en sesión multidisciplinar administrar radioterapia de consolidación sobre las cadenas ganglionares y la zona vulvar, con una dosis total de 57.2 Gy (11 sesiones de 5.2 Gy). En la primera TC tras la radioterapia, la paciente mantenía la respuesta parcial. No obstante, en febrero de 2019 presenta progresión hepática, con estabilidad de las lesiones ganglionares. Tras el mismo, el resultado de la determinación de HER-2 resulta positivo mediante inmunohistoquímica. En este momento, se solicita determinación de HER-2, resultando positiva por inmunohistoquímica con valor de tres cruces (+++). Se decide entonces iniciar una segunda línea de tratamiento con trastuzumab 600 mg subcutáneo cada 21 días y paclitaxel 80 mg/m2 días 1, 8 y 15. El paclitaxel se redujo a 40 mg/m2 en el ciclo 1, día 8 por neurotoxicidad, teniendo que ser suspendido a partir del 2º ciclo, continuando exclusivamente con trastuzumab 600 mg subcutáneo cada 21 días. Se realiza TC de control tras el 4º ciclo, donde se evidencia respuesta parcial. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 75 años sin antecedentes personales de interés, que se encontraba en seguimiento por enfermedad de Paget vulvar. La paciente consulta en diciembre de 2017 por empeoramiento del prurito en la zona vulvo-vaginal. Exploración física Se aprecia neoformación vulvar en introito vaginal, con crecimiento hacia vagina y extensión superficial al resto de la vulva en forma de enfermedad de Paget. Pruebas complementarias Se realiza una tomografía computarizada (TC) en enero de 2018, describiéndose adenopatías de aspecto patológico en la cadena iliaca externa-femoral derecha de al menos 5,5 x 2,6 cm, así como adenopatías inguinales ipsilaterales sospechosas de 2,9 x 1,6 cm. Engrosamiento nodular en cúpula vaginal izquierda y ligero engrosamiento cutáneo en la región vulvar. Se toma biopsia del introito vaginal, mostrándose infiltración por carcinoma compatible con primario vulvar. También se realiza biopsia de las adenopatías inguinales, mostrando infiltrados de células grandes con morfología que corresponde a adenocarcinoma mal diferenciado. El perfil inmunohistoquímico (positividad para CK7, EMA, receptores de andrógenos y CEA; negatividad para CK20, estrógenos, progesterona y GCDFP-15) orienta a origen vulvar. Ante estos hallazgos, se completa con una tomografía por emisión de positrones (PET), donde se objetiva captación en hemivulva derecha, cúpula vaginal izquierda y adenopatías inguinales derechas, en la cadena iliaca externa derecha y en la bifurcación iliaca común derecha. Diagnóstico Enfermedad de Paget vulvar estadio IV por afectación ganglionar. Tratamiento Se inicia tratamiento de primera línea con carboplatino AUC 4 y paclitaxel 135 mg/m2 cada 21 días. Dosis reducidas por fragilidad de la paciente. Evolución La paciente inicia tratamiento en marzo de 2018. Tras tres ciclos, en la TC de reevaluación se objetiva respuesta parcial a nivel ganglionar, manteniéndose dicha respuesta tras otros 3 ciclos más (6 en total). Se decide en sesión multidisciplinar administrar radioterapia de consolidación sobre las cadenas ganglionares y la zona vulvar, con una dosis total de 57.2 Gy (11 sesiones de 5.2 Gy). En la primera TC tras la radioterapia, la paciente mantenía la respuesta parcial. No obstante, en febrero de 2019 presenta progresión hepática, con estabilidad de las lesiones ganglionares. Tras el mismo, el resultado de la determinación de HER-2 resulta positivo mediante inmunohistoquímica. En este momento, se solicita determinación de HER-2, resultando positiva por inmunohistoquímica con valor de tres cruces (+++). Se decide entonces iniciar una segunda línea de tratamiento con trastuzumab 600 mg subcutáneo cada 21 días y paclitaxel 80 mg/m2 días 1, 8 y 15. El paclitaxel se redujo a 40 mg/m2 en el ciclo 1, día 8 por neurotoxicidad, teniendo que ser suspendido a partir del 2º ciclo, continuando exclusivamente con trastuzumab 600 mg subcutáneo cada 21 días. Se realiza TC de control tras el 4º ciclo, donde se evidencia respuesta parcial.
[ "Anamnesis", "\n", "Mujer", "de", "75", "años", "sin", "antecedentes", "personales", "de", "interés", ",", "que", "se", "encontraba", "en", "seguimiento", "por", "enfermedad", "de", "Paget", "vulvar", ".", "La", "paciente", "consulta", "en", "diciembre", "de", "2017", "por", "empeoramiento", "del", "prurito", "en", "la", "zona", "vulvo", "-", "vaginal", ".", "\n\n", "Exploración", "física", "\n", "Se", "aprecia", "neoformación", "vulvar", "en", "introito", "vaginal", ",", "con", "crecimiento", "hacia", "vagina", "y", "extensión", "superficial", "al", "resto", "de", "la", "vulva", "en", "forma", "de", "enfermedad", "de", "Paget", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "en", "enero", "de", "2018", ",", "describiéndose", "adenopatías", "de", "aspecto", "patológico", "en", "la", "cadena", "iliaca", "externa", "-", "femoral", "derecha", "de", "al", "menos", "5,5", "x", "2,6", "cm", ",", "así", "como", "adenopatías", "inguinales", "ipsilaterales", "sospechosas", "de", "2,9", "x", "1,6", "cm", ".", "Engrosamiento", "nodular", "en", "cúpula", "vaginal", "izquierda", "y", "ligero", "engrosamiento", "cutáneo", "en", "la", "región", "vulvar", ".", "\n", "Se", "toma", "biopsia", "del", "introito", "vaginal", ",", "mostrándose", "infiltración", "por", "carcinoma", "compatible", "con", "primario", "vulvar", ".", "También", "se", "realiza", "biopsia", "de", "las", "adenopatías", "inguinales", ",", "mostrando", "infiltrados", "de", "células", "grandes", "con", "morfología", "que", "corresponde", "a", "adenocarcinoma", "mal", "diferenciado", ".", "El", "perfil", "inmunohistoquímico", "(", "positividad", "para", "CK7", ",", "EMA", ",", "receptores", "de", "andrógenos", "y", "CEA", ";", "negatividad", "para", "CK20", ",", "estrógenos", ",", "progesterona", "y", "GCDFP-15", ")", "orienta", "a", "origen", "vulvar", ".", "\n", "Ante", "estos", "hallazgos", ",", "se", "completa", "con", "una", "tomografía", "por", "emisión", "de", "positrones", "(", "PET", ")", ",", "donde", "se", "objetiva", "captación", "en", "hemivulva", "derecha", ",", "cúpula", "vaginal", "izquierda", "y", "adenopatías", "inguinales", "derechas", ",", "en", "la", "cadena", "iliaca", "externa", "derecha", "y", "en", "la", "bifurcación", "iliaca", "común", "derecha", ".", "\n\n", "Diagnóstico", "\n", "Enfermedad", "de", "Paget", "vulvar", "estadio", "IV", "por", "afectación", "ganglionar", ".", "\n\n", "Tratamiento", "\n", "Se", "inicia", "tratamiento", "de", "primera", "línea", "con", "carboplatino", "AUC", "4", "y", "paclitaxel", "135", "mg", "/", "m2", "cada", "21", "días", ".", "Dosis", "reducidas", "por", "fragilidad", "de", "la", "paciente", ".", "\n\n", "Evolución", "\n", "La", "paciente", "inicia", "tratamiento", "en", "marzo", "de", "2018", ".", "Tras", "tres", "ciclos", ",", "en", "la", "TC", "de", "reevaluación", "se", "objetiva", "respuesta", "parcial", "a", "nivel", "ganglionar", ",", "manteniéndose", "dicha", "respuesta", "tras", "otros", "3", "ciclos", "más", "(", "6", "en", "total", ")", ".", "\n", "Se", "decide", "en", "sesión", "multidisciplinar", "administrar", "radioterapia", "de", "consolidación", "sobre", "las", "cadenas", "ganglionares", "y", "la", "zona", "vulvar", ",", "con", "una", "dosis", "total", "de", "57.2", "Gy", "(", "11", "sesiones", "de", "5.2", "Gy", ")", ".", "En", "la", "primera", "TC", "tras", "la", "radioterapia", ",", "la", "paciente", "mantenía", "la", "respuesta", "parcial", ".", "No", "obstante", ",", "en", "febrero", "de", "2019", "presenta", "progresión", "hepática", ",", "con", "estabilidad", "de", "las", "lesiones", "ganglionares", ".", "Tras", "el", "mismo", ",", "el", "resultado", "de", "la", "determinación", "de", "HER-2", "resulta", "positivo", "mediante", "inmunohistoquímica", ".", "\n", "En", "este", "momento", ",", "se", "solicita", "determinación", "de", "HER-2", ",", "resultando", "positiva", "por", "inmunohistoquímica", "con", "valor", "de", "tres", "cruces", "(", "+", "+", "+", ")", ".", "Se", "decide", "entonces", "iniciar", "una", "segunda", "línea", "de", "tratamiento", "con", "trastuzumab", "600", "mg", "subcutáneo", "cada", "21", "días", "y", "paclitaxel", "80", "mg", "/", "m2", "días", "1", ",", "8", "y", "15", ".", "El", "paclitaxel", "se", "redujo", "a", "40", "mg", "/", "m2", "en", "el", "ciclo", "1", ",", "día", "8", "por", "neurotoxicidad", ",", "teniendo", "que", "ser", "suspendido", "a", "partir", "del", "2º", "ciclo", ",", "continuando", "exclusivamente", "con", "trastuzumab", "600", "mg", "subcutáneo", "cada", "21", "días", ".", "Se", "realiza", "TC", "de", "control", "tras", "el", "4º", "ciclo", ",", "donde", "se", "evidencia", "respuesta", "parcial", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoformación is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma mal diferenciado is a MORFOLOGIA_NEOPLASIA, progresión hepática is a MORFOLOGIA_NEOPLASIA
517_task1
Sentence: Anamnesis Mujer de 75 años sin antecedentes personales de interés, que se encontraba en seguimiento por enfermedad de Paget vulvar. La paciente consulta en diciembre de 2017 por empeoramiento del prurito en la zona vulvo-vaginal. Exploración física Se aprecia neoformación vulvar en introito vaginal, con crecimiento hacia vagina y extensión superficial al resto de la vulva en forma de enfermedad de Paget. Pruebas complementarias Se realiza una tomografía computarizada (TC) en enero de 2018, describiéndose adenopatías de aspecto patológico en la cadena iliaca externa-femoral derecha de al menos 5,5 x 2,6 cm, así como adenopatías inguinales ipsilaterales sospechosas de 2,9 x 1,6 cm. Engrosamiento nodular en cúpula vaginal izquierda y ligero engrosamiento cutáneo en la región vulvar. Se toma biopsia del introito vaginal, mostrándose infiltración por carcinoma compatible con primario vulvar. También se realiza biopsia de las adenopatías inguinales, mostrando infiltrados de células grandes con morfología que corresponde a adenocarcinoma mal diferenciado. El perfil inmunohistoquímico (positividad para CK7, EMA, receptores de andrógenos y CEA; negatividad para CK20, estrógenos, progesterona y GCDFP-15) orienta a origen vulvar. Ante estos hallazgos, se completa con una tomografía por emisión de positrones (PET), donde se objetiva captación en hemivulva derecha, cúpula vaginal izquierda y adenopatías inguinales derechas, en la cadena iliaca externa derecha y en la bifurcación iliaca común derecha. Diagnóstico Enfermedad de Paget vulvar estadio IV por afectación ganglionar. Tratamiento Se inicia tratamiento de primera línea con carboplatino AUC 4 y paclitaxel 135 mg/m2 cada 21 días. Dosis reducidas por fragilidad de la paciente. Evolución La paciente inicia tratamiento en marzo de 2018. Tras tres ciclos, en la TC de reevaluación se objetiva respuesta parcial a nivel ganglionar, manteniéndose dicha respuesta tras otros 3 ciclos más (6 en total). Se decide en sesión multidisciplinar administrar radioterapia de consolidación sobre las cadenas ganglionares y la zona vulvar, con una dosis total de 57.2 Gy (11 sesiones de 5.2 Gy). En la primera TC tras la radioterapia, la paciente mantenía la respuesta parcial. No obstante, en febrero de 2019 presenta progresión hepática, con estabilidad de las lesiones ganglionares. Tras el mismo, el resultado de la determinación de HER-2 resulta positivo mediante inmunohistoquímica. En este momento, se solicita determinación de HER-2, resultando positiva por inmunohistoquímica con valor de tres cruces (+++). Se decide entonces iniciar una segunda línea de tratamiento con trastuzumab 600 mg subcutáneo cada 21 días y paclitaxel 80 mg/m2 días 1, 8 y 15. El paclitaxel se redujo a 40 mg/m2 en el ciclo 1, día 8 por neurotoxicidad, teniendo que ser suspendido a partir del 2º ciclo, continuando exclusivamente con trastuzumab 600 mg subcutáneo cada 21 días. Se realiza TC de control tras el 4º ciclo, donde se evidencia respuesta parcial. Instructions: please typing these entity words according to sentence: neoformación, carcinoma, adenocarcinoma mal diferenciado, progresión hepática Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 75 años sin antecedentes personales de interés, que se encontraba en seguimiento por enfermedad de Paget vulvar. La paciente consulta en diciembre de 2017 por empeoramiento del prurito en la zona vulvo-vaginal. Exploración física Se aprecia neoformación vulvar en introito vaginal, con crecimiento hacia vagina y extensión superficial al resto de la vulva en forma de enfermedad de Paget. Pruebas complementarias Se realiza una tomografía computarizada (TC) en enero de 2018, describiéndose adenopatías de aspecto patológico en la cadena iliaca externa-femoral derecha de al menos 5,5 x 2,6 cm, así como adenopatías inguinales ipsilaterales sospechosas de 2,9 x 1,6 cm. Engrosamiento nodular en cúpula vaginal izquierda y ligero engrosamiento cutáneo en la región vulvar. Se toma biopsia del introito vaginal, mostrándose infiltración por carcinoma compatible con primario vulvar. También se realiza biopsia de las adenopatías inguinales, mostrando infiltrados de células grandes con morfología que corresponde a adenocarcinoma mal diferenciado. El perfil inmunohistoquímico (positividad para CK7, EMA, receptores de andrógenos y CEA; negatividad para CK20, estrógenos, progesterona y GCDFP-15) orienta a origen vulvar. Ante estos hallazgos, se completa con una tomografía por emisión de positrones (PET), donde se objetiva captación en hemivulva derecha, cúpula vaginal izquierda y adenopatías inguinales derechas, en la cadena iliaca externa derecha y en la bifurcación iliaca común derecha. Diagnóstico Enfermedad de Paget vulvar estadio IV por afectación ganglionar. Tratamiento Se inicia tratamiento de primera línea con carboplatino AUC 4 y paclitaxel 135 mg/m2 cada 21 días. Dosis reducidas por fragilidad de la paciente. Evolución La paciente inicia tratamiento en marzo de 2018. Tras tres ciclos, en la TC de reevaluación se objetiva respuesta parcial a nivel ganglionar, manteniéndose dicha respuesta tras otros 3 ciclos más (6 en total). Se decide en sesión multidisciplinar administrar radioterapia de consolidación sobre las cadenas ganglionares y la zona vulvar, con una dosis total de 57.2 Gy (11 sesiones de 5.2 Gy). En la primera TC tras la radioterapia, la paciente mantenía la respuesta parcial. No obstante, en febrero de 2019 presenta progresión hepática, con estabilidad de las lesiones ganglionares. Tras el mismo, el resultado de la determinación de HER-2 resulta positivo mediante inmunohistoquímica. En este momento, se solicita determinación de HER-2, resultando positiva por inmunohistoquímica con valor de tres cruces (+++). Se decide entonces iniciar una segunda línea de tratamiento con trastuzumab 600 mg subcutáneo cada 21 días y paclitaxel 80 mg/m2 días 1, 8 y 15. El paclitaxel se redujo a 40 mg/m2 en el ciclo 1, día 8 por neurotoxicidad, teniendo que ser suspendido a partir del 2º ciclo, continuando exclusivamente con trastuzumab 600 mg subcutáneo cada 21 días. Se realiza TC de control tras el 4º ciclo, donde se evidencia respuesta parcial.
[ "Anamnesis", "\n", "Mujer", "de", "75", "años", "sin", "antecedentes", "personales", "de", "interés", ",", "que", "se", "encontraba", "en", "seguimiento", "por", "enfermedad", "de", "Paget", "vulvar", ".", "La", "paciente", "consulta", "en", "diciembre", "de", "2017", "por", "empeoramiento", "del", "prurito", "en", "la", "zona", "vulvo", "-", "vaginal", ".", "\n\n", "Exploración", "física", "\n", "Se", "aprecia", "neoformación", "vulvar", "en", "introito", "vaginal", ",", "con", "crecimiento", "hacia", "vagina", "y", "extensión", "superficial", "al", "resto", "de", "la", "vulva", "en", "forma", "de", "enfermedad", "de", "Paget", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "en", "enero", "de", "2018", ",", "describiéndose", "adenopatías", "de", "aspecto", "patológico", "en", "la", "cadena", "iliaca", "externa", "-", "femoral", "derecha", "de", "al", "menos", "5,5", "x", "2,6", "cm", ",", "así", "como", "adenopatías", "inguinales", "ipsilaterales", "sospechosas", "de", "2,9", "x", "1,6", "cm", ".", "Engrosamiento", "nodular", "en", "cúpula", "vaginal", "izquierda", "y", "ligero", "engrosamiento", "cutáneo", "en", "la", "región", "vulvar", ".", "\n", "Se", "toma", "biopsia", "del", "introito", "vaginal", ",", "mostrándose", "infiltración", "por", "carcinoma", "compatible", "con", "primario", "vulvar", ".", "También", "se", "realiza", "biopsia", "de", "las", "adenopatías", "inguinales", ",", "mostrando", "infiltrados", "de", "células", "grandes", "con", "morfología", "que", "corresponde", "a", "adenocarcinoma", "mal", "diferenciado", ".", "El", "perfil", "inmunohistoquímico", "(", "positividad", "para", "CK7", ",", "EMA", ",", "receptores", "de", "andrógenos", "y", "CEA", ";", "negatividad", "para", "CK20", ",", "estrógenos", ",", "progesterona", "y", "GCDFP-15", ")", "orienta", "a", "origen", "vulvar", ".", "\n", "Ante", "estos", "hallazgos", ",", "se", "completa", "con", "una", "tomografía", "por", "emisión", "de", "positrones", "(", "PET", ")", ",", "donde", "se", "objetiva", "captación", "en", "hemivulva", "derecha", ",", "cúpula", "vaginal", "izquierda", "y", "adenopatías", "inguinales", "derechas", ",", "en", "la", "cadena", "iliaca", "externa", "derecha", "y", "en", "la", "bifurcación", "iliaca", "común", "derecha", ".", "\n\n", "Diagnóstico", "\n", "Enfermedad", "de", "Paget", "vulvar", "estadio", "IV", "por", "afectación", "ganglionar", ".", "\n\n", "Tratamiento", "\n", "Se", "inicia", "tratamiento", "de", "primera", "línea", "con", "carboplatino", "AUC", "4", "y", "paclitaxel", "135", "mg", "/", "m2", "cada", "21", "días", ".", "Dosis", "reducidas", "por", "fragilidad", "de", "la", "paciente", ".", "\n\n", "Evolución", "\n", "La", "paciente", "inicia", "tratamiento", "en", "marzo", "de", "2018", ".", "Tras", "tres", "ciclos", ",", "en", "la", "TC", "de", "reevaluación", "se", "objetiva", "respuesta", "parcial", "a", "nivel", "ganglionar", ",", "manteniéndose", "dicha", "respuesta", "tras", "otros", "3", "ciclos", "más", "(", "6", "en", "total", ")", ".", "\n", "Se", "decide", "en", "sesión", "multidisciplinar", "administrar", "radioterapia", "de", "consolidación", "sobre", "las", "cadenas", "ganglionares", "y", "la", "zona", "vulvar", ",", "con", "una", "dosis", "total", "de", "57.2", "Gy", "(", "11", "sesiones", "de", "5.2", "Gy", ")", ".", "En", "la", "primera", "TC", "tras", "la", "radioterapia", ",", "la", "paciente", "mantenía", "la", "respuesta", "parcial", ".", "No", "obstante", ",", "en", "febrero", "de", "2019", "presenta", "progresión", "hepática", ",", "con", "estabilidad", "de", "las", "lesiones", "ganglionares", ".", "Tras", "el", "mismo", ",", "el", "resultado", "de", "la", "determinación", "de", "HER-2", "resulta", "positivo", "mediante", "inmunohistoquímica", ".", "\n", "En", "este", "momento", ",", "se", "solicita", "determinación", "de", "HER-2", ",", "resultando", "positiva", "por", "inmunohistoquímica", "con", "valor", "de", "tres", "cruces", "(", "+", "+", "+", ")", ".", "Se", "decide", "entonces", "iniciar", "una", "segunda", "línea", "de", "tratamiento", "con", "trastuzumab", "600", "mg", "subcutáneo", "cada", "21", "días", "y", "paclitaxel", "80", "mg", "/", "m2", "días", "1", ",", "8", "y", "15", ".", "El", "paclitaxel", "se", "redujo", "a", "40", "mg", "/", "m2", "en", "el", "ciclo", "1", ",", "día", "8", "por", "neurotoxicidad", ",", "teniendo", "que", "ser", "suspendido", "a", "partir", "del", "2º", "ciclo", ",", "continuando", "exclusivamente", "con", "trastuzumab", "600", "mg", "subcutáneo", "cada", "21", "días", ".", "Se", "realiza", "TC", "de", "control", "tras", "el", "4º", "ciclo", ",", "donde", "se", "evidencia", "respuesta", "parcial", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoformación, carcinoma, adenocarcinoma mal diferenciado, progresión hepática
517_task2
Sentence: Anamnesis Mujer de 75 años sin antecedentes personales de interés, que se encontraba en seguimiento por enfermedad de Paget vulvar. La paciente consulta en diciembre de 2017 por empeoramiento del prurito en la zona vulvo-vaginal. Exploración física Se aprecia neoformación vulvar en introito vaginal, con crecimiento hacia vagina y extensión superficial al resto de la vulva en forma de enfermedad de Paget. Pruebas complementarias Se realiza una tomografía computarizada (TC) en enero de 2018, describiéndose adenopatías de aspecto patológico en la cadena iliaca externa-femoral derecha de al menos 5,5 x 2,6 cm, así como adenopatías inguinales ipsilaterales sospechosas de 2,9 x 1,6 cm. Engrosamiento nodular en cúpula vaginal izquierda y ligero engrosamiento cutáneo en la región vulvar. Se toma biopsia del introito vaginal, mostrándose infiltración por carcinoma compatible con primario vulvar. También se realiza biopsia de las adenopatías inguinales, mostrando infiltrados de células grandes con morfología que corresponde a adenocarcinoma mal diferenciado. El perfil inmunohistoquímico (positividad para CK7, EMA, receptores de andrógenos y CEA; negatividad para CK20, estrógenos, progesterona y GCDFP-15) orienta a origen vulvar. Ante estos hallazgos, se completa con una tomografía por emisión de positrones (PET), donde se objetiva captación en hemivulva derecha, cúpula vaginal izquierda y adenopatías inguinales derechas, en la cadena iliaca externa derecha y en la bifurcación iliaca común derecha. Diagnóstico Enfermedad de Paget vulvar estadio IV por afectación ganglionar. Tratamiento Se inicia tratamiento de primera línea con carboplatino AUC 4 y paclitaxel 135 mg/m2 cada 21 días. Dosis reducidas por fragilidad de la paciente. Evolución La paciente inicia tratamiento en marzo de 2018. Tras tres ciclos, en la TC de reevaluación se objetiva respuesta parcial a nivel ganglionar, manteniéndose dicha respuesta tras otros 3 ciclos más (6 en total). Se decide en sesión multidisciplinar administrar radioterapia de consolidación sobre las cadenas ganglionares y la zona vulvar, con una dosis total de 57.2 Gy (11 sesiones de 5.2 Gy). En la primera TC tras la radioterapia, la paciente mantenía la respuesta parcial. No obstante, en febrero de 2019 presenta progresión hepática, con estabilidad de las lesiones ganglionares. Tras el mismo, el resultado de la determinación de HER-2 resulta positivo mediante inmunohistoquímica. En este momento, se solicita determinación de HER-2, resultando positiva por inmunohistoquímica con valor de tres cruces (+++). Se decide entonces iniciar una segunda línea de tratamiento con trastuzumab 600 mg subcutáneo cada 21 días y paclitaxel 80 mg/m2 días 1, 8 y 15. El paclitaxel se redujo a 40 mg/m2 en el ciclo 1, día 8 por neurotoxicidad, teniendo que ser suspendido a partir del 2º ciclo, continuando exclusivamente con trastuzumab 600 mg subcutáneo cada 21 días. Se realiza TC de control tras el 4º ciclo, donde se evidencia respuesta parcial. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Mujer de 75 años sin antecedentes personales de interés, que se encontraba en seguimiento por enfermedad de Paget vulvar. La paciente consulta en diciembre de 2017 por empeoramiento del prurito en la zona vulvo-vaginal. Exploración física Se aprecia neoformación vulvar en introito vaginal, con crecimiento hacia vagina y extensión superficial al resto de la vulva en forma de enfermedad de Paget. Pruebas complementarias Se realiza una tomografía computarizada (TC) en enero de 2018, describiéndose adenopatías de aspecto patológico en la cadena iliaca externa-femoral derecha de al menos 5,5 x 2,6 cm, así como adenopatías inguinales ipsilaterales sospechosas de 2,9 x 1,6 cm. Engrosamiento nodular en cúpula vaginal izquierda y ligero engrosamiento cutáneo en la región vulvar. Se toma biopsia del introito vaginal, mostrándose infiltración por carcinoma compatible con primario vulvar. También se realiza biopsia de las adenopatías inguinales, mostrando infiltrados de células grandes con morfología que corresponde a adenocarcinoma mal diferenciado. El perfil inmunohistoquímico (positividad para CK7, EMA, receptores de andrógenos y CEA; negatividad para CK20, estrógenos, progesterona y GCDFP-15) orienta a origen vulvar. Ante estos hallazgos, se completa con una tomografía por emisión de positrones (PET), donde se objetiva captación en hemivulva derecha, cúpula vaginal izquierda y adenopatías inguinales derechas, en la cadena iliaca externa derecha y en la bifurcación iliaca común derecha. Diagnóstico Enfermedad de Paget vulvar estadio IV por afectación ganglionar. Tratamiento Se inicia tratamiento de primera línea con carboplatino AUC 4 y paclitaxel 135 mg/m2 cada 21 días. Dosis reducidas por fragilidad de la paciente. Evolución La paciente inicia tratamiento en marzo de 2018. Tras tres ciclos, en la TC de reevaluación se objetiva respuesta parcial a nivel ganglionar, manteniéndose dicha respuesta tras otros 3 ciclos más (6 en total). Se decide en sesión multidisciplinar administrar radioterapia de consolidación sobre las cadenas ganglionares y la zona vulvar, con una dosis total de 57.2 Gy (11 sesiones de 5.2 Gy). En la primera TC tras la radioterapia, la paciente mantenía la respuesta parcial. No obstante, en febrero de 2019 presenta progresión hepática, con estabilidad de las lesiones ganglionares. Tras el mismo, el resultado de la determinación de HER-2 resulta positivo mediante inmunohistoquímica. En este momento, se solicita determinación de HER-2, resultando positiva por inmunohistoquímica con valor de tres cruces (+++). Se decide entonces iniciar una segunda línea de tratamiento con trastuzumab 600 mg subcutáneo cada 21 días y paclitaxel 80 mg/m2 días 1, 8 y 15. El paclitaxel se redujo a 40 mg/m2 en el ciclo 1, día 8 por neurotoxicidad, teniendo que ser suspendido a partir del 2º ciclo, continuando exclusivamente con trastuzumab 600 mg subcutáneo cada 21 días. Se realiza TC de control tras el 4º ciclo, donde se evidencia respuesta parcial.
[ "Anamnesis", "\n", "Mujer", "de", "75", "años", "sin", "antecedentes", "personales", "de", "interés", ",", "que", "se", "encontraba", "en", "seguimiento", "por", "enfermedad", "de", "Paget", "vulvar", ".", "La", "paciente", "consulta", "en", "diciembre", "de", "2017", "por", "empeoramiento", "del", "prurito", "en", "la", "zona", "vulvo", "-", "vaginal", ".", "\n\n", "Exploración", "física", "\n", "Se", "aprecia", "neoformación", "vulvar", "en", "introito", "vaginal", ",", "con", "crecimiento", "hacia", "vagina", "y", "extensión", "superficial", "al", "resto", "de", "la", "vulva", "en", "forma", "de", "enfermedad", "de", "Paget", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "en", "enero", "de", "2018", ",", "describiéndose", "adenopatías", "de", "aspecto", "patológico", "en", "la", "cadena", "iliaca", "externa", "-", "femoral", "derecha", "de", "al", "menos", "5,5", "x", "2,6", "cm", ",", "así", "como", "adenopatías", "inguinales", "ipsilaterales", "sospechosas", "de", "2,9", "x", "1,6", "cm", ".", "Engrosamiento", "nodular", "en", "cúpula", "vaginal", "izquierda", "y", "ligero", "engrosamiento", "cutáneo", "en", "la", "región", "vulvar", ".", "\n", "Se", "toma", "biopsia", "del", "introito", "vaginal", ",", "mostrándose", "infiltración", "por", "carcinoma", "compatible", "con", "primario", "vulvar", ".", "También", "se", "realiza", "biopsia", "de", "las", "adenopatías", "inguinales", ",", "mostrando", "infiltrados", "de", "células", "grandes", "con", "morfología", "que", "corresponde", "a", "adenocarcinoma", "mal", "diferenciado", ".", "El", "perfil", "inmunohistoquímico", "(", "positividad", "para", "CK7", ",", "EMA", ",", "receptores", "de", "andrógenos", "y", "CEA", ";", "negatividad", "para", "CK20", ",", "estrógenos", ",", "progesterona", "y", "GCDFP-15", ")", "orienta", "a", "origen", "vulvar", ".", "\n", "Ante", "estos", "hallazgos", ",", "se", "completa", "con", "una", "tomografía", "por", "emisión", "de", "positrones", "(", "PET", ")", ",", "donde", "se", "objetiva", "captación", "en", "hemivulva", "derecha", ",", "cúpula", "vaginal", "izquierda", "y", "adenopatías", "inguinales", "derechas", ",", "en", "la", "cadena", "iliaca", "externa", "derecha", "y", "en", "la", "bifurcación", "iliaca", "común", "derecha", ".", "\n\n", "Diagnóstico", "\n", "Enfermedad", "de", "Paget", "vulvar", "estadio", "IV", "por", "afectación", "ganglionar", ".", "\n\n", "Tratamiento", "\n", "Se", "inicia", "tratamiento", "de", "primera", "línea", "con", "carboplatino", "AUC", "4", "y", "paclitaxel", "135", "mg", "/", "m2", "cada", "21", "días", ".", "Dosis", "reducidas", "por", "fragilidad", "de", "la", "paciente", ".", "\n\n", "Evolución", "\n", "La", "paciente", "inicia", "tratamiento", "en", "marzo", "de", "2018", ".", "Tras", "tres", "ciclos", ",", "en", "la", "TC", "de", "reevaluación", "se", "objetiva", "respuesta", "parcial", "a", "nivel", "ganglionar", ",", "manteniéndose", "dicha", "respuesta", "tras", "otros", "3", "ciclos", "más", "(", "6", "en", "total", ")", ".", "\n", "Se", "decide", "en", "sesión", "multidisciplinar", "administrar", "radioterapia", "de", "consolidación", "sobre", "las", "cadenas", "ganglionares", "y", "la", "zona", "vulvar", ",", "con", "una", "dosis", "total", "de", "57.2", "Gy", "(", "11", "sesiones", "de", "5.2", "Gy", ")", ".", "En", "la", "primera", "TC", "tras", "la", "radioterapia", ",", "la", "paciente", "mantenía", "la", "respuesta", "parcial", ".", "No", "obstante", ",", "en", "febrero", "de", "2019", "presenta", "progresión", "hepática", ",", "con", "estabilidad", "de", "las", "lesiones", "ganglionares", ".", "Tras", "el", "mismo", ",", "el", "resultado", "de", "la", "determinación", "de", "HER-2", "resulta", "positivo", "mediante", "inmunohistoquímica", ".", "\n", "En", "este", "momento", ",", "se", "solicita", "determinación", "de", "HER-2", ",", "resultando", "positiva", "por", "inmunohistoquímica", "con", "valor", "de", "tres", "cruces", "(", "+", "+", "+", ")", ".", "Se", "decide", "entonces", "iniciar", "una", "segunda", "línea", "de", "tratamiento", "con", "trastuzumab", "600", "mg", "subcutáneo", "cada", "21", "días", "y", "paclitaxel", "80", "mg", "/", "m2", "días", "1", ",", "8", "y", "15", ".", "El", "paclitaxel", "se", "redujo", "a", "40", "mg", "/", "m2", "en", "el", "ciclo", "1", ",", "día", "8", "por", "neurotoxicidad", ",", "teniendo", "que", "ser", "suspendido", "a", "partir", "del", "2º", "ciclo", ",", "continuando", "exclusivamente", "con", "trastuzumab", "600", "mg", "subcutáneo", "cada", "21", "días", ".", "Se", "realiza", "TC", "de", "control", "tras", "el", "4º", "ciclo", ",", "donde", "se", "evidencia", "respuesta", "parcial", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
incentives is a Intervention_Educational, intrinsic motivation is a Outcome_Mental, use of lottery tickets as incentives is a Intervention_Educational, epidemiologic control group . is a Participant_Condition, self - administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of is a Participant_Condition, children is a Participant_Age, with cancer . is a Participant_Condition, 450 is a Participant_Sample-size, no incentive is a Intervention_Control, promised incentive of one lottery ticket to be received upon reply is a Intervention_Educational, promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week is a Intervention_Educational, response rate is a Outcome_Mental, no incentive group is a Intervention_Control, one plus one lottery ticket group is a Intervention_Educational, survival analysis is a Outcome_Mortality, increase participation is a Outcome_Mental, Incentives is a Intervention_Educational
44473_task0
Sentence: Can incentives undermine intrinsic motivation to participate in epidemiologic surveys ? Response rates to surveys are decreasing . The purpose of this study was to evaluate the use of lottery tickets as incentives in an epidemiologic control group . A self-administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of children with cancer . A stratified random sample of 450 parents were randomized into three incentive groups : ( a ) no incentive ; ( b ) a promised incentive of one lottery ticket to be received upon reply ; ( c ) a promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week . The overall response rate across the three groups was 65.3 % . The response rate was highest in the no incentive group ( 69.3 % ) and lowest in the one plus one lottery ticket group ( 62.0 % ) . In a survival analysis , the difference between the two response curves was significant by the log-rank test ( P = 0.04 ) , with the no incentive group having a shorter time to response than the incentive group . Our findings suggest that the use of lottery tickets as incentives to increase participation in a mail questionnaire among parents may be less valuable or even harmful . Incentives may undermine motivation in studies in which the intrinsic motivation of the respondents is already high . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Control, Outcome_Mortality, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental
[ "O", "B-Intervention_Educational", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Can incentives undermine intrinsic motivation to participate in epidemiologic surveys ? Response rates to surveys are decreasing . The purpose of this study was to evaluate the use of lottery tickets as incentives in an epidemiologic control group . A self-administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of children with cancer . A stratified random sample of 450 parents were randomized into three incentive groups : ( a ) no incentive ; ( b ) a promised incentive of one lottery ticket to be received upon reply ; ( c ) a promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week . The overall response rate across the three groups was 65.3 % . The response rate was highest in the no incentive group ( 69.3 % ) and lowest in the one plus one lottery ticket group ( 62.0 % ) . In a survival analysis , the difference between the two response curves was significant by the log-rank test ( P = 0.04 ) , with the no incentive group having a shorter time to response than the incentive group . Our findings suggest that the use of lottery tickets as incentives to increase participation in a mail questionnaire among parents may be less valuable or even harmful . Incentives may undermine motivation in studies in which the intrinsic motivation of the respondents is already high .
[ "Can", "incentives", "undermine", "intrinsic", "motivation", "to", "participate", "in", "epidemiologic", "surveys", "?", "Response", "rates", "to", "surveys", "are", "decreasing", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "use", "of", "lottery", "tickets", "as", "incentives", "in", "an", "epidemiologic", "control", "group", ".", "A", "self", "-", "administered", "questionnaire", "was", "sent", "to", "parents", "in", "the", "municipality", "of", "Stockholm", ",", "Sweden", ",", "who", "were", "to", "be", "used", "as", "a", "control", "group", "in", "a", "study", "addressing", "stress", "in", "parents", "of", "children", "with", "cancer", ".", "A", "stratified", "random", "sample", "of", "450", "parents", "were", "randomized", "into", "three", "incentive", "groups", ":", "(", "a", ")", "no", "incentive", ";", "(", "b", ")", "a", "promised", "incentive", "of", "one", "lottery", "ticket", "to", "be", "received", "upon", "reply", ";", "(", "c", ")", "a", "promised", "incentive", "of", "one", "lottery", "ticket", "to", "be", "received", "upon", "reply", "and", "an", "additional", "lottery", "ticket", "upon", "reply", "within", "1", "week", ".", "The", "overall", "response", "rate", "across", "the", "three", "groups", "was", "65.3", "%", ".", "The", "response", "rate", "was", "highest", "in", "the", "no", "incentive", "group", "(", "69.3", "%", ")", "and", "lowest", "in", "the", "one", "plus", "one", "lottery", "ticket", "group", "(", "62.0", "%", ")", ".", "In", "a", "survival", "analysis", ",", "the", "difference", "between", "the", "two", "response", "curves", "was", "significant", "by", "the", "log", "-", "rank", "test", "(", "P", "=", "0.04", ")", ",", "with", "the", "no", "incentive", "group", "having", "a", "shorter", "time", "to", "response", "than", "the", "incentive", "group", ".", "Our", "findings", "suggest", "that", "the", "use", "of", "lottery", "tickets", "as", "incentives", "to", "increase", "participation", "in", "a", "mail", "questionnaire", "among", "parents", "may", "be", "less", "valuable", "or", "even", "harmful", ".", "Incentives", "may", "undermine", "motivation", "in", "studies", "in", "which", "the", "intrinsic", "motivation", "of", "the", "respondents", "is", "already", "high", "." ]
[ "Participant_Condition", "Intervention_Educational", "Outcome_Mental", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
incentives is a Intervention_Educational, intrinsic motivation is a Outcome_Mental, use of lottery tickets as incentives is a Intervention_Educational, epidemiologic control group . is a Participant_Condition, self - administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of is a Participant_Condition, children is a Participant_Age, with cancer . is a Participant_Condition, 450 is a Participant_Sample-size, no incentive is a Intervention_Control, promised incentive of one lottery ticket to be received upon reply is a Intervention_Educational, promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week is a Intervention_Educational, response rate is a Outcome_Mental, no incentive group is a Intervention_Control, one plus one lottery ticket group is a Intervention_Educational, survival analysis is a Outcome_Mortality, increase participation is a Outcome_Mental, Incentives is a Intervention_Educational
44473_task1
Sentence: Can incentives undermine intrinsic motivation to participate in epidemiologic surveys ? Response rates to surveys are decreasing . The purpose of this study was to evaluate the use of lottery tickets as incentives in an epidemiologic control group . A self-administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of children with cancer . A stratified random sample of 450 parents were randomized into three incentive groups : ( a ) no incentive ; ( b ) a promised incentive of one lottery ticket to be received upon reply ; ( c ) a promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week . The overall response rate across the three groups was 65.3 % . The response rate was highest in the no incentive group ( 69.3 % ) and lowest in the one plus one lottery ticket group ( 62.0 % ) . In a survival analysis , the difference between the two response curves was significant by the log-rank test ( P = 0.04 ) , with the no incentive group having a shorter time to response than the incentive group . Our findings suggest that the use of lottery tickets as incentives to increase participation in a mail questionnaire among parents may be less valuable or even harmful . Incentives may undermine motivation in studies in which the intrinsic motivation of the respondents is already high . Instructions: please typing these entity words according to sentence: incentives, intrinsic motivation, use of lottery tickets as incentives, epidemiologic control group ., self - administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of, children, with cancer ., 450, no incentive, promised incentive of one lottery ticket to be received upon reply, promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week, response rate, no incentive group, one plus one lottery ticket group, survival analysis, increase participation, Incentives Options: Participant_Condition, Intervention_Control, Outcome_Mortality, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental
[ "O", "B-Intervention_Educational", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Can incentives undermine intrinsic motivation to participate in epidemiologic surveys ? Response rates to surveys are decreasing . The purpose of this study was to evaluate the use of lottery tickets as incentives in an epidemiologic control group . A self-administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of children with cancer . A stratified random sample of 450 parents were randomized into three incentive groups : ( a ) no incentive ; ( b ) a promised incentive of one lottery ticket to be received upon reply ; ( c ) a promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week . The overall response rate across the three groups was 65.3 % . The response rate was highest in the no incentive group ( 69.3 % ) and lowest in the one plus one lottery ticket group ( 62.0 % ) . In a survival analysis , the difference between the two response curves was significant by the log-rank test ( P = 0.04 ) , with the no incentive group having a shorter time to response than the incentive group . Our findings suggest that the use of lottery tickets as incentives to increase participation in a mail questionnaire among parents may be less valuable or even harmful . Incentives may undermine motivation in studies in which the intrinsic motivation of the respondents is already high .
[ "Can", "incentives", "undermine", "intrinsic", "motivation", "to", "participate", "in", "epidemiologic", "surveys", "?", "Response", "rates", "to", "surveys", "are", "decreasing", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "use", "of", "lottery", "tickets", "as", "incentives", "in", "an", "epidemiologic", "control", "group", ".", "A", "self", "-", "administered", "questionnaire", "was", "sent", "to", "parents", "in", "the", "municipality", "of", "Stockholm", ",", "Sweden", ",", "who", "were", "to", "be", "used", "as", "a", "control", "group", "in", "a", "study", "addressing", "stress", "in", "parents", "of", "children", "with", "cancer", ".", "A", "stratified", "random", "sample", "of", "450", "parents", "were", "randomized", "into", "three", "incentive", "groups", ":", "(", "a", ")", "no", "incentive", ";", "(", "b", ")", "a", "promised", "incentive", "of", "one", "lottery", "ticket", "to", "be", "received", "upon", "reply", ";", "(", "c", ")", "a", "promised", "incentive", "of", "one", "lottery", "ticket", "to", "be", "received", "upon", "reply", "and", "an", "additional", "lottery", "ticket", "upon", "reply", "within", "1", "week", ".", "The", "overall", "response", "rate", "across", "the", "three", "groups", "was", "65.3", "%", ".", "The", "response", "rate", "was", "highest", "in", "the", "no", "incentive", "group", "(", "69.3", "%", ")", "and", "lowest", "in", "the", "one", "plus", "one", "lottery", "ticket", "group", "(", "62.0", "%", ")", ".", "In", "a", "survival", "analysis", ",", "the", "difference", "between", "the", "two", "response", "curves", "was", "significant", "by", "the", "log", "-", "rank", "test", "(", "P", "=", "0.04", ")", ",", "with", "the", "no", "incentive", "group", "having", "a", "shorter", "time", "to", "response", "than", "the", "incentive", "group", ".", "Our", "findings", "suggest", "that", "the", "use", "of", "lottery", "tickets", "as", "incentives", "to", "increase", "participation", "in", "a", "mail", "questionnaire", "among", "parents", "may", "be", "less", "valuable", "or", "even", "harmful", ".", "Incentives", "may", "undermine", "motivation", "in", "studies", "in", "which", "the", "intrinsic", "motivation", "of", "the", "respondents", "is", "already", "high", "." ]
[ "Participant_Condition", "Intervention_Educational", "Outcome_Mental", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
incentives, intrinsic motivation, use of lottery tickets as incentives, epidemiologic control group ., self - administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of, children, with cancer ., 450, no incentive, promised incentive of one lottery ticket to be received upon reply, promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week, response rate, no incentive group, one plus one lottery ticket group, survival analysis, increase participation, Incentives
44473_task2
Sentence: Can incentives undermine intrinsic motivation to participate in epidemiologic surveys ? Response rates to surveys are decreasing . The purpose of this study was to evaluate the use of lottery tickets as incentives in an epidemiologic control group . A self-administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of children with cancer . A stratified random sample of 450 parents were randomized into three incentive groups : ( a ) no incentive ; ( b ) a promised incentive of one lottery ticket to be received upon reply ; ( c ) a promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week . The overall response rate across the three groups was 65.3 % . The response rate was highest in the no incentive group ( 69.3 % ) and lowest in the one plus one lottery ticket group ( 62.0 % ) . In a survival analysis , the difference between the two response curves was significant by the log-rank test ( P = 0.04 ) , with the no incentive group having a shorter time to response than the incentive group . Our findings suggest that the use of lottery tickets as incentives to increase participation in a mail questionnaire among parents may be less valuable or even harmful . Incentives may undermine motivation in studies in which the intrinsic motivation of the respondents is already high . Instructions: please extract entity words from the input sentence
[ "O", "B-Intervention_Educational", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Can incentives undermine intrinsic motivation to participate in epidemiologic surveys ? Response rates to surveys are decreasing . The purpose of this study was to evaluate the use of lottery tickets as incentives in an epidemiologic control group . A self-administered questionnaire was sent to parents in the municipality of Stockholm , Sweden , who were to be used as a control group in a study addressing stress in parents of children with cancer . A stratified random sample of 450 parents were randomized into three incentive groups : ( a ) no incentive ; ( b ) a promised incentive of one lottery ticket to be received upon reply ; ( c ) a promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week . The overall response rate across the three groups was 65.3 % . The response rate was highest in the no incentive group ( 69.3 % ) and lowest in the one plus one lottery ticket group ( 62.0 % ) . In a survival analysis , the difference between the two response curves was significant by the log-rank test ( P = 0.04 ) , with the no incentive group having a shorter time to response than the incentive group . Our findings suggest that the use of lottery tickets as incentives to increase participation in a mail questionnaire among parents may be less valuable or even harmful . Incentives may undermine motivation in studies in which the intrinsic motivation of the respondents is already high .
[ "Can", "incentives", "undermine", "intrinsic", "motivation", "to", "participate", "in", "epidemiologic", "surveys", "?", "Response", "rates", "to", "surveys", "are", "decreasing", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "use", "of", "lottery", "tickets", "as", "incentives", "in", "an", "epidemiologic", "control", "group", ".", "A", "self", "-", "administered", "questionnaire", "was", "sent", "to", "parents", "in", "the", "municipality", "of", "Stockholm", ",", "Sweden", ",", "who", "were", "to", "be", "used", "as", "a", "control", "group", "in", "a", "study", "addressing", "stress", "in", "parents", "of", "children", "with", "cancer", ".", "A", "stratified", "random", "sample", "of", "450", "parents", "were", "randomized", "into", "three", "incentive", "groups", ":", "(", "a", ")", "no", "incentive", ";", "(", "b", ")", "a", "promised", "incentive", "of", "one", "lottery", "ticket", "to", "be", "received", "upon", "reply", ";", "(", "c", ")", "a", "promised", "incentive", "of", "one", "lottery", "ticket", "to", "be", "received", "upon", "reply", "and", "an", "additional", "lottery", "ticket", "upon", "reply", "within", "1", "week", ".", "The", "overall", "response", "rate", "across", "the", "three", "groups", "was", "65.3", "%", ".", "The", "response", "rate", "was", "highest", "in", "the", "no", "incentive", "group", "(", "69.3", "%", ")", "and", "lowest", "in", "the", "one", "plus", "one", "lottery", "ticket", "group", "(", "62.0", "%", ")", ".", "In", "a", "survival", "analysis", ",", "the", "difference", "between", "the", "two", "response", "curves", "was", "significant", "by", "the", "log", "-", "rank", "test", "(", "P", "=", "0.04", ")", ",", "with", "the", "no", "incentive", "group", "having", "a", "shorter", "time", "to", "response", "than", "the", "incentive", "group", ".", "Our", "findings", "suggest", "that", "the", "use", "of", "lottery", "tickets", "as", "incentives", "to", "increase", "participation", "in", "a", "mail", "questionnaire", "among", "parents", "may", "be", "less", "valuable", "or", "even", "harmful", ".", "Incentives", "may", "undermine", "motivation", "in", "studies", "in", "which", "the", "intrinsic", "motivation", "of", "the", "respondents", "is", "already", "high", "." ]
[ "Participant_Condition", "Intervention_Educational", "Outcome_Mental", "Intervention_Control", "Outcome_Mortality", "Participant_Age", "Participant_Sample-size" ]
xenogenic ( porcine ) acellular dermal matrix is a Intervention_Pharmacological, second - degree burns is a Participant_Condition, burn patients is a Participant_Condition, second - degree burn wounds is a Participant_Condition, Seventy - two is a Participant_Sample-size, acute second - degree burns is a Participant_Condition, xenogenic acellular dermal matrix . is a Intervention_Pharmacological, betadine ointment gauzes . is a Intervention_Pharmacological, porcine acellular dermal matrix . is a Intervention_Pharmacological, serum level of CRP is a Outcome_Physical
30034_task0
Sentence: The study of inhibiting systematic inflammatory response syndrome by applying xenogenic ( porcine ) acellular dermal matrix on second-degree burns . OBJECTIVE To investigate the influence of xenogenic ( porcine ) acellular dermal matrix on the systematic inflammatory reaction syndrome ( SIRS ) , and the reaction of burn patients to tissue damage upon application to second-degree burn wounds . METHOD Seventy-two cases of patients with acute second-degree burns were enrolled in the study . According to the total burn surface area ( TBSA ) and the treatment methods , we randomly divided the patients into four groups . Group A ( treatment group ) : patients with less than 30 % TBSA covered with xenogenic acellular dermal matrix . Group B ( control group ) : patients with less than 30 % TBSA covered with betadine ointment gauzes . Group C ( treatment group ) : patients with more than 30 % TBSA covered with porcine acellular dermal matrix . Group D ( control group ) : patients with more than 30 % TBSA covered with betadine ointment gauzes . Serum level of C-reactive protein ( CRP ) was measured by single radial immunodiffusion method on 1 , 4 , 7 and 14 days postburn . RESULTS The serum level of CRP in group A was significantly less than that of in group B ( P < 0.05 ) on days 4 , 7 and 14 . The serum level of CRP in group C increased slowly , descended quickly and was significantly less than that of in group D on days 4 , 7 and 14 . CONCLUSION The application of xenogenic ( porcine ) acellular dermal matrix on second-degree burn wound can decrease serum level of CRP of the patients , which may play an important role in reducing SIRS and sepsis incidence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Participant_Sample-size
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The study of inhibiting systematic inflammatory response syndrome by applying xenogenic ( porcine ) acellular dermal matrix on second-degree burns . OBJECTIVE To investigate the influence of xenogenic ( porcine ) acellular dermal matrix on the systematic inflammatory reaction syndrome ( SIRS ) , and the reaction of burn patients to tissue damage upon application to second-degree burn wounds . METHOD Seventy-two cases of patients with acute second-degree burns were enrolled in the study . According to the total burn surface area ( TBSA ) and the treatment methods , we randomly divided the patients into four groups . Group A ( treatment group ) : patients with less than 30 % TBSA covered with xenogenic acellular dermal matrix . Group B ( control group ) : patients with less than 30 % TBSA covered with betadine ointment gauzes . Group C ( treatment group ) : patients with more than 30 % TBSA covered with porcine acellular dermal matrix . Group D ( control group ) : patients with more than 30 % TBSA covered with betadine ointment gauzes . Serum level of C-reactive protein ( CRP ) was measured by single radial immunodiffusion method on 1 , 4 , 7 and 14 days postburn . RESULTS The serum level of CRP in group A was significantly less than that of in group B ( P < 0.05 ) on days 4 , 7 and 14 . The serum level of CRP in group C increased slowly , descended quickly and was significantly less than that of in group D on days 4 , 7 and 14 . CONCLUSION The application of xenogenic ( porcine ) acellular dermal matrix on second-degree burn wound can decrease serum level of CRP of the patients , which may play an important role in reducing SIRS and sepsis incidence .
[ "The", "study", "of", "inhibiting", "systematic", "inflammatory", "response", "syndrome", "by", "applying", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "second", "-", "degree", "burns", ".", "OBJECTIVE", "To", "investigate", "the", "influence", "of", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "the", "systematic", "inflammatory", "reaction", "syndrome", "(", "SIRS", ")", ",", "and", "the", "reaction", "of", "burn", "patients", "to", "tissue", "damage", "upon", "application", "to", "second", "-", "degree", "burn", "wounds", ".", "METHOD", "Seventy", "-", "two", "cases", "of", "patients", "with", "acute", "second", "-", "degree", "burns", "were", "enrolled", "in", "the", "study", ".", "According", "to", "the", "total", "burn", "surface", "area", "(", "TBSA", ")", "and", "the", "treatment", "methods", ",", "we", "randomly", "divided", "the", "patients", "into", "four", "groups", ".", "Group", "A", "(", "treatment", "group", ")", ":", "patients", "with", "less", "than", "30", "%", "TBSA", "covered", "with", "xenogenic", "acellular", "dermal", "matrix", ".", "Group", "B", "(", "control", "group", ")", ":", "patients", "with", "less", "than", "30", "%", "TBSA", "covered", "with", "betadine", "ointment", "gauzes", ".", "Group", "C", "(", "treatment", "group", ")", ":", "patients", "with", "more", "than", "30", "%", "TBSA", "covered", "with", "porcine", "acellular", "dermal", "matrix", ".", "Group", "D", "(", "control", "group", ")", ":", "patients", "with", "more", "than", "30", "%", "TBSA", "covered", "with", "betadine", "ointment", "gauzes", ".", "Serum", "level", "of", "C", "-", "reactive", "protein", "(", "CRP", ")", "was", "measured", "by", "single", "radial", "immunodiffusion", "method", "on", "1", ",", "4", ",", "7", "and", "14", "days", "postburn", ".", "RESULTS", "The", "serum", "level", "of", "CRP", "in", "group", "A", "was", "significantly", "less", "than", "that", "of", "in", "group", "B", "(", "P", "<", "0.05", ")", "on", "days", "4", ",", "7", "and", "14", ".", "The", "serum", "level", "of", "CRP", "in", "group", "C", "increased", "slowly", ",", "descended", "quickly", "and", "was", "significantly", "less", "than", "that", "of", "in", "group", "D", "on", "days", "4", ",", "7", "and", "14", ".", "CONCLUSION", "The", "application", "of", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "second", "-", "degree", "burn", "wound", "can", "decrease", "serum", "level", "of", "CRP", "of", "the", "patients", ",", "which", "may", "play", "an", "important", "role", "in", "reducing", "SIRS", "and", "sepsis", "incidence", "." ]
[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size" ]
xenogenic ( porcine ) acellular dermal matrix is a Intervention_Pharmacological, second - degree burns is a Participant_Condition, burn patients is a Participant_Condition, second - degree burn wounds is a Participant_Condition, Seventy - two is a Participant_Sample-size, acute second - degree burns is a Participant_Condition, xenogenic acellular dermal matrix . is a Intervention_Pharmacological, betadine ointment gauzes . is a Intervention_Pharmacological, porcine acellular dermal matrix . is a Intervention_Pharmacological, serum level of CRP is a Outcome_Physical
30034_task1
Sentence: The study of inhibiting systematic inflammatory response syndrome by applying xenogenic ( porcine ) acellular dermal matrix on second-degree burns . OBJECTIVE To investigate the influence of xenogenic ( porcine ) acellular dermal matrix on the systematic inflammatory reaction syndrome ( SIRS ) , and the reaction of burn patients to tissue damage upon application to second-degree burn wounds . METHOD Seventy-two cases of patients with acute second-degree burns were enrolled in the study . According to the total burn surface area ( TBSA ) and the treatment methods , we randomly divided the patients into four groups . Group A ( treatment group ) : patients with less than 30 % TBSA covered with xenogenic acellular dermal matrix . Group B ( control group ) : patients with less than 30 % TBSA covered with betadine ointment gauzes . Group C ( treatment group ) : patients with more than 30 % TBSA covered with porcine acellular dermal matrix . Group D ( control group ) : patients with more than 30 % TBSA covered with betadine ointment gauzes . Serum level of C-reactive protein ( CRP ) was measured by single radial immunodiffusion method on 1 , 4 , 7 and 14 days postburn . RESULTS The serum level of CRP in group A was significantly less than that of in group B ( P < 0.05 ) on days 4 , 7 and 14 . The serum level of CRP in group C increased slowly , descended quickly and was significantly less than that of in group D on days 4 , 7 and 14 . CONCLUSION The application of xenogenic ( porcine ) acellular dermal matrix on second-degree burn wound can decrease serum level of CRP of the patients , which may play an important role in reducing SIRS and sepsis incidence . Instructions: please typing these entity words according to sentence: xenogenic ( porcine ) acellular dermal matrix, second - degree burns, burn patients, second - degree burn wounds, Seventy - two, acute second - degree burns, xenogenic acellular dermal matrix ., betadine ointment gauzes ., porcine acellular dermal matrix ., serum level of CRP Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Participant_Sample-size
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The study of inhibiting systematic inflammatory response syndrome by applying xenogenic ( porcine ) acellular dermal matrix on second-degree burns . OBJECTIVE To investigate the influence of xenogenic ( porcine ) acellular dermal matrix on the systematic inflammatory reaction syndrome ( SIRS ) , and the reaction of burn patients to tissue damage upon application to second-degree burn wounds . METHOD Seventy-two cases of patients with acute second-degree burns were enrolled in the study . According to the total burn surface area ( TBSA ) and the treatment methods , we randomly divided the patients into four groups . Group A ( treatment group ) : patients with less than 30 % TBSA covered with xenogenic acellular dermal matrix . Group B ( control group ) : patients with less than 30 % TBSA covered with betadine ointment gauzes . Group C ( treatment group ) : patients with more than 30 % TBSA covered with porcine acellular dermal matrix . Group D ( control group ) : patients with more than 30 % TBSA covered with betadine ointment gauzes . Serum level of C-reactive protein ( CRP ) was measured by single radial immunodiffusion method on 1 , 4 , 7 and 14 days postburn . RESULTS The serum level of CRP in group A was significantly less than that of in group B ( P < 0.05 ) on days 4 , 7 and 14 . The serum level of CRP in group C increased slowly , descended quickly and was significantly less than that of in group D on days 4 , 7 and 14 . CONCLUSION The application of xenogenic ( porcine ) acellular dermal matrix on second-degree burn wound can decrease serum level of CRP of the patients , which may play an important role in reducing SIRS and sepsis incidence .
[ "The", "study", "of", "inhibiting", "systematic", "inflammatory", "response", "syndrome", "by", "applying", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "second", "-", "degree", "burns", ".", "OBJECTIVE", "To", "investigate", "the", "influence", "of", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "the", "systematic", "inflammatory", "reaction", "syndrome", "(", "SIRS", ")", ",", "and", "the", "reaction", "of", "burn", "patients", "to", "tissue", "damage", "upon", "application", "to", "second", "-", "degree", "burn", "wounds", ".", "METHOD", "Seventy", "-", "two", "cases", "of", "patients", "with", "acute", "second", "-", "degree", "burns", "were", "enrolled", "in", "the", "study", ".", "According", "to", "the", "total", "burn", "surface", "area", "(", "TBSA", ")", "and", "the", "treatment", "methods", ",", "we", "randomly", "divided", "the", "patients", "into", "four", "groups", ".", "Group", "A", "(", "treatment", "group", ")", ":", "patients", "with", "less", "than", "30", "%", "TBSA", "covered", "with", "xenogenic", "acellular", "dermal", "matrix", ".", "Group", "B", "(", "control", "group", ")", ":", "patients", "with", "less", "than", "30", "%", "TBSA", "covered", "with", "betadine", "ointment", "gauzes", ".", "Group", "C", "(", "treatment", "group", ")", ":", "patients", "with", "more", "than", "30", "%", "TBSA", "covered", "with", "porcine", "acellular", "dermal", "matrix", ".", "Group", "D", "(", "control", "group", ")", ":", "patients", "with", "more", "than", "30", "%", "TBSA", "covered", "with", "betadine", "ointment", "gauzes", ".", "Serum", "level", "of", "C", "-", "reactive", "protein", "(", "CRP", ")", "was", "measured", "by", "single", "radial", "immunodiffusion", "method", "on", "1", ",", "4", ",", "7", "and", "14", "days", "postburn", ".", "RESULTS", "The", "serum", "level", "of", "CRP", "in", "group", "A", "was", "significantly", "less", "than", "that", "of", "in", "group", "B", "(", "P", "<", "0.05", ")", "on", "days", "4", ",", "7", "and", "14", ".", "The", "serum", "level", "of", "CRP", "in", "group", "C", "increased", "slowly", ",", "descended", "quickly", "and", "was", "significantly", "less", "than", "that", "of", "in", "group", "D", "on", "days", "4", ",", "7", "and", "14", ".", "CONCLUSION", "The", "application", "of", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "second", "-", "degree", "burn", "wound", "can", "decrease", "serum", "level", "of", "CRP", "of", "the", "patients", ",", "which", "may", "play", "an", "important", "role", "in", "reducing", "SIRS", "and", "sepsis", "incidence", "." ]
[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size" ]
xenogenic ( porcine ) acellular dermal matrix, second - degree burns, burn patients, second - degree burn wounds, Seventy - two, acute second - degree burns, xenogenic acellular dermal matrix ., betadine ointment gauzes ., porcine acellular dermal matrix ., serum level of CRP
30034_task2
Sentence: The study of inhibiting systematic inflammatory response syndrome by applying xenogenic ( porcine ) acellular dermal matrix on second-degree burns . OBJECTIVE To investigate the influence of xenogenic ( porcine ) acellular dermal matrix on the systematic inflammatory reaction syndrome ( SIRS ) , and the reaction of burn patients to tissue damage upon application to second-degree burn wounds . METHOD Seventy-two cases of patients with acute second-degree burns were enrolled in the study . According to the total burn surface area ( TBSA ) and the treatment methods , we randomly divided the patients into four groups . Group A ( treatment group ) : patients with less than 30 % TBSA covered with xenogenic acellular dermal matrix . Group B ( control group ) : patients with less than 30 % TBSA covered with betadine ointment gauzes . Group C ( treatment group ) : patients with more than 30 % TBSA covered with porcine acellular dermal matrix . Group D ( control group ) : patients with more than 30 % TBSA covered with betadine ointment gauzes . Serum level of C-reactive protein ( CRP ) was measured by single radial immunodiffusion method on 1 , 4 , 7 and 14 days postburn . RESULTS The serum level of CRP in group A was significantly less than that of in group B ( P < 0.05 ) on days 4 , 7 and 14 . The serum level of CRP in group C increased slowly , descended quickly and was significantly less than that of in group D on days 4 , 7 and 14 . CONCLUSION The application of xenogenic ( porcine ) acellular dermal matrix on second-degree burn wound can decrease serum level of CRP of the patients , which may play an important role in reducing SIRS and sepsis incidence . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The study of inhibiting systematic inflammatory response syndrome by applying xenogenic ( porcine ) acellular dermal matrix on second-degree burns . OBJECTIVE To investigate the influence of xenogenic ( porcine ) acellular dermal matrix on the systematic inflammatory reaction syndrome ( SIRS ) , and the reaction of burn patients to tissue damage upon application to second-degree burn wounds . METHOD Seventy-two cases of patients with acute second-degree burns were enrolled in the study . According to the total burn surface area ( TBSA ) and the treatment methods , we randomly divided the patients into four groups . Group A ( treatment group ) : patients with less than 30 % TBSA covered with xenogenic acellular dermal matrix . Group B ( control group ) : patients with less than 30 % TBSA covered with betadine ointment gauzes . Group C ( treatment group ) : patients with more than 30 % TBSA covered with porcine acellular dermal matrix . Group D ( control group ) : patients with more than 30 % TBSA covered with betadine ointment gauzes . Serum level of C-reactive protein ( CRP ) was measured by single radial immunodiffusion method on 1 , 4 , 7 and 14 days postburn . RESULTS The serum level of CRP in group A was significantly less than that of in group B ( P < 0.05 ) on days 4 , 7 and 14 . The serum level of CRP in group C increased slowly , descended quickly and was significantly less than that of in group D on days 4 , 7 and 14 . CONCLUSION The application of xenogenic ( porcine ) acellular dermal matrix on second-degree burn wound can decrease serum level of CRP of the patients , which may play an important role in reducing SIRS and sepsis incidence .
[ "The", "study", "of", "inhibiting", "systematic", "inflammatory", "response", "syndrome", "by", "applying", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "second", "-", "degree", "burns", ".", "OBJECTIVE", "To", "investigate", "the", "influence", "of", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "the", "systematic", "inflammatory", "reaction", "syndrome", "(", "SIRS", ")", ",", "and", "the", "reaction", "of", "burn", "patients", "to", "tissue", "damage", "upon", "application", "to", "second", "-", "degree", "burn", "wounds", ".", "METHOD", "Seventy", "-", "two", "cases", "of", "patients", "with", "acute", "second", "-", "degree", "burns", "were", "enrolled", "in", "the", "study", ".", "According", "to", "the", "total", "burn", "surface", "area", "(", "TBSA", ")", "and", "the", "treatment", "methods", ",", "we", "randomly", "divided", "the", "patients", "into", "four", "groups", ".", "Group", "A", "(", "treatment", "group", ")", ":", "patients", "with", "less", "than", "30", "%", "TBSA", "covered", "with", "xenogenic", "acellular", "dermal", "matrix", ".", "Group", "B", "(", "control", "group", ")", ":", "patients", "with", "less", "than", "30", "%", "TBSA", "covered", "with", "betadine", "ointment", "gauzes", ".", "Group", "C", "(", "treatment", "group", ")", ":", "patients", "with", "more", "than", "30", "%", "TBSA", "covered", "with", "porcine", "acellular", "dermal", "matrix", ".", "Group", "D", "(", "control", "group", ")", ":", "patients", "with", "more", "than", "30", "%", "TBSA", "covered", "with", "betadine", "ointment", "gauzes", ".", "Serum", "level", "of", "C", "-", "reactive", "protein", "(", "CRP", ")", "was", "measured", "by", "single", "radial", "immunodiffusion", "method", "on", "1", ",", "4", ",", "7", "and", "14", "days", "postburn", ".", "RESULTS", "The", "serum", "level", "of", "CRP", "in", "group", "A", "was", "significantly", "less", "than", "that", "of", "in", "group", "B", "(", "P", "<", "0.05", ")", "on", "days", "4", ",", "7", "and", "14", ".", "The", "serum", "level", "of", "CRP", "in", "group", "C", "increased", "slowly", ",", "descended", "quickly", "and", "was", "significantly", "less", "than", "that", "of", "in", "group", "D", "on", "days", "4", ",", "7", "and", "14", ".", "CONCLUSION", "The", "application", "of", "xenogenic", "(", "porcine", ")", "acellular", "dermal", "matrix", "on", "second", "-", "degree", "burn", "wound", "can", "decrease", "serum", "level", "of", "CRP", "of", "the", "patients", ",", "which", "may", "play", "an", "important", "role", "in", "reducing", "SIRS", "and", "sepsis", "incidence", "." ]
[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Participant_Sample-size" ]
MDMA - assisted therapy is a Intervention_Physical, social anxiety in autistic is a Participant_Condition, 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy is a Intervention_Pharmacological, social anxiety in autistic adults commenced in the spring of 2014 is a Participant_Condition, Serious Adverse Events ( SAEs ) is a Outcome_Adverse-effects, MDMA has been administered is a Participant_Condition, 1133 individuals is a Participant_Sample-size, unexpected drug - related SAEs is a Outcome_Adverse-effects, MDMA - assisted therapeutic interventions is a Intervention_Physical, social adaptability is a Outcome_Mental, openness and introspection is a Outcome_Mental, adverse event frequency is a Outcome_Adverse-effects, the risk / benefit ratio of MDMA is a Outcome_Physical
70764_task0
Sentence: MDMA-assisted therapy : A new treatment model for social anxiety in autistic adults . The first study of 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014 . The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population . Serious Adverse Events ( SAEs ) involving the administration of MDMA in clinical trials have been rare and non-life threatening . To date , MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations . Now that safety parameters for limited use of MDMA in clinical settings have been established , a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population . As in the case with classic hallucinogens and other psychedelic drugs , MDMA catalyzes shifts toward openness and introspection that do not require ongoing administration to achieve lasting benefits . This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA , which may provide a significant advantage over medications that require daily dosing . Consequently , clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
MDMA-assisted therapy : A new treatment model for social anxiety in autistic adults . The first study of 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014 . The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population . Serious Adverse Events ( SAEs ) involving the administration of MDMA in clinical trials have been rare and non-life threatening . To date , MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations . Now that safety parameters for limited use of MDMA in clinical settings have been established , a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population . As in the case with classic hallucinogens and other psychedelic drugs , MDMA catalyzes shifts toward openness and introspection that do not require ongoing administration to achieve lasting benefits . This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA , which may provide a significant advantage over medications that require daily dosing . Consequently , clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol .
[ "MDMA", "-", "assisted", "therapy", ":", "A", "new", "treatment", "model", "for", "social", "anxiety", "in", "autistic", "adults", ".", "The", "first", "study", "of", "3,4-methylenedioxymethamphetamine", "(", "MDMA", ")", "-assisted", "therapy", "for", "the", "treatment", "of", "social", "anxiety", "in", "autistic", "adults", "commenced", "in", "the", "spring", "of", "2014", ".", "The", "search", "for", "psychotherapeutic", "options", "for", "autistic", "individuals", "is", "imperative", "considering", "the", "lack", "of", "effective", "conventional", "treatments", "for", "mental", "health", "diagnoses", "that", "are", "common", "in", "this", "population", ".", "Serious", "Adverse", "Events", "(", "SAEs", ")", "involving", "the", "administration", "of", "MDMA", "in", "clinical", "trials", "have", "been", "rare", "and", "non", "-", "life", "threatening", ".", "To", "date", ",", "MDMA", "has", "been", "administered", "to", "over", "1133", "individuals", "for", "research", "purposes", "without", "the", "occurrence", "of", "unexpected", "drug", "-", "related", "SAEs", "that", "require", "expedited", "reporting", "per", "FDA", "regulations", ".", "Now", "that", "safety", "parameters", "for", "limited", "use", "of", "MDMA", "in", "clinical", "settings", "have", "been", "established", ",", "a", "case", "can", "be", "made", "to", "further", "develop", "MDMA", "-", "assisted", "therapeutic", "interventions", "that", "could", "support", "autistic", "adults", "in", "increasing", "social", "adaptability", "among", "the", "typically", "developing", "population", ".", "As", "in", "the", "case", "with", "classic", "hallucinogens", "and", "other", "psychedelic", "drugs", ",", "MDMA", "catalyzes", "shifts", "toward", "openness", "and", "introspection", "that", "do", "not", "require", "ongoing", "administration", "to", "achieve", "lasting", "benefits", ".", "This", "infrequent", "dosing", "mitigates", "adverse", "event", "frequency", "and", "improves", "the", "risk", "/", "benefit", "ratio", "of", "MDMA", ",", "which", "may", "provide", "a", "significant", "advantage", "over", "medications", "that", "require", "daily", "dosing", ".", "Consequently", ",", "clinicians", "could", "employ", "new", "treatment", "models", "for", "social", "anxiety", "or", "similar", "types", "of", "distress", "administering", "MDMA", "on", "one", "to", "several", "occasions", "within", "the", "context", "of", "a", "supportive", "and", "integrative", "psychotherapy", "protocol", "." ]
[ "Participant_Condition", "Intervention_Pharmacological", "Intervention_Physical", "Outcome_Adverse-effects", "Outcome_Physical", "Outcome_Mental", "Participant_Sample-size" ]
MDMA - assisted therapy is a Intervention_Physical, social anxiety in autistic is a Participant_Condition, 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy is a Intervention_Pharmacological, social anxiety in autistic adults commenced in the spring of 2014 is a Participant_Condition, Serious Adverse Events ( SAEs ) is a Outcome_Adverse-effects, MDMA has been administered is a Participant_Condition, 1133 individuals is a Participant_Sample-size, unexpected drug - related SAEs is a Outcome_Adverse-effects, MDMA - assisted therapeutic interventions is a Intervention_Physical, social adaptability is a Outcome_Mental, openness and introspection is a Outcome_Mental, adverse event frequency is a Outcome_Adverse-effects, the risk / benefit ratio of MDMA is a Outcome_Physical
70764_task1
Sentence: MDMA-assisted therapy : A new treatment model for social anxiety in autistic adults . The first study of 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014 . The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population . Serious Adverse Events ( SAEs ) involving the administration of MDMA in clinical trials have been rare and non-life threatening . To date , MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations . Now that safety parameters for limited use of MDMA in clinical settings have been established , a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population . As in the case with classic hallucinogens and other psychedelic drugs , MDMA catalyzes shifts toward openness and introspection that do not require ongoing administration to achieve lasting benefits . This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA , which may provide a significant advantage over medications that require daily dosing . Consequently , clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol . Instructions: please typing these entity words according to sentence: MDMA - assisted therapy, social anxiety in autistic, 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy, social anxiety in autistic adults commenced in the spring of 2014, Serious Adverse Events ( SAEs ), MDMA has been administered, 1133 individuals, unexpected drug - related SAEs, MDMA - assisted therapeutic interventions, social adaptability, openness and introspection, adverse event frequency, the risk / benefit ratio of MDMA Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
MDMA-assisted therapy : A new treatment model for social anxiety in autistic adults . The first study of 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014 . The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population . Serious Adverse Events ( SAEs ) involving the administration of MDMA in clinical trials have been rare and non-life threatening . To date , MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations . Now that safety parameters for limited use of MDMA in clinical settings have been established , a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population . As in the case with classic hallucinogens and other psychedelic drugs , MDMA catalyzes shifts toward openness and introspection that do not require ongoing administration to achieve lasting benefits . This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA , which may provide a significant advantage over medications that require daily dosing . Consequently , clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol .
[ "MDMA", "-", "assisted", "therapy", ":", "A", "new", "treatment", "model", "for", "social", "anxiety", "in", "autistic", "adults", ".", "The", "first", "study", "of", "3,4-methylenedioxymethamphetamine", "(", "MDMA", ")", "-assisted", "therapy", "for", "the", "treatment", "of", "social", "anxiety", "in", "autistic", "adults", "commenced", "in", "the", "spring", "of", "2014", ".", "The", "search", "for", "psychotherapeutic", "options", "for", "autistic", "individuals", "is", "imperative", "considering", "the", "lack", "of", "effective", "conventional", "treatments", "for", "mental", "health", "diagnoses", "that", "are", "common", "in", "this", "population", ".", "Serious", "Adverse", "Events", "(", "SAEs", ")", "involving", "the", "administration", "of", "MDMA", "in", "clinical", "trials", "have", "been", "rare", "and", "non", "-", "life", "threatening", ".", "To", "date", ",", "MDMA", "has", "been", "administered", "to", "over", "1133", "individuals", "for", "research", "purposes", "without", "the", "occurrence", "of", "unexpected", "drug", "-", "related", "SAEs", "that", "require", "expedited", "reporting", "per", "FDA", "regulations", ".", "Now", "that", "safety", "parameters", "for", "limited", "use", "of", "MDMA", "in", "clinical", "settings", "have", "been", "established", ",", "a", "case", "can", "be", "made", "to", "further", "develop", "MDMA", "-", "assisted", "therapeutic", "interventions", "that", "could", "support", "autistic", "adults", "in", "increasing", "social", "adaptability", "among", "the", "typically", "developing", "population", ".", "As", "in", "the", "case", "with", "classic", "hallucinogens", "and", "other", "psychedelic", "drugs", ",", "MDMA", "catalyzes", "shifts", "toward", "openness", "and", "introspection", "that", "do", "not", "require", "ongoing", "administration", "to", "achieve", "lasting", "benefits", ".", "This", "infrequent", "dosing", "mitigates", "adverse", "event", "frequency", "and", "improves", "the", "risk", "/", "benefit", "ratio", "of", "MDMA", ",", "which", "may", "provide", "a", "significant", "advantage", "over", "medications", "that", "require", "daily", "dosing", ".", "Consequently", ",", "clinicians", "could", "employ", "new", "treatment", "models", "for", "social", "anxiety", "or", "similar", "types", "of", "distress", "administering", "MDMA", "on", "one", "to", "several", "occasions", "within", "the", "context", "of", "a", "supportive", "and", "integrative", "psychotherapy", "protocol", "." ]
[ "Participant_Condition", "Intervention_Pharmacological", "Intervention_Physical", "Outcome_Adverse-effects", "Outcome_Physical", "Outcome_Mental", "Participant_Sample-size" ]
MDMA - assisted therapy, social anxiety in autistic, 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy, social anxiety in autistic adults commenced in the spring of 2014, Serious Adverse Events ( SAEs ), MDMA has been administered, 1133 individuals, unexpected drug - related SAEs, MDMA - assisted therapeutic interventions, social adaptability, openness and introspection, adverse event frequency, the risk / benefit ratio of MDMA
70764_task2
Sentence: MDMA-assisted therapy : A new treatment model for social anxiety in autistic adults . The first study of 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014 . The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population . Serious Adverse Events ( SAEs ) involving the administration of MDMA in clinical trials have been rare and non-life threatening . To date , MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations . Now that safety parameters for limited use of MDMA in clinical settings have been established , a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population . As in the case with classic hallucinogens and other psychedelic drugs , MDMA catalyzes shifts toward openness and introspection that do not require ongoing administration to achieve lasting benefits . This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA , which may provide a significant advantage over medications that require daily dosing . Consequently , clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
MDMA-assisted therapy : A new treatment model for social anxiety in autistic adults . The first study of 3,4-methylenedioxymethamphetamine ( MDMA ) -assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014 . The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population . Serious Adverse Events ( SAEs ) involving the administration of MDMA in clinical trials have been rare and non-life threatening . To date , MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations . Now that safety parameters for limited use of MDMA in clinical settings have been established , a case can be made to further develop MDMA-assisted therapeutic interventions that could support autistic adults in increasing social adaptability among the typically developing population . As in the case with classic hallucinogens and other psychedelic drugs , MDMA catalyzes shifts toward openness and introspection that do not require ongoing administration to achieve lasting benefits . This infrequent dosing mitigates adverse event frequency and improves the risk/benefit ratio of MDMA , which may provide a significant advantage over medications that require daily dosing . Consequently , clinicians could employ new treatment models for social anxiety or similar types of distress administering MDMA on one to several occasions within the context of a supportive and integrative psychotherapy protocol .
[ "MDMA", "-", "assisted", "therapy", ":", "A", "new", "treatment", "model", "for", "social", "anxiety", "in", "autistic", "adults", ".", "The", "first", "study", "of", "3,4-methylenedioxymethamphetamine", "(", "MDMA", ")", "-assisted", "therapy", "for", "the", "treatment", "of", "social", "anxiety", "in", "autistic", "adults", "commenced", "in", "the", "spring", "of", "2014", ".", "The", "search", "for", "psychotherapeutic", "options", "for", "autistic", "individuals", "is", "imperative", "considering", "the", "lack", "of", "effective", "conventional", "treatments", "for", "mental", "health", "diagnoses", "that", "are", "common", "in", "this", "population", ".", "Serious", "Adverse", "Events", "(", "SAEs", ")", "involving", "the", "administration", "of", "MDMA", "in", "clinical", "trials", "have", "been", "rare", "and", "non", "-", "life", "threatening", ".", "To", "date", ",", "MDMA", "has", "been", "administered", "to", "over", "1133", "individuals", "for", "research", "purposes", "without", "the", "occurrence", "of", "unexpected", "drug", "-", "related", "SAEs", "that", "require", "expedited", "reporting", "per", "FDA", "regulations", ".", "Now", "that", "safety", "parameters", "for", "limited", "use", "of", "MDMA", "in", "clinical", "settings", "have", "been", "established", ",", "a", "case", "can", "be", "made", "to", "further", "develop", "MDMA", "-", "assisted", "therapeutic", "interventions", "that", "could", "support", "autistic", "adults", "in", "increasing", "social", "adaptability", "among", "the", "typically", "developing", "population", ".", "As", "in", "the", "case", "with", "classic", "hallucinogens", "and", "other", "psychedelic", "drugs", ",", "MDMA", "catalyzes", "shifts", "toward", "openness", "and", "introspection", "that", "do", "not", "require", "ongoing", "administration", "to", "achieve", "lasting", "benefits", ".", "This", "infrequent", "dosing", "mitigates", "adverse", "event", "frequency", "and", "improves", "the", "risk", "/", "benefit", "ratio", "of", "MDMA", ",", "which", "may", "provide", "a", "significant", "advantage", "over", "medications", "that", "require", "daily", "dosing", ".", "Consequently", ",", "clinicians", "could", "employ", "new", "treatment", "models", "for", "social", "anxiety", "or", "similar", "types", "of", "distress", "administering", "MDMA", "on", "one", "to", "several", "occasions", "within", "the", "context", "of", "a", "supportive", "and", "integrative", "psychotherapy", "protocol", "." ]
[ "Participant_Condition", "Intervention_Pharmacological", "Intervention_Physical", "Outcome_Adverse-effects", "Outcome_Physical", "Outcome_Mental", "Participant_Sample-size" ]
Chondrosarcomas is an umlsterm, malignant is an umlsterm, bone tumors is an umlsterm, chondrosarcoma is an umlsterm, chondrosarcomas is an umlsterm, chondrosarcoma is an umlsterm, chondroma is an umlsterm, chondrosarcoma is an umlsterm, chondrosarcoma is an umlsterm, institutes is an umlsterm, therapy is an umlsterm, Bone Tumor is an umlsterm, Registry is an umlsterm, tumors is an umlsterm, criteria is an umlsterm, chondrosarcomas is an umlsterm, classification is an umlsterm, classifications is an umlsterm, chondrosarcomas is an umlsterm, growth is an umlsterm, criteria is an umlsterm, nuclei is an umlsterm, chromatin is an umlsterm, chondrosarcomas is an umlsterm, nuclei is an umlsterm, chromatin is an umlsterm, chondrocytes is an umlsterm, nuclei is an umlsterm, forms is an umlsterm, mitoses is an umlsterm, methods is an umlsterm, therapeutic is an umlsterm, classification is an umlsterm, curettage is an umlsterm, tumors is an umlsterm, method is an umlsterm, diagnostic is an umlsterm, chondrosarcomas is an umlsterm
DerPathologe.60170018.eng.abstr_task0
Sentence: Chondrosarcomas are frequent malignant bone tumors . Aside from different subtypes , such as dedifferentiated , mesenchymal and clear-cell chondrosarcoma , chondrosarcomas ( classical chondrosarcoma ) show different grades of differentiation . The borderline between chondroma and classical chondrosarcoma is not clearly defined . The same chondrosarcoma can be graded differently at different institutes . Standardized therapy concepts are currently in preparation . As the Hamburg Bone Tumor Registry is often consulted for chondrogenic tumors , the histological criteria are based on a series of 74 chondrosarcomas recorded there . The emphasis has been laid on a classification which can be used in daily routine and which is reproducible and in agreement with the classifications of other international groups . Grade I chondrosarcomas ( 50 % ) can be distinguished only by growth criteria . The nuclei are small and show high chromatin density . Grade II chondrosarcomas ( 42 % ) have medium-sized , regular nuclei with loose chromatin structure . The chondrocytes of grade III cases ( 8 % ) show polymorphic nuclei . Binucleas forms , the number of mitoses and cellularity all show considerable overlap for all three grades . So far there are no immunohistological and molecular biological methods for reliable differentiation . The therapeutic consequences of the classification into grades are thorough curettage , in the case of grade I tumors , or complete resection , for grade II and III cases . The long-term results , however , need to be confirmed by a larger number of cases . From 1991 to 1995 the method was applied and proved to be easily practicable in daily diagnostic routine . Some 104 cases of classical chondrosarcomas ( grade I 53 % , grade II 39 % , grade III 8 % ) were analyzed . Two pathologists both assigned the same grade in 90 % of cases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Chondrosarcomas are frequent malignant bone tumors . Aside from different subtypes , such as dedifferentiated , mesenchymal and clear-cell chondrosarcoma , chondrosarcomas ( classical chondrosarcoma ) show different grades of differentiation . The borderline between chondroma and classical chondrosarcoma is not clearly defined . The same chondrosarcoma can be graded differently at different institutes . Standardized therapy concepts are currently in preparation . As the Hamburg Bone Tumor Registry is often consulted for chondrogenic tumors , the histological criteria are based on a series of 74 chondrosarcomas recorded there . The emphasis has been laid on a classification which can be used in daily routine and which is reproducible and in agreement with the classifications of other international groups . Grade I chondrosarcomas ( 50 % ) can be distinguished only by growth criteria . The nuclei are small and show high chromatin density . Grade II chondrosarcomas ( 42 % ) have medium-sized , regular nuclei with loose chromatin structure . The chondrocytes of grade III cases ( 8 % ) show polymorphic nuclei . Binucleas forms , the number of mitoses and cellularity all show considerable overlap for all three grades . So far there are no immunohistological and molecular biological methods for reliable differentiation . The therapeutic consequences of the classification into grades are thorough curettage , in the case of grade I tumors , or complete resection , for grade II and III cases . The long-term results , however , need to be confirmed by a larger number of cases . From 1991 to 1995 the method was applied and proved to be easily practicable in daily diagnostic routine . Some 104 cases of classical chondrosarcomas ( grade I 53 % , grade II 39 % , grade III 8 % ) were analyzed . Two pathologists both assigned the same grade in 90 % of cases .
[ "Chondrosarcomas", "are", "frequent", "malignant", "bone", "tumors", ".", "Aside", "from", "different", "subtypes", ",", "such", "as", "dedifferentiated", ",", "mesenchymal", "and", "clear", "-", "cell", "chondrosarcoma", ",", "chondrosarcomas", "(", "classical", "chondrosarcoma", ")", "show", "different", "grades", "of", "differentiation", ".", "The", "borderline", "between", "chondroma", "and", "classical", "chondrosarcoma", "is", "not", "clearly", "defined", ".", "The", "same", "chondrosarcoma", "can", "be", "graded", "differently", "at", "different", "institutes", ".", "Standardized", "therapy", "concepts", "are", "currently", "in", "preparation", ".", "As", "the", "Hamburg", "Bone", "Tumor", "Registry", "is", "often", "consulted", "for", "chondrogenic", "tumors", ",", "the", "histological", "criteria", "are", "based", "on", "a", "series", "of", "74", "chondrosarcomas", "recorded", "there", ".", "The", "emphasis", "has", "been", "laid", "on", "a", "classification", "which", "can", "be", "used", "in", "daily", "routine", "and", "which", "is", "reproducible", "and", "in", "agreement", "with", "the", "classifications", "of", "other", "international", "groups", ".", "Grade", "I", "chondrosarcomas", "(", "50", "%", ")", "can", "be", "distinguished", "only", "by", "growth", "criteria", ".", "The", "nuclei", "are", "small", "and", "show", "high", "chromatin", "density", ".", "Grade", "II", "chondrosarcomas", "(", "42", "%", ")", "have", "medium", "-", "sized", ",", "regular", "nuclei", "with", "loose", "chromatin", "structure", ".", "The", "chondrocytes", "of", "grade", "III", "cases", "(", "8", "%", ")", "show", "polymorphic", "nuclei", ".", "Binucleas", "forms", ",", "the", "number", "of", "mitoses", "and", "cellularity", "all", "show", "considerable", "overlap", "for", "all", "three", "grades", ".", "So", "far", "there", "are", "no", "immunohistological", "and", "molecular", "biological", "methods", "for", "reliable", "differentiation", ".", "The", "therapeutic", "consequences", "of", "the", "classification", "into", "grades", "are", "thorough", "curettage", ",", "in", "the", "case", "of", "grade", "I", "tumors", ",", "or", "complete", "resection", ",", "for", "grade", "II", "and", "III", "cases", ".", "The", "long", "-", "term", "results", ",", "however", ",", "need", "to", "be", "confirmed", "by", "a", "larger", "number", "of", "cases", ".", "From", "1991", "to", "1995", "the", "method", "was", "applied", "and", "proved", "to", "be", "easily", "practicable", "in", "daily", "diagnostic", "routine", ".", "Some", "104", "cases", "of", "classical", "chondrosarcomas", "(", "grade", "I", "53", "%", ",", "grade", "II", "39", "%", ",", "grade", "III", "8", "%", ")", "were", "analyzed", ".", "Two", "pathologists", "both", "assigned", "the", "same", "grade", "in", "90", "%", "of", "cases", "." ]
[ "umlsterm" ]
Chondrosarcomas is an umlsterm, malignant is an umlsterm, bone tumors is an umlsterm, chondrosarcoma is an umlsterm, chondrosarcomas is an umlsterm, chondrosarcoma is an umlsterm, chondroma is an umlsterm, chondrosarcoma is an umlsterm, chondrosarcoma is an umlsterm, institutes is an umlsterm, therapy is an umlsterm, Bone Tumor is an umlsterm, Registry is an umlsterm, tumors is an umlsterm, criteria is an umlsterm, chondrosarcomas is an umlsterm, classification is an umlsterm, classifications is an umlsterm, chondrosarcomas is an umlsterm, growth is an umlsterm, criteria is an umlsterm, nuclei is an umlsterm, chromatin is an umlsterm, chondrosarcomas is an umlsterm, nuclei is an umlsterm, chromatin is an umlsterm, chondrocytes is an umlsterm, nuclei is an umlsterm, forms is an umlsterm, mitoses is an umlsterm, methods is an umlsterm, therapeutic is an umlsterm, classification is an umlsterm, curettage is an umlsterm, tumors is an umlsterm, method is an umlsterm, diagnostic is an umlsterm, chondrosarcomas is an umlsterm
DerPathologe.60170018.eng.abstr_task1
Sentence: Chondrosarcomas are frequent malignant bone tumors . Aside from different subtypes , such as dedifferentiated , mesenchymal and clear-cell chondrosarcoma , chondrosarcomas ( classical chondrosarcoma ) show different grades of differentiation . The borderline between chondroma and classical chondrosarcoma is not clearly defined . The same chondrosarcoma can be graded differently at different institutes . Standardized therapy concepts are currently in preparation . As the Hamburg Bone Tumor Registry is often consulted for chondrogenic tumors , the histological criteria are based on a series of 74 chondrosarcomas recorded there . The emphasis has been laid on a classification which can be used in daily routine and which is reproducible and in agreement with the classifications of other international groups . Grade I chondrosarcomas ( 50 % ) can be distinguished only by growth criteria . The nuclei are small and show high chromatin density . Grade II chondrosarcomas ( 42 % ) have medium-sized , regular nuclei with loose chromatin structure . The chondrocytes of grade III cases ( 8 % ) show polymorphic nuclei . Binucleas forms , the number of mitoses and cellularity all show considerable overlap for all three grades . So far there are no immunohistological and molecular biological methods for reliable differentiation . The therapeutic consequences of the classification into grades are thorough curettage , in the case of grade I tumors , or complete resection , for grade II and III cases . The long-term results , however , need to be confirmed by a larger number of cases . From 1991 to 1995 the method was applied and proved to be easily practicable in daily diagnostic routine . Some 104 cases of classical chondrosarcomas ( grade I 53 % , grade II 39 % , grade III 8 % ) were analyzed . Two pathologists both assigned the same grade in 90 % of cases . Instructions: please typing these entity words according to sentence: Chondrosarcomas, malignant, bone tumors, chondrosarcoma, chondrosarcomas, chondrosarcoma, chondroma, chondrosarcoma, chondrosarcoma, institutes, therapy, Bone Tumor, Registry, tumors, criteria, chondrosarcomas, classification, classifications, chondrosarcomas, growth, criteria, nuclei, chromatin, chondrosarcomas, nuclei, chromatin, chondrocytes, nuclei, forms, mitoses, methods, therapeutic, classification, curettage, tumors, method, diagnostic, chondrosarcomas Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Chondrosarcomas are frequent malignant bone tumors . Aside from different subtypes , such as dedifferentiated , mesenchymal and clear-cell chondrosarcoma , chondrosarcomas ( classical chondrosarcoma ) show different grades of differentiation . The borderline between chondroma and classical chondrosarcoma is not clearly defined . The same chondrosarcoma can be graded differently at different institutes . Standardized therapy concepts are currently in preparation . As the Hamburg Bone Tumor Registry is often consulted for chondrogenic tumors , the histological criteria are based on a series of 74 chondrosarcomas recorded there . The emphasis has been laid on a classification which can be used in daily routine and which is reproducible and in agreement with the classifications of other international groups . Grade I chondrosarcomas ( 50 % ) can be distinguished only by growth criteria . The nuclei are small and show high chromatin density . Grade II chondrosarcomas ( 42 % ) have medium-sized , regular nuclei with loose chromatin structure . The chondrocytes of grade III cases ( 8 % ) show polymorphic nuclei . Binucleas forms , the number of mitoses and cellularity all show considerable overlap for all three grades . So far there are no immunohistological and molecular biological methods for reliable differentiation . The therapeutic consequences of the classification into grades are thorough curettage , in the case of grade I tumors , or complete resection , for grade II and III cases . The long-term results , however , need to be confirmed by a larger number of cases . From 1991 to 1995 the method was applied and proved to be easily practicable in daily diagnostic routine . Some 104 cases of classical chondrosarcomas ( grade I 53 % , grade II 39 % , grade III 8 % ) were analyzed . Two pathologists both assigned the same grade in 90 % of cases .
[ "Chondrosarcomas", "are", "frequent", "malignant", "bone", "tumors", ".", "Aside", "from", "different", "subtypes", ",", "such", "as", "dedifferentiated", ",", "mesenchymal", "and", "clear", "-", "cell", "chondrosarcoma", ",", "chondrosarcomas", "(", "classical", "chondrosarcoma", ")", "show", "different", "grades", "of", "differentiation", ".", "The", "borderline", "between", "chondroma", "and", "classical", "chondrosarcoma", "is", "not", "clearly", "defined", ".", "The", "same", "chondrosarcoma", "can", "be", "graded", "differently", "at", "different", "institutes", ".", "Standardized", "therapy", "concepts", "are", "currently", "in", "preparation", ".", "As", "the", "Hamburg", "Bone", "Tumor", "Registry", "is", "often", "consulted", "for", "chondrogenic", "tumors", ",", "the", "histological", "criteria", "are", "based", "on", "a", "series", "of", "74", "chondrosarcomas", "recorded", "there", ".", "The", "emphasis", "has", "been", "laid", "on", "a", "classification", "which", "can", "be", "used", "in", "daily", "routine", "and", "which", "is", "reproducible", "and", "in", "agreement", "with", "the", "classifications", "of", "other", "international", "groups", ".", "Grade", "I", "chondrosarcomas", "(", "50", "%", ")", "can", "be", "distinguished", "only", "by", "growth", "criteria", ".", "The", "nuclei", "are", "small", "and", "show", "high", "chromatin", "density", ".", "Grade", "II", "chondrosarcomas", "(", "42", "%", ")", "have", "medium", "-", "sized", ",", "regular", "nuclei", "with", "loose", "chromatin", "structure", ".", "The", "chondrocytes", "of", "grade", "III", "cases", "(", "8", "%", ")", "show", "polymorphic", "nuclei", ".", "Binucleas", "forms", ",", "the", "number", "of", "mitoses", "and", "cellularity", "all", "show", "considerable", "overlap", "for", "all", "three", "grades", ".", "So", "far", "there", "are", "no", "immunohistological", "and", "molecular", "biological", "methods", "for", "reliable", "differentiation", ".", "The", "therapeutic", "consequences", "of", "the", "classification", "into", "grades", "are", "thorough", "curettage", ",", "in", "the", "case", "of", "grade", "I", "tumors", ",", "or", "complete", "resection", ",", "for", "grade", "II", "and", "III", "cases", ".", "The", "long", "-", "term", "results", ",", "however", ",", "need", "to", "be", "confirmed", "by", "a", "larger", "number", "of", "cases", ".", "From", "1991", "to", "1995", "the", "method", "was", "applied", "and", "proved", "to", "be", "easily", "practicable", "in", "daily", "diagnostic", "routine", ".", "Some", "104", "cases", "of", "classical", "chondrosarcomas", "(", "grade", "I", "53", "%", ",", "grade", "II", "39", "%", ",", "grade", "III", "8", "%", ")", "were", "analyzed", ".", "Two", "pathologists", "both", "assigned", "the", "same", "grade", "in", "90", "%", "of", "cases", "." ]
[ "umlsterm" ]
Chondrosarcomas, malignant, bone tumors, chondrosarcoma, chondrosarcomas, chondrosarcoma, chondroma, chondrosarcoma, chondrosarcoma, institutes, therapy, Bone Tumor, Registry, tumors, criteria, chondrosarcomas, classification, classifications, chondrosarcomas, growth, criteria, nuclei, chromatin, chondrosarcomas, nuclei, chromatin, chondrocytes, nuclei, forms, mitoses, methods, therapeutic, classification, curettage, tumors, method, diagnostic, chondrosarcomas
DerPathologe.60170018.eng.abstr_task2
Sentence: Chondrosarcomas are frequent malignant bone tumors . Aside from different subtypes , such as dedifferentiated , mesenchymal and clear-cell chondrosarcoma , chondrosarcomas ( classical chondrosarcoma ) show different grades of differentiation . The borderline between chondroma and classical chondrosarcoma is not clearly defined . The same chondrosarcoma can be graded differently at different institutes . Standardized therapy concepts are currently in preparation . As the Hamburg Bone Tumor Registry is often consulted for chondrogenic tumors , the histological criteria are based on a series of 74 chondrosarcomas recorded there . The emphasis has been laid on a classification which can be used in daily routine and which is reproducible and in agreement with the classifications of other international groups . Grade I chondrosarcomas ( 50 % ) can be distinguished only by growth criteria . The nuclei are small and show high chromatin density . Grade II chondrosarcomas ( 42 % ) have medium-sized , regular nuclei with loose chromatin structure . The chondrocytes of grade III cases ( 8 % ) show polymorphic nuclei . Binucleas forms , the number of mitoses and cellularity all show considerable overlap for all three grades . So far there are no immunohistological and molecular biological methods for reliable differentiation . The therapeutic consequences of the classification into grades are thorough curettage , in the case of grade I tumors , or complete resection , for grade II and III cases . The long-term results , however , need to be confirmed by a larger number of cases . From 1991 to 1995 the method was applied and proved to be easily practicable in daily diagnostic routine . Some 104 cases of classical chondrosarcomas ( grade I 53 % , grade II 39 % , grade III 8 % ) were analyzed . Two pathologists both assigned the same grade in 90 % of cases . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Chondrosarcomas are frequent malignant bone tumors . Aside from different subtypes , such as dedifferentiated , mesenchymal and clear-cell chondrosarcoma , chondrosarcomas ( classical chondrosarcoma ) show different grades of differentiation . The borderline between chondroma and classical chondrosarcoma is not clearly defined . The same chondrosarcoma can be graded differently at different institutes . Standardized therapy concepts are currently in preparation . As the Hamburg Bone Tumor Registry is often consulted for chondrogenic tumors , the histological criteria are based on a series of 74 chondrosarcomas recorded there . The emphasis has been laid on a classification which can be used in daily routine and which is reproducible and in agreement with the classifications of other international groups . Grade I chondrosarcomas ( 50 % ) can be distinguished only by growth criteria . The nuclei are small and show high chromatin density . Grade II chondrosarcomas ( 42 % ) have medium-sized , regular nuclei with loose chromatin structure . The chondrocytes of grade III cases ( 8 % ) show polymorphic nuclei . Binucleas forms , the number of mitoses and cellularity all show considerable overlap for all three grades . So far there are no immunohistological and molecular biological methods for reliable differentiation . The therapeutic consequences of the classification into grades are thorough curettage , in the case of grade I tumors , or complete resection , for grade II and III cases . The long-term results , however , need to be confirmed by a larger number of cases . From 1991 to 1995 the method was applied and proved to be easily practicable in daily diagnostic routine . Some 104 cases of classical chondrosarcomas ( grade I 53 % , grade II 39 % , grade III 8 % ) were analyzed . Two pathologists both assigned the same grade in 90 % of cases .
[ "Chondrosarcomas", "are", "frequent", "malignant", "bone", "tumors", ".", "Aside", "from", "different", "subtypes", ",", "such", "as", "dedifferentiated", ",", "mesenchymal", "and", "clear", "-", "cell", "chondrosarcoma", ",", "chondrosarcomas", "(", "classical", "chondrosarcoma", ")", "show", "different", "grades", "of", "differentiation", ".", "The", "borderline", "between", "chondroma", "and", "classical", "chondrosarcoma", "is", "not", "clearly", "defined", ".", "The", "same", "chondrosarcoma", "can", "be", "graded", "differently", "at", "different", "institutes", ".", "Standardized", "therapy", "concepts", "are", "currently", "in", "preparation", ".", "As", "the", "Hamburg", "Bone", "Tumor", "Registry", "is", "often", "consulted", "for", "chondrogenic", "tumors", ",", "the", "histological", "criteria", "are", "based", "on", "a", "series", "of", "74", "chondrosarcomas", "recorded", "there", ".", "The", "emphasis", "has", "been", "laid", "on", "a", "classification", "which", "can", "be", "used", "in", "daily", "routine", "and", "which", "is", "reproducible", "and", "in", "agreement", "with", "the", "classifications", "of", "other", "international", "groups", ".", "Grade", "I", "chondrosarcomas", "(", "50", "%", ")", "can", "be", "distinguished", "only", "by", "growth", "criteria", ".", "The", "nuclei", "are", "small", "and", "show", "high", "chromatin", "density", ".", "Grade", "II", "chondrosarcomas", "(", "42", "%", ")", "have", "medium", "-", "sized", ",", "regular", "nuclei", "with", "loose", "chromatin", "structure", ".", "The", "chondrocytes", "of", "grade", "III", "cases", "(", "8", "%", ")", "show", "polymorphic", "nuclei", ".", "Binucleas", "forms", ",", "the", "number", "of", "mitoses", "and", "cellularity", "all", "show", "considerable", "overlap", "for", "all", "three", "grades", ".", "So", "far", "there", "are", "no", "immunohistological", "and", "molecular", "biological", "methods", "for", "reliable", "differentiation", ".", "The", "therapeutic", "consequences", "of", "the", "classification", "into", "grades", "are", "thorough", "curettage", ",", "in", "the", "case", "of", "grade", "I", "tumors", ",", "or", "complete", "resection", ",", "for", "grade", "II", "and", "III", "cases", ".", "The", "long", "-", "term", "results", ",", "however", ",", "need", "to", "be", "confirmed", "by", "a", "larger", "number", "of", "cases", ".", "From", "1991", "to", "1995", "the", "method", "was", "applied", "and", "proved", "to", "be", "easily", "practicable", "in", "daily", "diagnostic", "routine", ".", "Some", "104", "cases", "of", "classical", "chondrosarcomas", "(", "grade", "I", "53", "%", ",", "grade", "II", "39", "%", ",", "grade", "III", "8", "%", ")", "were", "analyzed", ".", "Two", "pathologists", "both", "assigned", "the", "same", "grade", "in", "90", "%", "of", "cases", "." ]
[ "umlsterm" ]
laryngectomy is a Intervention_Physical, sound - producing voice prosthesis is a Intervention_Other, improve the voice quality is a Outcome_Physical, female is a Participant_Sex, laryngectomees is a Participant_Condition, laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment is a Participant_Condition, pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . is a Outcome_Physical, pneumatic sound source is a Intervention_Other, six is a Participant_Sample-size, speech rate , maximal phonation time , perceptual voice evaluation of read - aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self - assessment by the patients . is a Outcome_Physical, extensive acoustical and is a Outcome_Other, aerodynamic in vivo registrations is a Outcome_Physical, newly developed data acquisition system . is a Outcome_Other, laryngectomees with a hypotonic PE segment is a Participant_Condition, improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation is a Outcome_Physical, feasible is a Outcome_Other
5514_task0
Sentence: Alternative voice after laryngectomy using a sound-producing voice prosthesis . OBJECTIVE To improve the voice quality of female laryngectomees and/or laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment by means of a pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . STUDY DESIGN Experimental , randomized , crossover trial . METHODS The new sound source consists of a single silicone lip , which performs an oscillatory movement driven by expired pulmonary air flowing along the outward-striking lip through the TE shunt valve . A prototype of this pneumatic sound source is evaluated in vitro and in six laryngectomees . In vivo evaluation includes speech rate , maximal phonation time , perceptual voice evaluation of read-aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self-assessment by the patients . Moreover , extensive acoustical and aerodynamic in vivo registrations are performed using a newly developed data acquisition system . RESULTS The current prototype seems beneficial in female laryngectomees with a hypotonic PE segment only . For them the sound-producing voice prosthesis improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation of this prosthetic voice is possible , yet limited . CONCLUSIONS The mechanism is feasible and does not result in unacceptable airflow resistance . For this new mechanism of alaryngeal voice to become an established technique for postlaryngectomy voice restoration , a voice suitably pitched for male laryngectomees has to be generated and a large part of the melodic and dynamic range of the sound source has to be attainable within physiological airflow rates . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Sex, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Intervention_Physical", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Alternative voice after laryngectomy using a sound-producing voice prosthesis . OBJECTIVE To improve the voice quality of female laryngectomees and/or laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment by means of a pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . STUDY DESIGN Experimental , randomized , crossover trial . METHODS The new sound source consists of a single silicone lip , which performs an oscillatory movement driven by expired pulmonary air flowing along the outward-striking lip through the TE shunt valve . A prototype of this pneumatic sound source is evaluated in vitro and in six laryngectomees . In vivo evaluation includes speech rate , maximal phonation time , perceptual voice evaluation of read-aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self-assessment by the patients . Moreover , extensive acoustical and aerodynamic in vivo registrations are performed using a newly developed data acquisition system . RESULTS The current prototype seems beneficial in female laryngectomees with a hypotonic PE segment only . For them the sound-producing voice prosthesis improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation of this prosthetic voice is possible , yet limited . CONCLUSIONS The mechanism is feasible and does not result in unacceptable airflow resistance . For this new mechanism of alaryngeal voice to become an established technique for postlaryngectomy voice restoration , a voice suitably pitched for male laryngectomees has to be generated and a large part of the melodic and dynamic range of the sound source has to be attainable within physiological airflow rates .
[ "Alternative", "voice", "after", "laryngectomy", "using", "a", "sound", "-", "producing", "voice", "prosthesis", ".", "OBJECTIVE", "To", "improve", "the", "voice", "quality", "of", "female", "laryngectomees", "and", "/", "or", "laryngectomees", "with", "a", "hypotonic", "pharyngoesophageal", "(", "PE", ")", "segment", "by", "means", "of", "a", "pneumatic", "artificial", "source", "of", "voice", "incorporated", "in", "a", "regular", "tracheoesophageal", "(", "TE", ")", "shunt", "valve", ".", "STUDY", "DESIGN", "Experimental", ",", "randomized", ",", "crossover", "trial", ".", "METHODS", "The", "new", "sound", "source", "consists", "of", "a", "single", "silicone", "lip", ",", "which", "performs", "an", "oscillatory", "movement", "driven", "by", "expired", "pulmonary", "air", "flowing", "along", "the", "outward", "-", "striking", "lip", "through", "the", "TE", "shunt", "valve", ".", "A", "prototype", "of", "this", "pneumatic", "sound", "source", "is", "evaluated", "in", "vitro", "and", "in", "six", "laryngectomees", ".", "In", "vivo", "evaluation", "includes", "speech", "rate", ",", "maximal", "phonation", "time", ",", "perceptual", "voice", "evaluation", "of", "read", "-", "aloud", "prose", "by", "an", "expert", "listener", ",", "speech", "intelligibility", "measurements", "with", "12", "listeners", ",", "and", "self", "-", "assessment", "by", "the", "patients", ".", "Moreover", ",", "extensive", "acoustical", "and", "aerodynamic", "in", "vivo", "registrations", "are", "performed", "using", "a", "newly", "developed", "data", "acquisition", "system", ".", "RESULTS", "The", "current", "prototype", "seems", "beneficial", "in", "female", "laryngectomees", "with", "a", "hypotonic", "PE", "segment", "only", ".", "For", "them", "the", "sound", "-", "producing", "voice", "prosthesis", "improves", "voice", "quality", "and", "increases", "the", "average", "pitch", "of", "voice", ",", "without", "decreasing", "intelligibility", "or", "necessitating", "other", "pressure", "and", "airflow", "rates", "than", "regular", "TE", "shunt", "speech", ".", "Pitch", "regulation", "of", "this", "prosthetic", "voice", "is", "possible", ",", "yet", "limited", ".", "CONCLUSIONS", "The", "mechanism", "is", "feasible", "and", "does", "not", "result", "in", "unacceptable", "airflow", "resistance", ".", "For", "this", "new", "mechanism", "of", "alaryngeal", "voice", "to", "become", "an", "established", "technique", "for", "postlaryngectomy", "voice", "restoration", ",", "a", "voice", "suitably", "pitched", "for", "male", "laryngectomees", "has", "to", "be", "generated", "and", "a", "large", "part", "of", "the", "melodic", "and", "dynamic", "range", "of", "the", "sound", "source", "has", "to", "be", "attainable", "within", "physiological", "airflow", "rates", "." ]
[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Participant_Sex", "Participant_Sample-size" ]
laryngectomy is a Intervention_Physical, sound - producing voice prosthesis is a Intervention_Other, improve the voice quality is a Outcome_Physical, female is a Participant_Sex, laryngectomees is a Participant_Condition, laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment is a Participant_Condition, pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . is a Outcome_Physical, pneumatic sound source is a Intervention_Other, six is a Participant_Sample-size, speech rate , maximal phonation time , perceptual voice evaluation of read - aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self - assessment by the patients . is a Outcome_Physical, extensive acoustical and is a Outcome_Other, aerodynamic in vivo registrations is a Outcome_Physical, newly developed data acquisition system . is a Outcome_Other, laryngectomees with a hypotonic PE segment is a Participant_Condition, improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation is a Outcome_Physical, feasible is a Outcome_Other
5514_task1
Sentence: Alternative voice after laryngectomy using a sound-producing voice prosthesis . OBJECTIVE To improve the voice quality of female laryngectomees and/or laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment by means of a pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . STUDY DESIGN Experimental , randomized , crossover trial . METHODS The new sound source consists of a single silicone lip , which performs an oscillatory movement driven by expired pulmonary air flowing along the outward-striking lip through the TE shunt valve . A prototype of this pneumatic sound source is evaluated in vitro and in six laryngectomees . In vivo evaluation includes speech rate , maximal phonation time , perceptual voice evaluation of read-aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self-assessment by the patients . Moreover , extensive acoustical and aerodynamic in vivo registrations are performed using a newly developed data acquisition system . RESULTS The current prototype seems beneficial in female laryngectomees with a hypotonic PE segment only . For them the sound-producing voice prosthesis improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation of this prosthetic voice is possible , yet limited . CONCLUSIONS The mechanism is feasible and does not result in unacceptable airflow resistance . For this new mechanism of alaryngeal voice to become an established technique for postlaryngectomy voice restoration , a voice suitably pitched for male laryngectomees has to be generated and a large part of the melodic and dynamic range of the sound source has to be attainable within physiological airflow rates . Instructions: please typing these entity words according to sentence: laryngectomy, sound - producing voice prosthesis, improve the voice quality, female, laryngectomees, laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment, pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve ., pneumatic sound source, six, speech rate , maximal phonation time , perceptual voice evaluation of read - aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self - assessment by the patients ., extensive acoustical and, aerodynamic in vivo registrations, newly developed data acquisition system ., laryngectomees with a hypotonic PE segment, improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation, feasible Options: Intervention_Physical, Participant_Sex, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Intervention_Physical", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Alternative voice after laryngectomy using a sound-producing voice prosthesis . OBJECTIVE To improve the voice quality of female laryngectomees and/or laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment by means of a pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . STUDY DESIGN Experimental , randomized , crossover trial . METHODS The new sound source consists of a single silicone lip , which performs an oscillatory movement driven by expired pulmonary air flowing along the outward-striking lip through the TE shunt valve . A prototype of this pneumatic sound source is evaluated in vitro and in six laryngectomees . In vivo evaluation includes speech rate , maximal phonation time , perceptual voice evaluation of read-aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self-assessment by the patients . Moreover , extensive acoustical and aerodynamic in vivo registrations are performed using a newly developed data acquisition system . RESULTS The current prototype seems beneficial in female laryngectomees with a hypotonic PE segment only . For them the sound-producing voice prosthesis improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation of this prosthetic voice is possible , yet limited . CONCLUSIONS The mechanism is feasible and does not result in unacceptable airflow resistance . For this new mechanism of alaryngeal voice to become an established technique for postlaryngectomy voice restoration , a voice suitably pitched for male laryngectomees has to be generated and a large part of the melodic and dynamic range of the sound source has to be attainable within physiological airflow rates .
[ "Alternative", "voice", "after", "laryngectomy", "using", "a", "sound", "-", "producing", "voice", "prosthesis", ".", "OBJECTIVE", "To", "improve", "the", "voice", "quality", "of", "female", "laryngectomees", "and", "/", "or", "laryngectomees", "with", "a", "hypotonic", "pharyngoesophageal", "(", "PE", ")", "segment", "by", "means", "of", "a", "pneumatic", "artificial", "source", "of", "voice", "incorporated", "in", "a", "regular", "tracheoesophageal", "(", "TE", ")", "shunt", "valve", ".", "STUDY", "DESIGN", "Experimental", ",", "randomized", ",", "crossover", "trial", ".", "METHODS", "The", "new", "sound", "source", "consists", "of", "a", "single", "silicone", "lip", ",", "which", "performs", "an", "oscillatory", "movement", "driven", "by", "expired", "pulmonary", "air", "flowing", "along", "the", "outward", "-", "striking", "lip", "through", "the", "TE", "shunt", "valve", ".", "A", "prototype", "of", "this", "pneumatic", "sound", "source", "is", "evaluated", "in", "vitro", "and", "in", "six", "laryngectomees", ".", "In", "vivo", "evaluation", "includes", "speech", "rate", ",", "maximal", "phonation", "time", ",", "perceptual", "voice", "evaluation", "of", "read", "-", "aloud", "prose", "by", "an", "expert", "listener", ",", "speech", "intelligibility", "measurements", "with", "12", "listeners", ",", "and", "self", "-", "assessment", "by", "the", "patients", ".", "Moreover", ",", "extensive", "acoustical", "and", "aerodynamic", "in", "vivo", "registrations", "are", "performed", "using", "a", "newly", "developed", "data", "acquisition", "system", ".", "RESULTS", "The", "current", "prototype", "seems", "beneficial", "in", "female", "laryngectomees", "with", "a", "hypotonic", "PE", "segment", "only", ".", "For", "them", "the", "sound", "-", "producing", "voice", "prosthesis", "improves", "voice", "quality", "and", "increases", "the", "average", "pitch", "of", "voice", ",", "without", "decreasing", "intelligibility", "or", "necessitating", "other", "pressure", "and", "airflow", "rates", "than", "regular", "TE", "shunt", "speech", ".", "Pitch", "regulation", "of", "this", "prosthetic", "voice", "is", "possible", ",", "yet", "limited", ".", "CONCLUSIONS", "The", "mechanism", "is", "feasible", "and", "does", "not", "result", "in", "unacceptable", "airflow", "resistance", ".", "For", "this", "new", "mechanism", "of", "alaryngeal", "voice", "to", "become", "an", "established", "technique", "for", "postlaryngectomy", "voice", "restoration", ",", "a", "voice", "suitably", "pitched", "for", "male", "laryngectomees", "has", "to", "be", "generated", "and", "a", "large", "part", "of", "the", "melodic", "and", "dynamic", "range", "of", "the", "sound", "source", "has", "to", "be", "attainable", "within", "physiological", "airflow", "rates", "." ]
[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Participant_Sex", "Participant_Sample-size" ]
laryngectomy, sound - producing voice prosthesis, improve the voice quality, female, laryngectomees, laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment, pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve ., pneumatic sound source, six, speech rate , maximal phonation time , perceptual voice evaluation of read - aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self - assessment by the patients ., extensive acoustical and, aerodynamic in vivo registrations, newly developed data acquisition system ., laryngectomees with a hypotonic PE segment, improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation, feasible
5514_task2
Sentence: Alternative voice after laryngectomy using a sound-producing voice prosthesis . OBJECTIVE To improve the voice quality of female laryngectomees and/or laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment by means of a pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . STUDY DESIGN Experimental , randomized , crossover trial . METHODS The new sound source consists of a single silicone lip , which performs an oscillatory movement driven by expired pulmonary air flowing along the outward-striking lip through the TE shunt valve . A prototype of this pneumatic sound source is evaluated in vitro and in six laryngectomees . In vivo evaluation includes speech rate , maximal phonation time , perceptual voice evaluation of read-aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self-assessment by the patients . Moreover , extensive acoustical and aerodynamic in vivo registrations are performed using a newly developed data acquisition system . RESULTS The current prototype seems beneficial in female laryngectomees with a hypotonic PE segment only . For them the sound-producing voice prosthesis improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation of this prosthetic voice is possible , yet limited . CONCLUSIONS The mechanism is feasible and does not result in unacceptable airflow resistance . For this new mechanism of alaryngeal voice to become an established technique for postlaryngectomy voice restoration , a voice suitably pitched for male laryngectomees has to be generated and a large part of the melodic and dynamic range of the sound source has to be attainable within physiological airflow rates . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Physical", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Alternative voice after laryngectomy using a sound-producing voice prosthesis . OBJECTIVE To improve the voice quality of female laryngectomees and/or laryngectomees with a hypotonic pharyngoesophageal ( PE ) segment by means of a pneumatic artificial source of voice incorporated in a regular tracheoesophageal ( TE ) shunt valve . STUDY DESIGN Experimental , randomized , crossover trial . METHODS The new sound source consists of a single silicone lip , which performs an oscillatory movement driven by expired pulmonary air flowing along the outward-striking lip through the TE shunt valve . A prototype of this pneumatic sound source is evaluated in vitro and in six laryngectomees . In vivo evaluation includes speech rate , maximal phonation time , perceptual voice evaluation of read-aloud prose by an expert listener , speech intelligibility measurements with 12 listeners , and self-assessment by the patients . Moreover , extensive acoustical and aerodynamic in vivo registrations are performed using a newly developed data acquisition system . RESULTS The current prototype seems beneficial in female laryngectomees with a hypotonic PE segment only . For them the sound-producing voice prosthesis improves voice quality and increases the average pitch of voice , without decreasing intelligibility or necessitating other pressure and airflow rates than regular TE shunt speech . Pitch regulation of this prosthetic voice is possible , yet limited . CONCLUSIONS The mechanism is feasible and does not result in unacceptable airflow resistance . For this new mechanism of alaryngeal voice to become an established technique for postlaryngectomy voice restoration , a voice suitably pitched for male laryngectomees has to be generated and a large part of the melodic and dynamic range of the sound source has to be attainable within physiological airflow rates .
[ "Alternative", "voice", "after", "laryngectomy", "using", "a", "sound", "-", "producing", "voice", "prosthesis", ".", "OBJECTIVE", "To", "improve", "the", "voice", "quality", "of", "female", "laryngectomees", "and", "/", "or", "laryngectomees", "with", "a", "hypotonic", "pharyngoesophageal", "(", "PE", ")", "segment", "by", "means", "of", "a", "pneumatic", "artificial", "source", "of", "voice", "incorporated", "in", "a", "regular", "tracheoesophageal", "(", "TE", ")", "shunt", "valve", ".", "STUDY", "DESIGN", "Experimental", ",", "randomized", ",", "crossover", "trial", ".", "METHODS", "The", "new", "sound", "source", "consists", "of", "a", "single", "silicone", "lip", ",", "which", "performs", "an", "oscillatory", "movement", "driven", "by", "expired", "pulmonary", "air", "flowing", "along", "the", "outward", "-", "striking", "lip", "through", "the", "TE", "shunt", "valve", ".", "A", "prototype", "of", "this", "pneumatic", "sound", "source", "is", "evaluated", "in", "vitro", "and", "in", "six", "laryngectomees", ".", "In", "vivo", "evaluation", "includes", "speech", "rate", ",", "maximal", "phonation", "time", ",", "perceptual", "voice", "evaluation", "of", "read", "-", "aloud", "prose", "by", "an", "expert", "listener", ",", "speech", "intelligibility", "measurements", "with", "12", "listeners", ",", "and", "self", "-", "assessment", "by", "the", "patients", ".", "Moreover", ",", "extensive", "acoustical", "and", "aerodynamic", "in", "vivo", "registrations", "are", "performed", "using", "a", "newly", "developed", "data", "acquisition", "system", ".", "RESULTS", "The", "current", "prototype", "seems", "beneficial", "in", "female", "laryngectomees", "with", "a", "hypotonic", "PE", "segment", "only", ".", "For", "them", "the", "sound", "-", "producing", "voice", "prosthesis", "improves", "voice", "quality", "and", "increases", "the", "average", "pitch", "of", "voice", ",", "without", "decreasing", "intelligibility", "or", "necessitating", "other", "pressure", "and", "airflow", "rates", "than", "regular", "TE", "shunt", "speech", ".", "Pitch", "regulation", "of", "this", "prosthetic", "voice", "is", "possible", ",", "yet", "limited", ".", "CONCLUSIONS", "The", "mechanism", "is", "feasible", "and", "does", "not", "result", "in", "unacceptable", "airflow", "resistance", ".", "For", "this", "new", "mechanism", "of", "alaryngeal", "voice", "to", "become", "an", "established", "technique", "for", "postlaryngectomy", "voice", "restoration", ",", "a", "voice", "suitably", "pitched", "for", "male", "laryngectomees", "has", "to", "be", "generated", "and", "a", "large", "part", "of", "the", "melodic", "and", "dynamic", "range", "of", "the", "sound", "source", "has", "to", "be", "attainable", "within", "physiological", "airflow", "rates", "." ]
[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition", "Outcome_Other", "Intervention_Other", "Participant_Sex", "Participant_Sample-size" ]
Infektionen is an umlsterm, Streptokokken is an umlsterm, Deutschland is an umlsterm, Infektion is an umlsterm, Geburten is an umlsterm, Antibiotikatherapie is an umlsterm, gewebeschaedigenden is an umlsterm, Erkennung is an umlsterm, Infektion is an umlsterm, Antibiotikagabe is an umlsterm, Entbindung is an umlsterm, Infektion is an umlsterm, Schmerzen is an umlsterm, Geburt is an umlsterm, Kinder is an umlsterm, Ehemann is an umlsterm
DerGynaekologe.90320512.ger.abstr_task0
Sentence: Bei schweren Puerperalsepsisfaellen handelt es sich fast immer um Infektionen durch Streptokokken der Gruppe A. Ihre Haeufigkeit in Deutschland ist nicht bekannt . Groessenordnungsmaessig kommt mindestens eine schwere Infektion auf 100 000 Geburten . Es werden nur diejenigen Faelle erkannt , die besonders schwer verlaufen sind und bei denen vor der Antibiotikatherapie ein mikrobiologischer Abstrich entnommen wurde . Die besondere enzymatische Ausstattung der A-Streptokokken , insbesondere wenn sie das Gen fuer das M-Protein 1 besitzen , befaehigt sie zu sehr rasch verlaufenden , schwersten gewebeschaedigenden Verlaeufen . Nur die fruehzeitige Erkennung der Infektion und die fruehzeitige Antibiotikagabe verhindern den fatalen Verlauf oder bleibende Schaeden . Besonders gefaehrdet sind Patientinnen sowohl nach vaginaler Entbindung als auch nach Sectio , deren erste Zeichen der Infektion nur Schmerzen und diffuse Abdominalbeschwerden sind . In den meisten Faellen bringen die Patientinnen die Keime zur Geburt mit , wobei Kinder und der Ehemann die Quelle sein koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Bei schweren Puerperalsepsisfaellen handelt es sich fast immer um Infektionen durch Streptokokken der Gruppe A. Ihre Haeufigkeit in Deutschland ist nicht bekannt . Groessenordnungsmaessig kommt mindestens eine schwere Infektion auf 100 000 Geburten . Es werden nur diejenigen Faelle erkannt , die besonders schwer verlaufen sind und bei denen vor der Antibiotikatherapie ein mikrobiologischer Abstrich entnommen wurde . Die besondere enzymatische Ausstattung der A-Streptokokken , insbesondere wenn sie das Gen fuer das M-Protein 1 besitzen , befaehigt sie zu sehr rasch verlaufenden , schwersten gewebeschaedigenden Verlaeufen . Nur die fruehzeitige Erkennung der Infektion und die fruehzeitige Antibiotikagabe verhindern den fatalen Verlauf oder bleibende Schaeden . Besonders gefaehrdet sind Patientinnen sowohl nach vaginaler Entbindung als auch nach Sectio , deren erste Zeichen der Infektion nur Schmerzen und diffuse Abdominalbeschwerden sind . In den meisten Faellen bringen die Patientinnen die Keime zur Geburt mit , wobei Kinder und der Ehemann die Quelle sein koennen .
[ "Bei", "schweren", "Puerperalsepsisfaellen", "handelt", "es", "sich", "fast", "immer", "um", "Infektionen", "durch", "Streptokokken", "der", "Gruppe", "A.", "Ihre", "Haeufigkeit", "in", "Deutschland", "ist", "nicht", "bekannt", ".", "Groessenordnungsmaessig", "kommt", "mindestens", "eine", "schwere", "Infektion", "auf", "100", "000", "Geburten", ".", "Es", "werden", "nur", "diejenigen", "Faelle", "erkannt", ",", "die", "besonders", "schwer", "verlaufen", "sind", "und", "bei", "denen", "vor", "der", "Antibiotikatherapie", "ein", "mikrobiologischer", "Abstrich", "entnommen", "wurde", ".", "Die", "besondere", "enzymatische", "Ausstattung", "der", "A", "-", "Streptokokken", ",", "insbesondere", "wenn", "sie", "das", "Gen", "fuer", "das", "M", "-", "Protein", "1", "besitzen", ",", "befaehigt", "sie", "zu", "sehr", "rasch", "verlaufenden", ",", "schwersten", "gewebeschaedigenden", "Verlaeufen", ".", "Nur", "die", "fruehzeitige", "Erkennung", "der", "Infektion", "und", "die", "fruehzeitige", "Antibiotikagabe", "verhindern", "den", "fatalen", "Verlauf", "oder", "bleibende", "Schaeden", ".", "Besonders", "gefaehrdet", "sind", "Patientinnen", "sowohl", "nach", "vaginaler", "Entbindung", "als", "auch", "nach", "Sectio", ",", "deren", "erste", "Zeichen", "der", "Infektion", "nur", "Schmerzen", "und", "diffuse", "Abdominalbeschwerden", "sind", ".", "In", "den", "meisten", "Faellen", "bringen", "die", "Patientinnen", "die", "Keime", "zur", "Geburt", "mit", ",", "wobei", "Kinder", "und", "der", "Ehemann", "die", "Quelle", "sein", "koennen", "." ]
[ "umlsterm" ]
Infektionen is an umlsterm, Streptokokken is an umlsterm, Deutschland is an umlsterm, Infektion is an umlsterm, Geburten is an umlsterm, Antibiotikatherapie is an umlsterm, gewebeschaedigenden is an umlsterm, Erkennung is an umlsterm, Infektion is an umlsterm, Antibiotikagabe is an umlsterm, Entbindung is an umlsterm, Infektion is an umlsterm, Schmerzen is an umlsterm, Geburt is an umlsterm, Kinder is an umlsterm, Ehemann is an umlsterm
DerGynaekologe.90320512.ger.abstr_task1
Sentence: Bei schweren Puerperalsepsisfaellen handelt es sich fast immer um Infektionen durch Streptokokken der Gruppe A. Ihre Haeufigkeit in Deutschland ist nicht bekannt . Groessenordnungsmaessig kommt mindestens eine schwere Infektion auf 100 000 Geburten . Es werden nur diejenigen Faelle erkannt , die besonders schwer verlaufen sind und bei denen vor der Antibiotikatherapie ein mikrobiologischer Abstrich entnommen wurde . Die besondere enzymatische Ausstattung der A-Streptokokken , insbesondere wenn sie das Gen fuer das M-Protein 1 besitzen , befaehigt sie zu sehr rasch verlaufenden , schwersten gewebeschaedigenden Verlaeufen . Nur die fruehzeitige Erkennung der Infektion und die fruehzeitige Antibiotikagabe verhindern den fatalen Verlauf oder bleibende Schaeden . Besonders gefaehrdet sind Patientinnen sowohl nach vaginaler Entbindung als auch nach Sectio , deren erste Zeichen der Infektion nur Schmerzen und diffuse Abdominalbeschwerden sind . In den meisten Faellen bringen die Patientinnen die Keime zur Geburt mit , wobei Kinder und der Ehemann die Quelle sein koennen . Instructions: please typing these entity words according to sentence: Infektionen, Streptokokken, Deutschland, Infektion, Geburten, Antibiotikatherapie, gewebeschaedigenden, Erkennung, Infektion, Antibiotikagabe, Entbindung, Infektion, Schmerzen, Geburt, Kinder, Ehemann Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Bei schweren Puerperalsepsisfaellen handelt es sich fast immer um Infektionen durch Streptokokken der Gruppe A. Ihre Haeufigkeit in Deutschland ist nicht bekannt . Groessenordnungsmaessig kommt mindestens eine schwere Infektion auf 100 000 Geburten . Es werden nur diejenigen Faelle erkannt , die besonders schwer verlaufen sind und bei denen vor der Antibiotikatherapie ein mikrobiologischer Abstrich entnommen wurde . Die besondere enzymatische Ausstattung der A-Streptokokken , insbesondere wenn sie das Gen fuer das M-Protein 1 besitzen , befaehigt sie zu sehr rasch verlaufenden , schwersten gewebeschaedigenden Verlaeufen . Nur die fruehzeitige Erkennung der Infektion und die fruehzeitige Antibiotikagabe verhindern den fatalen Verlauf oder bleibende Schaeden . Besonders gefaehrdet sind Patientinnen sowohl nach vaginaler Entbindung als auch nach Sectio , deren erste Zeichen der Infektion nur Schmerzen und diffuse Abdominalbeschwerden sind . In den meisten Faellen bringen die Patientinnen die Keime zur Geburt mit , wobei Kinder und der Ehemann die Quelle sein koennen .
[ "Bei", "schweren", "Puerperalsepsisfaellen", "handelt", "es", "sich", "fast", "immer", "um", "Infektionen", "durch", "Streptokokken", "der", "Gruppe", "A.", "Ihre", "Haeufigkeit", "in", "Deutschland", "ist", "nicht", "bekannt", ".", "Groessenordnungsmaessig", "kommt", "mindestens", "eine", "schwere", "Infektion", "auf", "100", "000", "Geburten", ".", "Es", "werden", "nur", "diejenigen", "Faelle", "erkannt", ",", "die", "besonders", "schwer", "verlaufen", "sind", "und", "bei", "denen", "vor", "der", "Antibiotikatherapie", "ein", "mikrobiologischer", "Abstrich", "entnommen", "wurde", ".", "Die", "besondere", "enzymatische", "Ausstattung", "der", "A", "-", "Streptokokken", ",", "insbesondere", "wenn", "sie", "das", "Gen", "fuer", "das", "M", "-", "Protein", "1", "besitzen", ",", "befaehigt", "sie", "zu", "sehr", "rasch", "verlaufenden", ",", "schwersten", "gewebeschaedigenden", "Verlaeufen", ".", "Nur", "die", "fruehzeitige", "Erkennung", "der", "Infektion", "und", "die", "fruehzeitige", "Antibiotikagabe", "verhindern", "den", "fatalen", "Verlauf", "oder", "bleibende", "Schaeden", ".", "Besonders", "gefaehrdet", "sind", "Patientinnen", "sowohl", "nach", "vaginaler", "Entbindung", "als", "auch", "nach", "Sectio", ",", "deren", "erste", "Zeichen", "der", "Infektion", "nur", "Schmerzen", "und", "diffuse", "Abdominalbeschwerden", "sind", ".", "In", "den", "meisten", "Faellen", "bringen", "die", "Patientinnen", "die", "Keime", "zur", "Geburt", "mit", ",", "wobei", "Kinder", "und", "der", "Ehemann", "die", "Quelle", "sein", "koennen", "." ]
[ "umlsterm" ]
Infektionen, Streptokokken, Deutschland, Infektion, Geburten, Antibiotikatherapie, gewebeschaedigenden, Erkennung, Infektion, Antibiotikagabe, Entbindung, Infektion, Schmerzen, Geburt, Kinder, Ehemann
DerGynaekologe.90320512.ger.abstr_task2
Sentence: Bei schweren Puerperalsepsisfaellen handelt es sich fast immer um Infektionen durch Streptokokken der Gruppe A. Ihre Haeufigkeit in Deutschland ist nicht bekannt . Groessenordnungsmaessig kommt mindestens eine schwere Infektion auf 100 000 Geburten . Es werden nur diejenigen Faelle erkannt , die besonders schwer verlaufen sind und bei denen vor der Antibiotikatherapie ein mikrobiologischer Abstrich entnommen wurde . Die besondere enzymatische Ausstattung der A-Streptokokken , insbesondere wenn sie das Gen fuer das M-Protein 1 besitzen , befaehigt sie zu sehr rasch verlaufenden , schwersten gewebeschaedigenden Verlaeufen . Nur die fruehzeitige Erkennung der Infektion und die fruehzeitige Antibiotikagabe verhindern den fatalen Verlauf oder bleibende Schaeden . Besonders gefaehrdet sind Patientinnen sowohl nach vaginaler Entbindung als auch nach Sectio , deren erste Zeichen der Infektion nur Schmerzen und diffuse Abdominalbeschwerden sind . In den meisten Faellen bringen die Patientinnen die Keime zur Geburt mit , wobei Kinder und der Ehemann die Quelle sein koennen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Bei schweren Puerperalsepsisfaellen handelt es sich fast immer um Infektionen durch Streptokokken der Gruppe A. Ihre Haeufigkeit in Deutschland ist nicht bekannt . Groessenordnungsmaessig kommt mindestens eine schwere Infektion auf 100 000 Geburten . Es werden nur diejenigen Faelle erkannt , die besonders schwer verlaufen sind und bei denen vor der Antibiotikatherapie ein mikrobiologischer Abstrich entnommen wurde . Die besondere enzymatische Ausstattung der A-Streptokokken , insbesondere wenn sie das Gen fuer das M-Protein 1 besitzen , befaehigt sie zu sehr rasch verlaufenden , schwersten gewebeschaedigenden Verlaeufen . Nur die fruehzeitige Erkennung der Infektion und die fruehzeitige Antibiotikagabe verhindern den fatalen Verlauf oder bleibende Schaeden . Besonders gefaehrdet sind Patientinnen sowohl nach vaginaler Entbindung als auch nach Sectio , deren erste Zeichen der Infektion nur Schmerzen und diffuse Abdominalbeschwerden sind . In den meisten Faellen bringen die Patientinnen die Keime zur Geburt mit , wobei Kinder und der Ehemann die Quelle sein koennen .
[ "Bei", "schweren", "Puerperalsepsisfaellen", "handelt", "es", "sich", "fast", "immer", "um", "Infektionen", "durch", "Streptokokken", "der", "Gruppe", "A.", "Ihre", "Haeufigkeit", "in", "Deutschland", "ist", "nicht", "bekannt", ".", "Groessenordnungsmaessig", "kommt", "mindestens", "eine", "schwere", "Infektion", "auf", "100", "000", "Geburten", ".", "Es", "werden", "nur", "diejenigen", "Faelle", "erkannt", ",", "die", "besonders", "schwer", "verlaufen", "sind", "und", "bei", "denen", "vor", "der", "Antibiotikatherapie", "ein", "mikrobiologischer", "Abstrich", "entnommen", "wurde", ".", "Die", "besondere", "enzymatische", "Ausstattung", "der", "A", "-", "Streptokokken", ",", "insbesondere", "wenn", "sie", "das", "Gen", "fuer", "das", "M", "-", "Protein", "1", "besitzen", ",", "befaehigt", "sie", "zu", "sehr", "rasch", "verlaufenden", ",", "schwersten", "gewebeschaedigenden", "Verlaeufen", ".", "Nur", "die", "fruehzeitige", "Erkennung", "der", "Infektion", "und", "die", "fruehzeitige", "Antibiotikagabe", "verhindern", "den", "fatalen", "Verlauf", "oder", "bleibende", "Schaeden", ".", "Besonders", "gefaehrdet", "sind", "Patientinnen", "sowohl", "nach", "vaginaler", "Entbindung", "als", "auch", "nach", "Sectio", ",", "deren", "erste", "Zeichen", "der", "Infektion", "nur", "Schmerzen", "und", "diffuse", "Abdominalbeschwerden", "sind", ".", "In", "den", "meisten", "Faellen", "bringen", "die", "Patientinnen", "die", "Keime", "zur", "Geburt", "mit", ",", "wobei", "Kinder", "und", "der", "Ehemann", "die", "Quelle", "sein", "koennen", "." ]
[ "umlsterm" ]
GATA-3 is a protein_molecule, gp91phox gene expression is an other_name, eosinophil - committed HL-60-C15 cells is a cell_line
72398_task0
Sentence: GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, cell_line, protein_molecule
[ "B-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]
GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells.
[ "GATA-3", "represses", "gp91phox", "gene", "expression", "in", "eosinophil", "-", "committed", "HL-60-C15", "cells", "." ]
[ "other_name", "cell_line", "DNA_family_or_group", "DNA_molecule", "DNA_domain_or_region", "protein_molecule" ]
GATA-3 is a protein_molecule, gp91phox gene expression is an other_name, eosinophil - committed HL-60-C15 cells is a cell_line
72398_task1
Sentence: GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells. Instructions: please typing these entity words according to sentence: GATA-3, gp91phox gene expression, eosinophil - committed HL-60-C15 cells Options: other_name, cell_line, protein_molecule
[ "B-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]
GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells.
[ "GATA-3", "represses", "gp91phox", "gene", "expression", "in", "eosinophil", "-", "committed", "HL-60-C15", "cells", "." ]
[ "other_name", "cell_line", "DNA_family_or_group", "DNA_molecule", "DNA_domain_or_region", "protein_molecule" ]
GATA-3, gp91phox gene expression, eosinophil - committed HL-60-C15 cells
72398_task2
Sentence: GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells. Instructions: please extract entity words from the input sentence
[ "B-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]
GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells.
[ "GATA-3", "represses", "gp91phox", "gene", "expression", "in", "eosinophil", "-", "committed", "HL-60-C15", "cells", "." ]
[ "other_name", "cell_line", "DNA_family_or_group", "DNA_molecule", "DNA_domain_or_region", "protein_molecule" ]
Schmerzempfindung is an umlsterm, Schmerzdiagnostik is an umlsterm, Diagnoseinstrumenten is an umlsterm, Computerversion is an umlsterm, Papier - Bleistift - Version is an umlsterm
DerSchmerz.80120205.ger.abstr_task0
Sentence: Fragestellung : Die Bestimmung der Schmerzempfindung ist ein notwendiger Bestandteil einer umfassenden Schmerzdiagnostik . Zu den neueren Diagnoseinstrumenten zaehlt die Schmerzempfindungsskala SES , zu der eine Computerversion " " entwickelt wurde , deren Aequivalenz zur Papier-Bleistift-Version " " ueberprueft werden sollte . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]
Fragestellung : Die Bestimmung der Schmerzempfindung ist ein notwendiger Bestandteil einer umfassenden Schmerzdiagnostik . Zu den neueren Diagnoseinstrumenten zaehlt die Schmerzempfindungsskala SES , zu der eine Computerversion " " entwickelt wurde , deren Aequivalenz zur Papier-Bleistift-Version " " ueberprueft werden sollte .
[ "Fragestellung", ":", "Die", "Bestimmung", "der", "Schmerzempfindung", "ist", "ein", "notwendiger", "Bestandteil", "einer", "umfassenden", "Schmerzdiagnostik", ".", "Zu", "den", "neueren", "Diagnoseinstrumenten", "zaehlt", "die", "Schmerzempfindungsskala", "SES", ",", "zu", "der", "eine", "Computerversion", "\"", "\"", "entwickelt", "wurde", ",", "deren", "Aequivalenz", "zur", "Papier", "-", "Bleistift", "-", "Version", "\"", "\"", "ueberprueft", "werden", "sollte", "." ]
[ "umlsterm" ]
Schmerzempfindung is an umlsterm, Schmerzdiagnostik is an umlsterm, Diagnoseinstrumenten is an umlsterm, Computerversion is an umlsterm, Papier - Bleistift - Version is an umlsterm
DerSchmerz.80120205.ger.abstr_task1
Sentence: Fragestellung : Die Bestimmung der Schmerzempfindung ist ein notwendiger Bestandteil einer umfassenden Schmerzdiagnostik . Zu den neueren Diagnoseinstrumenten zaehlt die Schmerzempfindungsskala SES , zu der eine Computerversion " " entwickelt wurde , deren Aequivalenz zur Papier-Bleistift-Version " " ueberprueft werden sollte . Instructions: please typing these entity words according to sentence: Schmerzempfindung, Schmerzdiagnostik, Diagnoseinstrumenten, Computerversion, Papier - Bleistift - Version Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]
Fragestellung : Die Bestimmung der Schmerzempfindung ist ein notwendiger Bestandteil einer umfassenden Schmerzdiagnostik . Zu den neueren Diagnoseinstrumenten zaehlt die Schmerzempfindungsskala SES , zu der eine Computerversion " " entwickelt wurde , deren Aequivalenz zur Papier-Bleistift-Version " " ueberprueft werden sollte .
[ "Fragestellung", ":", "Die", "Bestimmung", "der", "Schmerzempfindung", "ist", "ein", "notwendiger", "Bestandteil", "einer", "umfassenden", "Schmerzdiagnostik", ".", "Zu", "den", "neueren", "Diagnoseinstrumenten", "zaehlt", "die", "Schmerzempfindungsskala", "SES", ",", "zu", "der", "eine", "Computerversion", "\"", "\"", "entwickelt", "wurde", ",", "deren", "Aequivalenz", "zur", "Papier", "-", "Bleistift", "-", "Version", "\"", "\"", "ueberprueft", "werden", "sollte", "." ]
[ "umlsterm" ]
Schmerzempfindung, Schmerzdiagnostik, Diagnoseinstrumenten, Computerversion, Papier - Bleistift - Version
DerSchmerz.80120205.ger.abstr_task2
Sentence: Fragestellung : Die Bestimmung der Schmerzempfindung ist ein notwendiger Bestandteil einer umfassenden Schmerzdiagnostik . Zu den neueren Diagnoseinstrumenten zaehlt die Schmerzempfindungsskala SES , zu der eine Computerversion " " entwickelt wurde , deren Aequivalenz zur Papier-Bleistift-Version " " ueberprueft werden sollte . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]
Fragestellung : Die Bestimmung der Schmerzempfindung ist ein notwendiger Bestandteil einer umfassenden Schmerzdiagnostik . Zu den neueren Diagnoseinstrumenten zaehlt die Schmerzempfindungsskala SES , zu der eine Computerversion " " entwickelt wurde , deren Aequivalenz zur Papier-Bleistift-Version " " ueberprueft werden sollte .
[ "Fragestellung", ":", "Die", "Bestimmung", "der", "Schmerzempfindung", "ist", "ein", "notwendiger", "Bestandteil", "einer", "umfassenden", "Schmerzdiagnostik", ".", "Zu", "den", "neueren", "Diagnoseinstrumenten", "zaehlt", "die", "Schmerzempfindungsskala", "SES", ",", "zu", "der", "eine", "Computerversion", "\"", "\"", "entwickelt", "wurde", ",", "deren", "Aequivalenz", "zur", "Papier", "-", "Bleistift", "-", "Version", "\"", "\"", "ueberprueft", "werden", "sollte", "." ]
[ "umlsterm" ]
Tracheotomie is an umlsterm, Geschichte is an umlsterm, Chirurgie is an umlsterm, Intensivpatienten is an umlsterm, Tracheotomie is an umlsterm, Tracheotomie is an umlsterm, Methode is an umlsterm, Tracheotomie is an umlsterm, Tracheotomie is an umlsterm, Technik is an umlsterm, Aerzten is an umlsterm, Technik is an umlsterm, Tracheotomie is an umlsterm, Kontraindikationen is an umlsterm, Techniken is an umlsterm, Tracheotomie is an umlsterm, Patienten is an umlsterm
DerAnaesthesist.90480142.ger.abstr_task0
Sentence: Die Tracheotomie ist einer der aeltesten Eingriffe in der Geschichte der Chirurgie und hat sich in den vergangenen Jahrzehnten zum Verfahren der Wahl im langfristigen Atemwegsmanagement beatmeter Intensivpatienten entwickelt . Alternativ zur klassisch-konventionellen Tracheotomie existieren inzwischen verschiedene Verfahren zur perkutanen Tracheotomie . Hierzu zaehlen die perkutanen Dilatationstracheotomien nach Ciaglia ( PDT Griggs ( ) , GWDF ) und Schachner ( Rapitrach ) . Vor allem die 1985 eingefuehrte PDT nach Ciaglia hat sich gegenwaertig im intensivmedizinischen Bereich als eine sichere und konstenaermere Methode im Vergleich zur chirurgisch durchgefuehrten Tracheotomie etabliert . Seit 1996 steht mit der translaryngealen Tracheotomie nach Fantoni eine weitere perkutane Technik zur Verfuegung , die sich durch eine niedrige Komplikationsrate auszeichnet . Trotz der niedrigen Komplikationsraten der perkutanen Verfahren sollten diese , auch wenn sie rasch erlernbar und technisch wenig aufwendig sind , nur von Aerzten angewendet werden , die die Technik der Reintubation und Maskenbeatmung sicher beherrschen . Auch sollte die Moeglichkeit bestehen , ggf. rasch eine konventionelle Tracheotomie durchfuehren zu koennen . Nur unter sorgfaeltiger Beachtung der Kontraindikationen werden die Techniken der perkutanen Tracheotomie ihren Stellenwert behaupten und entsprechende Vorteile fuer die Patienten bieten koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die Tracheotomie ist einer der aeltesten Eingriffe in der Geschichte der Chirurgie und hat sich in den vergangenen Jahrzehnten zum Verfahren der Wahl im langfristigen Atemwegsmanagement beatmeter Intensivpatienten entwickelt . Alternativ zur klassisch-konventionellen Tracheotomie existieren inzwischen verschiedene Verfahren zur perkutanen Tracheotomie . Hierzu zaehlen die perkutanen Dilatationstracheotomien nach Ciaglia ( PDT Griggs ( ) , GWDF ) und Schachner ( Rapitrach ) . Vor allem die 1985 eingefuehrte PDT nach Ciaglia hat sich gegenwaertig im intensivmedizinischen Bereich als eine sichere und konstenaermere Methode im Vergleich zur chirurgisch durchgefuehrten Tracheotomie etabliert . Seit 1996 steht mit der translaryngealen Tracheotomie nach Fantoni eine weitere perkutane Technik zur Verfuegung , die sich durch eine niedrige Komplikationsrate auszeichnet . Trotz der niedrigen Komplikationsraten der perkutanen Verfahren sollten diese , auch wenn sie rasch erlernbar und technisch wenig aufwendig sind , nur von Aerzten angewendet werden , die die Technik der Reintubation und Maskenbeatmung sicher beherrschen . Auch sollte die Moeglichkeit bestehen , ggf. rasch eine konventionelle Tracheotomie durchfuehren zu koennen . Nur unter sorgfaeltiger Beachtung der Kontraindikationen werden die Techniken der perkutanen Tracheotomie ihren Stellenwert behaupten und entsprechende Vorteile fuer die Patienten bieten koennen .
[ "Die", "Tracheotomie", "ist", "einer", "der", "aeltesten", "Eingriffe", "in", "der", "Geschichte", "der", "Chirurgie", "und", "hat", "sich", "in", "den", "vergangenen", "Jahrzehnten", "zum", "Verfahren", "der", "Wahl", "im", "langfristigen", "Atemwegsmanagement", "beatmeter", "Intensivpatienten", "entwickelt", ".", "Alternativ", "zur", "klassisch", "-", "konventionellen", "Tracheotomie", "existieren", "inzwischen", "verschiedene", "Verfahren", "zur", "perkutanen", "Tracheotomie", ".", "Hierzu", "zaehlen", "die", "perkutanen", "Dilatationstracheotomien", "nach", "Ciaglia", "(", "PDT", "Griggs", "(", ")", ",", "GWDF", ")", "und", "Schachner", "(", "Rapitrach", ")", ".", "Vor", "allem", "die", "1985", "eingefuehrte", "PDT", "nach", "Ciaglia", "hat", "sich", "gegenwaertig", "im", "intensivmedizinischen", "Bereich", "als", "eine", "sichere", "und", "konstenaermere", "Methode", "im", "Vergleich", "zur", "chirurgisch", "durchgefuehrten", "Tracheotomie", "etabliert", ".", "Seit", "1996", "steht", "mit", "der", "translaryngealen", "Tracheotomie", "nach", "Fantoni", "eine", "weitere", "perkutane", "Technik", "zur", "Verfuegung", ",", "die", "sich", "durch", "eine", "niedrige", "Komplikationsrate", "auszeichnet", ".", "Trotz", "der", "niedrigen", "Komplikationsraten", "der", "perkutanen", "Verfahren", "sollten", "diese", ",", "auch", "wenn", "sie", "rasch", "erlernbar", "und", "technisch", "wenig", "aufwendig", "sind", ",", "nur", "von", "Aerzten", "angewendet", "werden", ",", "die", "die", "Technik", "der", "Reintubation", "und", "Maskenbeatmung", "sicher", "beherrschen", ".", "Auch", "sollte", "die", "Moeglichkeit", "bestehen", ",", "ggf", ".", "rasch", "eine", "konventionelle", "Tracheotomie", "durchfuehren", "zu", "koennen", ".", "Nur", "unter", "sorgfaeltiger", "Beachtung", "der", "Kontraindikationen", "werden", "die", "Techniken", "der", "perkutanen", "Tracheotomie", "ihren", "Stellenwert", "behaupten", "und", "entsprechende", "Vorteile", "fuer", "die", "Patienten", "bieten", "koennen", "." ]
[ "umlsterm" ]
Tracheotomie is an umlsterm, Geschichte is an umlsterm, Chirurgie is an umlsterm, Intensivpatienten is an umlsterm, Tracheotomie is an umlsterm, Tracheotomie is an umlsterm, Methode is an umlsterm, Tracheotomie is an umlsterm, Tracheotomie is an umlsterm, Technik is an umlsterm, Aerzten is an umlsterm, Technik is an umlsterm, Tracheotomie is an umlsterm, Kontraindikationen is an umlsterm, Techniken is an umlsterm, Tracheotomie is an umlsterm, Patienten is an umlsterm
DerAnaesthesist.90480142.ger.abstr_task1
Sentence: Die Tracheotomie ist einer der aeltesten Eingriffe in der Geschichte der Chirurgie und hat sich in den vergangenen Jahrzehnten zum Verfahren der Wahl im langfristigen Atemwegsmanagement beatmeter Intensivpatienten entwickelt . Alternativ zur klassisch-konventionellen Tracheotomie existieren inzwischen verschiedene Verfahren zur perkutanen Tracheotomie . Hierzu zaehlen die perkutanen Dilatationstracheotomien nach Ciaglia ( PDT Griggs ( ) , GWDF ) und Schachner ( Rapitrach ) . Vor allem die 1985 eingefuehrte PDT nach Ciaglia hat sich gegenwaertig im intensivmedizinischen Bereich als eine sichere und konstenaermere Methode im Vergleich zur chirurgisch durchgefuehrten Tracheotomie etabliert . Seit 1996 steht mit der translaryngealen Tracheotomie nach Fantoni eine weitere perkutane Technik zur Verfuegung , die sich durch eine niedrige Komplikationsrate auszeichnet . Trotz der niedrigen Komplikationsraten der perkutanen Verfahren sollten diese , auch wenn sie rasch erlernbar und technisch wenig aufwendig sind , nur von Aerzten angewendet werden , die die Technik der Reintubation und Maskenbeatmung sicher beherrschen . Auch sollte die Moeglichkeit bestehen , ggf. rasch eine konventionelle Tracheotomie durchfuehren zu koennen . Nur unter sorgfaeltiger Beachtung der Kontraindikationen werden die Techniken der perkutanen Tracheotomie ihren Stellenwert behaupten und entsprechende Vorteile fuer die Patienten bieten koennen . Instructions: please typing these entity words according to sentence: Tracheotomie, Geschichte, Chirurgie, Intensivpatienten, Tracheotomie, Tracheotomie, Methode, Tracheotomie, Tracheotomie, Technik, Aerzten, Technik, Tracheotomie, Kontraindikationen, Techniken, Tracheotomie, Patienten Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die Tracheotomie ist einer der aeltesten Eingriffe in der Geschichte der Chirurgie und hat sich in den vergangenen Jahrzehnten zum Verfahren der Wahl im langfristigen Atemwegsmanagement beatmeter Intensivpatienten entwickelt . Alternativ zur klassisch-konventionellen Tracheotomie existieren inzwischen verschiedene Verfahren zur perkutanen Tracheotomie . Hierzu zaehlen die perkutanen Dilatationstracheotomien nach Ciaglia ( PDT Griggs ( ) , GWDF ) und Schachner ( Rapitrach ) . Vor allem die 1985 eingefuehrte PDT nach Ciaglia hat sich gegenwaertig im intensivmedizinischen Bereich als eine sichere und konstenaermere Methode im Vergleich zur chirurgisch durchgefuehrten Tracheotomie etabliert . Seit 1996 steht mit der translaryngealen Tracheotomie nach Fantoni eine weitere perkutane Technik zur Verfuegung , die sich durch eine niedrige Komplikationsrate auszeichnet . Trotz der niedrigen Komplikationsraten der perkutanen Verfahren sollten diese , auch wenn sie rasch erlernbar und technisch wenig aufwendig sind , nur von Aerzten angewendet werden , die die Technik der Reintubation und Maskenbeatmung sicher beherrschen . Auch sollte die Moeglichkeit bestehen , ggf. rasch eine konventionelle Tracheotomie durchfuehren zu koennen . Nur unter sorgfaeltiger Beachtung der Kontraindikationen werden die Techniken der perkutanen Tracheotomie ihren Stellenwert behaupten und entsprechende Vorteile fuer die Patienten bieten koennen .
[ "Die", "Tracheotomie", "ist", "einer", "der", "aeltesten", "Eingriffe", "in", "der", "Geschichte", "der", "Chirurgie", "und", "hat", "sich", "in", "den", "vergangenen", "Jahrzehnten", "zum", "Verfahren", "der", "Wahl", "im", "langfristigen", "Atemwegsmanagement", "beatmeter", "Intensivpatienten", "entwickelt", ".", "Alternativ", "zur", "klassisch", "-", "konventionellen", "Tracheotomie", "existieren", "inzwischen", "verschiedene", "Verfahren", "zur", "perkutanen", "Tracheotomie", ".", "Hierzu", "zaehlen", "die", "perkutanen", "Dilatationstracheotomien", "nach", "Ciaglia", "(", "PDT", "Griggs", "(", ")", ",", "GWDF", ")", "und", "Schachner", "(", "Rapitrach", ")", ".", "Vor", "allem", "die", "1985", "eingefuehrte", "PDT", "nach", "Ciaglia", "hat", "sich", "gegenwaertig", "im", "intensivmedizinischen", "Bereich", "als", "eine", "sichere", "und", "konstenaermere", "Methode", "im", "Vergleich", "zur", "chirurgisch", "durchgefuehrten", "Tracheotomie", "etabliert", ".", "Seit", "1996", "steht", "mit", "der", "translaryngealen", "Tracheotomie", "nach", "Fantoni", "eine", "weitere", "perkutane", "Technik", "zur", "Verfuegung", ",", "die", "sich", "durch", "eine", "niedrige", "Komplikationsrate", "auszeichnet", ".", "Trotz", "der", "niedrigen", "Komplikationsraten", "der", "perkutanen", "Verfahren", "sollten", "diese", ",", "auch", "wenn", "sie", "rasch", "erlernbar", "und", "technisch", "wenig", "aufwendig", "sind", ",", "nur", "von", "Aerzten", "angewendet", "werden", ",", "die", "die", "Technik", "der", "Reintubation", "und", "Maskenbeatmung", "sicher", "beherrschen", ".", "Auch", "sollte", "die", "Moeglichkeit", "bestehen", ",", "ggf", ".", "rasch", "eine", "konventionelle", "Tracheotomie", "durchfuehren", "zu", "koennen", ".", "Nur", "unter", "sorgfaeltiger", "Beachtung", "der", "Kontraindikationen", "werden", "die", "Techniken", "der", "perkutanen", "Tracheotomie", "ihren", "Stellenwert", "behaupten", "und", "entsprechende", "Vorteile", "fuer", "die", "Patienten", "bieten", "koennen", "." ]
[ "umlsterm" ]
Tracheotomie, Geschichte, Chirurgie, Intensivpatienten, Tracheotomie, Tracheotomie, Methode, Tracheotomie, Tracheotomie, Technik, Aerzten, Technik, Tracheotomie, Kontraindikationen, Techniken, Tracheotomie, Patienten
DerAnaesthesist.90480142.ger.abstr_task2
Sentence: Die Tracheotomie ist einer der aeltesten Eingriffe in der Geschichte der Chirurgie und hat sich in den vergangenen Jahrzehnten zum Verfahren der Wahl im langfristigen Atemwegsmanagement beatmeter Intensivpatienten entwickelt . Alternativ zur klassisch-konventionellen Tracheotomie existieren inzwischen verschiedene Verfahren zur perkutanen Tracheotomie . Hierzu zaehlen die perkutanen Dilatationstracheotomien nach Ciaglia ( PDT Griggs ( ) , GWDF ) und Schachner ( Rapitrach ) . Vor allem die 1985 eingefuehrte PDT nach Ciaglia hat sich gegenwaertig im intensivmedizinischen Bereich als eine sichere und konstenaermere Methode im Vergleich zur chirurgisch durchgefuehrten Tracheotomie etabliert . Seit 1996 steht mit der translaryngealen Tracheotomie nach Fantoni eine weitere perkutane Technik zur Verfuegung , die sich durch eine niedrige Komplikationsrate auszeichnet . Trotz der niedrigen Komplikationsraten der perkutanen Verfahren sollten diese , auch wenn sie rasch erlernbar und technisch wenig aufwendig sind , nur von Aerzten angewendet werden , die die Technik der Reintubation und Maskenbeatmung sicher beherrschen . Auch sollte die Moeglichkeit bestehen , ggf. rasch eine konventionelle Tracheotomie durchfuehren zu koennen . Nur unter sorgfaeltiger Beachtung der Kontraindikationen werden die Techniken der perkutanen Tracheotomie ihren Stellenwert behaupten und entsprechende Vorteile fuer die Patienten bieten koennen . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Die Tracheotomie ist einer der aeltesten Eingriffe in der Geschichte der Chirurgie und hat sich in den vergangenen Jahrzehnten zum Verfahren der Wahl im langfristigen Atemwegsmanagement beatmeter Intensivpatienten entwickelt . Alternativ zur klassisch-konventionellen Tracheotomie existieren inzwischen verschiedene Verfahren zur perkutanen Tracheotomie . Hierzu zaehlen die perkutanen Dilatationstracheotomien nach Ciaglia ( PDT Griggs ( ) , GWDF ) und Schachner ( Rapitrach ) . Vor allem die 1985 eingefuehrte PDT nach Ciaglia hat sich gegenwaertig im intensivmedizinischen Bereich als eine sichere und konstenaermere Methode im Vergleich zur chirurgisch durchgefuehrten Tracheotomie etabliert . Seit 1996 steht mit der translaryngealen Tracheotomie nach Fantoni eine weitere perkutane Technik zur Verfuegung , die sich durch eine niedrige Komplikationsrate auszeichnet . Trotz der niedrigen Komplikationsraten der perkutanen Verfahren sollten diese , auch wenn sie rasch erlernbar und technisch wenig aufwendig sind , nur von Aerzten angewendet werden , die die Technik der Reintubation und Maskenbeatmung sicher beherrschen . Auch sollte die Moeglichkeit bestehen , ggf. rasch eine konventionelle Tracheotomie durchfuehren zu koennen . Nur unter sorgfaeltiger Beachtung der Kontraindikationen werden die Techniken der perkutanen Tracheotomie ihren Stellenwert behaupten und entsprechende Vorteile fuer die Patienten bieten koennen .
[ "Die", "Tracheotomie", "ist", "einer", "der", "aeltesten", "Eingriffe", "in", "der", "Geschichte", "der", "Chirurgie", "und", "hat", "sich", "in", "den", "vergangenen", "Jahrzehnten", "zum", "Verfahren", "der", "Wahl", "im", "langfristigen", "Atemwegsmanagement", "beatmeter", "Intensivpatienten", "entwickelt", ".", "Alternativ", "zur", "klassisch", "-", "konventionellen", "Tracheotomie", "existieren", "inzwischen", "verschiedene", "Verfahren", "zur", "perkutanen", "Tracheotomie", ".", "Hierzu", "zaehlen", "die", "perkutanen", "Dilatationstracheotomien", "nach", "Ciaglia", "(", "PDT", "Griggs", "(", ")", ",", "GWDF", ")", "und", "Schachner", "(", "Rapitrach", ")", ".", "Vor", "allem", "die", "1985", "eingefuehrte", "PDT", "nach", "Ciaglia", "hat", "sich", "gegenwaertig", "im", "intensivmedizinischen", "Bereich", "als", "eine", "sichere", "und", "konstenaermere", "Methode", "im", "Vergleich", "zur", "chirurgisch", "durchgefuehrten", "Tracheotomie", "etabliert", ".", "Seit", "1996", "steht", "mit", "der", "translaryngealen", "Tracheotomie", "nach", "Fantoni", "eine", "weitere", "perkutane", "Technik", "zur", "Verfuegung", ",", "die", "sich", "durch", "eine", "niedrige", "Komplikationsrate", "auszeichnet", ".", "Trotz", "der", "niedrigen", "Komplikationsraten", "der", "perkutanen", "Verfahren", "sollten", "diese", ",", "auch", "wenn", "sie", "rasch", "erlernbar", "und", "technisch", "wenig", "aufwendig", "sind", ",", "nur", "von", "Aerzten", "angewendet", "werden", ",", "die", "die", "Technik", "der", "Reintubation", "und", "Maskenbeatmung", "sicher", "beherrschen", ".", "Auch", "sollte", "die", "Moeglichkeit", "bestehen", ",", "ggf", ".", "rasch", "eine", "konventionelle", "Tracheotomie", "durchfuehren", "zu", "koennen", ".", "Nur", "unter", "sorgfaeltiger", "Beachtung", "der", "Kontraindikationen", "werden", "die", "Techniken", "der", "perkutanen", "Tracheotomie", "ihren", "Stellenwert", "behaupten", "und", "entsprechende", "Vorteile", "fuer", "die", "Patienten", "bieten", "koennen", "." ]
[ "umlsterm" ]
saphenous vein is an umlsterm, graft is an umlsterm, knee is an umlsterm, vein is an umlsterm, human is an umlsterm, umbilical vein is an umlsterm, grafts is an umlsterm, graft is an umlsterm, generation is an umlsterm, human is an umlsterm, umbilical vein is an umlsterm, graft is an umlsterm, knee is an umlsterm, vein is an umlsterm, knee is an umlsterm, patients is an umlsterm, operation is an umlsterm, leg is an umlsterm, ischemia is an umlsterm, ischemia is an umlsterm, patients is an umlsterm, saphenous vein is an umlsterm, graft is an umlsterm, thrombosis is an umlsterm, patients is an umlsterm, thrombectomy is an umlsterm, secondary is an umlsterm, limb is an umlsterm, graft is an umlsterm, graft is an umlsterm, use is an umlsterm, generation is an umlsterm, human is an umlsterm, umbilical vein is an umlsterm, surgery is an umlsterm, vein is an umlsterm
Gefaesschirurgie.00050091.eng.abstr_task0
Sentence: Greater saphenous vein is the preferred graft material for below knee bypass . In the case of absent autologous vein , modified human umbilical vein ( HUV ) is used less frequently than synthetic grafts . To assess long-term graft patency and degenerative changes , the second generation of modified human umbilical vein graft was chosen for below knee femoropopliteal bypass when autologous vein was not available . Fifty-five below knee femoropopliteal bypasses were performed in 54 patients . In most cases the operation was performed for critical leg ischemia , disabling claudication , or severe acute ischemia . In 25% of patients , previous ipsilateral bypass had been performed . In no case was ipsilateral greater saphenous vein suitable . Early graft thrombosis occurred in 30.9% of patients . In 65% , revision with thrombectomy was successful . Primary ( secondary ) patency rate was 55.2% ( 75 . 5% ) with a limb salvage rate of 88.3% after 48 months . After a maximal follow-up of 57.4 months , duplex scanning could not demonstrate significant aneurysmal graft degeneration . Good graft patency and duplex scan results justify continued use of the second generation of modified human umbilical vein in peripheral bypass surgery when autogenous vein is not suitable . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Greater saphenous vein is the preferred graft material for below knee bypass . In the case of absent autologous vein , modified human umbilical vein ( HUV ) is used less frequently than synthetic grafts . To assess long-term graft patency and degenerative changes , the second generation of modified human umbilical vein graft was chosen for below knee femoropopliteal bypass when autologous vein was not available . Fifty-five below knee femoropopliteal bypasses were performed in 54 patients . In most cases the operation was performed for critical leg ischemia , disabling claudication , or severe acute ischemia . In 25% of patients , previous ipsilateral bypass had been performed . In no case was ipsilateral greater saphenous vein suitable . Early graft thrombosis occurred in 30.9% of patients . In 65% , revision with thrombectomy was successful . Primary ( secondary ) patency rate was 55.2% ( 75 . 5% ) with a limb salvage rate of 88.3% after 48 months . After a maximal follow-up of 57.4 months , duplex scanning could not demonstrate significant aneurysmal graft degeneration . Good graft patency and duplex scan results justify continued use of the second generation of modified human umbilical vein in peripheral bypass surgery when autogenous vein is not suitable .
[ "Greater", "saphenous", "vein", "is", "the", "preferred", "graft", "material", "for", "below", "knee", "bypass", ".", "In", "the", "case", "of", "absent", "autologous", "vein", ",", "modified", "human", "umbilical", "vein", "(", "HUV", ")", "is", "used", "less", "frequently", "than", "synthetic", "grafts", ".", "To", "assess", "long", "-", "term", "graft", "patency", "and", "degenerative", "changes", ",", "the", "second", "generation", "of", "modified", "human", "umbilical", "vein", "graft", "was", "chosen", "for", "below", "knee", "femoropopliteal", "bypass", "when", "autologous", "vein", "was", "not", "available", ".", "Fifty", "-", "five", "below", "knee", "femoropopliteal", "bypasses", "were", "performed", "in", "54", "patients", ".", "In", "most", "cases", "the", "operation", "was", "performed", "for", "critical", "leg", "ischemia", ",", "disabling", "claudication", ",", "or", "severe", "acute", "ischemia", ".", "In", "25", "%", "of", "patients", ",", "previous", "ipsilateral", "bypass", "had", "been", "performed", ".", "In", "no", "case", "was", "ipsilateral", "greater", "saphenous", "vein", "suitable", ".", "Early", "graft", "thrombosis", "occurred", "in", "30.9", "%", "of", "patients", ".", "In", "65", "%", ",", "revision", "with", "thrombectomy", "was", "successful", ".", "Primary", "(", "secondary", ")", "patency", "rate", "was", "55.2", "%", "(", "75", ".", "5", "%", ")", "with", "a", "limb", "salvage", "rate", "of", "88.3", "%", "after", "48", "months", ".", "After", "a", "maximal", "follow", "-", "up", "of", "57.4", "months", ",", "duplex", "scanning", "could", "not", "demonstrate", "significant", "aneurysmal", "graft", "degeneration", ".", "Good", "graft", "patency", "and", "duplex", "scan", "results", "justify", "continued", "use", "of", "the", "second", "generation", "of", "modified", "human", "umbilical", "vein", "in", "peripheral", "bypass", "surgery", "when", "autogenous", "vein", "is", "not", "suitable", "." ]
[ "umlsterm" ]
saphenous vein is an umlsterm, graft is an umlsterm, knee is an umlsterm, vein is an umlsterm, human is an umlsterm, umbilical vein is an umlsterm, grafts is an umlsterm, graft is an umlsterm, generation is an umlsterm, human is an umlsterm, umbilical vein is an umlsterm, graft is an umlsterm, knee is an umlsterm, vein is an umlsterm, knee is an umlsterm, patients is an umlsterm, operation is an umlsterm, leg is an umlsterm, ischemia is an umlsterm, ischemia is an umlsterm, patients is an umlsterm, saphenous vein is an umlsterm, graft is an umlsterm, thrombosis is an umlsterm, patients is an umlsterm, thrombectomy is an umlsterm, secondary is an umlsterm, limb is an umlsterm, graft is an umlsterm, graft is an umlsterm, use is an umlsterm, generation is an umlsterm, human is an umlsterm, umbilical vein is an umlsterm, surgery is an umlsterm, vein is an umlsterm
Gefaesschirurgie.00050091.eng.abstr_task1
Sentence: Greater saphenous vein is the preferred graft material for below knee bypass . In the case of absent autologous vein , modified human umbilical vein ( HUV ) is used less frequently than synthetic grafts . To assess long-term graft patency and degenerative changes , the second generation of modified human umbilical vein graft was chosen for below knee femoropopliteal bypass when autologous vein was not available . Fifty-five below knee femoropopliteal bypasses were performed in 54 patients . In most cases the operation was performed for critical leg ischemia , disabling claudication , or severe acute ischemia . In 25% of patients , previous ipsilateral bypass had been performed . In no case was ipsilateral greater saphenous vein suitable . Early graft thrombosis occurred in 30.9% of patients . In 65% , revision with thrombectomy was successful . Primary ( secondary ) patency rate was 55.2% ( 75 . 5% ) with a limb salvage rate of 88.3% after 48 months . After a maximal follow-up of 57.4 months , duplex scanning could not demonstrate significant aneurysmal graft degeneration . Good graft patency and duplex scan results justify continued use of the second generation of modified human umbilical vein in peripheral bypass surgery when autogenous vein is not suitable . Instructions: please typing these entity words according to sentence: saphenous vein, graft, knee, vein, human, umbilical vein, grafts, graft, generation, human, umbilical vein, graft, knee, vein, knee, patients, operation, leg, ischemia, ischemia, patients, saphenous vein, graft, thrombosis, patients, thrombectomy, secondary, limb, graft, graft, use, generation, human, umbilical vein, surgery, vein Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Greater saphenous vein is the preferred graft material for below knee bypass . In the case of absent autologous vein , modified human umbilical vein ( HUV ) is used less frequently than synthetic grafts . To assess long-term graft patency and degenerative changes , the second generation of modified human umbilical vein graft was chosen for below knee femoropopliteal bypass when autologous vein was not available . Fifty-five below knee femoropopliteal bypasses were performed in 54 patients . In most cases the operation was performed for critical leg ischemia , disabling claudication , or severe acute ischemia . In 25% of patients , previous ipsilateral bypass had been performed . In no case was ipsilateral greater saphenous vein suitable . Early graft thrombosis occurred in 30.9% of patients . In 65% , revision with thrombectomy was successful . Primary ( secondary ) patency rate was 55.2% ( 75 . 5% ) with a limb salvage rate of 88.3% after 48 months . After a maximal follow-up of 57.4 months , duplex scanning could not demonstrate significant aneurysmal graft degeneration . Good graft patency and duplex scan results justify continued use of the second generation of modified human umbilical vein in peripheral bypass surgery when autogenous vein is not suitable .
[ "Greater", "saphenous", "vein", "is", "the", "preferred", "graft", "material", "for", "below", "knee", "bypass", ".", "In", "the", "case", "of", "absent", "autologous", "vein", ",", "modified", "human", "umbilical", "vein", "(", "HUV", ")", "is", "used", "less", "frequently", "than", "synthetic", "grafts", ".", "To", "assess", "long", "-", "term", "graft", "patency", "and", "degenerative", "changes", ",", "the", "second", "generation", "of", "modified", "human", "umbilical", "vein", "graft", "was", "chosen", "for", "below", "knee", "femoropopliteal", "bypass", "when", "autologous", "vein", "was", "not", "available", ".", "Fifty", "-", "five", "below", "knee", "femoropopliteal", "bypasses", "were", "performed", "in", "54", "patients", ".", "In", "most", "cases", "the", "operation", "was", "performed", "for", "critical", "leg", "ischemia", ",", "disabling", "claudication", ",", "or", "severe", "acute", "ischemia", ".", "In", "25", "%", "of", "patients", ",", "previous", "ipsilateral", "bypass", "had", "been", "performed", ".", "In", "no", "case", "was", "ipsilateral", "greater", "saphenous", "vein", "suitable", ".", "Early", "graft", "thrombosis", "occurred", "in", "30.9", "%", "of", "patients", ".", "In", "65", "%", ",", "revision", "with", "thrombectomy", "was", "successful", ".", "Primary", "(", "secondary", ")", "patency", "rate", "was", "55.2", "%", "(", "75", ".", "5", "%", ")", "with", "a", "limb", "salvage", "rate", "of", "88.3", "%", "after", "48", "months", ".", "After", "a", "maximal", "follow", "-", "up", "of", "57.4", "months", ",", "duplex", "scanning", "could", "not", "demonstrate", "significant", "aneurysmal", "graft", "degeneration", ".", "Good", "graft", "patency", "and", "duplex", "scan", "results", "justify", "continued", "use", "of", "the", "second", "generation", "of", "modified", "human", "umbilical", "vein", "in", "peripheral", "bypass", "surgery", "when", "autogenous", "vein", "is", "not", "suitable", "." ]
[ "umlsterm" ]
saphenous vein, graft, knee, vein, human, umbilical vein, grafts, graft, generation, human, umbilical vein, graft, knee, vein, knee, patients, operation, leg, ischemia, ischemia, patients, saphenous vein, graft, thrombosis, patients, thrombectomy, secondary, limb, graft, graft, use, generation, human, umbilical vein, surgery, vein
Gefaesschirurgie.00050091.eng.abstr_task2
Sentence: Greater saphenous vein is the preferred graft material for below knee bypass . In the case of absent autologous vein , modified human umbilical vein ( HUV ) is used less frequently than synthetic grafts . To assess long-term graft patency and degenerative changes , the second generation of modified human umbilical vein graft was chosen for below knee femoropopliteal bypass when autologous vein was not available . Fifty-five below knee femoropopliteal bypasses were performed in 54 patients . In most cases the operation was performed for critical leg ischemia , disabling claudication , or severe acute ischemia . In 25% of patients , previous ipsilateral bypass had been performed . In no case was ipsilateral greater saphenous vein suitable . Early graft thrombosis occurred in 30.9% of patients . In 65% , revision with thrombectomy was successful . Primary ( secondary ) patency rate was 55.2% ( 75 . 5% ) with a limb salvage rate of 88.3% after 48 months . After a maximal follow-up of 57.4 months , duplex scanning could not demonstrate significant aneurysmal graft degeneration . Good graft patency and duplex scan results justify continued use of the second generation of modified human umbilical vein in peripheral bypass surgery when autogenous vein is not suitable . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Greater saphenous vein is the preferred graft material for below knee bypass . In the case of absent autologous vein , modified human umbilical vein ( HUV ) is used less frequently than synthetic grafts . To assess long-term graft patency and degenerative changes , the second generation of modified human umbilical vein graft was chosen for below knee femoropopliteal bypass when autologous vein was not available . Fifty-five below knee femoropopliteal bypasses were performed in 54 patients . In most cases the operation was performed for critical leg ischemia , disabling claudication , or severe acute ischemia . In 25% of patients , previous ipsilateral bypass had been performed . In no case was ipsilateral greater saphenous vein suitable . Early graft thrombosis occurred in 30.9% of patients . In 65% , revision with thrombectomy was successful . Primary ( secondary ) patency rate was 55.2% ( 75 . 5% ) with a limb salvage rate of 88.3% after 48 months . After a maximal follow-up of 57.4 months , duplex scanning could not demonstrate significant aneurysmal graft degeneration . Good graft patency and duplex scan results justify continued use of the second generation of modified human umbilical vein in peripheral bypass surgery when autogenous vein is not suitable .
[ "Greater", "saphenous", "vein", "is", "the", "preferred", "graft", "material", "for", "below", "knee", "bypass", ".", "In", "the", "case", "of", "absent", "autologous", "vein", ",", "modified", "human", "umbilical", "vein", "(", "HUV", ")", "is", "used", "less", "frequently", "than", "synthetic", "grafts", ".", "To", "assess", "long", "-", "term", "graft", "patency", "and", "degenerative", "changes", ",", "the", "second", "generation", "of", "modified", "human", "umbilical", "vein", "graft", "was", "chosen", "for", "below", "knee", "femoropopliteal", "bypass", "when", "autologous", "vein", "was", "not", "available", ".", "Fifty", "-", "five", "below", "knee", "femoropopliteal", "bypasses", "were", "performed", "in", "54", "patients", ".", "In", "most", "cases", "the", "operation", "was", "performed", "for", "critical", "leg", "ischemia", ",", "disabling", "claudication", ",", "or", "severe", "acute", "ischemia", ".", "In", "25", "%", "of", "patients", ",", "previous", "ipsilateral", "bypass", "had", "been", "performed", ".", "In", "no", "case", "was", "ipsilateral", "greater", "saphenous", "vein", "suitable", ".", "Early", "graft", "thrombosis", "occurred", "in", "30.9", "%", "of", "patients", ".", "In", "65", "%", ",", "revision", "with", "thrombectomy", "was", "successful", ".", "Primary", "(", "secondary", ")", "patency", "rate", "was", "55.2", "%", "(", "75", ".", "5", "%", ")", "with", "a", "limb", "salvage", "rate", "of", "88.3", "%", "after", "48", "months", ".", "After", "a", "maximal", "follow", "-", "up", "of", "57.4", "months", ",", "duplex", "scanning", "could", "not", "demonstrate", "significant", "aneurysmal", "graft", "degeneration", ".", "Good", "graft", "patency", "and", "duplex", "scan", "results", "justify", "continued", "use", "of", "the", "second", "generation", "of", "modified", "human", "umbilical", "vein", "in", "peripheral", "bypass", "surgery", "when", "autogenous", "vein", "is", "not", "suitable", "." ]
[ "umlsterm" ]
ectasia is an umlsterm, enlargement is an umlsterm, basilar artery is an umlsterm, aneurysm is an umlsterm, incidence is an umlsterm, All is an umlsterm, patients is an umlsterm, brainstem is an umlsterm, syndrome is an umlsterm, patient is an umlsterm, intensive care is an umlsterm, respiratory insufficiency is an umlsterm, patients died is an umlsterm, care is an umlsterm, patients is an umlsterm, therapeutic is an umlsterm, anticoagulation is an umlsterm, All is an umlsterm, patient is an umlsterm, cerebrovascular ischemia is an umlsterm, risk factors is an umlsterm, patients is an umlsterm, patient is an umlsterm, vertebrobasilar ischemia is an umlsterm, intensive care is an umlsterm, medicine is an umlsterm, Recurrence is an umlsterm, ischemia is an umlsterm, brainstem is an umlsterm, syndrome is an umlsterm, anticoagulation is an umlsterm, risk factors is an umlsterm, employment is an umlsterm, treatment is an umlsterm
DerNervenarzt.70680674.eng.abstr_task0
Sentence: An ectasia and enlargement of the basilar artery by a fusiform aneurysm is called megadolicho basilaris . We report five cases with this condition identified at our clinic since 1989 , reflecting an incidence of 0,05 percent ( 5/9300 scans ) . All patients presented with an acute brainstem syndrome ( medullary in 2 , pontine in 1 and pontomedullary in 2 patient ) . With one exception , all cases required intensive care due to respiratory insufficiency . Two patients died , one required total care , and two patients made a good recovery , one of these under therapeutic anticoagulation . All but one patient experienced additional episodes of cerebrovascular ischemia before or after presentation . Vascular risk factors were found in four patients . The detection of a megadolicho basilaris identifies a patient subgroup that is highly prone to vertebrobasilar ischemia and therefore of high significance for neurological intensive care medicine . Recurrence rate for ischemia is high . While even a severe brainstem syndrome may be reversed under anticoagulation in the individual case , presence of multiple vascular risk factors often prevents the employment of this treatment modality . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
An ectasia and enlargement of the basilar artery by a fusiform aneurysm is called megadolicho basilaris . We report five cases with this condition identified at our clinic since 1989 , reflecting an incidence of 0,05 percent ( 5/9300 scans ) . All patients presented with an acute brainstem syndrome ( medullary in 2 , pontine in 1 and pontomedullary in 2 patient ) . With one exception , all cases required intensive care due to respiratory insufficiency . Two patients died , one required total care , and two patients made a good recovery , one of these under therapeutic anticoagulation . All but one patient experienced additional episodes of cerebrovascular ischemia before or after presentation . Vascular risk factors were found in four patients . The detection of a megadolicho basilaris identifies a patient subgroup that is highly prone to vertebrobasilar ischemia and therefore of high significance for neurological intensive care medicine . Recurrence rate for ischemia is high . While even a severe brainstem syndrome may be reversed under anticoagulation in the individual case , presence of multiple vascular risk factors often prevents the employment of this treatment modality .
[ "An", "ectasia", "and", "enlargement", "of", "the", "basilar", "artery", "by", "a", "fusiform", "aneurysm", "is", "called", "megadolicho", "basilaris", ".", "We", "report", "five", "cases", "with", "this", "condition", "identified", "at", "our", "clinic", "since", "1989", ",", "reflecting", "an", "incidence", "of", "0,05", "percent", "(", "5/9300", "scans", ")", ".", "All", "patients", "presented", "with", "an", "acute", "brainstem", "syndrome", "(", "medullary", "in", "2", ",", "pontine", "in", "1", "and", "pontomedullary", "in", "2", "patient", ")", ".", "With", "one", "exception", ",", "all", "cases", "required", "intensive", "care", "due", "to", "respiratory", "insufficiency", ".", "Two", "patients", "died", ",", "one", "required", "total", "care", ",", "and", "two", "patients", "made", "a", "good", "recovery", ",", "one", "of", "these", "under", "therapeutic", "anticoagulation", ".", "All", "but", "one", "patient", "experienced", "additional", "episodes", "of", "cerebrovascular", "ischemia", "before", "or", "after", "presentation", ".", "Vascular", "risk", "factors", "were", "found", "in", "four", "patients", ".", "The", "detection", "of", "a", "megadolicho", "basilaris", "identifies", "a", "patient", "subgroup", "that", "is", "highly", "prone", "to", "vertebrobasilar", "ischemia", "and", "therefore", "of", "high", "significance", "for", "neurological", "intensive", "care", "medicine", ".", "Recurrence", "rate", "for", "ischemia", "is", "high", ".", "While", "even", "a", "severe", "brainstem", "syndrome", "may", "be", "reversed", "under", "anticoagulation", "in", "the", "individual", "case", ",", "presence", "of", "multiple", "vascular", "risk", "factors", "often", "prevents", "the", "employment", "of", "this", "treatment", "modality", "." ]
[ "umlsterm" ]
ectasia is an umlsterm, enlargement is an umlsterm, basilar artery is an umlsterm, aneurysm is an umlsterm, incidence is an umlsterm, All is an umlsterm, patients is an umlsterm, brainstem is an umlsterm, syndrome is an umlsterm, patient is an umlsterm, intensive care is an umlsterm, respiratory insufficiency is an umlsterm, patients died is an umlsterm, care is an umlsterm, patients is an umlsterm, therapeutic is an umlsterm, anticoagulation is an umlsterm, All is an umlsterm, patient is an umlsterm, cerebrovascular ischemia is an umlsterm, risk factors is an umlsterm, patients is an umlsterm, patient is an umlsterm, vertebrobasilar ischemia is an umlsterm, intensive care is an umlsterm, medicine is an umlsterm, Recurrence is an umlsterm, ischemia is an umlsterm, brainstem is an umlsterm, syndrome is an umlsterm, anticoagulation is an umlsterm, risk factors is an umlsterm, employment is an umlsterm, treatment is an umlsterm
DerNervenarzt.70680674.eng.abstr_task1
Sentence: An ectasia and enlargement of the basilar artery by a fusiform aneurysm is called megadolicho basilaris . We report five cases with this condition identified at our clinic since 1989 , reflecting an incidence of 0,05 percent ( 5/9300 scans ) . All patients presented with an acute brainstem syndrome ( medullary in 2 , pontine in 1 and pontomedullary in 2 patient ) . With one exception , all cases required intensive care due to respiratory insufficiency . Two patients died , one required total care , and two patients made a good recovery , one of these under therapeutic anticoagulation . All but one patient experienced additional episodes of cerebrovascular ischemia before or after presentation . Vascular risk factors were found in four patients . The detection of a megadolicho basilaris identifies a patient subgroup that is highly prone to vertebrobasilar ischemia and therefore of high significance for neurological intensive care medicine . Recurrence rate for ischemia is high . While even a severe brainstem syndrome may be reversed under anticoagulation in the individual case , presence of multiple vascular risk factors often prevents the employment of this treatment modality . Instructions: please typing these entity words according to sentence: ectasia, enlargement, basilar artery, aneurysm, incidence, All, patients, brainstem, syndrome, patient, intensive care, respiratory insufficiency, patients died, care, patients, therapeutic, anticoagulation, All, patient, cerebrovascular ischemia, risk factors, patients, patient, vertebrobasilar ischemia, intensive care, medicine, Recurrence, ischemia, brainstem, syndrome, anticoagulation, risk factors, employment, treatment Options: umlsterm
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
An ectasia and enlargement of the basilar artery by a fusiform aneurysm is called megadolicho basilaris . We report five cases with this condition identified at our clinic since 1989 , reflecting an incidence of 0,05 percent ( 5/9300 scans ) . All patients presented with an acute brainstem syndrome ( medullary in 2 , pontine in 1 and pontomedullary in 2 patient ) . With one exception , all cases required intensive care due to respiratory insufficiency . Two patients died , one required total care , and two patients made a good recovery , one of these under therapeutic anticoagulation . All but one patient experienced additional episodes of cerebrovascular ischemia before or after presentation . Vascular risk factors were found in four patients . The detection of a megadolicho basilaris identifies a patient subgroup that is highly prone to vertebrobasilar ischemia and therefore of high significance for neurological intensive care medicine . Recurrence rate for ischemia is high . While even a severe brainstem syndrome may be reversed under anticoagulation in the individual case , presence of multiple vascular risk factors often prevents the employment of this treatment modality .
[ "An", "ectasia", "and", "enlargement", "of", "the", "basilar", "artery", "by", "a", "fusiform", "aneurysm", "is", "called", "megadolicho", "basilaris", ".", "We", "report", "five", "cases", "with", "this", "condition", "identified", "at", "our", "clinic", "since", "1989", ",", "reflecting", "an", "incidence", "of", "0,05", "percent", "(", "5/9300", "scans", ")", ".", "All", "patients", "presented", "with", "an", "acute", "brainstem", "syndrome", "(", "medullary", "in", "2", ",", "pontine", "in", "1", "and", "pontomedullary", "in", "2", "patient", ")", ".", "With", "one", "exception", ",", "all", "cases", "required", "intensive", "care", "due", "to", "respiratory", "insufficiency", ".", "Two", "patients", "died", ",", "one", "required", "total", "care", ",", "and", "two", "patients", "made", "a", "good", "recovery", ",", "one", "of", "these", "under", "therapeutic", "anticoagulation", ".", "All", "but", "one", "patient", "experienced", "additional", "episodes", "of", "cerebrovascular", "ischemia", "before", "or", "after", "presentation", ".", "Vascular", "risk", "factors", "were", "found", "in", "four", "patients", ".", "The", "detection", "of", "a", "megadolicho", "basilaris", "identifies", "a", "patient", "subgroup", "that", "is", "highly", "prone", "to", "vertebrobasilar", "ischemia", "and", "therefore", "of", "high", "significance", "for", "neurological", "intensive", "care", "medicine", ".", "Recurrence", "rate", "for", "ischemia", "is", "high", ".", "While", "even", "a", "severe", "brainstem", "syndrome", "may", "be", "reversed", "under", "anticoagulation", "in", "the", "individual", "case", ",", "presence", "of", "multiple", "vascular", "risk", "factors", "often", "prevents", "the", "employment", "of", "this", "treatment", "modality", "." ]
[ "umlsterm" ]
ectasia, enlargement, basilar artery, aneurysm, incidence, All, patients, brainstem, syndrome, patient, intensive care, respiratory insufficiency, patients died, care, patients, therapeutic, anticoagulation, All, patient, cerebrovascular ischemia, risk factors, patients, patient, vertebrobasilar ischemia, intensive care, medicine, Recurrence, ischemia, brainstem, syndrome, anticoagulation, risk factors, employment, treatment
DerNervenarzt.70680674.eng.abstr_task2
Sentence: An ectasia and enlargement of the basilar artery by a fusiform aneurysm is called megadolicho basilaris . We report five cases with this condition identified at our clinic since 1989 , reflecting an incidence of 0,05 percent ( 5/9300 scans ) . All patients presented with an acute brainstem syndrome ( medullary in 2 , pontine in 1 and pontomedullary in 2 patient ) . With one exception , all cases required intensive care due to respiratory insufficiency . Two patients died , one required total care , and two patients made a good recovery , one of these under therapeutic anticoagulation . All but one patient experienced additional episodes of cerebrovascular ischemia before or after presentation . Vascular risk factors were found in four patients . The detection of a megadolicho basilaris identifies a patient subgroup that is highly prone to vertebrobasilar ischemia and therefore of high significance for neurological intensive care medicine . Recurrence rate for ischemia is high . While even a severe brainstem syndrome may be reversed under anticoagulation in the individual case , presence of multiple vascular risk factors often prevents the employment of this treatment modality . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
An ectasia and enlargement of the basilar artery by a fusiform aneurysm is called megadolicho basilaris . We report five cases with this condition identified at our clinic since 1989 , reflecting an incidence of 0,05 percent ( 5/9300 scans ) . All patients presented with an acute brainstem syndrome ( medullary in 2 , pontine in 1 and pontomedullary in 2 patient ) . With one exception , all cases required intensive care due to respiratory insufficiency . Two patients died , one required total care , and two patients made a good recovery , one of these under therapeutic anticoagulation . All but one patient experienced additional episodes of cerebrovascular ischemia before or after presentation . Vascular risk factors were found in four patients . The detection of a megadolicho basilaris identifies a patient subgroup that is highly prone to vertebrobasilar ischemia and therefore of high significance for neurological intensive care medicine . Recurrence rate for ischemia is high . While even a severe brainstem syndrome may be reversed under anticoagulation in the individual case , presence of multiple vascular risk factors often prevents the employment of this treatment modality .
[ "An", "ectasia", "and", "enlargement", "of", "the", "basilar", "artery", "by", "a", "fusiform", "aneurysm", "is", "called", "megadolicho", "basilaris", ".", "We", "report", "five", "cases", "with", "this", "condition", "identified", "at", "our", "clinic", "since", "1989", ",", "reflecting", "an", "incidence", "of", "0,05", "percent", "(", "5/9300", "scans", ")", ".", "All", "patients", "presented", "with", "an", "acute", "brainstem", "syndrome", "(", "medullary", "in", "2", ",", "pontine", "in", "1", "and", "pontomedullary", "in", "2", "patient", ")", ".", "With", "one", "exception", ",", "all", "cases", "required", "intensive", "care", "due", "to", "respiratory", "insufficiency", ".", "Two", "patients", "died", ",", "one", "required", "total", "care", ",", "and", "two", "patients", "made", "a", "good", "recovery", ",", "one", "of", "these", "under", "therapeutic", "anticoagulation", ".", "All", "but", "one", "patient", "experienced", "additional", "episodes", "of", "cerebrovascular", "ischemia", "before", "or", "after", "presentation", ".", "Vascular", "risk", "factors", "were", "found", "in", "four", "patients", ".", "The", "detection", "of", "a", "megadolicho", "basilaris", "identifies", "a", "patient", "subgroup", "that", "is", "highly", "prone", "to", "vertebrobasilar", "ischemia", "and", "therefore", "of", "high", "significance", "for", "neurological", "intensive", "care", "medicine", ".", "Recurrence", "rate", "for", "ischemia", "is", "high", ".", "While", "even", "a", "severe", "brainstem", "syndrome", "may", "be", "reversed", "under", "anticoagulation", "in", "the", "individual", "case", ",", "presence", "of", "multiple", "vascular", "risk", "factors", "often", "prevents", "the", "employment", "of", "this", "treatment", "modality", "." ]
[ "umlsterm" ]
carcinoma urotelial de vejiga superficial de alto grado is a MORFOLOGIA_NEOPLASIA, carcinoma transicional de alto grado is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de próstata multifocal gleason 6 is a MORFOLOGIA_NEOPLASIA, carcinoma transicional de vejiga , G3 is a MORFOLOGIA_NEOPLASIA, enfermedad a distancia is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis de carcinoma urotelial is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, lesiones óseas is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA
349_task0
Sentence: ANAMNESIS: Varón de 75 años sin alergias conocidas, fumador de 2 paquetes de tabaco al día y con antecedentes de hipertensión arterial, diabetes mellitus tipo 2 y cardiopatía isquémica crónica. Comerciante jubilado, vivía con su esposa y era independiente para las actividades básicas. En tratamiento con metformina 850 mg/12h, ácido acetil salicílico 100 mg/24h, atenolol 100 mg/24h y ramipril 5 mg/24h. En estudio por Sº Urología desde el año 2011, el paciente se había intervenido en dos ocasiones mediante resección transuretral por carcinoma urotelial de vejiga superficial de alto grado, recibiendo BCG tras la última intervención a primeros de 2012. En noviembre de ese mismo año se objetiva nueva recidiva local en tomografía computerizada (TC), realizándose una tercera RTU con diagnóstico de carcinoma transicional de alto grado pT2. En TC postquirúrgico se aprecia recidiva local que provoca una uropatía obstructiva bilateral asociada sin enfermedad regional ni a distancia, por lo que en junio de 2013 se interviene de manera reglada mediante cistoprostatectomía radical con linfadenectomía ilio-obturatriz bilateral y anastomosis tipo Bricker. El diagnóstico anatomopatológico final fue: adenocarcinoma de próstata multifocal gleason 6 (3+3) estadio pT2 pNx; carcinoma transicional de vejiga, G3, estadio pT2b pN1 (2/4). Inicia seguimiento por parte del Sº Urología. En enero de 2015 se detecta recidiva de la enfermedad a distancia, con aparición de metástasis óseas en calota craneal, parrilla costal, esqueleto axial, pelvis y huesos largos. Se realiza biopsia de fémur con diagnóstico compatible con metástasis de carcinoma urotelial, motivo por el cual es derivado a consulta de oncología médica para valoración de tratamiento específico. Dado que el paciente no era apto para cisplatino por aclaramiento de creatinina menor de 60 ml/min se incluye en un ensayo clínico fase II con pembrolizumab, a dosis de 200 mg cada 21 días. Tras la primera dosis presentó mucositis grado I, astenia y anorexia grado II, así como nauseas y vómitos ocasionales con pérdida de peso significativa, por lo que fue valorado por el Sº Nutrición para plantear suplementos dietéticos. Tras la segunda dosis acudió al Sº Urgencias en varias ocasiones por empeoramiento del cuadro constitucional, con imposibilidad para la deambulación y cefalea moderada de predominio vespertino. Ingresa finalmente al presentar deterioro severo del estado general y anorexia extrema que impedía una adecuada nutrición del paciente. Exploración física Al ingreso el paciente presentaba regular estado general, con un ECOG performance status de 4. A la exploración se encontraba hemodinámicamente estable, sin otros hallazgos de interés salvo sequedad de piel y mucosas y muguet oral. Pruebas complementarias Se realizó analítica urgente con bioquímica, en la que destacaba un discreto deterioro crónico de la función renal con elevación de la urea ya conocido, así como hiponatremia e hiperpotasemia leves. En el hemograma se observó una discreta anemia crónica microcítica-hipocrómica ya conocida, con serie blanca y plaquetas sin alteraciones de interés. El estudio de coagulación presentaba INR ligeramente alargado pero estable respecto a valores previos. Una vez en planta, se solicitó analítica completa con perfiles, destacando en la bioquímica hipoproteinemia leve, así como datos de colestasis disociada ya conocidos y discreta elevación de la proteína C reactiva. El proteinograma reveló una hipoalbuminemia moderada. El perfil lipídico mostraba una hipertrigliceridemia. El estudio de anemia fue compatible con anemia de trastornos crónicos. Ante la sospecha clínica de hipopituitarismo secundario a hipofisitis autoinmune (HA) inducida por pembrolizumab, se solicitó perfil hormonal/hipofisario que demostró la existencia de hipocortisolismo severo e hipotiroidismo central (tabla 1). Los niveles de adrenocorticotropina (ACTH) no se pudieron determinar en un primer momento, siendo normales en una segunda extracción bajo los efectos del tratamiento con corticoides. Los niveles de gonadotropinas, testosterona y prolactina fueron normales. Se realizó TC de cráneo que descartó la presencia de metástasis cerebrales, y un TC de tórax y abdomen que descartó asimismo progresión de la enfermedad tumoral, manteniéndose estables las múltiples lesiones óseas y los cambios residuales postquirúrgicos. Diagnóstico Hipopituitarismo parcial secundario a hipofisitis autoinmune inducida por pembrolizumab. Tratamiento Se solicitó valoración conjunta tanto con el Sº Nutrición, que pautó nutrición enteral por sonda nasogástrica para asegurar un adecuado aporte nutricional, así como con Sº Endocrinología, que apoyó el diagnóstico, iniciando tratamiento con hidrocortisona 50 mg cada 8 horas y levotiroxina 75 mcg cada 24 horas por vía intravenosa (iv). Evolución Durante el ingreso toleró adecuadamente la nutrición enteral con suplementos hiperproteicos, inicialmente por sonda nasogástrica y posteriormente por vía oral, con notable mejoría del estado nutricional. Como complicación se produjo un descenso de los niveles de fósforo en sangre en el contexto de posible síndrome de renutrición, por lo que se añadió tiamina 300 mg iv al tratamiento y se redujeron progresivamente los aportes nutricionales. Por otro lado se simplificó el tratamiento hormonal sustitutivo a vía oral, inicialmente con hidrocortisona 20 mg cada 8 horas y levotiroxina 50 mcg, disminuyendo al alta la dosis de hidrocortisona a 20 mg en la mañana y 10 mg en la noche. El paciente experimentó mejoría progresiva del cuadro constitucional, con disminución de la astenia y movilización paulatina. La cefalea referida inicialmente también mejoró notablemente hasta su práctica desaparición. Ante el cuadro de toxicidad grave inducido por pembrolizumab el paciente salió del ensayo clínico. En gammagrafía ósea posterior se objetivó aumento de lesiones metastásicas por lo que se pautó tratamiento con ácido zoledrónico cada 28 días ajustado a su función renal y aportes diarios de vitamina D y calcio. A las seis semanas del alta hospitalaria, el paciente presenta nuevo empeoramiento clínico con anorexia severa, dolor óseo no controlado e impotencia funcional. Se se deriva a la unidad de hospitalización domiciliaria para seguimiento y tratamiento siendo finalmente éxitus. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
ANAMNESIS: Varón de 75 años sin alergias conocidas, fumador de 2 paquetes de tabaco al día y con antecedentes de hipertensión arterial, diabetes mellitus tipo 2 y cardiopatía isquémica crónica. Comerciante jubilado, vivía con su esposa y era independiente para las actividades básicas. En tratamiento con metformina 850 mg/12h, ácido acetil salicílico 100 mg/24h, atenolol 100 mg/24h y ramipril 5 mg/24h. En estudio por Sº Urología desde el año 2011, el paciente se había intervenido en dos ocasiones mediante resección transuretral por carcinoma urotelial de vejiga superficial de alto grado, recibiendo BCG tras la última intervención a primeros de 2012. En noviembre de ese mismo año se objetiva nueva recidiva local en tomografía computerizada (TC), realizándose una tercera RTU con diagnóstico de carcinoma transicional de alto grado pT2. En TC postquirúrgico se aprecia recidiva local que provoca una uropatía obstructiva bilateral asociada sin enfermedad regional ni a distancia, por lo que en junio de 2013 se interviene de manera reglada mediante cistoprostatectomía radical con linfadenectomía ilio-obturatriz bilateral y anastomosis tipo Bricker. El diagnóstico anatomopatológico final fue: adenocarcinoma de próstata multifocal gleason 6 (3+3) estadio pT2 pNx; carcinoma transicional de vejiga, G3, estadio pT2b pN1 (2/4). Inicia seguimiento por parte del Sº Urología. En enero de 2015 se detecta recidiva de la enfermedad a distancia, con aparición de metástasis óseas en calota craneal, parrilla costal, esqueleto axial, pelvis y huesos largos. Se realiza biopsia de fémur con diagnóstico compatible con metástasis de carcinoma urotelial, motivo por el cual es derivado a consulta de oncología médica para valoración de tratamiento específico. Dado que el paciente no era apto para cisplatino por aclaramiento de creatinina menor de 60 ml/min se incluye en un ensayo clínico fase II con pembrolizumab, a dosis de 200 mg cada 21 días. Tras la primera dosis presentó mucositis grado I, astenia y anorexia grado II, así como nauseas y vómitos ocasionales con pérdida de peso significativa, por lo que fue valorado por el Sº Nutrición para plantear suplementos dietéticos. Tras la segunda dosis acudió al Sº Urgencias en varias ocasiones por empeoramiento del cuadro constitucional, con imposibilidad para la deambulación y cefalea moderada de predominio vespertino. Ingresa finalmente al presentar deterioro severo del estado general y anorexia extrema que impedía una adecuada nutrición del paciente. Exploración física Al ingreso el paciente presentaba regular estado general, con un ECOG performance status de 4. A la exploración se encontraba hemodinámicamente estable, sin otros hallazgos de interés salvo sequedad de piel y mucosas y muguet oral. Pruebas complementarias Se realizó analítica urgente con bioquímica, en la que destacaba un discreto deterioro crónico de la función renal con elevación de la urea ya conocido, así como hiponatremia e hiperpotasemia leves. En el hemograma se observó una discreta anemia crónica microcítica-hipocrómica ya conocida, con serie blanca y plaquetas sin alteraciones de interés. El estudio de coagulación presentaba INR ligeramente alargado pero estable respecto a valores previos. Una vez en planta, se solicitó analítica completa con perfiles, destacando en la bioquímica hipoproteinemia leve, así como datos de colestasis disociada ya conocidos y discreta elevación de la proteína C reactiva. El proteinograma reveló una hipoalbuminemia moderada. El perfil lipídico mostraba una hipertrigliceridemia. El estudio de anemia fue compatible con anemia de trastornos crónicos. Ante la sospecha clínica de hipopituitarismo secundario a hipofisitis autoinmune (HA) inducida por pembrolizumab, se solicitó perfil hormonal/hipofisario que demostró la existencia de hipocortisolismo severo e hipotiroidismo central (tabla 1). Los niveles de adrenocorticotropina (ACTH) no se pudieron determinar en un primer momento, siendo normales en una segunda extracción bajo los efectos del tratamiento con corticoides. Los niveles de gonadotropinas, testosterona y prolactina fueron normales. Se realizó TC de cráneo que descartó la presencia de metástasis cerebrales, y un TC de tórax y abdomen que descartó asimismo progresión de la enfermedad tumoral, manteniéndose estables las múltiples lesiones óseas y los cambios residuales postquirúrgicos. Diagnóstico Hipopituitarismo parcial secundario a hipofisitis autoinmune inducida por pembrolizumab. Tratamiento Se solicitó valoración conjunta tanto con el Sº Nutrición, que pautó nutrición enteral por sonda nasogástrica para asegurar un adecuado aporte nutricional, así como con Sº Endocrinología, que apoyó el diagnóstico, iniciando tratamiento con hidrocortisona 50 mg cada 8 horas y levotiroxina 75 mcg cada 24 horas por vía intravenosa (iv). Evolución Durante el ingreso toleró adecuadamente la nutrición enteral con suplementos hiperproteicos, inicialmente por sonda nasogástrica y posteriormente por vía oral, con notable mejoría del estado nutricional. Como complicación se produjo un descenso de los niveles de fósforo en sangre en el contexto de posible síndrome de renutrición, por lo que se añadió tiamina 300 mg iv al tratamiento y se redujeron progresivamente los aportes nutricionales. Por otro lado se simplificó el tratamiento hormonal sustitutivo a vía oral, inicialmente con hidrocortisona 20 mg cada 8 horas y levotiroxina 50 mcg, disminuyendo al alta la dosis de hidrocortisona a 20 mg en la mañana y 10 mg en la noche. El paciente experimentó mejoría progresiva del cuadro constitucional, con disminución de la astenia y movilización paulatina. La cefalea referida inicialmente también mejoró notablemente hasta su práctica desaparición. Ante el cuadro de toxicidad grave inducido por pembrolizumab el paciente salió del ensayo clínico. En gammagrafía ósea posterior se objetivó aumento de lesiones metastásicas por lo que se pautó tratamiento con ácido zoledrónico cada 28 días ajustado a su función renal y aportes diarios de vitamina D y calcio. A las seis semanas del alta hospitalaria, el paciente presenta nuevo empeoramiento clínico con anorexia severa, dolor óseo no controlado e impotencia funcional. Se se deriva a la unidad de hospitalización domiciliaria para seguimiento y tratamiento siendo finalmente éxitus.
[ "ANAMNESIS", ":", "\n", "Varón", "de", "75", "años", "sin", "alergias", "conocidas", ",", "fumador", "de", "2", "paquetes", "de", "tabaco", "al", "día", "y", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", "y", "cardiopatía", "isquémica", "crónica", ".", "Comerciante", "jubilado", ",", "vivía", "con", "su", "esposa", "y", "era", "independiente", "para", "las", "actividades", "básicas", ".", "En", "tratamiento", "con", "metformina", "850", "mg/12h", ",", "ácido", "acetil", "salicílico", "100", "mg/24h", ",", "atenolol", "100", "mg/24h", "y", "ramipril", "5", "mg/24h", ".", "En", "estudio", "por", "Sº", "Urología", "desde", "el", "año", "2011", ",", "el", "paciente", "se", "había", "intervenido", "en", "dos", "ocasiones", "mediante", "resección", "transuretral", "por", "carcinoma", "urotelial", "de", "vejiga", "superficial", "de", "alto", "grado", ",", "recibiendo", "BCG", "tras", "la", "última", "intervención", "a", "primeros", "de", "2012", ".", "En", "noviembre", "de", "ese", "mismo", "año", "se", "objetiva", "nueva", "recidiva", "local", "en", "tomografía", "computerizada", "(", "TC", ")", ",", "realizándose", "una", "tercera", "RTU", "con", "diagnóstico", "de", "carcinoma", "transicional", "de", "alto", "grado", "pT2", ".", "En", "TC", "postquirúrgico", "se", "aprecia", "recidiva", "local", "que", "provoca", "una", "uropatía", "obstructiva", "bilateral", "asociada", "sin", "enfermedad", "regional", "ni", "a", "distancia", ",", "por", "lo", "que", "en", "junio", "de", "2013", "se", "interviene", "de", "manera", "reglada", "mediante", "cistoprostatectomía", "radical", "con", "linfadenectomía", "ilio", "-", "obturatriz", "bilateral", "y", "anastomosis", "tipo", "Bricker", ".", "El", "diagnóstico", "anatomopatológico", "final", "fue", ":", "adenocarcinoma", "de", "próstata", "multifocal", "gleason", "6", "(", "3", "+", "3", ")", "estadio", "pT2", "pNx", ";", "carcinoma", "transicional", "de", "vejiga", ",", "G3", ",", "estadio", "pT2b", "pN1", "(", "2/4", ")", ".", "Inicia", "seguimiento", "por", "parte", "del", "Sº", "Urología", ".", "En", "enero", "de", "2015", "se", "detecta", "recidiva", "de", "la", "enfermedad", "a", "distancia", ",", "con", "aparición", "de", "metástasis", "óseas", "en", "calota", "craneal", ",", "parrilla", "costal", ",", "esqueleto", "axial", ",", "pelvis", "y", "huesos", "largos", ".", "Se", "realiza", "biopsia", "de", "fémur", "con", "diagnóstico", "compatible", "con", "metástasis", "de", "carcinoma", "urotelial", ",", "motivo", "por", "el", "cual", "es", "derivado", "a", "consulta", "de", "oncología", "médica", "para", "valoración", "de", "tratamiento", "específico", ".", "Dado", "que", "el", "paciente", "no", "era", "apto", "para", "cisplatino", "por", "aclaramiento", "de", "creatinina", "menor", "de", "60", "ml", "/", "min", "se", "incluye", "en", "un", "ensayo", "clínico", "fase", "II", "con", "pembrolizumab", ",", "a", "dosis", "de", "200", "mg", "cada", "21", "días", ".", "Tras", "la", "primera", "dosis", "presentó", "mucositis", "grado", "I", ",", "astenia", "y", "anorexia", "grado", "II", ",", "así", "como", "nauseas", "y", "vómitos", "ocasionales", "con", "pérdida", "de", "peso", "significativa", ",", "por", "lo", "que", "fue", "valorado", "por", "el", "Sº", "Nutrición", "para", "plantear", "suplementos", "dietéticos", ".", "Tras", "la", "segunda", "dosis", "acudió", "al", "Sº", "Urgencias", "en", "varias", "ocasiones", "por", "empeoramiento", "del", "cuadro", "constitucional", ",", "con", "imposibilidad", "para", "la", "deambulación", "y", "cefalea", "moderada", "de", "predominio", "vespertino", ".", "Ingresa", "finalmente", "al", "presentar", "deterioro", "severo", "del", "estado", "general", "y", "anorexia", "extrema", "que", "impedía", "una", "adecuada", "nutrición", "del", "paciente", ".", "\n\n", "Exploración", "física", "\n", "Al", "ingreso", "el", "paciente", "presentaba", "regular", "estado", "general", ",", "con", "un", "ECOG", "performance", "status", "de", "4", ".", "A", "la", "exploración", "se", "encontraba", "hemodinámicamente", "estable", ",", "sin", "otros", "hallazgos", "de", "interés", "salvo", "sequedad", "de", "piel", "y", "mucosas", "y", "muguet", "oral", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realizó", "analítica", "urgente", "con", "bioquímica", ",", "en", "la", "que", "destacaba", "un", "discreto", "deterioro", "crónico", "de", "la", "función", "renal", "con", "elevación", "de", "la", "urea", "ya", "conocido", ",", "así", "como", "hiponatremia", "e", "hiperpotasemia", "leves", ".", "En", "el", "hemograma", "se", "observó", "una", "discreta", "anemia", "crónica", "microcítica", "-", "hipocrómica", "ya", "conocida", ",", "con", "serie", "blanca", "y", "plaquetas", "sin", "alteraciones", "de", "interés", ".", "El", "estudio", "de", "coagulación", "presentaba", "INR", "ligeramente", "alargado", "pero", "estable", "respecto", "a", "valores", "previos", ".", "\n", "Una", "vez", "en", "planta", ",", "se", "solicitó", "analítica", "completa", "con", "perfiles", ",", "destacando", "en", "la", "bioquímica", "hipoproteinemia", "leve", ",", "así", "como", "datos", "de", "colestasis", "disociada", "ya", "conocidos", "y", "discreta", "elevación", "de", "la", "proteína", "C", "reactiva", ".", "El", "proteinograma", "reveló", "una", "hipoalbuminemia", "moderada", ".", "El", "perfil", "lipídico", "mostraba", "una", "hipertrigliceridemia", ".", "El", "estudio", "de", "anemia", "fue", "compatible", "con", "anemia", "de", "trastornos", "crónicos", ".", "Ante", "la", "sospecha", "clínica", "de", "hipopituitarismo", "secundario", "a", "hipofisitis", "autoinmune", "(", "HA", ")", "inducida", "por", "pembrolizumab", ",", "se", "solicitó", "perfil", "hormonal", "/", "hipofisario", "que", "demostró", "la", "existencia", "de", "hipocortisolismo", "severo", "e", "hipotiroidismo", "central", "(", "tabla", "1", ")", ".", "Los", "niveles", "de", "adrenocorticotropina", "(", "ACTH", ")", "no", "se", "pudieron", "determinar", "en", "un", "primer", "momento", ",", "siendo", "normales", "en", "una", "segunda", "extracción", "bajo", "los", "efectos", "del", "tratamiento", "con", "corticoides", ".", "Los", "niveles", "de", "gonadotropinas", ",", "testosterona", "y", "prolactina", "fueron", "normales", ".", "Se", "realizó", "TC", "de", "cráneo", "que", "descartó", "la", "presencia", "de", "metástasis", "cerebrales", ",", "y", "un", "TC", "de", "tórax", "y", "abdomen", "que", "descartó", "asimismo", "progresión", "de", "la", "enfermedad", "tumoral", ",", "manteniéndose", "estables", "las", "múltiples", "lesiones", "óseas", "y", "los", "cambios", "residuales", "postquirúrgicos", ".", "\n\n", "Diagnóstico", "\n", "Hipopituitarismo", "parcial", "secundario", "a", "hipofisitis", "autoinmune", "inducida", "por", "pembrolizumab", ".", "\n\n", "Tratamiento", "\n", "Se", "solicitó", "valoración", "conjunta", "tanto", "con", "el", "Sº", "Nutrición", ",", "que", "pautó", "nutrición", "enteral", "por", "sonda", "nasogástrica", "para", "asegurar", "un", "adecuado", "aporte", "nutricional", ",", "así", "como", "con", "Sº", "Endocrinología", ",", "que", "apoyó", "el", "diagnóstico", ",", "iniciando", "tratamiento", "con", "hidrocortisona", "50", "mg", "cada", "8", "horas", "y", "levotiroxina", "75", "mcg", "cada", "24", "horas", "por", "vía", "intravenosa", "(", "iv", ")", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", "toleró", "adecuadamente", "la", "nutrición", "enteral", "con", "suplementos", "hiperproteicos", ",", "inicialmente", "por", "sonda", "nasogástrica", "y", "posteriormente", "por", "vía", "oral", ",", "con", "notable", "mejoría", "del", "estado", "nutricional", ".", "Como", "complicación", "se", "produjo", "un", "descenso", "de", "los", "niveles", "de", "fósforo", "en", "sangre", "en", "el", "contexto", "de", "posible", "síndrome", "de", "renutrición", ",", "por", "lo", "que", "se", "añadió", "tiamina", "300", "mg", "iv", "al", "tratamiento", "y", "se", "redujeron", "progresivamente", "los", "aportes", "nutricionales", ".", "\n", "Por", "otro", "lado", "se", "simplificó", "el", "tratamiento", "hormonal", "sustitutivo", "a", "vía", "oral", ",", "inicialmente", "con", "hidrocortisona", "20", "mg", "cada", "8", "horas", "y", "levotiroxina", "50", "mcg", ",", "disminuyendo", "al", "alta", "la", "dosis", "de", "hidrocortisona", "a", "20", "mg", "en", "la", "mañana", "y", "10", "mg", "en", "la", "noche", ".", "El", "paciente", "experimentó", "mejoría", "progresiva", "del", "cuadro", "constitucional", ",", "con", "disminución", "de", "la", "astenia", "y", "movilización", "paulatina", ".", "La", "cefalea", "referida", "inicialmente", "también", "mejoró", "notablemente", "hasta", "su", "práctica", "desaparición", ".", "\n", "Ante", "el", "cuadro", "de", "toxicidad", "grave", "inducido", "por", "pembrolizumab", "el", "paciente", "salió", "del", "ensayo", "clínico", ".", "En", "gammagrafía", "ósea", "posterior", "se", "objetivó", "aumento", "de", "lesiones", "metastásicas", "por", "lo", "que", "se", "pautó", "tratamiento", "con", "ácido", "zoledrónico", "cada", "28", "días", "ajustado", "a", "su", "función", "renal", "y", "aportes", "diarios", "de", "vitamina", "D", "y", "calcio", ".", "A", "las", "seis", "semanas", "del", "alta", "hospitalaria", ",", "el", "paciente", "presenta", "nuevo", "empeoramiento", "clínico", "con", "anorexia", "severa", ",", "dolor", "óseo", "no", "controlado", "e", "impotencia", "funcional", ".", "Se", "se", "deriva", "a", "la", "unidad", "de", "hospitalización", "domiciliaria", "para", "seguimiento", "y", "tratamiento", "siendo", "finalmente", "éxitus", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
carcinoma urotelial de vejiga superficial de alto grado is a MORFOLOGIA_NEOPLASIA, carcinoma transicional de alto grado is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de próstata multifocal gleason 6 is a MORFOLOGIA_NEOPLASIA, carcinoma transicional de vejiga , G3 is a MORFOLOGIA_NEOPLASIA, enfermedad a distancia is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis de carcinoma urotelial is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, lesiones óseas is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA
349_task1
Sentence: ANAMNESIS: Varón de 75 años sin alergias conocidas, fumador de 2 paquetes de tabaco al día y con antecedentes de hipertensión arterial, diabetes mellitus tipo 2 y cardiopatía isquémica crónica. Comerciante jubilado, vivía con su esposa y era independiente para las actividades básicas. En tratamiento con metformina 850 mg/12h, ácido acetil salicílico 100 mg/24h, atenolol 100 mg/24h y ramipril 5 mg/24h. En estudio por Sº Urología desde el año 2011, el paciente se había intervenido en dos ocasiones mediante resección transuretral por carcinoma urotelial de vejiga superficial de alto grado, recibiendo BCG tras la última intervención a primeros de 2012. En noviembre de ese mismo año se objetiva nueva recidiva local en tomografía computerizada (TC), realizándose una tercera RTU con diagnóstico de carcinoma transicional de alto grado pT2. En TC postquirúrgico se aprecia recidiva local que provoca una uropatía obstructiva bilateral asociada sin enfermedad regional ni a distancia, por lo que en junio de 2013 se interviene de manera reglada mediante cistoprostatectomía radical con linfadenectomía ilio-obturatriz bilateral y anastomosis tipo Bricker. El diagnóstico anatomopatológico final fue: adenocarcinoma de próstata multifocal gleason 6 (3+3) estadio pT2 pNx; carcinoma transicional de vejiga, G3, estadio pT2b pN1 (2/4). Inicia seguimiento por parte del Sº Urología. En enero de 2015 se detecta recidiva de la enfermedad a distancia, con aparición de metástasis óseas en calota craneal, parrilla costal, esqueleto axial, pelvis y huesos largos. Se realiza biopsia de fémur con diagnóstico compatible con metástasis de carcinoma urotelial, motivo por el cual es derivado a consulta de oncología médica para valoración de tratamiento específico. Dado que el paciente no era apto para cisplatino por aclaramiento de creatinina menor de 60 ml/min se incluye en un ensayo clínico fase II con pembrolizumab, a dosis de 200 mg cada 21 días. Tras la primera dosis presentó mucositis grado I, astenia y anorexia grado II, así como nauseas y vómitos ocasionales con pérdida de peso significativa, por lo que fue valorado por el Sº Nutrición para plantear suplementos dietéticos. Tras la segunda dosis acudió al Sº Urgencias en varias ocasiones por empeoramiento del cuadro constitucional, con imposibilidad para la deambulación y cefalea moderada de predominio vespertino. Ingresa finalmente al presentar deterioro severo del estado general y anorexia extrema que impedía una adecuada nutrición del paciente. Exploración física Al ingreso el paciente presentaba regular estado general, con un ECOG performance status de 4. A la exploración se encontraba hemodinámicamente estable, sin otros hallazgos de interés salvo sequedad de piel y mucosas y muguet oral. Pruebas complementarias Se realizó analítica urgente con bioquímica, en la que destacaba un discreto deterioro crónico de la función renal con elevación de la urea ya conocido, así como hiponatremia e hiperpotasemia leves. En el hemograma se observó una discreta anemia crónica microcítica-hipocrómica ya conocida, con serie blanca y plaquetas sin alteraciones de interés. El estudio de coagulación presentaba INR ligeramente alargado pero estable respecto a valores previos. Una vez en planta, se solicitó analítica completa con perfiles, destacando en la bioquímica hipoproteinemia leve, así como datos de colestasis disociada ya conocidos y discreta elevación de la proteína C reactiva. El proteinograma reveló una hipoalbuminemia moderada. El perfil lipídico mostraba una hipertrigliceridemia. El estudio de anemia fue compatible con anemia de trastornos crónicos. Ante la sospecha clínica de hipopituitarismo secundario a hipofisitis autoinmune (HA) inducida por pembrolizumab, se solicitó perfil hormonal/hipofisario que demostró la existencia de hipocortisolismo severo e hipotiroidismo central (tabla 1). Los niveles de adrenocorticotropina (ACTH) no se pudieron determinar en un primer momento, siendo normales en una segunda extracción bajo los efectos del tratamiento con corticoides. Los niveles de gonadotropinas, testosterona y prolactina fueron normales. Se realizó TC de cráneo que descartó la presencia de metástasis cerebrales, y un TC de tórax y abdomen que descartó asimismo progresión de la enfermedad tumoral, manteniéndose estables las múltiples lesiones óseas y los cambios residuales postquirúrgicos. Diagnóstico Hipopituitarismo parcial secundario a hipofisitis autoinmune inducida por pembrolizumab. Tratamiento Se solicitó valoración conjunta tanto con el Sº Nutrición, que pautó nutrición enteral por sonda nasogástrica para asegurar un adecuado aporte nutricional, así como con Sº Endocrinología, que apoyó el diagnóstico, iniciando tratamiento con hidrocortisona 50 mg cada 8 horas y levotiroxina 75 mcg cada 24 horas por vía intravenosa (iv). Evolución Durante el ingreso toleró adecuadamente la nutrición enteral con suplementos hiperproteicos, inicialmente por sonda nasogástrica y posteriormente por vía oral, con notable mejoría del estado nutricional. Como complicación se produjo un descenso de los niveles de fósforo en sangre en el contexto de posible síndrome de renutrición, por lo que se añadió tiamina 300 mg iv al tratamiento y se redujeron progresivamente los aportes nutricionales. Por otro lado se simplificó el tratamiento hormonal sustitutivo a vía oral, inicialmente con hidrocortisona 20 mg cada 8 horas y levotiroxina 50 mcg, disminuyendo al alta la dosis de hidrocortisona a 20 mg en la mañana y 10 mg en la noche. El paciente experimentó mejoría progresiva del cuadro constitucional, con disminución de la astenia y movilización paulatina. La cefalea referida inicialmente también mejoró notablemente hasta su práctica desaparición. Ante el cuadro de toxicidad grave inducido por pembrolizumab el paciente salió del ensayo clínico. En gammagrafía ósea posterior se objetivó aumento de lesiones metastásicas por lo que se pautó tratamiento con ácido zoledrónico cada 28 días ajustado a su función renal y aportes diarios de vitamina D y calcio. A las seis semanas del alta hospitalaria, el paciente presenta nuevo empeoramiento clínico con anorexia severa, dolor óseo no controlado e impotencia funcional. Se se deriva a la unidad de hospitalización domiciliaria para seguimiento y tratamiento siendo finalmente éxitus. Instructions: please typing these entity words according to sentence: carcinoma urotelial de vejiga superficial de alto grado, carcinoma transicional de alto grado, adenocarcinoma de próstata multifocal gleason 6, carcinoma transicional de vejiga , G3, enfermedad a distancia, metástasis, metástasis de carcinoma urotelial, metástasis, tumoral, lesiones óseas, metastásicas Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
ANAMNESIS: Varón de 75 años sin alergias conocidas, fumador de 2 paquetes de tabaco al día y con antecedentes de hipertensión arterial, diabetes mellitus tipo 2 y cardiopatía isquémica crónica. Comerciante jubilado, vivía con su esposa y era independiente para las actividades básicas. En tratamiento con metformina 850 mg/12h, ácido acetil salicílico 100 mg/24h, atenolol 100 mg/24h y ramipril 5 mg/24h. En estudio por Sº Urología desde el año 2011, el paciente se había intervenido en dos ocasiones mediante resección transuretral por carcinoma urotelial de vejiga superficial de alto grado, recibiendo BCG tras la última intervención a primeros de 2012. En noviembre de ese mismo año se objetiva nueva recidiva local en tomografía computerizada (TC), realizándose una tercera RTU con diagnóstico de carcinoma transicional de alto grado pT2. En TC postquirúrgico se aprecia recidiva local que provoca una uropatía obstructiva bilateral asociada sin enfermedad regional ni a distancia, por lo que en junio de 2013 se interviene de manera reglada mediante cistoprostatectomía radical con linfadenectomía ilio-obturatriz bilateral y anastomosis tipo Bricker. El diagnóstico anatomopatológico final fue: adenocarcinoma de próstata multifocal gleason 6 (3+3) estadio pT2 pNx; carcinoma transicional de vejiga, G3, estadio pT2b pN1 (2/4). Inicia seguimiento por parte del Sº Urología. En enero de 2015 se detecta recidiva de la enfermedad a distancia, con aparición de metástasis óseas en calota craneal, parrilla costal, esqueleto axial, pelvis y huesos largos. Se realiza biopsia de fémur con diagnóstico compatible con metástasis de carcinoma urotelial, motivo por el cual es derivado a consulta de oncología médica para valoración de tratamiento específico. Dado que el paciente no era apto para cisplatino por aclaramiento de creatinina menor de 60 ml/min se incluye en un ensayo clínico fase II con pembrolizumab, a dosis de 200 mg cada 21 días. Tras la primera dosis presentó mucositis grado I, astenia y anorexia grado II, así como nauseas y vómitos ocasionales con pérdida de peso significativa, por lo que fue valorado por el Sº Nutrición para plantear suplementos dietéticos. Tras la segunda dosis acudió al Sº Urgencias en varias ocasiones por empeoramiento del cuadro constitucional, con imposibilidad para la deambulación y cefalea moderada de predominio vespertino. Ingresa finalmente al presentar deterioro severo del estado general y anorexia extrema que impedía una adecuada nutrición del paciente. Exploración física Al ingreso el paciente presentaba regular estado general, con un ECOG performance status de 4. A la exploración se encontraba hemodinámicamente estable, sin otros hallazgos de interés salvo sequedad de piel y mucosas y muguet oral. Pruebas complementarias Se realizó analítica urgente con bioquímica, en la que destacaba un discreto deterioro crónico de la función renal con elevación de la urea ya conocido, así como hiponatremia e hiperpotasemia leves. En el hemograma se observó una discreta anemia crónica microcítica-hipocrómica ya conocida, con serie blanca y plaquetas sin alteraciones de interés. El estudio de coagulación presentaba INR ligeramente alargado pero estable respecto a valores previos. Una vez en planta, se solicitó analítica completa con perfiles, destacando en la bioquímica hipoproteinemia leve, así como datos de colestasis disociada ya conocidos y discreta elevación de la proteína C reactiva. El proteinograma reveló una hipoalbuminemia moderada. El perfil lipídico mostraba una hipertrigliceridemia. El estudio de anemia fue compatible con anemia de trastornos crónicos. Ante la sospecha clínica de hipopituitarismo secundario a hipofisitis autoinmune (HA) inducida por pembrolizumab, se solicitó perfil hormonal/hipofisario que demostró la existencia de hipocortisolismo severo e hipotiroidismo central (tabla 1). Los niveles de adrenocorticotropina (ACTH) no se pudieron determinar en un primer momento, siendo normales en una segunda extracción bajo los efectos del tratamiento con corticoides. Los niveles de gonadotropinas, testosterona y prolactina fueron normales. Se realizó TC de cráneo que descartó la presencia de metástasis cerebrales, y un TC de tórax y abdomen que descartó asimismo progresión de la enfermedad tumoral, manteniéndose estables las múltiples lesiones óseas y los cambios residuales postquirúrgicos. Diagnóstico Hipopituitarismo parcial secundario a hipofisitis autoinmune inducida por pembrolizumab. Tratamiento Se solicitó valoración conjunta tanto con el Sº Nutrición, que pautó nutrición enteral por sonda nasogástrica para asegurar un adecuado aporte nutricional, así como con Sº Endocrinología, que apoyó el diagnóstico, iniciando tratamiento con hidrocortisona 50 mg cada 8 horas y levotiroxina 75 mcg cada 24 horas por vía intravenosa (iv). Evolución Durante el ingreso toleró adecuadamente la nutrición enteral con suplementos hiperproteicos, inicialmente por sonda nasogástrica y posteriormente por vía oral, con notable mejoría del estado nutricional. Como complicación se produjo un descenso de los niveles de fósforo en sangre en el contexto de posible síndrome de renutrición, por lo que se añadió tiamina 300 mg iv al tratamiento y se redujeron progresivamente los aportes nutricionales. Por otro lado se simplificó el tratamiento hormonal sustitutivo a vía oral, inicialmente con hidrocortisona 20 mg cada 8 horas y levotiroxina 50 mcg, disminuyendo al alta la dosis de hidrocortisona a 20 mg en la mañana y 10 mg en la noche. El paciente experimentó mejoría progresiva del cuadro constitucional, con disminución de la astenia y movilización paulatina. La cefalea referida inicialmente también mejoró notablemente hasta su práctica desaparición. Ante el cuadro de toxicidad grave inducido por pembrolizumab el paciente salió del ensayo clínico. En gammagrafía ósea posterior se objetivó aumento de lesiones metastásicas por lo que se pautó tratamiento con ácido zoledrónico cada 28 días ajustado a su función renal y aportes diarios de vitamina D y calcio. A las seis semanas del alta hospitalaria, el paciente presenta nuevo empeoramiento clínico con anorexia severa, dolor óseo no controlado e impotencia funcional. Se se deriva a la unidad de hospitalización domiciliaria para seguimiento y tratamiento siendo finalmente éxitus.
[ "ANAMNESIS", ":", "\n", "Varón", "de", "75", "años", "sin", "alergias", "conocidas", ",", "fumador", "de", "2", "paquetes", "de", "tabaco", "al", "día", "y", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", "y", "cardiopatía", "isquémica", "crónica", ".", "Comerciante", "jubilado", ",", "vivía", "con", "su", "esposa", "y", "era", "independiente", "para", "las", "actividades", "básicas", ".", "En", "tratamiento", "con", "metformina", "850", "mg/12h", ",", "ácido", "acetil", "salicílico", "100", "mg/24h", ",", "atenolol", "100", "mg/24h", "y", "ramipril", "5", "mg/24h", ".", "En", "estudio", "por", "Sº", "Urología", "desde", "el", "año", "2011", ",", "el", "paciente", "se", "había", "intervenido", "en", "dos", "ocasiones", "mediante", "resección", "transuretral", "por", "carcinoma", "urotelial", "de", "vejiga", "superficial", "de", "alto", "grado", ",", "recibiendo", "BCG", "tras", "la", "última", "intervención", "a", "primeros", "de", "2012", ".", "En", "noviembre", "de", "ese", "mismo", "año", "se", "objetiva", "nueva", "recidiva", "local", "en", "tomografía", "computerizada", "(", "TC", ")", ",", "realizándose", "una", "tercera", "RTU", "con", "diagnóstico", "de", "carcinoma", "transicional", "de", "alto", "grado", "pT2", ".", "En", "TC", "postquirúrgico", "se", "aprecia", "recidiva", "local", "que", "provoca", "una", "uropatía", "obstructiva", "bilateral", "asociada", "sin", "enfermedad", "regional", "ni", "a", "distancia", ",", "por", "lo", "que", "en", "junio", "de", "2013", "se", "interviene", "de", "manera", "reglada", "mediante", "cistoprostatectomía", "radical", "con", "linfadenectomía", "ilio", "-", "obturatriz", "bilateral", "y", "anastomosis", "tipo", "Bricker", ".", "El", "diagnóstico", "anatomopatológico", "final", "fue", ":", "adenocarcinoma", "de", "próstata", "multifocal", "gleason", "6", "(", "3", "+", "3", ")", "estadio", "pT2", "pNx", ";", "carcinoma", "transicional", "de", "vejiga", ",", "G3", ",", "estadio", "pT2b", "pN1", "(", "2/4", ")", ".", "Inicia", "seguimiento", "por", "parte", "del", "Sº", "Urología", ".", "En", "enero", "de", "2015", "se", "detecta", "recidiva", "de", "la", "enfermedad", "a", "distancia", ",", "con", "aparición", "de", "metástasis", "óseas", "en", "calota", "craneal", ",", "parrilla", "costal", ",", "esqueleto", "axial", ",", "pelvis", "y", "huesos", "largos", ".", "Se", "realiza", "biopsia", "de", "fémur", "con", "diagnóstico", "compatible", "con", "metástasis", "de", "carcinoma", "urotelial", ",", "motivo", "por", "el", "cual", "es", "derivado", "a", "consulta", "de", "oncología", "médica", "para", "valoración", "de", "tratamiento", "específico", ".", "Dado", "que", "el", "paciente", "no", "era", "apto", "para", "cisplatino", "por", "aclaramiento", "de", "creatinina", "menor", "de", "60", "ml", "/", "min", "se", "incluye", "en", "un", "ensayo", "clínico", "fase", "II", "con", "pembrolizumab", ",", "a", "dosis", "de", "200", "mg", "cada", "21", "días", ".", "Tras", "la", "primera", "dosis", "presentó", "mucositis", "grado", "I", ",", "astenia", "y", "anorexia", "grado", "II", ",", "así", "como", "nauseas", "y", "vómitos", "ocasionales", "con", "pérdida", "de", "peso", "significativa", ",", "por", "lo", "que", "fue", "valorado", "por", "el", "Sº", "Nutrición", "para", "plantear", "suplementos", "dietéticos", ".", "Tras", "la", "segunda", "dosis", "acudió", "al", "Sº", "Urgencias", "en", "varias", "ocasiones", "por", "empeoramiento", "del", "cuadro", "constitucional", ",", "con", "imposibilidad", "para", "la", "deambulación", "y", "cefalea", "moderada", "de", "predominio", "vespertino", ".", "Ingresa", "finalmente", "al", "presentar", "deterioro", "severo", "del", "estado", "general", "y", "anorexia", "extrema", "que", "impedía", "una", "adecuada", "nutrición", "del", "paciente", ".", "\n\n", "Exploración", "física", "\n", "Al", "ingreso", "el", "paciente", "presentaba", "regular", "estado", "general", ",", "con", "un", "ECOG", "performance", "status", "de", "4", ".", "A", "la", "exploración", "se", "encontraba", "hemodinámicamente", "estable", ",", "sin", "otros", "hallazgos", "de", "interés", "salvo", "sequedad", "de", "piel", "y", "mucosas", "y", "muguet", "oral", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realizó", "analítica", "urgente", "con", "bioquímica", ",", "en", "la", "que", "destacaba", "un", "discreto", "deterioro", "crónico", "de", "la", "función", "renal", "con", "elevación", "de", "la", "urea", "ya", "conocido", ",", "así", "como", "hiponatremia", "e", "hiperpotasemia", "leves", ".", "En", "el", "hemograma", "se", "observó", "una", "discreta", "anemia", "crónica", "microcítica", "-", "hipocrómica", "ya", "conocida", ",", "con", "serie", "blanca", "y", "plaquetas", "sin", "alteraciones", "de", "interés", ".", "El", "estudio", "de", "coagulación", "presentaba", "INR", "ligeramente", "alargado", "pero", "estable", "respecto", "a", "valores", "previos", ".", "\n", "Una", "vez", "en", "planta", ",", "se", "solicitó", "analítica", "completa", "con", "perfiles", ",", "destacando", "en", "la", "bioquímica", "hipoproteinemia", "leve", ",", "así", "como", "datos", "de", "colestasis", "disociada", "ya", "conocidos", "y", "discreta", "elevación", "de", "la", "proteína", "C", "reactiva", ".", "El", "proteinograma", "reveló", "una", "hipoalbuminemia", "moderada", ".", "El", "perfil", "lipídico", "mostraba", "una", "hipertrigliceridemia", ".", "El", "estudio", "de", "anemia", "fue", "compatible", "con", "anemia", "de", "trastornos", "crónicos", ".", "Ante", "la", "sospecha", "clínica", "de", "hipopituitarismo", "secundario", "a", "hipofisitis", "autoinmune", "(", "HA", ")", "inducida", "por", "pembrolizumab", ",", "se", "solicitó", "perfil", "hormonal", "/", "hipofisario", "que", "demostró", "la", "existencia", "de", "hipocortisolismo", "severo", "e", "hipotiroidismo", "central", "(", "tabla", "1", ")", ".", "Los", "niveles", "de", "adrenocorticotropina", "(", "ACTH", ")", "no", "se", "pudieron", "determinar", "en", "un", "primer", "momento", ",", "siendo", "normales", "en", "una", "segunda", "extracción", "bajo", "los", "efectos", "del", "tratamiento", "con", "corticoides", ".", "Los", "niveles", "de", "gonadotropinas", ",", "testosterona", "y", "prolactina", "fueron", "normales", ".", "Se", "realizó", "TC", "de", "cráneo", "que", "descartó", "la", "presencia", "de", "metástasis", "cerebrales", ",", "y", "un", "TC", "de", "tórax", "y", "abdomen", "que", "descartó", "asimismo", "progresión", "de", "la", "enfermedad", "tumoral", ",", "manteniéndose", "estables", "las", "múltiples", "lesiones", "óseas", "y", "los", "cambios", "residuales", "postquirúrgicos", ".", "\n\n", "Diagnóstico", "\n", "Hipopituitarismo", "parcial", "secundario", "a", "hipofisitis", "autoinmune", "inducida", "por", "pembrolizumab", ".", "\n\n", "Tratamiento", "\n", "Se", "solicitó", "valoración", "conjunta", "tanto", "con", "el", "Sº", "Nutrición", ",", "que", "pautó", "nutrición", "enteral", "por", "sonda", "nasogástrica", "para", "asegurar", "un", "adecuado", "aporte", "nutricional", ",", "así", "como", "con", "Sº", "Endocrinología", ",", "que", "apoyó", "el", "diagnóstico", ",", "iniciando", "tratamiento", "con", "hidrocortisona", "50", "mg", "cada", "8", "horas", "y", "levotiroxina", "75", "mcg", "cada", "24", "horas", "por", "vía", "intravenosa", "(", "iv", ")", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", "toleró", "adecuadamente", "la", "nutrición", "enteral", "con", "suplementos", "hiperproteicos", ",", "inicialmente", "por", "sonda", "nasogástrica", "y", "posteriormente", "por", "vía", "oral", ",", "con", "notable", "mejoría", "del", "estado", "nutricional", ".", "Como", "complicación", "se", "produjo", "un", "descenso", "de", "los", "niveles", "de", "fósforo", "en", "sangre", "en", "el", "contexto", "de", "posible", "síndrome", "de", "renutrición", ",", "por", "lo", "que", "se", "añadió", "tiamina", "300", "mg", "iv", "al", "tratamiento", "y", "se", "redujeron", "progresivamente", "los", "aportes", "nutricionales", ".", "\n", "Por", "otro", "lado", "se", "simplificó", "el", "tratamiento", "hormonal", "sustitutivo", "a", "vía", "oral", ",", "inicialmente", "con", "hidrocortisona", "20", "mg", "cada", "8", "horas", "y", "levotiroxina", "50", "mcg", ",", "disminuyendo", "al", "alta", "la", "dosis", "de", "hidrocortisona", "a", "20", "mg", "en", "la", "mañana", "y", "10", "mg", "en", "la", "noche", ".", "El", "paciente", "experimentó", "mejoría", "progresiva", "del", "cuadro", "constitucional", ",", "con", "disminución", "de", "la", "astenia", "y", "movilización", "paulatina", ".", "La", "cefalea", "referida", "inicialmente", "también", "mejoró", "notablemente", "hasta", "su", "práctica", "desaparición", ".", "\n", "Ante", "el", "cuadro", "de", "toxicidad", "grave", "inducido", "por", "pembrolizumab", "el", "paciente", "salió", "del", "ensayo", "clínico", ".", "En", "gammagrafía", "ósea", "posterior", "se", "objetivó", "aumento", "de", "lesiones", "metastásicas", "por", "lo", "que", "se", "pautó", "tratamiento", "con", "ácido", "zoledrónico", "cada", "28", "días", "ajustado", "a", "su", "función", "renal", "y", "aportes", "diarios", "de", "vitamina", "D", "y", "calcio", ".", "A", "las", "seis", "semanas", "del", "alta", "hospitalaria", ",", "el", "paciente", "presenta", "nuevo", "empeoramiento", "clínico", "con", "anorexia", "severa", ",", "dolor", "óseo", "no", "controlado", "e", "impotencia", "funcional", ".", "Se", "se", "deriva", "a", "la", "unidad", "de", "hospitalización", "domiciliaria", "para", "seguimiento", "y", "tratamiento", "siendo", "finalmente", "éxitus", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
carcinoma urotelial de vejiga superficial de alto grado, carcinoma transicional de alto grado, adenocarcinoma de próstata multifocal gleason 6, carcinoma transicional de vejiga , G3, enfermedad a distancia, metástasis, metástasis de carcinoma urotelial, metástasis, tumoral, lesiones óseas, metastásicas
349_task2
Sentence: ANAMNESIS: Varón de 75 años sin alergias conocidas, fumador de 2 paquetes de tabaco al día y con antecedentes de hipertensión arterial, diabetes mellitus tipo 2 y cardiopatía isquémica crónica. Comerciante jubilado, vivía con su esposa y era independiente para las actividades básicas. En tratamiento con metformina 850 mg/12h, ácido acetil salicílico 100 mg/24h, atenolol 100 mg/24h y ramipril 5 mg/24h. En estudio por Sº Urología desde el año 2011, el paciente se había intervenido en dos ocasiones mediante resección transuretral por carcinoma urotelial de vejiga superficial de alto grado, recibiendo BCG tras la última intervención a primeros de 2012. En noviembre de ese mismo año se objetiva nueva recidiva local en tomografía computerizada (TC), realizándose una tercera RTU con diagnóstico de carcinoma transicional de alto grado pT2. En TC postquirúrgico se aprecia recidiva local que provoca una uropatía obstructiva bilateral asociada sin enfermedad regional ni a distancia, por lo que en junio de 2013 se interviene de manera reglada mediante cistoprostatectomía radical con linfadenectomía ilio-obturatriz bilateral y anastomosis tipo Bricker. El diagnóstico anatomopatológico final fue: adenocarcinoma de próstata multifocal gleason 6 (3+3) estadio pT2 pNx; carcinoma transicional de vejiga, G3, estadio pT2b pN1 (2/4). Inicia seguimiento por parte del Sº Urología. En enero de 2015 se detecta recidiva de la enfermedad a distancia, con aparición de metástasis óseas en calota craneal, parrilla costal, esqueleto axial, pelvis y huesos largos. Se realiza biopsia de fémur con diagnóstico compatible con metástasis de carcinoma urotelial, motivo por el cual es derivado a consulta de oncología médica para valoración de tratamiento específico. Dado que el paciente no era apto para cisplatino por aclaramiento de creatinina menor de 60 ml/min se incluye en un ensayo clínico fase II con pembrolizumab, a dosis de 200 mg cada 21 días. Tras la primera dosis presentó mucositis grado I, astenia y anorexia grado II, así como nauseas y vómitos ocasionales con pérdida de peso significativa, por lo que fue valorado por el Sº Nutrición para plantear suplementos dietéticos. Tras la segunda dosis acudió al Sº Urgencias en varias ocasiones por empeoramiento del cuadro constitucional, con imposibilidad para la deambulación y cefalea moderada de predominio vespertino. Ingresa finalmente al presentar deterioro severo del estado general y anorexia extrema que impedía una adecuada nutrición del paciente. Exploración física Al ingreso el paciente presentaba regular estado general, con un ECOG performance status de 4. A la exploración se encontraba hemodinámicamente estable, sin otros hallazgos de interés salvo sequedad de piel y mucosas y muguet oral. Pruebas complementarias Se realizó analítica urgente con bioquímica, en la que destacaba un discreto deterioro crónico de la función renal con elevación de la urea ya conocido, así como hiponatremia e hiperpotasemia leves. En el hemograma se observó una discreta anemia crónica microcítica-hipocrómica ya conocida, con serie blanca y plaquetas sin alteraciones de interés. El estudio de coagulación presentaba INR ligeramente alargado pero estable respecto a valores previos. Una vez en planta, se solicitó analítica completa con perfiles, destacando en la bioquímica hipoproteinemia leve, así como datos de colestasis disociada ya conocidos y discreta elevación de la proteína C reactiva. El proteinograma reveló una hipoalbuminemia moderada. El perfil lipídico mostraba una hipertrigliceridemia. El estudio de anemia fue compatible con anemia de trastornos crónicos. Ante la sospecha clínica de hipopituitarismo secundario a hipofisitis autoinmune (HA) inducida por pembrolizumab, se solicitó perfil hormonal/hipofisario que demostró la existencia de hipocortisolismo severo e hipotiroidismo central (tabla 1). Los niveles de adrenocorticotropina (ACTH) no se pudieron determinar en un primer momento, siendo normales en una segunda extracción bajo los efectos del tratamiento con corticoides. Los niveles de gonadotropinas, testosterona y prolactina fueron normales. Se realizó TC de cráneo que descartó la presencia de metástasis cerebrales, y un TC de tórax y abdomen que descartó asimismo progresión de la enfermedad tumoral, manteniéndose estables las múltiples lesiones óseas y los cambios residuales postquirúrgicos. Diagnóstico Hipopituitarismo parcial secundario a hipofisitis autoinmune inducida por pembrolizumab. Tratamiento Se solicitó valoración conjunta tanto con el Sº Nutrición, que pautó nutrición enteral por sonda nasogástrica para asegurar un adecuado aporte nutricional, así como con Sº Endocrinología, que apoyó el diagnóstico, iniciando tratamiento con hidrocortisona 50 mg cada 8 horas y levotiroxina 75 mcg cada 24 horas por vía intravenosa (iv). Evolución Durante el ingreso toleró adecuadamente la nutrición enteral con suplementos hiperproteicos, inicialmente por sonda nasogástrica y posteriormente por vía oral, con notable mejoría del estado nutricional. Como complicación se produjo un descenso de los niveles de fósforo en sangre en el contexto de posible síndrome de renutrición, por lo que se añadió tiamina 300 mg iv al tratamiento y se redujeron progresivamente los aportes nutricionales. Por otro lado se simplificó el tratamiento hormonal sustitutivo a vía oral, inicialmente con hidrocortisona 20 mg cada 8 horas y levotiroxina 50 mcg, disminuyendo al alta la dosis de hidrocortisona a 20 mg en la mañana y 10 mg en la noche. El paciente experimentó mejoría progresiva del cuadro constitucional, con disminución de la astenia y movilización paulatina. La cefalea referida inicialmente también mejoró notablemente hasta su práctica desaparición. Ante el cuadro de toxicidad grave inducido por pembrolizumab el paciente salió del ensayo clínico. En gammagrafía ósea posterior se objetivó aumento de lesiones metastásicas por lo que se pautó tratamiento con ácido zoledrónico cada 28 días ajustado a su función renal y aportes diarios de vitamina D y calcio. A las seis semanas del alta hospitalaria, el paciente presenta nuevo empeoramiento clínico con anorexia severa, dolor óseo no controlado e impotencia funcional. Se se deriva a la unidad de hospitalización domiciliaria para seguimiento y tratamiento siendo finalmente éxitus. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
ANAMNESIS: Varón de 75 años sin alergias conocidas, fumador de 2 paquetes de tabaco al día y con antecedentes de hipertensión arterial, diabetes mellitus tipo 2 y cardiopatía isquémica crónica. Comerciante jubilado, vivía con su esposa y era independiente para las actividades básicas. En tratamiento con metformina 850 mg/12h, ácido acetil salicílico 100 mg/24h, atenolol 100 mg/24h y ramipril 5 mg/24h. En estudio por Sº Urología desde el año 2011, el paciente se había intervenido en dos ocasiones mediante resección transuretral por carcinoma urotelial de vejiga superficial de alto grado, recibiendo BCG tras la última intervención a primeros de 2012. En noviembre de ese mismo año se objetiva nueva recidiva local en tomografía computerizada (TC), realizándose una tercera RTU con diagnóstico de carcinoma transicional de alto grado pT2. En TC postquirúrgico se aprecia recidiva local que provoca una uropatía obstructiva bilateral asociada sin enfermedad regional ni a distancia, por lo que en junio de 2013 se interviene de manera reglada mediante cistoprostatectomía radical con linfadenectomía ilio-obturatriz bilateral y anastomosis tipo Bricker. El diagnóstico anatomopatológico final fue: adenocarcinoma de próstata multifocal gleason 6 (3+3) estadio pT2 pNx; carcinoma transicional de vejiga, G3, estadio pT2b pN1 (2/4). Inicia seguimiento por parte del Sº Urología. En enero de 2015 se detecta recidiva de la enfermedad a distancia, con aparición de metástasis óseas en calota craneal, parrilla costal, esqueleto axial, pelvis y huesos largos. Se realiza biopsia de fémur con diagnóstico compatible con metástasis de carcinoma urotelial, motivo por el cual es derivado a consulta de oncología médica para valoración de tratamiento específico. Dado que el paciente no era apto para cisplatino por aclaramiento de creatinina menor de 60 ml/min se incluye en un ensayo clínico fase II con pembrolizumab, a dosis de 200 mg cada 21 días. Tras la primera dosis presentó mucositis grado I, astenia y anorexia grado II, así como nauseas y vómitos ocasionales con pérdida de peso significativa, por lo que fue valorado por el Sº Nutrición para plantear suplementos dietéticos. Tras la segunda dosis acudió al Sº Urgencias en varias ocasiones por empeoramiento del cuadro constitucional, con imposibilidad para la deambulación y cefalea moderada de predominio vespertino. Ingresa finalmente al presentar deterioro severo del estado general y anorexia extrema que impedía una adecuada nutrición del paciente. Exploración física Al ingreso el paciente presentaba regular estado general, con un ECOG performance status de 4. A la exploración se encontraba hemodinámicamente estable, sin otros hallazgos de interés salvo sequedad de piel y mucosas y muguet oral. Pruebas complementarias Se realizó analítica urgente con bioquímica, en la que destacaba un discreto deterioro crónico de la función renal con elevación de la urea ya conocido, así como hiponatremia e hiperpotasemia leves. En el hemograma se observó una discreta anemia crónica microcítica-hipocrómica ya conocida, con serie blanca y plaquetas sin alteraciones de interés. El estudio de coagulación presentaba INR ligeramente alargado pero estable respecto a valores previos. Una vez en planta, se solicitó analítica completa con perfiles, destacando en la bioquímica hipoproteinemia leve, así como datos de colestasis disociada ya conocidos y discreta elevación de la proteína C reactiva. El proteinograma reveló una hipoalbuminemia moderada. El perfil lipídico mostraba una hipertrigliceridemia. El estudio de anemia fue compatible con anemia de trastornos crónicos. Ante la sospecha clínica de hipopituitarismo secundario a hipofisitis autoinmune (HA) inducida por pembrolizumab, se solicitó perfil hormonal/hipofisario que demostró la existencia de hipocortisolismo severo e hipotiroidismo central (tabla 1). Los niveles de adrenocorticotropina (ACTH) no se pudieron determinar en un primer momento, siendo normales en una segunda extracción bajo los efectos del tratamiento con corticoides. Los niveles de gonadotropinas, testosterona y prolactina fueron normales. Se realizó TC de cráneo que descartó la presencia de metástasis cerebrales, y un TC de tórax y abdomen que descartó asimismo progresión de la enfermedad tumoral, manteniéndose estables las múltiples lesiones óseas y los cambios residuales postquirúrgicos. Diagnóstico Hipopituitarismo parcial secundario a hipofisitis autoinmune inducida por pembrolizumab. Tratamiento Se solicitó valoración conjunta tanto con el Sº Nutrición, que pautó nutrición enteral por sonda nasogástrica para asegurar un adecuado aporte nutricional, así como con Sº Endocrinología, que apoyó el diagnóstico, iniciando tratamiento con hidrocortisona 50 mg cada 8 horas y levotiroxina 75 mcg cada 24 horas por vía intravenosa (iv). Evolución Durante el ingreso toleró adecuadamente la nutrición enteral con suplementos hiperproteicos, inicialmente por sonda nasogástrica y posteriormente por vía oral, con notable mejoría del estado nutricional. Como complicación se produjo un descenso de los niveles de fósforo en sangre en el contexto de posible síndrome de renutrición, por lo que se añadió tiamina 300 mg iv al tratamiento y se redujeron progresivamente los aportes nutricionales. Por otro lado se simplificó el tratamiento hormonal sustitutivo a vía oral, inicialmente con hidrocortisona 20 mg cada 8 horas y levotiroxina 50 mcg, disminuyendo al alta la dosis de hidrocortisona a 20 mg en la mañana y 10 mg en la noche. El paciente experimentó mejoría progresiva del cuadro constitucional, con disminución de la astenia y movilización paulatina. La cefalea referida inicialmente también mejoró notablemente hasta su práctica desaparición. Ante el cuadro de toxicidad grave inducido por pembrolizumab el paciente salió del ensayo clínico. En gammagrafía ósea posterior se objetivó aumento de lesiones metastásicas por lo que se pautó tratamiento con ácido zoledrónico cada 28 días ajustado a su función renal y aportes diarios de vitamina D y calcio. A las seis semanas del alta hospitalaria, el paciente presenta nuevo empeoramiento clínico con anorexia severa, dolor óseo no controlado e impotencia funcional. Se se deriva a la unidad de hospitalización domiciliaria para seguimiento y tratamiento siendo finalmente éxitus.
[ "ANAMNESIS", ":", "\n", "Varón", "de", "75", "años", "sin", "alergias", "conocidas", ",", "fumador", "de", "2", "paquetes", "de", "tabaco", "al", "día", "y", "con", "antecedentes", "de", "hipertensión", "arterial", ",", "diabetes", "mellitus", "tipo", "2", "y", "cardiopatía", "isquémica", "crónica", ".", "Comerciante", "jubilado", ",", "vivía", "con", "su", "esposa", "y", "era", "independiente", "para", "las", "actividades", "básicas", ".", "En", "tratamiento", "con", "metformina", "850", "mg/12h", ",", "ácido", "acetil", "salicílico", "100", "mg/24h", ",", "atenolol", "100", "mg/24h", "y", "ramipril", "5", "mg/24h", ".", "En", "estudio", "por", "Sº", "Urología", "desde", "el", "año", "2011", ",", "el", "paciente", "se", "había", "intervenido", "en", "dos", "ocasiones", "mediante", "resección", "transuretral", "por", "carcinoma", "urotelial", "de", "vejiga", "superficial", "de", "alto", "grado", ",", "recibiendo", "BCG", "tras", "la", "última", "intervención", "a", "primeros", "de", "2012", ".", "En", "noviembre", "de", "ese", "mismo", "año", "se", "objetiva", "nueva", "recidiva", "local", "en", "tomografía", "computerizada", "(", "TC", ")", ",", "realizándose", "una", "tercera", "RTU", "con", "diagnóstico", "de", "carcinoma", "transicional", "de", "alto", "grado", "pT2", ".", "En", "TC", "postquirúrgico", "se", "aprecia", "recidiva", "local", "que", "provoca", "una", "uropatía", "obstructiva", "bilateral", "asociada", "sin", "enfermedad", "regional", "ni", "a", "distancia", ",", "por", "lo", "que", "en", "junio", "de", "2013", "se", "interviene", "de", "manera", "reglada", "mediante", "cistoprostatectomía", "radical", "con", "linfadenectomía", "ilio", "-", "obturatriz", "bilateral", "y", "anastomosis", "tipo", "Bricker", ".", "El", "diagnóstico", "anatomopatológico", "final", "fue", ":", "adenocarcinoma", "de", "próstata", "multifocal", "gleason", "6", "(", "3", "+", "3", ")", "estadio", "pT2", "pNx", ";", "carcinoma", "transicional", "de", "vejiga", ",", "G3", ",", "estadio", "pT2b", "pN1", "(", "2/4", ")", ".", "Inicia", "seguimiento", "por", "parte", "del", "Sº", "Urología", ".", "En", "enero", "de", "2015", "se", "detecta", "recidiva", "de", "la", "enfermedad", "a", "distancia", ",", "con", "aparición", "de", "metástasis", "óseas", "en", "calota", "craneal", ",", "parrilla", "costal", ",", "esqueleto", "axial", ",", "pelvis", "y", "huesos", "largos", ".", "Se", "realiza", "biopsia", "de", "fémur", "con", "diagnóstico", "compatible", "con", "metástasis", "de", "carcinoma", "urotelial", ",", "motivo", "por", "el", "cual", "es", "derivado", "a", "consulta", "de", "oncología", "médica", "para", "valoración", "de", "tratamiento", "específico", ".", "Dado", "que", "el", "paciente", "no", "era", "apto", "para", "cisplatino", "por", "aclaramiento", "de", "creatinina", "menor", "de", "60", "ml", "/", "min", "se", "incluye", "en", "un", "ensayo", "clínico", "fase", "II", "con", "pembrolizumab", ",", "a", "dosis", "de", "200", "mg", "cada", "21", "días", ".", "Tras", "la", "primera", "dosis", "presentó", "mucositis", "grado", "I", ",", "astenia", "y", "anorexia", "grado", "II", ",", "así", "como", "nauseas", "y", "vómitos", "ocasionales", "con", "pérdida", "de", "peso", "significativa", ",", "por", "lo", "que", "fue", "valorado", "por", "el", "Sº", "Nutrición", "para", "plantear", "suplementos", "dietéticos", ".", "Tras", "la", "segunda", "dosis", "acudió", "al", "Sº", "Urgencias", "en", "varias", "ocasiones", "por", "empeoramiento", "del", "cuadro", "constitucional", ",", "con", "imposibilidad", "para", "la", "deambulación", "y", "cefalea", "moderada", "de", "predominio", "vespertino", ".", "Ingresa", "finalmente", "al", "presentar", "deterioro", "severo", "del", "estado", "general", "y", "anorexia", "extrema", "que", "impedía", "una", "adecuada", "nutrición", "del", "paciente", ".", "\n\n", "Exploración", "física", "\n", "Al", "ingreso", "el", "paciente", "presentaba", "regular", "estado", "general", ",", "con", "un", "ECOG", "performance", "status", "de", "4", ".", "A", "la", "exploración", "se", "encontraba", "hemodinámicamente", "estable", ",", "sin", "otros", "hallazgos", "de", "interés", "salvo", "sequedad", "de", "piel", "y", "mucosas", "y", "muguet", "oral", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realizó", "analítica", "urgente", "con", "bioquímica", ",", "en", "la", "que", "destacaba", "un", "discreto", "deterioro", "crónico", "de", "la", "función", "renal", "con", "elevación", "de", "la", "urea", "ya", "conocido", ",", "así", "como", "hiponatremia", "e", "hiperpotasemia", "leves", ".", "En", "el", "hemograma", "se", "observó", "una", "discreta", "anemia", "crónica", "microcítica", "-", "hipocrómica", "ya", "conocida", ",", "con", "serie", "blanca", "y", "plaquetas", "sin", "alteraciones", "de", "interés", ".", "El", "estudio", "de", "coagulación", "presentaba", "INR", "ligeramente", "alargado", "pero", "estable", "respecto", "a", "valores", "previos", ".", "\n", "Una", "vez", "en", "planta", ",", "se", "solicitó", "analítica", "completa", "con", "perfiles", ",", "destacando", "en", "la", "bioquímica", "hipoproteinemia", "leve", ",", "así", "como", "datos", "de", "colestasis", "disociada", "ya", "conocidos", "y", "discreta", "elevación", "de", "la", "proteína", "C", "reactiva", ".", "El", "proteinograma", "reveló", "una", "hipoalbuminemia", "moderada", ".", "El", "perfil", "lipídico", "mostraba", "una", "hipertrigliceridemia", ".", "El", "estudio", "de", "anemia", "fue", "compatible", "con", "anemia", "de", "trastornos", "crónicos", ".", "Ante", "la", "sospecha", "clínica", "de", "hipopituitarismo", "secundario", "a", "hipofisitis", "autoinmune", "(", "HA", ")", "inducida", "por", "pembrolizumab", ",", "se", "solicitó", "perfil", "hormonal", "/", "hipofisario", "que", "demostró", "la", "existencia", "de", "hipocortisolismo", "severo", "e", "hipotiroidismo", "central", "(", "tabla", "1", ")", ".", "Los", "niveles", "de", "adrenocorticotropina", "(", "ACTH", ")", "no", "se", "pudieron", "determinar", "en", "un", "primer", "momento", ",", "siendo", "normales", "en", "una", "segunda", "extracción", "bajo", "los", "efectos", "del", "tratamiento", "con", "corticoides", ".", "Los", "niveles", "de", "gonadotropinas", ",", "testosterona", "y", "prolactina", "fueron", "normales", ".", "Se", "realizó", "TC", "de", "cráneo", "que", "descartó", "la", "presencia", "de", "metástasis", "cerebrales", ",", "y", "un", "TC", "de", "tórax", "y", "abdomen", "que", "descartó", "asimismo", "progresión", "de", "la", "enfermedad", "tumoral", ",", "manteniéndose", "estables", "las", "múltiples", "lesiones", "óseas", "y", "los", "cambios", "residuales", "postquirúrgicos", ".", "\n\n", "Diagnóstico", "\n", "Hipopituitarismo", "parcial", "secundario", "a", "hipofisitis", "autoinmune", "inducida", "por", "pembrolizumab", ".", "\n\n", "Tratamiento", "\n", "Se", "solicitó", "valoración", "conjunta", "tanto", "con", "el", "Sº", "Nutrición", ",", "que", "pautó", "nutrición", "enteral", "por", "sonda", "nasogástrica", "para", "asegurar", "un", "adecuado", "aporte", "nutricional", ",", "así", "como", "con", "Sº", "Endocrinología", ",", "que", "apoyó", "el", "diagnóstico", ",", "iniciando", "tratamiento", "con", "hidrocortisona", "50", "mg", "cada", "8", "horas", "y", "levotiroxina", "75", "mcg", "cada", "24", "horas", "por", "vía", "intravenosa", "(", "iv", ")", ".", "\n\n", "Evolución", "\n", "Durante", "el", "ingreso", "toleró", "adecuadamente", "la", "nutrición", "enteral", "con", "suplementos", "hiperproteicos", ",", "inicialmente", "por", "sonda", "nasogástrica", "y", "posteriormente", "por", "vía", "oral", ",", "con", "notable", "mejoría", "del", "estado", "nutricional", ".", "Como", "complicación", "se", "produjo", "un", "descenso", "de", "los", "niveles", "de", "fósforo", "en", "sangre", "en", "el", "contexto", "de", "posible", "síndrome", "de", "renutrición", ",", "por", "lo", "que", "se", "añadió", "tiamina", "300", "mg", "iv", "al", "tratamiento", "y", "se", "redujeron", "progresivamente", "los", "aportes", "nutricionales", ".", "\n", "Por", "otro", "lado", "se", "simplificó", "el", "tratamiento", "hormonal", "sustitutivo", "a", "vía", "oral", ",", "inicialmente", "con", "hidrocortisona", "20", "mg", "cada", "8", "horas", "y", "levotiroxina", "50", "mcg", ",", "disminuyendo", "al", "alta", "la", "dosis", "de", "hidrocortisona", "a", "20", "mg", "en", "la", "mañana", "y", "10", "mg", "en", "la", "noche", ".", "El", "paciente", "experimentó", "mejoría", "progresiva", "del", "cuadro", "constitucional", ",", "con", "disminución", "de", "la", "astenia", "y", "movilización", "paulatina", ".", "La", "cefalea", "referida", "inicialmente", "también", "mejoró", "notablemente", "hasta", "su", "práctica", "desaparición", ".", "\n", "Ante", "el", "cuadro", "de", "toxicidad", "grave", "inducido", "por", "pembrolizumab", "el", "paciente", "salió", "del", "ensayo", "clínico", ".", "En", "gammagrafía", "ósea", "posterior", "se", "objetivó", "aumento", "de", "lesiones", "metastásicas", "por", "lo", "que", "se", "pautó", "tratamiento", "con", "ácido", "zoledrónico", "cada", "28", "días", "ajustado", "a", "su", "función", "renal", "y", "aportes", "diarios", "de", "vitamina", "D", "y", "calcio", ".", "A", "las", "seis", "semanas", "del", "alta", "hospitalaria", ",", "el", "paciente", "presenta", "nuevo", "empeoramiento", "clínico", "con", "anorexia", "severa", ",", "dolor", "óseo", "no", "controlado", "e", "impotencia", "funcional", ".", "Se", "se", "deriva", "a", "la", "unidad", "de", "hospitalización", "domiciliaria", "para", "seguimiento", "y", "tratamiento", "siendo", "finalmente", "éxitus", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
Curcumin is a CHEMICAL
23454202_task0
Sentence: Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats.
[ "Curcumin", "loaded", "solid", "lipid", "nanoparticles", ":", "An", "efficient", "formulation", "approach", "for", "cerebral", "ischemic", "reperfusion", "injury", "in", "rats", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Curcumin is a CHEMICAL
23454202_task1
Sentence: Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats. Instructions: please typing these entity words according to sentence: Curcumin Options: CHEMICAL
[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats.
[ "Curcumin", "loaded", "solid", "lipid", "nanoparticles", ":", "An", "efficient", "formulation", "approach", "for", "cerebral", "ischemic", "reperfusion", "injury", "in", "rats", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Curcumin
23454202_task2
Sentence: Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats. Instructions: please extract entity words from the input sentence
[ "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Curcumin loaded solid lipid nanoparticles: An efficient formulation approach for cerebral ischemic reperfusion injury in rats.
[ "Curcumin", "loaded", "solid", "lipid", "nanoparticles", ":", "An", "efficient", "formulation", "approach", "for", "cerebral", "ischemic", "reperfusion", "injury", "in", "rats", "." ]
[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Elemente is an umlsterm, Gewebeanpassung is an umlsterm, Unterarmmuskeln is an umlsterm, Knochen is an umlsterm, radio- is an umlsterm, Baender is an umlsterm, Bandapparat is an umlsterm, Baender is an umlsterm, Bandapparats is an umlsterm, Handwurzel is an umlsterm, Bandapparats is an umlsterm, Elementen is an umlsterm, Elements is an umlsterm
DerOrthopaede.90280822.ger.abstr_task0
Sentence: Die Stabilitaet des Carpus wird vom exakten Zusammenspiel seiner knoechernen und ligamentaeren Elemente bestimmt . Als hauptsaechliche und damit fuer die Gewebeanpassung verantwortliche Beanspruchung ist eine longitudinale Kompression anzusehen , wie sie durch den Zug der Unterarmmuskeln bei nahezu jeder staerkeren Aktivitaet entsteht . Durch die keilfoermige Anordnung der Knochen der distalen Reihe wird die proximale Reihe einer Querdehnung ausgesetzt , die durch schraege radio- und ulnokarpale Baender aufgenommen wird . Auch die Retinacula sind als zirkulaere Sicherung aufzufassen . Der Bandapparat wird hier aufgrund des Verlaufes der einzelnen Faserbuendel in 3 Gruppen eingeteilt , wobei besonders auf die interossaeren Baender Bezug genommen wird . Der zur Aufnahme der betraechtlichen statischen und dynamischen Kraefte notwendige Materialaufwand wird dadurch minimiert , dass ueber die schraeg zu den Bewegungsebenen eingestellten Faserbuendel des komplexen Bandapparats der gesamte Carpus jeweils in den Kraftfluss einbezogen wird . Dies ist die Voraussetzung der weitgehenden Beweglichkeit der Handwurzel . Die strenge funktionelle Interaktion des differenzierten Bandapparats mit den knoechernen Elementen des Carpus bedingt allerdings , dass schon die Schaedigung eines einzigen Elements schwerwiegende Folgen fuer die Stabilitaet des Gesamtkomplexes hat . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Stabilitaet des Carpus wird vom exakten Zusammenspiel seiner knoechernen und ligamentaeren Elemente bestimmt . Als hauptsaechliche und damit fuer die Gewebeanpassung verantwortliche Beanspruchung ist eine longitudinale Kompression anzusehen , wie sie durch den Zug der Unterarmmuskeln bei nahezu jeder staerkeren Aktivitaet entsteht . Durch die keilfoermige Anordnung der Knochen der distalen Reihe wird die proximale Reihe einer Querdehnung ausgesetzt , die durch schraege radio- und ulnokarpale Baender aufgenommen wird . Auch die Retinacula sind als zirkulaere Sicherung aufzufassen . Der Bandapparat wird hier aufgrund des Verlaufes der einzelnen Faserbuendel in 3 Gruppen eingeteilt , wobei besonders auf die interossaeren Baender Bezug genommen wird . Der zur Aufnahme der betraechtlichen statischen und dynamischen Kraefte notwendige Materialaufwand wird dadurch minimiert , dass ueber die schraeg zu den Bewegungsebenen eingestellten Faserbuendel des komplexen Bandapparats der gesamte Carpus jeweils in den Kraftfluss einbezogen wird . Dies ist die Voraussetzung der weitgehenden Beweglichkeit der Handwurzel . Die strenge funktionelle Interaktion des differenzierten Bandapparats mit den knoechernen Elementen des Carpus bedingt allerdings , dass schon die Schaedigung eines einzigen Elements schwerwiegende Folgen fuer die Stabilitaet des Gesamtkomplexes hat .
[ "Die", "Stabilitaet", "des", "Carpus", "wird", "vom", "exakten", "Zusammenspiel", "seiner", "knoechernen", "und", "ligamentaeren", "Elemente", "bestimmt", ".", "Als", "hauptsaechliche", "und", "damit", "fuer", "die", "Gewebeanpassung", "verantwortliche", "Beanspruchung", "ist", "eine", "longitudinale", "Kompression", "anzusehen", ",", "wie", "sie", "durch", "den", "Zug", "der", "Unterarmmuskeln", "bei", "nahezu", "jeder", "staerkeren", "Aktivitaet", "entsteht", ".", "Durch", "die", "keilfoermige", "Anordnung", "der", "Knochen", "der", "distalen", "Reihe", "wird", "die", "proximale", "Reihe", "einer", "Querdehnung", "ausgesetzt", ",", "die", "durch", "schraege", "radio-", "und", "ulnokarpale", "Baender", "aufgenommen", "wird", ".", "Auch", "die", "Retinacula", "sind", "als", "zirkulaere", "Sicherung", "aufzufassen", ".", "Der", "Bandapparat", "wird", "hier", "aufgrund", "des", "Verlaufes", "der", "einzelnen", "Faserbuendel", "in", "3", "Gruppen", "eingeteilt", ",", "wobei", "besonders", "auf", "die", "interossaeren", "Baender", "Bezug", "genommen", "wird", ".", "Der", "zur", "Aufnahme", "der", "betraechtlichen", "statischen", "und", "dynamischen", "Kraefte", "notwendige", "Materialaufwand", "wird", "dadurch", "minimiert", ",", "dass", "ueber", "die", "schraeg", "zu", "den", "Bewegungsebenen", "eingestellten", "Faserbuendel", "des", "komplexen", "Bandapparats", "der", "gesamte", "Carpus", "jeweils", "in", "den", "Kraftfluss", "einbezogen", "wird", ".", "Dies", "ist", "die", "Voraussetzung", "der", "weitgehenden", "Beweglichkeit", "der", "Handwurzel", ".", "Die", "strenge", "funktionelle", "Interaktion", "des", "differenzierten", "Bandapparats", "mit", "den", "knoechernen", "Elementen", "des", "Carpus", "bedingt", "allerdings", ",", "dass", "schon", "die", "Schaedigung", "eines", "einzigen", "Elements", "schwerwiegende", "Folgen", "fuer", "die", "Stabilitaet", "des", "Gesamtkomplexes", "hat", "." ]
[ "umlsterm" ]
Elemente is an umlsterm, Gewebeanpassung is an umlsterm, Unterarmmuskeln is an umlsterm, Knochen is an umlsterm, radio- is an umlsterm, Baender is an umlsterm, Bandapparat is an umlsterm, Baender is an umlsterm, Bandapparats is an umlsterm, Handwurzel is an umlsterm, Bandapparats is an umlsterm, Elementen is an umlsterm, Elements is an umlsterm
DerOrthopaede.90280822.ger.abstr_task1
Sentence: Die Stabilitaet des Carpus wird vom exakten Zusammenspiel seiner knoechernen und ligamentaeren Elemente bestimmt . Als hauptsaechliche und damit fuer die Gewebeanpassung verantwortliche Beanspruchung ist eine longitudinale Kompression anzusehen , wie sie durch den Zug der Unterarmmuskeln bei nahezu jeder staerkeren Aktivitaet entsteht . Durch die keilfoermige Anordnung der Knochen der distalen Reihe wird die proximale Reihe einer Querdehnung ausgesetzt , die durch schraege radio- und ulnokarpale Baender aufgenommen wird . Auch die Retinacula sind als zirkulaere Sicherung aufzufassen . Der Bandapparat wird hier aufgrund des Verlaufes der einzelnen Faserbuendel in 3 Gruppen eingeteilt , wobei besonders auf die interossaeren Baender Bezug genommen wird . Der zur Aufnahme der betraechtlichen statischen und dynamischen Kraefte notwendige Materialaufwand wird dadurch minimiert , dass ueber die schraeg zu den Bewegungsebenen eingestellten Faserbuendel des komplexen Bandapparats der gesamte Carpus jeweils in den Kraftfluss einbezogen wird . Dies ist die Voraussetzung der weitgehenden Beweglichkeit der Handwurzel . Die strenge funktionelle Interaktion des differenzierten Bandapparats mit den knoechernen Elementen des Carpus bedingt allerdings , dass schon die Schaedigung eines einzigen Elements schwerwiegende Folgen fuer die Stabilitaet des Gesamtkomplexes hat . Instructions: please typing these entity words according to sentence: Elemente, Gewebeanpassung, Unterarmmuskeln, Knochen, radio-, Baender, Bandapparat, Baender, Bandapparats, Handwurzel, Bandapparats, Elementen, Elements Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Stabilitaet des Carpus wird vom exakten Zusammenspiel seiner knoechernen und ligamentaeren Elemente bestimmt . Als hauptsaechliche und damit fuer die Gewebeanpassung verantwortliche Beanspruchung ist eine longitudinale Kompression anzusehen , wie sie durch den Zug der Unterarmmuskeln bei nahezu jeder staerkeren Aktivitaet entsteht . Durch die keilfoermige Anordnung der Knochen der distalen Reihe wird die proximale Reihe einer Querdehnung ausgesetzt , die durch schraege radio- und ulnokarpale Baender aufgenommen wird . Auch die Retinacula sind als zirkulaere Sicherung aufzufassen . Der Bandapparat wird hier aufgrund des Verlaufes der einzelnen Faserbuendel in 3 Gruppen eingeteilt , wobei besonders auf die interossaeren Baender Bezug genommen wird . Der zur Aufnahme der betraechtlichen statischen und dynamischen Kraefte notwendige Materialaufwand wird dadurch minimiert , dass ueber die schraeg zu den Bewegungsebenen eingestellten Faserbuendel des komplexen Bandapparats der gesamte Carpus jeweils in den Kraftfluss einbezogen wird . Dies ist die Voraussetzung der weitgehenden Beweglichkeit der Handwurzel . Die strenge funktionelle Interaktion des differenzierten Bandapparats mit den knoechernen Elementen des Carpus bedingt allerdings , dass schon die Schaedigung eines einzigen Elements schwerwiegende Folgen fuer die Stabilitaet des Gesamtkomplexes hat .
[ "Die", "Stabilitaet", "des", "Carpus", "wird", "vom", "exakten", "Zusammenspiel", "seiner", "knoechernen", "und", "ligamentaeren", "Elemente", "bestimmt", ".", "Als", "hauptsaechliche", "und", "damit", "fuer", "die", "Gewebeanpassung", "verantwortliche", "Beanspruchung", "ist", "eine", "longitudinale", "Kompression", "anzusehen", ",", "wie", "sie", "durch", "den", "Zug", "der", "Unterarmmuskeln", "bei", "nahezu", "jeder", "staerkeren", "Aktivitaet", "entsteht", ".", "Durch", "die", "keilfoermige", "Anordnung", "der", "Knochen", "der", "distalen", "Reihe", "wird", "die", "proximale", "Reihe", "einer", "Querdehnung", "ausgesetzt", ",", "die", "durch", "schraege", "radio-", "und", "ulnokarpale", "Baender", "aufgenommen", "wird", ".", "Auch", "die", "Retinacula", "sind", "als", "zirkulaere", "Sicherung", "aufzufassen", ".", "Der", "Bandapparat", "wird", "hier", "aufgrund", "des", "Verlaufes", "der", "einzelnen", "Faserbuendel", "in", "3", "Gruppen", "eingeteilt", ",", "wobei", "besonders", "auf", "die", "interossaeren", "Baender", "Bezug", "genommen", "wird", ".", "Der", "zur", "Aufnahme", "der", "betraechtlichen", "statischen", "und", "dynamischen", "Kraefte", "notwendige", "Materialaufwand", "wird", "dadurch", "minimiert", ",", "dass", "ueber", "die", "schraeg", "zu", "den", "Bewegungsebenen", "eingestellten", "Faserbuendel", "des", "komplexen", "Bandapparats", "der", "gesamte", "Carpus", "jeweils", "in", "den", "Kraftfluss", "einbezogen", "wird", ".", "Dies", "ist", "die", "Voraussetzung", "der", "weitgehenden", "Beweglichkeit", "der", "Handwurzel", ".", "Die", "strenge", "funktionelle", "Interaktion", "des", "differenzierten", "Bandapparats", "mit", "den", "knoechernen", "Elementen", "des", "Carpus", "bedingt", "allerdings", ",", "dass", "schon", "die", "Schaedigung", "eines", "einzigen", "Elements", "schwerwiegende", "Folgen", "fuer", "die", "Stabilitaet", "des", "Gesamtkomplexes", "hat", "." ]
[ "umlsterm" ]
Elemente, Gewebeanpassung, Unterarmmuskeln, Knochen, radio-, Baender, Bandapparat, Baender, Bandapparats, Handwurzel, Bandapparats, Elementen, Elements
DerOrthopaede.90280822.ger.abstr_task2
Sentence: Die Stabilitaet des Carpus wird vom exakten Zusammenspiel seiner knoechernen und ligamentaeren Elemente bestimmt . Als hauptsaechliche und damit fuer die Gewebeanpassung verantwortliche Beanspruchung ist eine longitudinale Kompression anzusehen , wie sie durch den Zug der Unterarmmuskeln bei nahezu jeder staerkeren Aktivitaet entsteht . Durch die keilfoermige Anordnung der Knochen der distalen Reihe wird die proximale Reihe einer Querdehnung ausgesetzt , die durch schraege radio- und ulnokarpale Baender aufgenommen wird . Auch die Retinacula sind als zirkulaere Sicherung aufzufassen . Der Bandapparat wird hier aufgrund des Verlaufes der einzelnen Faserbuendel in 3 Gruppen eingeteilt , wobei besonders auf die interossaeren Baender Bezug genommen wird . Der zur Aufnahme der betraechtlichen statischen und dynamischen Kraefte notwendige Materialaufwand wird dadurch minimiert , dass ueber die schraeg zu den Bewegungsebenen eingestellten Faserbuendel des komplexen Bandapparats der gesamte Carpus jeweils in den Kraftfluss einbezogen wird . Dies ist die Voraussetzung der weitgehenden Beweglichkeit der Handwurzel . Die strenge funktionelle Interaktion des differenzierten Bandapparats mit den knoechernen Elementen des Carpus bedingt allerdings , dass schon die Schaedigung eines einzigen Elements schwerwiegende Folgen fuer die Stabilitaet des Gesamtkomplexes hat . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Stabilitaet des Carpus wird vom exakten Zusammenspiel seiner knoechernen und ligamentaeren Elemente bestimmt . Als hauptsaechliche und damit fuer die Gewebeanpassung verantwortliche Beanspruchung ist eine longitudinale Kompression anzusehen , wie sie durch den Zug der Unterarmmuskeln bei nahezu jeder staerkeren Aktivitaet entsteht . Durch die keilfoermige Anordnung der Knochen der distalen Reihe wird die proximale Reihe einer Querdehnung ausgesetzt , die durch schraege radio- und ulnokarpale Baender aufgenommen wird . Auch die Retinacula sind als zirkulaere Sicherung aufzufassen . Der Bandapparat wird hier aufgrund des Verlaufes der einzelnen Faserbuendel in 3 Gruppen eingeteilt , wobei besonders auf die interossaeren Baender Bezug genommen wird . Der zur Aufnahme der betraechtlichen statischen und dynamischen Kraefte notwendige Materialaufwand wird dadurch minimiert , dass ueber die schraeg zu den Bewegungsebenen eingestellten Faserbuendel des komplexen Bandapparats der gesamte Carpus jeweils in den Kraftfluss einbezogen wird . Dies ist die Voraussetzung der weitgehenden Beweglichkeit der Handwurzel . Die strenge funktionelle Interaktion des differenzierten Bandapparats mit den knoechernen Elementen des Carpus bedingt allerdings , dass schon die Schaedigung eines einzigen Elements schwerwiegende Folgen fuer die Stabilitaet des Gesamtkomplexes hat .
[ "Die", "Stabilitaet", "des", "Carpus", "wird", "vom", "exakten", "Zusammenspiel", "seiner", "knoechernen", "und", "ligamentaeren", "Elemente", "bestimmt", ".", "Als", "hauptsaechliche", "und", "damit", "fuer", "die", "Gewebeanpassung", "verantwortliche", "Beanspruchung", "ist", "eine", "longitudinale", "Kompression", "anzusehen", ",", "wie", "sie", "durch", "den", "Zug", "der", "Unterarmmuskeln", "bei", "nahezu", "jeder", "staerkeren", "Aktivitaet", "entsteht", ".", "Durch", "die", "keilfoermige", "Anordnung", "der", "Knochen", "der", "distalen", "Reihe", "wird", "die", "proximale", "Reihe", "einer", "Querdehnung", "ausgesetzt", ",", "die", "durch", "schraege", "radio-", "und", "ulnokarpale", "Baender", "aufgenommen", "wird", ".", "Auch", "die", "Retinacula", "sind", "als", "zirkulaere", "Sicherung", "aufzufassen", ".", "Der", "Bandapparat", "wird", "hier", "aufgrund", "des", "Verlaufes", "der", "einzelnen", "Faserbuendel", "in", "3", "Gruppen", "eingeteilt", ",", "wobei", "besonders", "auf", "die", "interossaeren", "Baender", "Bezug", "genommen", "wird", ".", "Der", "zur", "Aufnahme", "der", "betraechtlichen", "statischen", "und", "dynamischen", "Kraefte", "notwendige", "Materialaufwand", "wird", "dadurch", "minimiert", ",", "dass", "ueber", "die", "schraeg", "zu", "den", "Bewegungsebenen", "eingestellten", "Faserbuendel", "des", "komplexen", "Bandapparats", "der", "gesamte", "Carpus", "jeweils", "in", "den", "Kraftfluss", "einbezogen", "wird", ".", "Dies", "ist", "die", "Voraussetzung", "der", "weitgehenden", "Beweglichkeit", "der", "Handwurzel", ".", "Die", "strenge", "funktionelle", "Interaktion", "des", "differenzierten", "Bandapparats", "mit", "den", "knoechernen", "Elementen", "des", "Carpus", "bedingt", "allerdings", ",", "dass", "schon", "die", "Schaedigung", "eines", "einzigen", "Elements", "schwerwiegende", "Folgen", "fuer", "die", "Stabilitaet", "des", "Gesamtkomplexes", "hat", "." ]
[ "umlsterm" ]
Glycolate is a CHEMICAL, glyoxylate is a CHEMICAL
15240345_task0
Sentence: Glycolate and glyoxylate metabolism in HepG2 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
Glycolate and glyoxylate metabolism in HepG2 cells.
[ "Glycolate", "and", "glyoxylate", "metabolism", "in", "HepG2", "cells", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Glycolate is a CHEMICAL, glyoxylate is a CHEMICAL
15240345_task1
Sentence: Glycolate and glyoxylate metabolism in HepG2 cells. Instructions: please typing these entity words according to sentence: Glycolate, glyoxylate Options: CHEMICAL
[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
Glycolate and glyoxylate metabolism in HepG2 cells.
[ "Glycolate", "and", "glyoxylate", "metabolism", "in", "HepG2", "cells", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Glycolate, glyoxylate
15240345_task2
Sentence: Glycolate and glyoxylate metabolism in HepG2 cells. Instructions: please extract entity words from the input sentence
[ "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]
Glycolate and glyoxylate metabolism in HepG2 cells.
[ "Glycolate", "and", "glyoxylate", "metabolism", "in", "HepG2", "cells", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
parent - delivered intervention is a Intervention_Educational, young children is a Participant_Age, autism is a Participant_Condition, parent - coaching intervention is a Intervention_Educational, Early Start Denver Model ( P - ESDM ) is a Intervention_Educational, parenting - related stress is a Outcome_Mental, sense of competence . is a Outcome_Mental, 49 is a Participant_Sample-size, children aged 12 and 24 months is a Participant_Age
60440_task0
Sentence: The impact of parent-delivered intervention on parents of very young children with autism . This study investigated the impact of a parent-coaching intervention based on the Early Start Denver Model ( P-ESDM ) on parenting-related stress and sense of competence . This was part of a multisite , randomized trial comparing P-ESDM ( n = 49 ) with community intervention ( n = 49 ) for children aged 12 and 24 months . The P-ESDM group reported no increase in parenting stress , whereas the Community group experienced an increase over the same 3-month period . Parental sense of competence did not differ . Number of negative life events was a significant predictor of parenting stress and sense of competence across both groups . This suggests that a parent-coaching intervention may help maintain parental adjustment directly after a child is diagnosed with ASD . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The impact of parent-delivered intervention on parents of very young children with autism . This study investigated the impact of a parent-coaching intervention based on the Early Start Denver Model ( P-ESDM ) on parenting-related stress and sense of competence . This was part of a multisite , randomized trial comparing P-ESDM ( n = 49 ) with community intervention ( n = 49 ) for children aged 12 and 24 months . The P-ESDM group reported no increase in parenting stress , whereas the Community group experienced an increase over the same 3-month period . Parental sense of competence did not differ . Number of negative life events was a significant predictor of parenting stress and sense of competence across both groups . This suggests that a parent-coaching intervention may help maintain parental adjustment directly after a child is diagnosed with ASD .
[ "The", "impact", "of", "parent", "-", "delivered", "intervention", "on", "parents", "of", "very", "young", "children", "with", "autism", ".", "This", "study", "investigated", "the", "impact", "of", "a", "parent", "-", "coaching", "intervention", "based", "on", "the", "Early", "Start", "Denver", "Model", "(", "P", "-", "ESDM", ")", "on", "parenting", "-", "related", "stress", "and", "sense", "of", "competence", ".", "This", "was", "part", "of", "a", "multisite", ",", "randomized", "trial", "comparing", "P", "-", "ESDM", "(", "n", "=", "49", ")", "with", "community", "intervention", "(", "n", "=", "49", ")", "for", "children", "aged", "12", "and", "24", "months", ".", "The", "P", "-", "ESDM", "group", "reported", "no", "increase", "in", "parenting", "stress", ",", "whereas", "the", "Community", "group", "experienced", "an", "increase", "over", "the", "same", "3-month", "period", ".", "Parental", "sense", "of", "competence", "did", "not", "differ", ".", "Number", "of", "negative", "life", "events", "was", "a", "significant", "predictor", "of", "parenting", "stress", "and", "sense", "of", "competence", "across", "both", "groups", ".", "This", "suggests", "that", "a", "parent", "-", "coaching", "intervention", "may", "help", "maintain", "parental", "adjustment", "directly", "after", "a", "child", "is", "diagnosed", "with", "ASD", "." ]
[ "Intervention_Educational", "Participant_Age", "Outcome_Mental", "Participant_Condition", "Participant_Sample-size" ]
parent - delivered intervention is a Intervention_Educational, young children is a Participant_Age, autism is a Participant_Condition, parent - coaching intervention is a Intervention_Educational, Early Start Denver Model ( P - ESDM ) is a Intervention_Educational, parenting - related stress is a Outcome_Mental, sense of competence . is a Outcome_Mental, 49 is a Participant_Sample-size, children aged 12 and 24 months is a Participant_Age
60440_task1
Sentence: The impact of parent-delivered intervention on parents of very young children with autism . This study investigated the impact of a parent-coaching intervention based on the Early Start Denver Model ( P-ESDM ) on parenting-related stress and sense of competence . This was part of a multisite , randomized trial comparing P-ESDM ( n = 49 ) with community intervention ( n = 49 ) for children aged 12 and 24 months . The P-ESDM group reported no increase in parenting stress , whereas the Community group experienced an increase over the same 3-month period . Parental sense of competence did not differ . Number of negative life events was a significant predictor of parenting stress and sense of competence across both groups . This suggests that a parent-coaching intervention may help maintain parental adjustment directly after a child is diagnosed with ASD . Instructions: please typing these entity words according to sentence: parent - delivered intervention, young children, autism, parent - coaching intervention, Early Start Denver Model ( P - ESDM ), parenting - related stress, sense of competence ., 49, children aged 12 and 24 months Options: Participant_Condition, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The impact of parent-delivered intervention on parents of very young children with autism . This study investigated the impact of a parent-coaching intervention based on the Early Start Denver Model ( P-ESDM ) on parenting-related stress and sense of competence . This was part of a multisite , randomized trial comparing P-ESDM ( n = 49 ) with community intervention ( n = 49 ) for children aged 12 and 24 months . The P-ESDM group reported no increase in parenting stress , whereas the Community group experienced an increase over the same 3-month period . Parental sense of competence did not differ . Number of negative life events was a significant predictor of parenting stress and sense of competence across both groups . This suggests that a parent-coaching intervention may help maintain parental adjustment directly after a child is diagnosed with ASD .
[ "The", "impact", "of", "parent", "-", "delivered", "intervention", "on", "parents", "of", "very", "young", "children", "with", "autism", ".", "This", "study", "investigated", "the", "impact", "of", "a", "parent", "-", "coaching", "intervention", "based", "on", "the", "Early", "Start", "Denver", "Model", "(", "P", "-", "ESDM", ")", "on", "parenting", "-", "related", "stress", "and", "sense", "of", "competence", ".", "This", "was", "part", "of", "a", "multisite", ",", "randomized", "trial", "comparing", "P", "-", "ESDM", "(", "n", "=", "49", ")", "with", "community", "intervention", "(", "n", "=", "49", ")", "for", "children", "aged", "12", "and", "24", "months", ".", "The", "P", "-", "ESDM", "group", "reported", "no", "increase", "in", "parenting", "stress", ",", "whereas", "the", "Community", "group", "experienced", "an", "increase", "over", "the", "same", "3-month", "period", ".", "Parental", "sense", "of", "competence", "did", "not", "differ", ".", "Number", "of", "negative", "life", "events", "was", "a", "significant", "predictor", "of", "parenting", "stress", "and", "sense", "of", "competence", "across", "both", "groups", ".", "This", "suggests", "that", "a", "parent", "-", "coaching", "intervention", "may", "help", "maintain", "parental", "adjustment", "directly", "after", "a", "child", "is", "diagnosed", "with", "ASD", "." ]
[ "Intervention_Educational", "Participant_Age", "Outcome_Mental", "Participant_Condition", "Participant_Sample-size" ]
parent - delivered intervention, young children, autism, parent - coaching intervention, Early Start Denver Model ( P - ESDM ), parenting - related stress, sense of competence ., 49, children aged 12 and 24 months
60440_task2
Sentence: The impact of parent-delivered intervention on parents of very young children with autism . This study investigated the impact of a parent-coaching intervention based on the Early Start Denver Model ( P-ESDM ) on parenting-related stress and sense of competence . This was part of a multisite , randomized trial comparing P-ESDM ( n = 49 ) with community intervention ( n = 49 ) for children aged 12 and 24 months . The P-ESDM group reported no increase in parenting stress , whereas the Community group experienced an increase over the same 3-month period . Parental sense of competence did not differ . Number of negative life events was a significant predictor of parenting stress and sense of competence across both groups . This suggests that a parent-coaching intervention may help maintain parental adjustment directly after a child is diagnosed with ASD . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The impact of parent-delivered intervention on parents of very young children with autism . This study investigated the impact of a parent-coaching intervention based on the Early Start Denver Model ( P-ESDM ) on parenting-related stress and sense of competence . This was part of a multisite , randomized trial comparing P-ESDM ( n = 49 ) with community intervention ( n = 49 ) for children aged 12 and 24 months . The P-ESDM group reported no increase in parenting stress , whereas the Community group experienced an increase over the same 3-month period . Parental sense of competence did not differ . Number of negative life events was a significant predictor of parenting stress and sense of competence across both groups . This suggests that a parent-coaching intervention may help maintain parental adjustment directly after a child is diagnosed with ASD .
[ "The", "impact", "of", "parent", "-", "delivered", "intervention", "on", "parents", "of", "very", "young", "children", "with", "autism", ".", "This", "study", "investigated", "the", "impact", "of", "a", "parent", "-", "coaching", "intervention", "based", "on", "the", "Early", "Start", "Denver", "Model", "(", "P", "-", "ESDM", ")", "on", "parenting", "-", "related", "stress", "and", "sense", "of", "competence", ".", "This", "was", "part", "of", "a", "multisite", ",", "randomized", "trial", "comparing", "P", "-", "ESDM", "(", "n", "=", "49", ")", "with", "community", "intervention", "(", "n", "=", "49", ")", "for", "children", "aged", "12", "and", "24", "months", ".", "The", "P", "-", "ESDM", "group", "reported", "no", "increase", "in", "parenting", "stress", ",", "whereas", "the", "Community", "group", "experienced", "an", "increase", "over", "the", "same", "3-month", "period", ".", "Parental", "sense", "of", "competence", "did", "not", "differ", ".", "Number", "of", "negative", "life", "events", "was", "a", "significant", "predictor", "of", "parenting", "stress", "and", "sense", "of", "competence", "across", "both", "groups", ".", "This", "suggests", "that", "a", "parent", "-", "coaching", "intervention", "may", "help", "maintain", "parental", "adjustment", "directly", "after", "a", "child", "is", "diagnosed", "with", "ASD", "." ]
[ "Intervention_Educational", "Participant_Age", "Outcome_Mental", "Participant_Condition", "Participant_Sample-size" ]
No is a Negation, Down syndrome is a Condition, No is a Negation, other is a Qualifier, major disease is a Condition, severe is a Qualifier, congenital heart disease is a Condition, Not is a Negation, study therapy is a Procedure, complications is a Condition, No is a Negation, complications is a Condition, other is a Qualifier, interventions is a Procedure, No is a Negation
NCT00846703_exc_task0
Sentence: No Down syndrome No other major disease that prohibits study treatment (e.g., severe congenital heart disease) Not requiring significant therapy modification owing to study therapy associated complications No complications due to other interventions No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Procedure, Negation, Qualifier
[ "B-Negation", "B-Condition", "I-Condition", "O", "B-Negation", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Negation", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "O", "B-Negation", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "O", "B-Negation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
No Down syndrome No other major disease that prohibits study treatment (e.g., severe congenital heart disease) Not requiring significant therapy modification owing to study therapy associated complications No complications due to other interventions No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm
[ "No", "Down", "syndrome", "\n", "No", "other", "major", "disease", "that", "prohibits", "study", "treatment", "(", "e.g", ".", ",", "severe", "congenital", "heart", "disease", ")", "\n", "Not", "requiring", "significant", "therapy", "modification", "owing", "to", "study", "therapy", "associated", "complications", "\n", "No", "complications", "due", "to", "other", "interventions", "\n", "No", "one", "with", "missing", "data", "that", "are", "needed", "for", "the", "differential", "diagnosis", ",", "or", "for", "selection", "of", "the", "proper", "therapy", "arm", "\n" ]
[ "Condition", "Procedure", "Qualifier", "Negation" ]
No is a Negation, Down syndrome is a Condition, No is a Negation, other is a Qualifier, major disease is a Condition, severe is a Qualifier, congenital heart disease is a Condition, Not is a Negation, study therapy is a Procedure, complications is a Condition, No is a Negation, complications is a Condition, other is a Qualifier, interventions is a Procedure, No is a Negation
NCT00846703_exc_task1
Sentence: No Down syndrome No other major disease that prohibits study treatment (e.g., severe congenital heart disease) Not requiring significant therapy modification owing to study therapy associated complications No complications due to other interventions No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm Instructions: please typing these entity words according to sentence: No, Down syndrome, No, other, major disease, severe, congenital heart disease, Not, study therapy, complications, No, complications, other, interventions, No Options: Condition, Procedure, Negation, Qualifier
[ "B-Negation", "B-Condition", "I-Condition", "O", "B-Negation", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Negation", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "O", "B-Negation", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "O", "B-Negation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
No Down syndrome No other major disease that prohibits study treatment (e.g., severe congenital heart disease) Not requiring significant therapy modification owing to study therapy associated complications No complications due to other interventions No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm
[ "No", "Down", "syndrome", "\n", "No", "other", "major", "disease", "that", "prohibits", "study", "treatment", "(", "e.g", ".", ",", "severe", "congenital", "heart", "disease", ")", "\n", "Not", "requiring", "significant", "therapy", "modification", "owing", "to", "study", "therapy", "associated", "complications", "\n", "No", "complications", "due", "to", "other", "interventions", "\n", "No", "one", "with", "missing", "data", "that", "are", "needed", "for", "the", "differential", "diagnosis", ",", "or", "for", "selection", "of", "the", "proper", "therapy", "arm", "\n" ]
[ "Condition", "Procedure", "Qualifier", "Negation" ]
No, Down syndrome, No, other, major disease, severe, congenital heart disease, Not, study therapy, complications, No, complications, other, interventions, No
NCT00846703_exc_task2
Sentence: No Down syndrome No other major disease that prohibits study treatment (e.g., severe congenital heart disease) Not requiring significant therapy modification owing to study therapy associated complications No complications due to other interventions No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm Instructions: please extract entity words from the input sentence
[ "B-Negation", "B-Condition", "I-Condition", "O", "B-Negation", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Negation", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "O", "B-Negation", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "O", "B-Negation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
No Down syndrome No other major disease that prohibits study treatment (e.g., severe congenital heart disease) Not requiring significant therapy modification owing to study therapy associated complications No complications due to other interventions No one with missing data that are needed for the differential diagnosis, or for selection of the proper therapy arm
[ "No", "Down", "syndrome", "\n", "No", "other", "major", "disease", "that", "prohibits", "study", "treatment", "(", "e.g", ".", ",", "severe", "congenital", "heart", "disease", ")", "\n", "Not", "requiring", "significant", "therapy", "modification", "owing", "to", "study", "therapy", "associated", "complications", "\n", "No", "complications", "due", "to", "other", "interventions", "\n", "No", "one", "with", "missing", "data", "that", "are", "needed", "for", "the", "differential", "diagnosis", ",", "or", "for", "selection", "of", "the", "proper", "therapy", "arm", "\n" ]
[ "Condition", "Procedure", "Qualifier", "Negation" ]
Surfactant protein A is a Protein, tumor necrosis factor - alpha is a Protein
761_task0
Sentence: Surfactant protein A activates NF-kappa B in the THP-1 monocytic cell line. The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-kappa B. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-kappa B. We used gel shift assays to determine whether SP-A activated NF-kappa B in the THP-1 cell line, a human monocytic cell line. Activation of NF-kappa B in THP-1 cells by SP-A doses as low as 1 microgram/ml occurred within 30 min of SP-A treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-kappa B or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-kappa B inhibitors blocked SP-A-dependent increases in tumor necrosis factor-alpha mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Surfactant protein A activates NF-kappa B in the THP-1 monocytic cell line. The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-kappa B. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-kappa B. We used gel shift assays to determine whether SP-A activated NF-kappa B in the THP-1 cell line, a human monocytic cell line. Activation of NF-kappa B in THP-1 cells by SP-A doses as low as 1 microgram/ml occurred within 30 min of SP-A treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-kappa B or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-kappa B inhibitors blocked SP-A-dependent increases in tumor necrosis factor-alpha mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung.
[ "Surfactant", "protein", "A", "activates", "NF", "-", "kappa", "B", "in", "the", "THP-1", "monocytic", "cell", "line", ".", "\n", "The", "expression", "of", "many", "genes", "for", "which", "products", "are", "involved", "in", "inflammation", "is", "controlled", "by", "the", "transcriptional", "regulator", "nuclear", "factor", "(", "NF)-kappa", "B.", "Because", "surfactant", "protein", "(", "SP", ")", "A", "is", "involved", "in", "local", "host", "defense", "in", "the", "lung", "and", "alters", "immune", "cell", "function", "by", "modulating", "the", "expression", "of", "proinflammatory", "cytokines", "as", "well", "as", "surface", "proteins", "involved", "in", "inflammation", ",", "we", "hypothesized", "that", "SP", "-", "A", "exerts", "its", "action", ",", "at", "least", "in", "part", ",", "via", "activation", "of", "NF", "-", "kappa", "B.", "We", "used", "gel", "shift", "assays", "to", "determine", "whether", "SP", "-", "A", "activated", "NF", "-", "kappa", "B", "in", "the", "THP-1", "cell", "line", ",", "a", "human", "monocytic", "cell", "line", ".", "Activation", "of", "NF", "-", "kappa", "B", "in", "THP-1", "cells", "by", "SP", "-", "A", "doses", "as", "low", "as", "1", "microgram", "/", "ml", "occurred", "within", "30", "min", "of", "SP", "-", "A", "treatment", ",", "peaked", "at", "60", "min", ",", "and", "then", "declined", ".", "This", "activation", "is", "inhibited", "by", "known", "inhibitors", "of", "NF", "-", "kappa", "B", "or", "by", "simultaneous", "treatment", "of", "the", "cells", "with", "surfactant", "lipids", ".", "Moreover", ",", "the", "NF", "-", "kappa", "B", "inhibitors", "blocked", "SP", "-", "A", "-", "dependent", "increases", "in", "tumor", "necrosis", "factor", "-", "alpha", "mRNA", "levels", ".", "These", "observations", "suggest", "a", "mechanism", "by", "which", "SP", "-", "A", "plays", "a", "role", "in", "the", "pathogenesis", "of", "some", "lung", "conditions", "and", "point", "to", "potential", "therapeutic", "measures", "that", "could", "be", "used", "to", "prevent", "SP", "-", "A", "induced", "inflammation", "in", "the", "lung", "." ]
[ "Protein" ]
Surfactant protein A is a Protein, tumor necrosis factor - alpha is a Protein
761_task1
Sentence: Surfactant protein A activates NF-kappa B in the THP-1 monocytic cell line. The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-kappa B. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-kappa B. We used gel shift assays to determine whether SP-A activated NF-kappa B in the THP-1 cell line, a human monocytic cell line. Activation of NF-kappa B in THP-1 cells by SP-A doses as low as 1 microgram/ml occurred within 30 min of SP-A treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-kappa B or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-kappa B inhibitors blocked SP-A-dependent increases in tumor necrosis factor-alpha mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung. Instructions: please typing these entity words according to sentence: Surfactant protein A, tumor necrosis factor - alpha Options: Protein
[ "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Surfactant protein A activates NF-kappa B in the THP-1 monocytic cell line. The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-kappa B. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-kappa B. We used gel shift assays to determine whether SP-A activated NF-kappa B in the THP-1 cell line, a human monocytic cell line. Activation of NF-kappa B in THP-1 cells by SP-A doses as low as 1 microgram/ml occurred within 30 min of SP-A treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-kappa B or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-kappa B inhibitors blocked SP-A-dependent increases in tumor necrosis factor-alpha mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung.
[ "Surfactant", "protein", "A", "activates", "NF", "-", "kappa", "B", "in", "the", "THP-1", "monocytic", "cell", "line", ".", "\n", "The", "expression", "of", "many", "genes", "for", "which", "products", "are", "involved", "in", "inflammation", "is", "controlled", "by", "the", "transcriptional", "regulator", "nuclear", "factor", "(", "NF)-kappa", "B.", "Because", "surfactant", "protein", "(", "SP", ")", "A", "is", "involved", "in", "local", "host", "defense", "in", "the", "lung", "and", "alters", "immune", "cell", "function", "by", "modulating", "the", "expression", "of", "proinflammatory", "cytokines", "as", "well", "as", "surface", "proteins", "involved", "in", "inflammation", ",", "we", "hypothesized", "that", "SP", "-", "A", "exerts", "its", "action", ",", "at", "least", "in", "part", ",", "via", "activation", "of", "NF", "-", "kappa", "B.", "We", "used", "gel", "shift", "assays", "to", "determine", "whether", "SP", "-", "A", "activated", "NF", "-", "kappa", "B", "in", "the", "THP-1", "cell", "line", ",", "a", "human", "monocytic", "cell", "line", ".", "Activation", "of", "NF", "-", "kappa", "B", "in", "THP-1", "cells", "by", "SP", "-", "A", "doses", "as", "low", "as", "1", "microgram", "/", "ml", "occurred", "within", "30", "min", "of", "SP", "-", "A", "treatment", ",", "peaked", "at", "60", "min", ",", "and", "then", "declined", ".", "This", "activation", "is", "inhibited", "by", "known", "inhibitors", "of", "NF", "-", "kappa", "B", "or", "by", "simultaneous", "treatment", "of", "the", "cells", "with", "surfactant", "lipids", ".", "Moreover", ",", "the", "NF", "-", "kappa", "B", "inhibitors", "blocked", "SP", "-", "A", "-", "dependent", "increases", "in", "tumor", "necrosis", "factor", "-", "alpha", "mRNA", "levels", ".", "These", "observations", "suggest", "a", "mechanism", "by", "which", "SP", "-", "A", "plays", "a", "role", "in", "the", "pathogenesis", "of", "some", "lung", "conditions", "and", "point", "to", "potential", "therapeutic", "measures", "that", "could", "be", "used", "to", "prevent", "SP", "-", "A", "induced", "inflammation", "in", "the", "lung", "." ]
[ "Protein" ]
Surfactant protein A, tumor necrosis factor - alpha
761_task2
Sentence: Surfactant protein A activates NF-kappa B in the THP-1 monocytic cell line. The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-kappa B. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-kappa B. We used gel shift assays to determine whether SP-A activated NF-kappa B in the THP-1 cell line, a human monocytic cell line. Activation of NF-kappa B in THP-1 cells by SP-A doses as low as 1 microgram/ml occurred within 30 min of SP-A treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-kappa B or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-kappa B inhibitors blocked SP-A-dependent increases in tumor necrosis factor-alpha mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung. Instructions: please extract entity words from the input sentence
[ "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Surfactant protein A activates NF-kappa B in the THP-1 monocytic cell line. The expression of many genes for which products are involved in inflammation is controlled by the transcriptional regulator nuclear factor (NF)-kappa B. Because surfactant protein (SP) A is involved in local host defense in the lung and alters immune cell function by modulating the expression of proinflammatory cytokines as well as surface proteins involved in inflammation, we hypothesized that SP-A exerts its action, at least in part, via activation of NF-kappa B. We used gel shift assays to determine whether SP-A activated NF-kappa B in the THP-1 cell line, a human monocytic cell line. Activation of NF-kappa B in THP-1 cells by SP-A doses as low as 1 microgram/ml occurred within 30 min of SP-A treatment, peaked at 60 min, and then declined. This activation is inhibited by known inhibitors of NF-kappa B or by simultaneous treatment of the cells with surfactant lipids. Moreover, the NF-kappa B inhibitors blocked SP-A-dependent increases in tumor necrosis factor-alpha mRNA levels. These observations suggest a mechanism by which SP-A plays a role in the pathogenesis of some lung conditions and point to potential therapeutic measures that could be used to prevent SP-A induced inflammation in the lung.
[ "Surfactant", "protein", "A", "activates", "NF", "-", "kappa", "B", "in", "the", "THP-1", "monocytic", "cell", "line", ".", "\n", "The", "expression", "of", "many", "genes", "for", "which", "products", "are", "involved", "in", "inflammation", "is", "controlled", "by", "the", "transcriptional", "regulator", "nuclear", "factor", "(", "NF)-kappa", "B.", "Because", "surfactant", "protein", "(", "SP", ")", "A", "is", "involved", "in", "local", "host", "defense", "in", "the", "lung", "and", "alters", "immune", "cell", "function", "by", "modulating", "the", "expression", "of", "proinflammatory", "cytokines", "as", "well", "as", "surface", "proteins", "involved", "in", "inflammation", ",", "we", "hypothesized", "that", "SP", "-", "A", "exerts", "its", "action", ",", "at", "least", "in", "part", ",", "via", "activation", "of", "NF", "-", "kappa", "B.", "We", "used", "gel", "shift", "assays", "to", "determine", "whether", "SP", "-", "A", "activated", "NF", "-", "kappa", "B", "in", "the", "THP-1", "cell", "line", ",", "a", "human", "monocytic", "cell", "line", ".", "Activation", "of", "NF", "-", "kappa", "B", "in", "THP-1", "cells", "by", "SP", "-", "A", "doses", "as", "low", "as", "1", "microgram", "/", "ml", "occurred", "within", "30", "min", "of", "SP", "-", "A", "treatment", ",", "peaked", "at", "60", "min", ",", "and", "then", "declined", ".", "This", "activation", "is", "inhibited", "by", "known", "inhibitors", "of", "NF", "-", "kappa", "B", "or", "by", "simultaneous", "treatment", "of", "the", "cells", "with", "surfactant", "lipids", ".", "Moreover", ",", "the", "NF", "-", "kappa", "B", "inhibitors", "blocked", "SP", "-", "A", "-", "dependent", "increases", "in", "tumor", "necrosis", "factor", "-", "alpha", "mRNA", "levels", ".", "These", "observations", "suggest", "a", "mechanism", "by", "which", "SP", "-", "A", "plays", "a", "role", "in", "the", "pathogenesis", "of", "some", "lung", "conditions", "and", "point", "to", "potential", "therapeutic", "measures", "that", "could", "be", "used", "to", "prevent", "SP", "-", "A", "induced", "inflammation", "in", "the", "lung", "." ]
[ "Protein" ]
antisense transcript is a AntisenseRNA, SMAD5 is a Protein, fetal is a Tissue, tumor tissues is a Tissue, SMAD5 is a Protein, TGF - beta / BMP is a Protein, tumor suppressor is a Protein, human is a Eukaryote, chromosome is a Chromosome, gene is a Gene, TGF - beta / BMP is a Protein, transcript is a Transcript, DAMS is a Protein, 3 ' exonic sequences is a Exon, exon is a Exon, SMAD5 is a Protein, DAMS is a Protein, fetal tissues is a Tissue, heart is a Tissue, adrenal glands is a Tissue, total fetus is a Tissue, pancreatic tumor is a Tissue, cDNA is a DNA, SMAD5 is a Protein, DAMS is a Protein, adult and fetal tissues is a Tissue, SMAD5 is a Protein, DAMS is a Protein, transcripts is a Transcript, hematopoietic cells is a Cell, DAMS is a Protein, SMAD5 is a Protein, transcript is a Transcript
35_task0
Sentence: An antisense transcript to SMAD5 expressed in fetal and tumor tissues. SMAD5, a transducer of TGF-beta/BMP inhibitory signals and a tumor suppressor candidate, localizes to the region of invariant loss in human myeloid neoplasms, on chromosome 5q31.1. Recent evidence indicates a gene-dosage effect along the TGF-beta/BMP signaling pathways. We have identified a novel transcript designated DAMS, whose 3' exonic sequences contain in part an alternate 5' exon of SMAD5, in the antisense orientation. Expressed sequenced tags (ESTs) for DAMS are found in fetal tissues (heart, adrenal glands, and total fetus) and pancreatic tumor cDNA libraries. In contrast to SMAD5, DAMS expression is not readily detectable in adult and fetal tissues. Semiquantitative PCR suggests that the stoichiometry between SMAD5 and DAMS transcripts ranges between 15 and 120 in normal and malignant hematopoietic cells. The findings raise the possibility that DAMS may be a fail-safe mechanism for precise regulation of SMAD5 transcript levels that may be critical in maintaining normal homeostasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, Tissue, AntisenseRNA, Chromosome, Exon, Gene, Transcript, Eukaryote, Protein, Cell
[ "O", "B-AntisenseRNA", "I-AntisenseRNA", "O", "B-Protein", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "O", "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "B-Protein", "O", "O", "B-Exon", "I-Exon", "I-Exon", "I-Exon", "O", "O", "O", "O", "O", "O", "O", "B-Exon", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "B-DNA", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
An antisense transcript to SMAD5 expressed in fetal and tumor tissues. SMAD5, a transducer of TGF-beta/BMP inhibitory signals and a tumor suppressor candidate, localizes to the region of invariant loss in human myeloid neoplasms, on chromosome 5q31.1. Recent evidence indicates a gene-dosage effect along the TGF-beta/BMP signaling pathways. We have identified a novel transcript designated DAMS, whose 3' exonic sequences contain in part an alternate 5' exon of SMAD5, in the antisense orientation. Expressed sequenced tags (ESTs) for DAMS are found in fetal tissues (heart, adrenal glands, and total fetus) and pancreatic tumor cDNA libraries. In contrast to SMAD5, DAMS expression is not readily detectable in adult and fetal tissues. Semiquantitative PCR suggests that the stoichiometry between SMAD5 and DAMS transcripts ranges between 15 and 120 in normal and malignant hematopoietic cells. The findings raise the possibility that DAMS may be a fail-safe mechanism for precise regulation of SMAD5 transcript levels that may be critical in maintaining normal homeostasis.
[ "An", "antisense", "transcript", "to", "SMAD5", "expressed", "in", "fetal", "and", "tumor", "tissues", ".", "SMAD5", ",", "a", "transducer", "of", "TGF", "-", "beta", "/", "BMP", "inhibitory", "signals", "and", "a", "tumor", "suppressor", "candidate", ",", "localizes", "to", "the", "region", "of", "invariant", "loss", "in", "human", "myeloid", "neoplasms", ",", "on", "chromosome", "5q31.1", ".", "Recent", "evidence", "indicates", "a", "gene", "-", "dosage", "effect", "along", "the", "TGF", "-", "beta", "/", "BMP", "signaling", "pathways", ".", "We", "have", "identified", "a", "novel", "transcript", "designated", "DAMS", ",", "whose", "3", "'", "exonic", "sequences", "contain", "in", "part", "an", "alternate", "5", "'", "exon", "of", "SMAD5", ",", "in", "the", "antisense", "orientation", ".", "Expressed", "sequenced", "tags", "(", "ESTs", ")", "for", "DAMS", "are", "found", "in", "fetal", "tissues", "(", "heart", ",", "adrenal", "glands", ",", "and", "total", "fetus", ")", "and", "pancreatic", "tumor", "cDNA", "libraries", ".", "In", "contrast", "to", "SMAD5", ",", "DAMS", "expression", "is", "not", "readily", "detectable", "in", "adult", "and", "fetal", "tissues", ".", "Semiquantitative", "PCR", "suggests", "that", "the", "stoichiometry", "between", "SMAD5", "and", "DAMS", "transcripts", "ranges", "between", "15", "and", "120", "in", "normal", "and", "malignant", "hematopoietic", "cells", ".", "The", "findings", "raise", "the", "possibility", "that", "DAMS", "may", "be", "a", "fail", "-", "safe", "mechanism", "for", "precise", "regulation", "of", "SMAD5", "transcript", "levels", "that", "may", "be", "critical", "in", "maintaining", "normal", "homeostasis", ".", "\n" ]
[ "Tissue", "AntisenseRNA", "Exon", "Cell", "Protein", "Transcript", "Chromosome", "Eukaryote", "Gene", "DNA" ]
antisense transcript is a AntisenseRNA, SMAD5 is a Protein, fetal is a Tissue, tumor tissues is a Tissue, SMAD5 is a Protein, TGF - beta / BMP is a Protein, tumor suppressor is a Protein, human is a Eukaryote, chromosome is a Chromosome, gene is a Gene, TGF - beta / BMP is a Protein, transcript is a Transcript, DAMS is a Protein, 3 ' exonic sequences is a Exon, exon is a Exon, SMAD5 is a Protein, DAMS is a Protein, fetal tissues is a Tissue, heart is a Tissue, adrenal glands is a Tissue, total fetus is a Tissue, pancreatic tumor is a Tissue, cDNA is a DNA, SMAD5 is a Protein, DAMS is a Protein, adult and fetal tissues is a Tissue, SMAD5 is a Protein, DAMS is a Protein, transcripts is a Transcript, hematopoietic cells is a Cell, DAMS is a Protein, SMAD5 is a Protein, transcript is a Transcript
35_task1
Sentence: An antisense transcript to SMAD5 expressed in fetal and tumor tissues. SMAD5, a transducer of TGF-beta/BMP inhibitory signals and a tumor suppressor candidate, localizes to the region of invariant loss in human myeloid neoplasms, on chromosome 5q31.1. Recent evidence indicates a gene-dosage effect along the TGF-beta/BMP signaling pathways. We have identified a novel transcript designated DAMS, whose 3' exonic sequences contain in part an alternate 5' exon of SMAD5, in the antisense orientation. Expressed sequenced tags (ESTs) for DAMS are found in fetal tissues (heart, adrenal glands, and total fetus) and pancreatic tumor cDNA libraries. In contrast to SMAD5, DAMS expression is not readily detectable in adult and fetal tissues. Semiquantitative PCR suggests that the stoichiometry between SMAD5 and DAMS transcripts ranges between 15 and 120 in normal and malignant hematopoietic cells. The findings raise the possibility that DAMS may be a fail-safe mechanism for precise regulation of SMAD5 transcript levels that may be critical in maintaining normal homeostasis. Instructions: please typing these entity words according to sentence: antisense transcript, SMAD5, fetal, tumor tissues, SMAD5, TGF - beta / BMP, tumor suppressor, human, chromosome, gene, TGF - beta / BMP, transcript, DAMS, 3 ' exonic sequences, exon, SMAD5, DAMS, fetal tissues, heart, adrenal glands, total fetus, pancreatic tumor, cDNA, SMAD5, DAMS, adult and fetal tissues, SMAD5, DAMS, transcripts, hematopoietic cells, DAMS, SMAD5, transcript Options: DNA, Tissue, AntisenseRNA, Chromosome, Exon, Gene, Transcript, Eukaryote, Protein, Cell
[ "O", "B-AntisenseRNA", "I-AntisenseRNA", "O", "B-Protein", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "O", "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "B-Protein", "O", "O", "B-Exon", "I-Exon", "I-Exon", "I-Exon", "O", "O", "O", "O", "O", "O", "O", "B-Exon", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "B-DNA", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
An antisense transcript to SMAD5 expressed in fetal and tumor tissues. SMAD5, a transducer of TGF-beta/BMP inhibitory signals and a tumor suppressor candidate, localizes to the region of invariant loss in human myeloid neoplasms, on chromosome 5q31.1. Recent evidence indicates a gene-dosage effect along the TGF-beta/BMP signaling pathways. We have identified a novel transcript designated DAMS, whose 3' exonic sequences contain in part an alternate 5' exon of SMAD5, in the antisense orientation. Expressed sequenced tags (ESTs) for DAMS are found in fetal tissues (heart, adrenal glands, and total fetus) and pancreatic tumor cDNA libraries. In contrast to SMAD5, DAMS expression is not readily detectable in adult and fetal tissues. Semiquantitative PCR suggests that the stoichiometry between SMAD5 and DAMS transcripts ranges between 15 and 120 in normal and malignant hematopoietic cells. The findings raise the possibility that DAMS may be a fail-safe mechanism for precise regulation of SMAD5 transcript levels that may be critical in maintaining normal homeostasis.
[ "An", "antisense", "transcript", "to", "SMAD5", "expressed", "in", "fetal", "and", "tumor", "tissues", ".", "SMAD5", ",", "a", "transducer", "of", "TGF", "-", "beta", "/", "BMP", "inhibitory", "signals", "and", "a", "tumor", "suppressor", "candidate", ",", "localizes", "to", "the", "region", "of", "invariant", "loss", "in", "human", "myeloid", "neoplasms", ",", "on", "chromosome", "5q31.1", ".", "Recent", "evidence", "indicates", "a", "gene", "-", "dosage", "effect", "along", "the", "TGF", "-", "beta", "/", "BMP", "signaling", "pathways", ".", "We", "have", "identified", "a", "novel", "transcript", "designated", "DAMS", ",", "whose", "3", "'", "exonic", "sequences", "contain", "in", "part", "an", "alternate", "5", "'", "exon", "of", "SMAD5", ",", "in", "the", "antisense", "orientation", ".", "Expressed", "sequenced", "tags", "(", "ESTs", ")", "for", "DAMS", "are", "found", "in", "fetal", "tissues", "(", "heart", ",", "adrenal", "glands", ",", "and", "total", "fetus", ")", "and", "pancreatic", "tumor", "cDNA", "libraries", ".", "In", "contrast", "to", "SMAD5", ",", "DAMS", "expression", "is", "not", "readily", "detectable", "in", "adult", "and", "fetal", "tissues", ".", "Semiquantitative", "PCR", "suggests", "that", "the", "stoichiometry", "between", "SMAD5", "and", "DAMS", "transcripts", "ranges", "between", "15", "and", "120", "in", "normal", "and", "malignant", "hematopoietic", "cells", ".", "The", "findings", "raise", "the", "possibility", "that", "DAMS", "may", "be", "a", "fail", "-", "safe", "mechanism", "for", "precise", "regulation", "of", "SMAD5", "transcript", "levels", "that", "may", "be", "critical", "in", "maintaining", "normal", "homeostasis", ".", "\n" ]
[ "Tissue", "AntisenseRNA", "Exon", "Cell", "Protein", "Transcript", "Chromosome", "Eukaryote", "Gene", "DNA" ]
antisense transcript, SMAD5, fetal, tumor tissues, SMAD5, TGF - beta / BMP, tumor suppressor, human, chromosome, gene, TGF - beta / BMP, transcript, DAMS, 3 ' exonic sequences, exon, SMAD5, DAMS, fetal tissues, heart, adrenal glands, total fetus, pancreatic tumor, cDNA, SMAD5, DAMS, adult and fetal tissues, SMAD5, DAMS, transcripts, hematopoietic cells, DAMS, SMAD5, transcript
35_task2
Sentence: An antisense transcript to SMAD5 expressed in fetal and tumor tissues. SMAD5, a transducer of TGF-beta/BMP inhibitory signals and a tumor suppressor candidate, localizes to the region of invariant loss in human myeloid neoplasms, on chromosome 5q31.1. Recent evidence indicates a gene-dosage effect along the TGF-beta/BMP signaling pathways. We have identified a novel transcript designated DAMS, whose 3' exonic sequences contain in part an alternate 5' exon of SMAD5, in the antisense orientation. Expressed sequenced tags (ESTs) for DAMS are found in fetal tissues (heart, adrenal glands, and total fetus) and pancreatic tumor cDNA libraries. In contrast to SMAD5, DAMS expression is not readily detectable in adult and fetal tissues. Semiquantitative PCR suggests that the stoichiometry between SMAD5 and DAMS transcripts ranges between 15 and 120 in normal and malignant hematopoietic cells. The findings raise the possibility that DAMS may be a fail-safe mechanism for precise regulation of SMAD5 transcript levels that may be critical in maintaining normal homeostasis. Instructions: please extract entity words from the input sentence
[ "O", "B-AntisenseRNA", "I-AntisenseRNA", "O", "B-Protein", "O", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "O", "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Transcript", "O", "B-Protein", "O", "O", "B-Exon", "I-Exon", "I-Exon", "I-Exon", "O", "O", "O", "O", "O", "O", "O", "B-Exon", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "B-Tissue", "O", "B-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "B-DNA", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
An antisense transcript to SMAD5 expressed in fetal and tumor tissues. SMAD5, a transducer of TGF-beta/BMP inhibitory signals and a tumor suppressor candidate, localizes to the region of invariant loss in human myeloid neoplasms, on chromosome 5q31.1. Recent evidence indicates a gene-dosage effect along the TGF-beta/BMP signaling pathways. We have identified a novel transcript designated DAMS, whose 3' exonic sequences contain in part an alternate 5' exon of SMAD5, in the antisense orientation. Expressed sequenced tags (ESTs) for DAMS are found in fetal tissues (heart, adrenal glands, and total fetus) and pancreatic tumor cDNA libraries. In contrast to SMAD5, DAMS expression is not readily detectable in adult and fetal tissues. Semiquantitative PCR suggests that the stoichiometry between SMAD5 and DAMS transcripts ranges between 15 and 120 in normal and malignant hematopoietic cells. The findings raise the possibility that DAMS may be a fail-safe mechanism for precise regulation of SMAD5 transcript levels that may be critical in maintaining normal homeostasis.
[ "An", "antisense", "transcript", "to", "SMAD5", "expressed", "in", "fetal", "and", "tumor", "tissues", ".", "SMAD5", ",", "a", "transducer", "of", "TGF", "-", "beta", "/", "BMP", "inhibitory", "signals", "and", "a", "tumor", "suppressor", "candidate", ",", "localizes", "to", "the", "region", "of", "invariant", "loss", "in", "human", "myeloid", "neoplasms", ",", "on", "chromosome", "5q31.1", ".", "Recent", "evidence", "indicates", "a", "gene", "-", "dosage", "effect", "along", "the", "TGF", "-", "beta", "/", "BMP", "signaling", "pathways", ".", "We", "have", "identified", "a", "novel", "transcript", "designated", "DAMS", ",", "whose", "3", "'", "exonic", "sequences", "contain", "in", "part", "an", "alternate", "5", "'", "exon", "of", "SMAD5", ",", "in", "the", "antisense", "orientation", ".", "Expressed", "sequenced", "tags", "(", "ESTs", ")", "for", "DAMS", "are", "found", "in", "fetal", "tissues", "(", "heart", ",", "adrenal", "glands", ",", "and", "total", "fetus", ")", "and", "pancreatic", "tumor", "cDNA", "libraries", ".", "In", "contrast", "to", "SMAD5", ",", "DAMS", "expression", "is", "not", "readily", "detectable", "in", "adult", "and", "fetal", "tissues", ".", "Semiquantitative", "PCR", "suggests", "that", "the", "stoichiometry", "between", "SMAD5", "and", "DAMS", "transcripts", "ranges", "between", "15", "and", "120", "in", "normal", "and", "malignant", "hematopoietic", "cells", ".", "The", "findings", "raise", "the", "possibility", "that", "DAMS", "may", "be", "a", "fail", "-", "safe", "mechanism", "for", "precise", "regulation", "of", "SMAD5", "transcript", "levels", "that", "may", "be", "critical", "in", "maintaining", "normal", "homeostasis", ".", "\n" ]
[ "Tissue", "AntisenseRNA", "Exon", "Cell", "Protein", "Transcript", "Chromosome", "Eukaryote", "Gene", "DNA" ]
laserinduzierte is an umlsterm, Thermotherapie is an umlsterm, Therapie is an umlsterm, Tumoren is an umlsterm, Tumor is an umlsterm, Kopf- is an umlsterm, Halstumoren is an umlsterm, Magnetresonanztomographie- is an umlsterm, Verwendung is an umlsterm, Kopfspule is an umlsterm, Gd - DTPA is an umlsterm, Schichtfuehrung is an umlsterm, Temperaturverteilung is an umlsterm, Gewebe is an umlsterm, Patienten is an umlsterm, Tumoren is an umlsterm, Laserlichtleiter is an umlsterm, Temperaturverteilung is an umlsterm, Nekrose is an umlsterm, Kopf- is an umlsterm, Halstumoren is an umlsterm
DerRadiologe.60360236.ger.abstr_task0
Sentence: Als neues minimalinvasives Verfahren wird die laserinduzierte interstitielle Thermotherapie ( LITT ) zunehmend bei tumoroesen Raumforderungen eingesetzt . In der Therapie von ausgedehnten Tumoren der Orofazialregion liegen bisher keine Erfahrungen vor . Die anatomische Komplexitaet dieser Region mit eng benachbarten vaskulaeren und nervalen Strukturen , an die meist der Tumor reicht , erlaubt keine Eingriffe ohne eine kontinuierliche Ueberwachung . Ziel unserer Untersuchungen war die Etablierung einer LITT von ausgedehnten inoperablen Kopf- und Halstumoren unter MRT- ( Magnetresonanztomographie- ) Kontrolle . Die Untersuchungen wurden an einem 1,5-T-Ganzkoerpertomographen, unter Verwendung einer zirkularpolarisierten Kopfspule , durchgefuehrt . Mit T1- und T2-gewichteten Sequenzen und T1-gewichteten Sequenzen nach intravenoeser Applikation von Gd-DTPA wurde die zu therapierende Region in axialer und koronarer Schichtfuehrung kontrolliert . Die Ueberwachung der Temperaturverteilung im Gewebe erfolgte mit einer T1-gewichteten 2D-FLASH-(fast low angle shot ) Sequenz . Es wurden 5 Patienten mit inoperablen Tumoren der orofazialen Region mit LITT unter kontinuierlicher MRT-Kontrolle therapiert . Die Eingriffe erfolgten in Vollnarkose . Die Laserlichtleiter wurden unter MRT-Kontrolle eingebracht . Die Laserung wurde mit einem Nd : YAG-Laser durchgefuehrt . Mit Hilfe der T1-gewichteten 2D-FLASH-Sequenz gelang das Monitoring der Temperaturverteilung unter LITT . Die Nekrose konnte bereits auf den kontrastverstaerkten T1-gewichteten Bildern unmittelbar im Anschluss an die Intervention bestimmt werden . Sie entsprach in ihrer Groesse dem entstehenden Defekt . Nach unseren ersten Erfahrungen scheint die von uns vorgestellte interventionelle MRT zum Monitoren der LITT von Kopf- und Halstumoren geeignet zu sein . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]
Als neues minimalinvasives Verfahren wird die laserinduzierte interstitielle Thermotherapie ( LITT ) zunehmend bei tumoroesen Raumforderungen eingesetzt . In der Therapie von ausgedehnten Tumoren der Orofazialregion liegen bisher keine Erfahrungen vor . Die anatomische Komplexitaet dieser Region mit eng benachbarten vaskulaeren und nervalen Strukturen , an die meist der Tumor reicht , erlaubt keine Eingriffe ohne eine kontinuierliche Ueberwachung . Ziel unserer Untersuchungen war die Etablierung einer LITT von ausgedehnten inoperablen Kopf- und Halstumoren unter MRT- ( Magnetresonanztomographie- ) Kontrolle . Die Untersuchungen wurden an einem 1,5-T-Ganzkoerpertomographen, unter Verwendung einer zirkularpolarisierten Kopfspule , durchgefuehrt . Mit T1- und T2-gewichteten Sequenzen und T1-gewichteten Sequenzen nach intravenoeser Applikation von Gd-DTPA wurde die zu therapierende Region in axialer und koronarer Schichtfuehrung kontrolliert . Die Ueberwachung der Temperaturverteilung im Gewebe erfolgte mit einer T1-gewichteten 2D-FLASH-(fast low angle shot ) Sequenz . Es wurden 5 Patienten mit inoperablen Tumoren der orofazialen Region mit LITT unter kontinuierlicher MRT-Kontrolle therapiert . Die Eingriffe erfolgten in Vollnarkose . Die Laserlichtleiter wurden unter MRT-Kontrolle eingebracht . Die Laserung wurde mit einem Nd : YAG-Laser durchgefuehrt . Mit Hilfe der T1-gewichteten 2D-FLASH-Sequenz gelang das Monitoring der Temperaturverteilung unter LITT . Die Nekrose konnte bereits auf den kontrastverstaerkten T1-gewichteten Bildern unmittelbar im Anschluss an die Intervention bestimmt werden . Sie entsprach in ihrer Groesse dem entstehenden Defekt . Nach unseren ersten Erfahrungen scheint die von uns vorgestellte interventionelle MRT zum Monitoren der LITT von Kopf- und Halstumoren geeignet zu sein .
[ "Als", "neues", "minimalinvasives", "Verfahren", "wird", "die", "laserinduzierte", "interstitielle", "Thermotherapie", "(", "LITT", ")", "zunehmend", "bei", "tumoroesen", "Raumforderungen", "eingesetzt", ".", "In", "der", "Therapie", "von", "ausgedehnten", "Tumoren", "der", "Orofazialregion", "liegen", "bisher", "keine", "Erfahrungen", "vor", ".", "Die", "anatomische", "Komplexitaet", "dieser", "Region", "mit", "eng", "benachbarten", "vaskulaeren", "und", "nervalen", "Strukturen", ",", "an", "die", "meist", "der", "Tumor", "reicht", ",", "erlaubt", "keine", "Eingriffe", "ohne", "eine", "kontinuierliche", "Ueberwachung", ".", "Ziel", "unserer", "Untersuchungen", "war", "die", "Etablierung", "einer", "LITT", "von", "ausgedehnten", "inoperablen", "Kopf-", "und", "Halstumoren", "unter", "MRT-", "(", "Magnetresonanztomographie-", ")", "Kontrolle", ".", "Die", "Untersuchungen", "wurden", "an", "einem", "1,5-T", "-", "Ganzkoerpertomographen", ",", "unter", "Verwendung", "einer", "zirkularpolarisierten", "Kopfspule", ",", "durchgefuehrt", ".", "Mit", "T1-", "und", "T2-gewichteten", "Sequenzen", "und", "T1-gewichteten", "Sequenzen", "nach", "intravenoeser", "Applikation", "von", "Gd", "-", "DTPA", "wurde", "die", "zu", "therapierende", "Region", "in", "axialer", "und", "koronarer", "Schichtfuehrung", "kontrolliert", ".", "Die", "Ueberwachung", "der", "Temperaturverteilung", "im", "Gewebe", "erfolgte", "mit", "einer", "T1-gewichteten", "2D", "-", "FLASH-(fast", "low", "angle", "shot", ")", "Sequenz", ".", "Es", "wurden", "5", "Patienten", "mit", "inoperablen", "Tumoren", "der", "orofazialen", "Region", "mit", "LITT", "unter", "kontinuierlicher", "MRT", "-", "Kontrolle", "therapiert", ".", "Die", "Eingriffe", "erfolgten", "in", "Vollnarkose", ".", "Die", "Laserlichtleiter", "wurden", "unter", "MRT", "-", "Kontrolle", "eingebracht", ".", "Die", "Laserung", "wurde", "mit", "einem", "Nd", ":", "YAG", "-", "Laser", "durchgefuehrt", ".", "Mit", "Hilfe", "der", "T1-gewichteten", "2D", "-", "FLASH", "-", "Sequenz", "gelang", "das", "Monitoring", "der", "Temperaturverteilung", "unter", "LITT", ".", "Die", "Nekrose", "konnte", "bereits", "auf", "den", "kontrastverstaerkten", "T1-gewichteten", "Bildern", "unmittelbar", "im", "Anschluss", "an", "die", "Intervention", "bestimmt", "werden", ".", "Sie", "entsprach", "in", "ihrer", "Groesse", "dem", "entstehenden", "Defekt", ".", "Nach", "unseren", "ersten", "Erfahrungen", "scheint", "die", "von", "uns", "vorgestellte", "interventionelle", "MRT", "zum", "Monitoren", "der", "LITT", "von", "Kopf-", "und", "Halstumoren", "geeignet", "zu", "sein", "." ]
[ "umlsterm" ]
laserinduzierte is an umlsterm, Thermotherapie is an umlsterm, Therapie is an umlsterm, Tumoren is an umlsterm, Tumor is an umlsterm, Kopf- is an umlsterm, Halstumoren is an umlsterm, Magnetresonanztomographie- is an umlsterm, Verwendung is an umlsterm, Kopfspule is an umlsterm, Gd - DTPA is an umlsterm, Schichtfuehrung is an umlsterm, Temperaturverteilung is an umlsterm, Gewebe is an umlsterm, Patienten is an umlsterm, Tumoren is an umlsterm, Laserlichtleiter is an umlsterm, Temperaturverteilung is an umlsterm, Nekrose is an umlsterm, Kopf- is an umlsterm, Halstumoren is an umlsterm
DerRadiologe.60360236.ger.abstr_task1
Sentence: Als neues minimalinvasives Verfahren wird die laserinduzierte interstitielle Thermotherapie ( LITT ) zunehmend bei tumoroesen Raumforderungen eingesetzt . In der Therapie von ausgedehnten Tumoren der Orofazialregion liegen bisher keine Erfahrungen vor . Die anatomische Komplexitaet dieser Region mit eng benachbarten vaskulaeren und nervalen Strukturen , an die meist der Tumor reicht , erlaubt keine Eingriffe ohne eine kontinuierliche Ueberwachung . Ziel unserer Untersuchungen war die Etablierung einer LITT von ausgedehnten inoperablen Kopf- und Halstumoren unter MRT- ( Magnetresonanztomographie- ) Kontrolle . Die Untersuchungen wurden an einem 1,5-T-Ganzkoerpertomographen, unter Verwendung einer zirkularpolarisierten Kopfspule , durchgefuehrt . Mit T1- und T2-gewichteten Sequenzen und T1-gewichteten Sequenzen nach intravenoeser Applikation von Gd-DTPA wurde die zu therapierende Region in axialer und koronarer Schichtfuehrung kontrolliert . Die Ueberwachung der Temperaturverteilung im Gewebe erfolgte mit einer T1-gewichteten 2D-FLASH-(fast low angle shot ) Sequenz . Es wurden 5 Patienten mit inoperablen Tumoren der orofazialen Region mit LITT unter kontinuierlicher MRT-Kontrolle therapiert . Die Eingriffe erfolgten in Vollnarkose . Die Laserlichtleiter wurden unter MRT-Kontrolle eingebracht . Die Laserung wurde mit einem Nd : YAG-Laser durchgefuehrt . Mit Hilfe der T1-gewichteten 2D-FLASH-Sequenz gelang das Monitoring der Temperaturverteilung unter LITT . Die Nekrose konnte bereits auf den kontrastverstaerkten T1-gewichteten Bildern unmittelbar im Anschluss an die Intervention bestimmt werden . Sie entsprach in ihrer Groesse dem entstehenden Defekt . Nach unseren ersten Erfahrungen scheint die von uns vorgestellte interventionelle MRT zum Monitoren der LITT von Kopf- und Halstumoren geeignet zu sein . Instructions: please typing these entity words according to sentence: laserinduzierte, Thermotherapie, Therapie, Tumoren, Tumor, Kopf-, Halstumoren, Magnetresonanztomographie-, Verwendung, Kopfspule, Gd - DTPA, Schichtfuehrung, Temperaturverteilung, Gewebe, Patienten, Tumoren, Laserlichtleiter, Temperaturverteilung, Nekrose, Kopf-, Halstumoren Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]
Als neues minimalinvasives Verfahren wird die laserinduzierte interstitielle Thermotherapie ( LITT ) zunehmend bei tumoroesen Raumforderungen eingesetzt . In der Therapie von ausgedehnten Tumoren der Orofazialregion liegen bisher keine Erfahrungen vor . Die anatomische Komplexitaet dieser Region mit eng benachbarten vaskulaeren und nervalen Strukturen , an die meist der Tumor reicht , erlaubt keine Eingriffe ohne eine kontinuierliche Ueberwachung . Ziel unserer Untersuchungen war die Etablierung einer LITT von ausgedehnten inoperablen Kopf- und Halstumoren unter MRT- ( Magnetresonanztomographie- ) Kontrolle . Die Untersuchungen wurden an einem 1,5-T-Ganzkoerpertomographen, unter Verwendung einer zirkularpolarisierten Kopfspule , durchgefuehrt . Mit T1- und T2-gewichteten Sequenzen und T1-gewichteten Sequenzen nach intravenoeser Applikation von Gd-DTPA wurde die zu therapierende Region in axialer und koronarer Schichtfuehrung kontrolliert . Die Ueberwachung der Temperaturverteilung im Gewebe erfolgte mit einer T1-gewichteten 2D-FLASH-(fast low angle shot ) Sequenz . Es wurden 5 Patienten mit inoperablen Tumoren der orofazialen Region mit LITT unter kontinuierlicher MRT-Kontrolle therapiert . Die Eingriffe erfolgten in Vollnarkose . Die Laserlichtleiter wurden unter MRT-Kontrolle eingebracht . Die Laserung wurde mit einem Nd : YAG-Laser durchgefuehrt . Mit Hilfe der T1-gewichteten 2D-FLASH-Sequenz gelang das Monitoring der Temperaturverteilung unter LITT . Die Nekrose konnte bereits auf den kontrastverstaerkten T1-gewichteten Bildern unmittelbar im Anschluss an die Intervention bestimmt werden . Sie entsprach in ihrer Groesse dem entstehenden Defekt . Nach unseren ersten Erfahrungen scheint die von uns vorgestellte interventionelle MRT zum Monitoren der LITT von Kopf- und Halstumoren geeignet zu sein .
[ "Als", "neues", "minimalinvasives", "Verfahren", "wird", "die", "laserinduzierte", "interstitielle", "Thermotherapie", "(", "LITT", ")", "zunehmend", "bei", "tumoroesen", "Raumforderungen", "eingesetzt", ".", "In", "der", "Therapie", "von", "ausgedehnten", "Tumoren", "der", "Orofazialregion", "liegen", "bisher", "keine", "Erfahrungen", "vor", ".", "Die", "anatomische", "Komplexitaet", "dieser", "Region", "mit", "eng", "benachbarten", "vaskulaeren", "und", "nervalen", "Strukturen", ",", "an", "die", "meist", "der", "Tumor", "reicht", ",", "erlaubt", "keine", "Eingriffe", "ohne", "eine", "kontinuierliche", "Ueberwachung", ".", "Ziel", "unserer", "Untersuchungen", "war", "die", "Etablierung", "einer", "LITT", "von", "ausgedehnten", "inoperablen", "Kopf-", "und", "Halstumoren", "unter", "MRT-", "(", "Magnetresonanztomographie-", ")", "Kontrolle", ".", "Die", "Untersuchungen", "wurden", "an", "einem", "1,5-T", "-", "Ganzkoerpertomographen", ",", "unter", "Verwendung", "einer", "zirkularpolarisierten", "Kopfspule", ",", "durchgefuehrt", ".", "Mit", "T1-", "und", "T2-gewichteten", "Sequenzen", "und", "T1-gewichteten", "Sequenzen", "nach", "intravenoeser", "Applikation", "von", "Gd", "-", "DTPA", "wurde", "die", "zu", "therapierende", "Region", "in", "axialer", "und", "koronarer", "Schichtfuehrung", "kontrolliert", ".", "Die", "Ueberwachung", "der", "Temperaturverteilung", "im", "Gewebe", "erfolgte", "mit", "einer", "T1-gewichteten", "2D", "-", "FLASH-(fast", "low", "angle", "shot", ")", "Sequenz", ".", "Es", "wurden", "5", "Patienten", "mit", "inoperablen", "Tumoren", "der", "orofazialen", "Region", "mit", "LITT", "unter", "kontinuierlicher", "MRT", "-", "Kontrolle", "therapiert", ".", "Die", "Eingriffe", "erfolgten", "in", "Vollnarkose", ".", "Die", "Laserlichtleiter", "wurden", "unter", "MRT", "-", "Kontrolle", "eingebracht", ".", "Die", "Laserung", "wurde", "mit", "einem", "Nd", ":", "YAG", "-", "Laser", "durchgefuehrt", ".", "Mit", "Hilfe", "der", "T1-gewichteten", "2D", "-", "FLASH", "-", "Sequenz", "gelang", "das", "Monitoring", "der", "Temperaturverteilung", "unter", "LITT", ".", "Die", "Nekrose", "konnte", "bereits", "auf", "den", "kontrastverstaerkten", "T1-gewichteten", "Bildern", "unmittelbar", "im", "Anschluss", "an", "die", "Intervention", "bestimmt", "werden", ".", "Sie", "entsprach", "in", "ihrer", "Groesse", "dem", "entstehenden", "Defekt", ".", "Nach", "unseren", "ersten", "Erfahrungen", "scheint", "die", "von", "uns", "vorgestellte", "interventionelle", "MRT", "zum", "Monitoren", "der", "LITT", "von", "Kopf-", "und", "Halstumoren", "geeignet", "zu", "sein", "." ]
[ "umlsterm" ]
laserinduzierte, Thermotherapie, Therapie, Tumoren, Tumor, Kopf-, Halstumoren, Magnetresonanztomographie-, Verwendung, Kopfspule, Gd - DTPA, Schichtfuehrung, Temperaturverteilung, Gewebe, Patienten, Tumoren, Laserlichtleiter, Temperaturverteilung, Nekrose, Kopf-, Halstumoren
DerRadiologe.60360236.ger.abstr_task2
Sentence: Als neues minimalinvasives Verfahren wird die laserinduzierte interstitielle Thermotherapie ( LITT ) zunehmend bei tumoroesen Raumforderungen eingesetzt . In der Therapie von ausgedehnten Tumoren der Orofazialregion liegen bisher keine Erfahrungen vor . Die anatomische Komplexitaet dieser Region mit eng benachbarten vaskulaeren und nervalen Strukturen , an die meist der Tumor reicht , erlaubt keine Eingriffe ohne eine kontinuierliche Ueberwachung . Ziel unserer Untersuchungen war die Etablierung einer LITT von ausgedehnten inoperablen Kopf- und Halstumoren unter MRT- ( Magnetresonanztomographie- ) Kontrolle . Die Untersuchungen wurden an einem 1,5-T-Ganzkoerpertomographen, unter Verwendung einer zirkularpolarisierten Kopfspule , durchgefuehrt . Mit T1- und T2-gewichteten Sequenzen und T1-gewichteten Sequenzen nach intravenoeser Applikation von Gd-DTPA wurde die zu therapierende Region in axialer und koronarer Schichtfuehrung kontrolliert . Die Ueberwachung der Temperaturverteilung im Gewebe erfolgte mit einer T1-gewichteten 2D-FLASH-(fast low angle shot ) Sequenz . Es wurden 5 Patienten mit inoperablen Tumoren der orofazialen Region mit LITT unter kontinuierlicher MRT-Kontrolle therapiert . Die Eingriffe erfolgten in Vollnarkose . Die Laserlichtleiter wurden unter MRT-Kontrolle eingebracht . Die Laserung wurde mit einem Nd : YAG-Laser durchgefuehrt . Mit Hilfe der T1-gewichteten 2D-FLASH-Sequenz gelang das Monitoring der Temperaturverteilung unter LITT . Die Nekrose konnte bereits auf den kontrastverstaerkten T1-gewichteten Bildern unmittelbar im Anschluss an die Intervention bestimmt werden . Sie entsprach in ihrer Groesse dem entstehenden Defekt . Nach unseren ersten Erfahrungen scheint die von uns vorgestellte interventionelle MRT zum Monitoren der LITT von Kopf- und Halstumoren geeignet zu sein . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]
Als neues minimalinvasives Verfahren wird die laserinduzierte interstitielle Thermotherapie ( LITT ) zunehmend bei tumoroesen Raumforderungen eingesetzt . In der Therapie von ausgedehnten Tumoren der Orofazialregion liegen bisher keine Erfahrungen vor . Die anatomische Komplexitaet dieser Region mit eng benachbarten vaskulaeren und nervalen Strukturen , an die meist der Tumor reicht , erlaubt keine Eingriffe ohne eine kontinuierliche Ueberwachung . Ziel unserer Untersuchungen war die Etablierung einer LITT von ausgedehnten inoperablen Kopf- und Halstumoren unter MRT- ( Magnetresonanztomographie- ) Kontrolle . Die Untersuchungen wurden an einem 1,5-T-Ganzkoerpertomographen, unter Verwendung einer zirkularpolarisierten Kopfspule , durchgefuehrt . Mit T1- und T2-gewichteten Sequenzen und T1-gewichteten Sequenzen nach intravenoeser Applikation von Gd-DTPA wurde die zu therapierende Region in axialer und koronarer Schichtfuehrung kontrolliert . Die Ueberwachung der Temperaturverteilung im Gewebe erfolgte mit einer T1-gewichteten 2D-FLASH-(fast low angle shot ) Sequenz . Es wurden 5 Patienten mit inoperablen Tumoren der orofazialen Region mit LITT unter kontinuierlicher MRT-Kontrolle therapiert . Die Eingriffe erfolgten in Vollnarkose . Die Laserlichtleiter wurden unter MRT-Kontrolle eingebracht . Die Laserung wurde mit einem Nd : YAG-Laser durchgefuehrt . Mit Hilfe der T1-gewichteten 2D-FLASH-Sequenz gelang das Monitoring der Temperaturverteilung unter LITT . Die Nekrose konnte bereits auf den kontrastverstaerkten T1-gewichteten Bildern unmittelbar im Anschluss an die Intervention bestimmt werden . Sie entsprach in ihrer Groesse dem entstehenden Defekt . Nach unseren ersten Erfahrungen scheint die von uns vorgestellte interventionelle MRT zum Monitoren der LITT von Kopf- und Halstumoren geeignet zu sein .
[ "Als", "neues", "minimalinvasives", "Verfahren", "wird", "die", "laserinduzierte", "interstitielle", "Thermotherapie", "(", "LITT", ")", "zunehmend", "bei", "tumoroesen", "Raumforderungen", "eingesetzt", ".", "In", "der", "Therapie", "von", "ausgedehnten", "Tumoren", "der", "Orofazialregion", "liegen", "bisher", "keine", "Erfahrungen", "vor", ".", "Die", "anatomische", "Komplexitaet", "dieser", "Region", "mit", "eng", "benachbarten", "vaskulaeren", "und", "nervalen", "Strukturen", ",", "an", "die", "meist", "der", "Tumor", "reicht", ",", "erlaubt", "keine", "Eingriffe", "ohne", "eine", "kontinuierliche", "Ueberwachung", ".", "Ziel", "unserer", "Untersuchungen", "war", "die", "Etablierung", "einer", "LITT", "von", "ausgedehnten", "inoperablen", "Kopf-", "und", "Halstumoren", "unter", "MRT-", "(", "Magnetresonanztomographie-", ")", "Kontrolle", ".", "Die", "Untersuchungen", "wurden", "an", "einem", "1,5-T", "-", "Ganzkoerpertomographen", ",", "unter", "Verwendung", "einer", "zirkularpolarisierten", "Kopfspule", ",", "durchgefuehrt", ".", "Mit", "T1-", "und", "T2-gewichteten", "Sequenzen", "und", "T1-gewichteten", "Sequenzen", "nach", "intravenoeser", "Applikation", "von", "Gd", "-", "DTPA", "wurde", "die", "zu", "therapierende", "Region", "in", "axialer", "und", "koronarer", "Schichtfuehrung", "kontrolliert", ".", "Die", "Ueberwachung", "der", "Temperaturverteilung", "im", "Gewebe", "erfolgte", "mit", "einer", "T1-gewichteten", "2D", "-", "FLASH-(fast", "low", "angle", "shot", ")", "Sequenz", ".", "Es", "wurden", "5", "Patienten", "mit", "inoperablen", "Tumoren", "der", "orofazialen", "Region", "mit", "LITT", "unter", "kontinuierlicher", "MRT", "-", "Kontrolle", "therapiert", ".", "Die", "Eingriffe", "erfolgten", "in", "Vollnarkose", ".", "Die", "Laserlichtleiter", "wurden", "unter", "MRT", "-", "Kontrolle", "eingebracht", ".", "Die", "Laserung", "wurde", "mit", "einem", "Nd", ":", "YAG", "-", "Laser", "durchgefuehrt", ".", "Mit", "Hilfe", "der", "T1-gewichteten", "2D", "-", "FLASH", "-", "Sequenz", "gelang", "das", "Monitoring", "der", "Temperaturverteilung", "unter", "LITT", ".", "Die", "Nekrose", "konnte", "bereits", "auf", "den", "kontrastverstaerkten", "T1-gewichteten", "Bildern", "unmittelbar", "im", "Anschluss", "an", "die", "Intervention", "bestimmt", "werden", ".", "Sie", "entsprach", "in", "ihrer", "Groesse", "dem", "entstehenden", "Defekt", ".", "Nach", "unseren", "ersten", "Erfahrungen", "scheint", "die", "von", "uns", "vorgestellte", "interventionelle", "MRT", "zum", "Monitoren", "der", "LITT", "von", "Kopf-", "und", "Halstumoren", "geeignet", "zu", "sein", "." ]
[ "umlsterm" ]
Gesichtsfeldeinschraenkung is an umlsterm, Behandlung is an umlsterm, Antiepileptika is an umlsterm, Gesichtsfeldeinschraenkungen is an umlsterm, Patienten is an umlsterm, Vigabatrin is an umlsterm, Gesichtsfeldeinschraenkungen is an umlsterm, Antiepileptika is an umlsterm, Epilepsietherapie is an umlsterm, Medikamente is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Epilepsien is an umlsterm, Gesichtsfeldeinschraenkungen is an umlsterm, Perimetrie is an umlsterm, Patienten is an umlsterm, Epilepsien is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Antiepileptika is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Behandlung is an umlsterm, Gesichtsfeldmessungen is an umlsterm
DerNervenarzt.90700552.ger.abstr_task0
Sentence: In den letzten Jahren wurden einige Kasuistiken mit Gesichtsfeldeinschraenkung waehrend der Behandlung mit Antiepileptika veroeffentlicht . Hierbei handelt es sich ueberwiegend um konzentrische Gesichtsfeldeinschraenkungen bei Patienten , die mit Vigabatrin behandelt wurden . Bei der aetiopathogenetischen Diskussion konzentrischer Gesichtsfeldeinschraenkungen muessen ergaenzend zu Antiepileptika auch andere Ursachen beruecksichtigt werden ophthalmologische Erkrankungen , ( systemische Erkrankungen mit ophthalmologischer Manifestation , andere , mit Epilepsietherapie nicht im Zusammenhang stehende Medikamente ) . Gesichtsfeldstoerungen wurden unter Vigabatrin- , Tiagabin- , Gabapentin- , Diazepam- , Phenytoin- und Carbamazepin-Therapie beobachtet . Die exakte Haeufigkeit von Gesichtsfeldstoerungen bei Epilepsien ist unbekannt . Bisherige erste Untersuchungsergebnisse zeigen Gesichtsfeldeinschraenkungen in der kinetischen oder statischen Perimetrie zwischen 13% und 46% der untersuchten Patienten mit Epilepsien waehrend der antiepileptischen Behandlung auf . Hierbei handelt es sich in den meisten Faellen um subjektiv , vom Patienten nicht wahrgenommene Einschraenkungen . In einigen Faellen wurden ausserdem manifeste , vom Patienten bemerkte Gesichtsfeldstoerungen festgestellt . Der Verlauf nach Absetzen von Antiepileptika ist unterschiedlich . Zukuenftig sind prospektive epidemiologische , klinische Studien sowie praeklinische Studien erforderlich , die den Pathomechanismus konzentrischer Gesichtsfeldstoerungen klaeren . In der Zwischenzeit werden vor und waehrend der Behandlung mit Gaba-ergen-Antiepileptika Gesichtsfeldmessungen empfohlen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
In den letzten Jahren wurden einige Kasuistiken mit Gesichtsfeldeinschraenkung waehrend der Behandlung mit Antiepileptika veroeffentlicht . Hierbei handelt es sich ueberwiegend um konzentrische Gesichtsfeldeinschraenkungen bei Patienten , die mit Vigabatrin behandelt wurden . Bei der aetiopathogenetischen Diskussion konzentrischer Gesichtsfeldeinschraenkungen muessen ergaenzend zu Antiepileptika auch andere Ursachen beruecksichtigt werden ophthalmologische Erkrankungen , ( systemische Erkrankungen mit ophthalmologischer Manifestation , andere , mit Epilepsietherapie nicht im Zusammenhang stehende Medikamente ) . Gesichtsfeldstoerungen wurden unter Vigabatrin- , Tiagabin- , Gabapentin- , Diazepam- , Phenytoin- und Carbamazepin-Therapie beobachtet . Die exakte Haeufigkeit von Gesichtsfeldstoerungen bei Epilepsien ist unbekannt . Bisherige erste Untersuchungsergebnisse zeigen Gesichtsfeldeinschraenkungen in der kinetischen oder statischen Perimetrie zwischen 13% und 46% der untersuchten Patienten mit Epilepsien waehrend der antiepileptischen Behandlung auf . Hierbei handelt es sich in den meisten Faellen um subjektiv , vom Patienten nicht wahrgenommene Einschraenkungen . In einigen Faellen wurden ausserdem manifeste , vom Patienten bemerkte Gesichtsfeldstoerungen festgestellt . Der Verlauf nach Absetzen von Antiepileptika ist unterschiedlich . Zukuenftig sind prospektive epidemiologische , klinische Studien sowie praeklinische Studien erforderlich , die den Pathomechanismus konzentrischer Gesichtsfeldstoerungen klaeren . In der Zwischenzeit werden vor und waehrend der Behandlung mit Gaba-ergen-Antiepileptika Gesichtsfeldmessungen empfohlen .
[ "In", "den", "letzten", "Jahren", "wurden", "einige", "Kasuistiken", "mit", "Gesichtsfeldeinschraenkung", "waehrend", "der", "Behandlung", "mit", "Antiepileptika", "veroeffentlicht", ".", "Hierbei", "handelt", "es", "sich", "ueberwiegend", "um", "konzentrische", "Gesichtsfeldeinschraenkungen", "bei", "Patienten", ",", "die", "mit", "Vigabatrin", "behandelt", "wurden", ".", "Bei", "der", "aetiopathogenetischen", "Diskussion", "konzentrischer", "Gesichtsfeldeinschraenkungen", "muessen", "ergaenzend", "zu", "Antiepileptika", "auch", "andere", "Ursachen", "beruecksichtigt", "werden", "ophthalmologische", "Erkrankungen", ",", "(", "systemische", "Erkrankungen", "mit", "ophthalmologischer", "Manifestation", ",", "andere", ",", "mit", "Epilepsietherapie", "nicht", "im", "Zusammenhang", "stehende", "Medikamente", ")", ".", "Gesichtsfeldstoerungen", "wurden", "unter", "Vigabatrin-", ",", "Tiagabin-", ",", "Gabapentin-", ",", "Diazepam-", ",", "Phenytoin-", "und", "Carbamazepin", "-", "Therapie", "beobachtet", ".", "Die", "exakte", "Haeufigkeit", "von", "Gesichtsfeldstoerungen", "bei", "Epilepsien", "ist", "unbekannt", ".", "Bisherige", "erste", "Untersuchungsergebnisse", "zeigen", "Gesichtsfeldeinschraenkungen", "in", "der", "kinetischen", "oder", "statischen", "Perimetrie", "zwischen", "13", "%", "und", "46", "%", "der", "untersuchten", "Patienten", "mit", "Epilepsien", "waehrend", "der", "antiepileptischen", "Behandlung", "auf", ".", "Hierbei", "handelt", "es", "sich", "in", "den", "meisten", "Faellen", "um", "subjektiv", ",", "vom", "Patienten", "nicht", "wahrgenommene", "Einschraenkungen", ".", "In", "einigen", "Faellen", "wurden", "ausserdem", "manifeste", ",", "vom", "Patienten", "bemerkte", "Gesichtsfeldstoerungen", "festgestellt", ".", "Der", "Verlauf", "nach", "Absetzen", "von", "Antiepileptika", "ist", "unterschiedlich", ".", "Zukuenftig", "sind", "prospektive", "epidemiologische", ",", "klinische", "Studien", "sowie", "praeklinische", "Studien", "erforderlich", ",", "die", "den", "Pathomechanismus", "konzentrischer", "Gesichtsfeldstoerungen", "klaeren", ".", "In", "der", "Zwischenzeit", "werden", "vor", "und", "waehrend", "der", "Behandlung", "mit", "Gaba", "-", "ergen", "-", "Antiepileptika", "Gesichtsfeldmessungen", "empfohlen", "." ]
[ "umlsterm" ]
Gesichtsfeldeinschraenkung is an umlsterm, Behandlung is an umlsterm, Antiepileptika is an umlsterm, Gesichtsfeldeinschraenkungen is an umlsterm, Patienten is an umlsterm, Vigabatrin is an umlsterm, Gesichtsfeldeinschraenkungen is an umlsterm, Antiepileptika is an umlsterm, Epilepsietherapie is an umlsterm, Medikamente is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Epilepsien is an umlsterm, Gesichtsfeldeinschraenkungen is an umlsterm, Perimetrie is an umlsterm, Patienten is an umlsterm, Epilepsien is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Antiepileptika is an umlsterm, Gesichtsfeldstoerungen is an umlsterm, Behandlung is an umlsterm, Gesichtsfeldmessungen is an umlsterm
DerNervenarzt.90700552.ger.abstr_task1
Sentence: In den letzten Jahren wurden einige Kasuistiken mit Gesichtsfeldeinschraenkung waehrend der Behandlung mit Antiepileptika veroeffentlicht . Hierbei handelt es sich ueberwiegend um konzentrische Gesichtsfeldeinschraenkungen bei Patienten , die mit Vigabatrin behandelt wurden . Bei der aetiopathogenetischen Diskussion konzentrischer Gesichtsfeldeinschraenkungen muessen ergaenzend zu Antiepileptika auch andere Ursachen beruecksichtigt werden ophthalmologische Erkrankungen , ( systemische Erkrankungen mit ophthalmologischer Manifestation , andere , mit Epilepsietherapie nicht im Zusammenhang stehende Medikamente ) . Gesichtsfeldstoerungen wurden unter Vigabatrin- , Tiagabin- , Gabapentin- , Diazepam- , Phenytoin- und Carbamazepin-Therapie beobachtet . Die exakte Haeufigkeit von Gesichtsfeldstoerungen bei Epilepsien ist unbekannt . Bisherige erste Untersuchungsergebnisse zeigen Gesichtsfeldeinschraenkungen in der kinetischen oder statischen Perimetrie zwischen 13% und 46% der untersuchten Patienten mit Epilepsien waehrend der antiepileptischen Behandlung auf . Hierbei handelt es sich in den meisten Faellen um subjektiv , vom Patienten nicht wahrgenommene Einschraenkungen . In einigen Faellen wurden ausserdem manifeste , vom Patienten bemerkte Gesichtsfeldstoerungen festgestellt . Der Verlauf nach Absetzen von Antiepileptika ist unterschiedlich . Zukuenftig sind prospektive epidemiologische , klinische Studien sowie praeklinische Studien erforderlich , die den Pathomechanismus konzentrischer Gesichtsfeldstoerungen klaeren . In der Zwischenzeit werden vor und waehrend der Behandlung mit Gaba-ergen-Antiepileptika Gesichtsfeldmessungen empfohlen . Instructions: please typing these entity words according to sentence: Gesichtsfeldeinschraenkung, Behandlung, Antiepileptika, Gesichtsfeldeinschraenkungen, Patienten, Vigabatrin, Gesichtsfeldeinschraenkungen, Antiepileptika, Epilepsietherapie, Medikamente, Gesichtsfeldstoerungen, Gesichtsfeldstoerungen, Epilepsien, Gesichtsfeldeinschraenkungen, Perimetrie, Patienten, Epilepsien, Behandlung, Patienten, Patienten, Gesichtsfeldstoerungen, Antiepileptika, Gesichtsfeldstoerungen, Behandlung, Gesichtsfeldmessungen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
In den letzten Jahren wurden einige Kasuistiken mit Gesichtsfeldeinschraenkung waehrend der Behandlung mit Antiepileptika veroeffentlicht . Hierbei handelt es sich ueberwiegend um konzentrische Gesichtsfeldeinschraenkungen bei Patienten , die mit Vigabatrin behandelt wurden . Bei der aetiopathogenetischen Diskussion konzentrischer Gesichtsfeldeinschraenkungen muessen ergaenzend zu Antiepileptika auch andere Ursachen beruecksichtigt werden ophthalmologische Erkrankungen , ( systemische Erkrankungen mit ophthalmologischer Manifestation , andere , mit Epilepsietherapie nicht im Zusammenhang stehende Medikamente ) . Gesichtsfeldstoerungen wurden unter Vigabatrin- , Tiagabin- , Gabapentin- , Diazepam- , Phenytoin- und Carbamazepin-Therapie beobachtet . Die exakte Haeufigkeit von Gesichtsfeldstoerungen bei Epilepsien ist unbekannt . Bisherige erste Untersuchungsergebnisse zeigen Gesichtsfeldeinschraenkungen in der kinetischen oder statischen Perimetrie zwischen 13% und 46% der untersuchten Patienten mit Epilepsien waehrend der antiepileptischen Behandlung auf . Hierbei handelt es sich in den meisten Faellen um subjektiv , vom Patienten nicht wahrgenommene Einschraenkungen . In einigen Faellen wurden ausserdem manifeste , vom Patienten bemerkte Gesichtsfeldstoerungen festgestellt . Der Verlauf nach Absetzen von Antiepileptika ist unterschiedlich . Zukuenftig sind prospektive epidemiologische , klinische Studien sowie praeklinische Studien erforderlich , die den Pathomechanismus konzentrischer Gesichtsfeldstoerungen klaeren . In der Zwischenzeit werden vor und waehrend der Behandlung mit Gaba-ergen-Antiepileptika Gesichtsfeldmessungen empfohlen .
[ "In", "den", "letzten", "Jahren", "wurden", "einige", "Kasuistiken", "mit", "Gesichtsfeldeinschraenkung", "waehrend", "der", "Behandlung", "mit", "Antiepileptika", "veroeffentlicht", ".", "Hierbei", "handelt", "es", "sich", "ueberwiegend", "um", "konzentrische", "Gesichtsfeldeinschraenkungen", "bei", "Patienten", ",", "die", "mit", "Vigabatrin", "behandelt", "wurden", ".", "Bei", "der", "aetiopathogenetischen", "Diskussion", "konzentrischer", "Gesichtsfeldeinschraenkungen", "muessen", "ergaenzend", "zu", "Antiepileptika", "auch", "andere", "Ursachen", "beruecksichtigt", "werden", "ophthalmologische", "Erkrankungen", ",", "(", "systemische", "Erkrankungen", "mit", "ophthalmologischer", "Manifestation", ",", "andere", ",", "mit", "Epilepsietherapie", "nicht", "im", "Zusammenhang", "stehende", "Medikamente", ")", ".", "Gesichtsfeldstoerungen", "wurden", "unter", "Vigabatrin-", ",", "Tiagabin-", ",", "Gabapentin-", ",", "Diazepam-", ",", "Phenytoin-", "und", "Carbamazepin", "-", "Therapie", "beobachtet", ".", "Die", "exakte", "Haeufigkeit", "von", "Gesichtsfeldstoerungen", "bei", "Epilepsien", "ist", "unbekannt", ".", "Bisherige", "erste", "Untersuchungsergebnisse", "zeigen", "Gesichtsfeldeinschraenkungen", "in", "der", "kinetischen", "oder", "statischen", "Perimetrie", "zwischen", "13", "%", "und", "46", "%", "der", "untersuchten", "Patienten", "mit", "Epilepsien", "waehrend", "der", "antiepileptischen", "Behandlung", "auf", ".", "Hierbei", "handelt", "es", "sich", "in", "den", "meisten", "Faellen", "um", "subjektiv", ",", "vom", "Patienten", "nicht", "wahrgenommene", "Einschraenkungen", ".", "In", "einigen", "Faellen", "wurden", "ausserdem", "manifeste", ",", "vom", "Patienten", "bemerkte", "Gesichtsfeldstoerungen", "festgestellt", ".", "Der", "Verlauf", "nach", "Absetzen", "von", "Antiepileptika", "ist", "unterschiedlich", ".", "Zukuenftig", "sind", "prospektive", "epidemiologische", ",", "klinische", "Studien", "sowie", "praeklinische", "Studien", "erforderlich", ",", "die", "den", "Pathomechanismus", "konzentrischer", "Gesichtsfeldstoerungen", "klaeren", ".", "In", "der", "Zwischenzeit", "werden", "vor", "und", "waehrend", "der", "Behandlung", "mit", "Gaba", "-", "ergen", "-", "Antiepileptika", "Gesichtsfeldmessungen", "empfohlen", "." ]
[ "umlsterm" ]
Gesichtsfeldeinschraenkung, Behandlung, Antiepileptika, Gesichtsfeldeinschraenkungen, Patienten, Vigabatrin, Gesichtsfeldeinschraenkungen, Antiepileptika, Epilepsietherapie, Medikamente, Gesichtsfeldstoerungen, Gesichtsfeldstoerungen, Epilepsien, Gesichtsfeldeinschraenkungen, Perimetrie, Patienten, Epilepsien, Behandlung, Patienten, Patienten, Gesichtsfeldstoerungen, Antiepileptika, Gesichtsfeldstoerungen, Behandlung, Gesichtsfeldmessungen
DerNervenarzt.90700552.ger.abstr_task2
Sentence: In den letzten Jahren wurden einige Kasuistiken mit Gesichtsfeldeinschraenkung waehrend der Behandlung mit Antiepileptika veroeffentlicht . Hierbei handelt es sich ueberwiegend um konzentrische Gesichtsfeldeinschraenkungen bei Patienten , die mit Vigabatrin behandelt wurden . Bei der aetiopathogenetischen Diskussion konzentrischer Gesichtsfeldeinschraenkungen muessen ergaenzend zu Antiepileptika auch andere Ursachen beruecksichtigt werden ophthalmologische Erkrankungen , ( systemische Erkrankungen mit ophthalmologischer Manifestation , andere , mit Epilepsietherapie nicht im Zusammenhang stehende Medikamente ) . Gesichtsfeldstoerungen wurden unter Vigabatrin- , Tiagabin- , Gabapentin- , Diazepam- , Phenytoin- und Carbamazepin-Therapie beobachtet . Die exakte Haeufigkeit von Gesichtsfeldstoerungen bei Epilepsien ist unbekannt . Bisherige erste Untersuchungsergebnisse zeigen Gesichtsfeldeinschraenkungen in der kinetischen oder statischen Perimetrie zwischen 13% und 46% der untersuchten Patienten mit Epilepsien waehrend der antiepileptischen Behandlung auf . Hierbei handelt es sich in den meisten Faellen um subjektiv , vom Patienten nicht wahrgenommene Einschraenkungen . In einigen Faellen wurden ausserdem manifeste , vom Patienten bemerkte Gesichtsfeldstoerungen festgestellt . Der Verlauf nach Absetzen von Antiepileptika ist unterschiedlich . Zukuenftig sind prospektive epidemiologische , klinische Studien sowie praeklinische Studien erforderlich , die den Pathomechanismus konzentrischer Gesichtsfeldstoerungen klaeren . In der Zwischenzeit werden vor und waehrend der Behandlung mit Gaba-ergen-Antiepileptika Gesichtsfeldmessungen empfohlen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
In den letzten Jahren wurden einige Kasuistiken mit Gesichtsfeldeinschraenkung waehrend der Behandlung mit Antiepileptika veroeffentlicht . Hierbei handelt es sich ueberwiegend um konzentrische Gesichtsfeldeinschraenkungen bei Patienten , die mit Vigabatrin behandelt wurden . Bei der aetiopathogenetischen Diskussion konzentrischer Gesichtsfeldeinschraenkungen muessen ergaenzend zu Antiepileptika auch andere Ursachen beruecksichtigt werden ophthalmologische Erkrankungen , ( systemische Erkrankungen mit ophthalmologischer Manifestation , andere , mit Epilepsietherapie nicht im Zusammenhang stehende Medikamente ) . Gesichtsfeldstoerungen wurden unter Vigabatrin- , Tiagabin- , Gabapentin- , Diazepam- , Phenytoin- und Carbamazepin-Therapie beobachtet . Die exakte Haeufigkeit von Gesichtsfeldstoerungen bei Epilepsien ist unbekannt . Bisherige erste Untersuchungsergebnisse zeigen Gesichtsfeldeinschraenkungen in der kinetischen oder statischen Perimetrie zwischen 13% und 46% der untersuchten Patienten mit Epilepsien waehrend der antiepileptischen Behandlung auf . Hierbei handelt es sich in den meisten Faellen um subjektiv , vom Patienten nicht wahrgenommene Einschraenkungen . In einigen Faellen wurden ausserdem manifeste , vom Patienten bemerkte Gesichtsfeldstoerungen festgestellt . Der Verlauf nach Absetzen von Antiepileptika ist unterschiedlich . Zukuenftig sind prospektive epidemiologische , klinische Studien sowie praeklinische Studien erforderlich , die den Pathomechanismus konzentrischer Gesichtsfeldstoerungen klaeren . In der Zwischenzeit werden vor und waehrend der Behandlung mit Gaba-ergen-Antiepileptika Gesichtsfeldmessungen empfohlen .
[ "In", "den", "letzten", "Jahren", "wurden", "einige", "Kasuistiken", "mit", "Gesichtsfeldeinschraenkung", "waehrend", "der", "Behandlung", "mit", "Antiepileptika", "veroeffentlicht", ".", "Hierbei", "handelt", "es", "sich", "ueberwiegend", "um", "konzentrische", "Gesichtsfeldeinschraenkungen", "bei", "Patienten", ",", "die", "mit", "Vigabatrin", "behandelt", "wurden", ".", "Bei", "der", "aetiopathogenetischen", "Diskussion", "konzentrischer", "Gesichtsfeldeinschraenkungen", "muessen", "ergaenzend", "zu", "Antiepileptika", "auch", "andere", "Ursachen", "beruecksichtigt", "werden", "ophthalmologische", "Erkrankungen", ",", "(", "systemische", "Erkrankungen", "mit", "ophthalmologischer", "Manifestation", ",", "andere", ",", "mit", "Epilepsietherapie", "nicht", "im", "Zusammenhang", "stehende", "Medikamente", ")", ".", "Gesichtsfeldstoerungen", "wurden", "unter", "Vigabatrin-", ",", "Tiagabin-", ",", "Gabapentin-", ",", "Diazepam-", ",", "Phenytoin-", "und", "Carbamazepin", "-", "Therapie", "beobachtet", ".", "Die", "exakte", "Haeufigkeit", "von", "Gesichtsfeldstoerungen", "bei", "Epilepsien", "ist", "unbekannt", ".", "Bisherige", "erste", "Untersuchungsergebnisse", "zeigen", "Gesichtsfeldeinschraenkungen", "in", "der", "kinetischen", "oder", "statischen", "Perimetrie", "zwischen", "13", "%", "und", "46", "%", "der", "untersuchten", "Patienten", "mit", "Epilepsien", "waehrend", "der", "antiepileptischen", "Behandlung", "auf", ".", "Hierbei", "handelt", "es", "sich", "in", "den", "meisten", "Faellen", "um", "subjektiv", ",", "vom", "Patienten", "nicht", "wahrgenommene", "Einschraenkungen", ".", "In", "einigen", "Faellen", "wurden", "ausserdem", "manifeste", ",", "vom", "Patienten", "bemerkte", "Gesichtsfeldstoerungen", "festgestellt", ".", "Der", "Verlauf", "nach", "Absetzen", "von", "Antiepileptika", "ist", "unterschiedlich", ".", "Zukuenftig", "sind", "prospektive", "epidemiologische", ",", "klinische", "Studien", "sowie", "praeklinische", "Studien", "erforderlich", ",", "die", "den", "Pathomechanismus", "konzentrischer", "Gesichtsfeldstoerungen", "klaeren", ".", "In", "der", "Zwischenzeit", "werden", "vor", "und", "waehrend", "der", "Behandlung", "mit", "Gaba", "-", "ergen", "-", "Antiepileptika", "Gesichtsfeldmessungen", "empfohlen", "." ]
[ "umlsterm" ]
DR5 is a Individual_protein, DR4 is a Individual_protein, FADD is a Individual_protein, TRADD is a Individual_protein, RIP is a Individual_protein, FADD is a Gene/protein/RNA
277_task0
Sentence: Thus, both DR5 and DR4 use FADD, TRADD, and RIP in their signal transduction pathways, and FADD is the common mediator of apoptosis by all known death domain-containing receptors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein
[ "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thus, both DR5 and DR4 use FADD, TRADD, and RIP in their signal transduction pathways, and FADD is the common mediator of apoptosis by all known death domain-containing receptors.
[ "Thus", ",", "both", "DR5", "and", "DR4", "use", "FADD", ",", "TRADD", ",", "and", "RIP", "in", "their", "signal", "transduction", "pathways", ",", "and", "FADD", "is", "the", "common", "mediator", "of", "apoptosis", "by", "all", "known", "death", "domain", "-", "containing", "receptors", "." ]
[ "Individual_protein", "Gene/protein/RNA" ]
DR5 is a Individual_protein, DR4 is a Individual_protein, FADD is a Individual_protein, TRADD is a Individual_protein, RIP is a Individual_protein, FADD is a Gene/protein/RNA
277_task1
Sentence: Thus, both DR5 and DR4 use FADD, TRADD, and RIP in their signal transduction pathways, and FADD is the common mediator of apoptosis by all known death domain-containing receptors. Instructions: please typing these entity words according to sentence: DR5, DR4, FADD, TRADD, RIP, FADD Options: Gene/protein/RNA, Individual_protein
[ "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thus, both DR5 and DR4 use FADD, TRADD, and RIP in their signal transduction pathways, and FADD is the common mediator of apoptosis by all known death domain-containing receptors.
[ "Thus", ",", "both", "DR5", "and", "DR4", "use", "FADD", ",", "TRADD", ",", "and", "RIP", "in", "their", "signal", "transduction", "pathways", ",", "and", "FADD", "is", "the", "common", "mediator", "of", "apoptosis", "by", "all", "known", "death", "domain", "-", "containing", "receptors", "." ]
[ "Individual_protein", "Gene/protein/RNA" ]
DR5, DR4, FADD, TRADD, RIP, FADD
277_task2
Sentence: Thus, both DR5 and DR4 use FADD, TRADD, and RIP in their signal transduction pathways, and FADD is the common mediator of apoptosis by all known death domain-containing receptors. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Thus, both DR5 and DR4 use FADD, TRADD, and RIP in their signal transduction pathways, and FADD is the common mediator of apoptosis by all known death domain-containing receptors.
[ "Thus", ",", "both", "DR5", "and", "DR4", "use", "FADD", ",", "TRADD", ",", "and", "RIP", "in", "their", "signal", "transduction", "pathways", ",", "and", "FADD", "is", "the", "common", "mediator", "of", "apoptosis", "by", "all", "known", "death", "domain", "-", "containing", "receptors", "." ]
[ "Individual_protein", "Gene/protein/RNA" ]
ARF6 is a Enzyme, membrane is a CellComponent, cortical actin is a Protein, ARF6 GTPase is a Enzyme, endosomal - plasma membrane is a CellComponent, cortical actin is a Protein, ARF6 is a Enzyme, Rac1 is a Enzyme, GTPase is a Enzyme, cortical actin is a Protein, Rac1 is a Enzyme, ARF6 is a Enzyme, plasma membrane is a CellComponent, ARF6 is a Enzyme, endosome is a CellComponent, HeLa is a Cell, human is a Eukaryote, fibroblast cells is a Cell, HeLa cells is a Cell, Rac1 is a Enzyme, ARF6 is a Enzyme, Cells is a Cell, ARF6 is a Enzyme, Rac1 is a Enzyme, actin - containing surface protrusions is a CellComponent, membrane ruffles is a CellComponent, G protein is a Protein, aluminum fluoride is a InorganicChemical, Aluminum fluoride is a InorganicChemical, cells is a Cell, Rac is a Enzyme, GTP binding - defective ARF6 T27N mutant is a MutantProtein, aluminum fluoride is a InorganicChemical, cells is a Cell, Rac1 is a Enzyme, cells is a Cell, Rac1 Q61L mutant is a MutantProtein, GTP - binding - defective , T17N mutant is a MutantProtein, Rac1 is a Enzyme, Cdc42 is a Enzyme, ARF6 is a Enzyme, aluminum fluoride is a InorganicChemical, surface protrusions is a CellComponent, Rho is a Enzyme, C3-transferase is a Enzyme, ARF6 is a Enzyme, GTPase is a Enzyme, cortical actin is a Protein, Rac1 is a Enzyme, lamellipodia is a CellComponent, plasma membrane is a CellComponent
18_task0
Sentence: ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. The ARF6 GTPase regulates a novel endosomal-plasma membrane recycling pathway and influences cortical actin remodeling. Here we examined the relationship between ARF6 and Rac1, a Rho family GTPase, implicated in cortical actin rearrangements. Endogenous Rac1 colocalized with ARF6 at the plasma membrane and on the ARF6 recycling endosome in untransfected HeLa and primary human fibroblast cells. In transfected HeLa cells Rac1 and ARF6 also colocalized. Cells expressing wild-type ARF6 or Rac1 formed actin-containing surface protrusions and membrane ruffles, respectively, upon treatment with the G protein activator aluminum fluoride. Aluminum fluoride-treatment of cells transfected with equivalent amounts of plasmid resulted in enhanced membrane ruffling, with protrusions appearing as Rac expression was lowered. Co-expression of the dominant negative, GTP binding-defective ARF6 T27N mutant inhibited the aluminum fluoride-induced ruffling observed in cells expressing Rac1, and the constitutive ruffling observed in cells expressing the activated Rac1 Q61L mutant. In contrast, co-expression of the GTP-binding-defective, T17N mutant of either Rac1 or Cdc42 with ARF6 did not inhibit the aluminum fluoride-induced surface protrusions, nor did inactivation of Rho with C3-transferase. These observations suggest that ARF6, a non-Rho family GTPase, can, by itself, alter cortical actin and can influence the ability of Rac1 to form lamellipodia, in part, by regulating its trafficking to the plasma membrane. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MutantProtein, CellComponent, Enzyme, Eukaryote, InorganicChemical, Protein, Cell
[ "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "B-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Enzyme", "O", "O", "B-Enzyme", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "B-Enzyme", "O", "B-CellComponent", "O", "O", "B-Cell", "O", "O", "B-Eukaryote", "B-Cell", "I-Cell", "O", "O", "O", "B-Cell", "I-Cell", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "B-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "B-CellComponent", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O" ]
ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. The ARF6 GTPase regulates a novel endosomal-plasma membrane recycling pathway and influences cortical actin remodeling. Here we examined the relationship between ARF6 and Rac1, a Rho family GTPase, implicated in cortical actin rearrangements. Endogenous Rac1 colocalized with ARF6 at the plasma membrane and on the ARF6 recycling endosome in untransfected HeLa and primary human fibroblast cells. In transfected HeLa cells Rac1 and ARF6 also colocalized. Cells expressing wild-type ARF6 or Rac1 formed actin-containing surface protrusions and membrane ruffles, respectively, upon treatment with the G protein activator aluminum fluoride. Aluminum fluoride-treatment of cells transfected with equivalent amounts of plasmid resulted in enhanced membrane ruffling, with protrusions appearing as Rac expression was lowered. Co-expression of the dominant negative, GTP binding-defective ARF6 T27N mutant inhibited the aluminum fluoride-induced ruffling observed in cells expressing Rac1, and the constitutive ruffling observed in cells expressing the activated Rac1 Q61L mutant. In contrast, co-expression of the GTP-binding-defective, T17N mutant of either Rac1 or Cdc42 with ARF6 did not inhibit the aluminum fluoride-induced surface protrusions, nor did inactivation of Rho with C3-transferase. These observations suggest that ARF6, a non-Rho family GTPase, can, by itself, alter cortical actin and can influence the ability of Rac1 to form lamellipodia, in part, by regulating its trafficking to the plasma membrane.
[ "ARF6", "requirement", "for", "Rac", "ruffling", "suggests", "a", "role", "for", "membrane", "trafficking", "in", "cortical", "actin", "rearrangements", ".", "The", "ARF6", "GTPase", "regulates", "a", "novel", "endosomal", "-", "plasma", "membrane", "recycling", "pathway", "and", "influences", "cortical", "actin", "remodeling", ".", "Here", "we", "examined", "the", "relationship", "between", "ARF6", "and", "Rac1", ",", "a", "Rho", "family", "GTPase", ",", "implicated", "in", "cortical", "actin", "rearrangements", ".", "Endogenous", "Rac1", "colocalized", "with", "ARF6", "at", "the", "plasma", "membrane", "and", "on", "the", "ARF6", "recycling", "endosome", "in", "untransfected", "HeLa", "and", "primary", "human", "fibroblast", "cells", ".", "In", "transfected", "HeLa", "cells", "Rac1", "and", "ARF6", "also", "colocalized", ".", "Cells", "expressing", "wild", "-", "type", "ARF6", "or", "Rac1", "formed", "actin", "-", "containing", "surface", "protrusions", "and", "membrane", "ruffles", ",", "respectively", ",", "upon", "treatment", "with", "the", "G", "protein", "activator", "aluminum", "fluoride", ".", "Aluminum", "fluoride", "-", "treatment", "of", "cells", "transfected", "with", "equivalent", "amounts", "of", "plasmid", "resulted", "in", "enhanced", "membrane", "ruffling", ",", "with", "protrusions", "appearing", "as", "Rac", "expression", "was", "lowered", ".", "Co", "-", "expression", "of", "the", "dominant", "negative", ",", "GTP", "binding", "-", "defective", "ARF6", "T27N", "mutant", "inhibited", "the", "aluminum", "fluoride", "-", "induced", "ruffling", "observed", "in", "cells", "expressing", "Rac1", ",", "and", "the", "constitutive", "ruffling", "observed", "in", "cells", "expressing", "the", "activated", "Rac1", "Q61L", "mutant", ".", "In", "contrast", ",", "co", "-", "expression", "of", "the", "GTP", "-", "binding", "-", "defective", ",", "T17N", "mutant", "of", "either", "Rac1", "or", "Cdc42", "with", "ARF6", "did", "not", "inhibit", "the", "aluminum", "fluoride", "-", "induced", "surface", "protrusions", ",", "nor", "did", "inactivation", "of", "Rho", "with", "C3-transferase", ".", "These", "observations", "suggest", "that", "ARF6", ",", "a", "non", "-", "Rho", "family", "GTPase", ",", "can", ",", "by", "itself", ",", "alter", "cortical", "actin", "and", "can", "influence", "the", "ability", "of", "Rac1", "to", "form", "lamellipodia", ",", "in", "part", ",", "by", "regulating", "its", "trafficking", "to", "the", "plasma", "membrane", ".", "\n" ]
[ "MutantProtein", "CellComponent", "InorganicChemical", "Cell", "Protein", "Enzyme", "Eukaryote" ]
ARF6 is a Enzyme, membrane is a CellComponent, cortical actin is a Protein, ARF6 GTPase is a Enzyme, endosomal - plasma membrane is a CellComponent, cortical actin is a Protein, ARF6 is a Enzyme, Rac1 is a Enzyme, GTPase is a Enzyme, cortical actin is a Protein, Rac1 is a Enzyme, ARF6 is a Enzyme, plasma membrane is a CellComponent, ARF6 is a Enzyme, endosome is a CellComponent, HeLa is a Cell, human is a Eukaryote, fibroblast cells is a Cell, HeLa cells is a Cell, Rac1 is a Enzyme, ARF6 is a Enzyme, Cells is a Cell, ARF6 is a Enzyme, Rac1 is a Enzyme, actin - containing surface protrusions is a CellComponent, membrane ruffles is a CellComponent, G protein is a Protein, aluminum fluoride is a InorganicChemical, Aluminum fluoride is a InorganicChemical, cells is a Cell, Rac is a Enzyme, GTP binding - defective ARF6 T27N mutant is a MutantProtein, aluminum fluoride is a InorganicChemical, cells is a Cell, Rac1 is a Enzyme, cells is a Cell, Rac1 Q61L mutant is a MutantProtein, GTP - binding - defective , T17N mutant is a MutantProtein, Rac1 is a Enzyme, Cdc42 is a Enzyme, ARF6 is a Enzyme, aluminum fluoride is a InorganicChemical, surface protrusions is a CellComponent, Rho is a Enzyme, C3-transferase is a Enzyme, ARF6 is a Enzyme, GTPase is a Enzyme, cortical actin is a Protein, Rac1 is a Enzyme, lamellipodia is a CellComponent, plasma membrane is a CellComponent
18_task1
Sentence: ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. The ARF6 GTPase regulates a novel endosomal-plasma membrane recycling pathway and influences cortical actin remodeling. Here we examined the relationship between ARF6 and Rac1, a Rho family GTPase, implicated in cortical actin rearrangements. Endogenous Rac1 colocalized with ARF6 at the plasma membrane and on the ARF6 recycling endosome in untransfected HeLa and primary human fibroblast cells. In transfected HeLa cells Rac1 and ARF6 also colocalized. Cells expressing wild-type ARF6 or Rac1 formed actin-containing surface protrusions and membrane ruffles, respectively, upon treatment with the G protein activator aluminum fluoride. Aluminum fluoride-treatment of cells transfected with equivalent amounts of plasmid resulted in enhanced membrane ruffling, with protrusions appearing as Rac expression was lowered. Co-expression of the dominant negative, GTP binding-defective ARF6 T27N mutant inhibited the aluminum fluoride-induced ruffling observed in cells expressing Rac1, and the constitutive ruffling observed in cells expressing the activated Rac1 Q61L mutant. In contrast, co-expression of the GTP-binding-defective, T17N mutant of either Rac1 or Cdc42 with ARF6 did not inhibit the aluminum fluoride-induced surface protrusions, nor did inactivation of Rho with C3-transferase. These observations suggest that ARF6, a non-Rho family GTPase, can, by itself, alter cortical actin and can influence the ability of Rac1 to form lamellipodia, in part, by regulating its trafficking to the plasma membrane. Instructions: please typing these entity words according to sentence: ARF6, membrane, cortical actin, ARF6 GTPase, endosomal - plasma membrane, cortical actin, ARF6, Rac1, GTPase, cortical actin, Rac1, ARF6, plasma membrane, ARF6, endosome, HeLa, human, fibroblast cells, HeLa cells, Rac1, ARF6, Cells, ARF6, Rac1, actin - containing surface protrusions, membrane ruffles, G protein, aluminum fluoride, Aluminum fluoride, cells, Rac, GTP binding - defective ARF6 T27N mutant, aluminum fluoride, cells, Rac1, cells, Rac1 Q61L mutant, GTP - binding - defective , T17N mutant, Rac1, Cdc42, ARF6, aluminum fluoride, surface protrusions, Rho, C3-transferase, ARF6, GTPase, cortical actin, Rac1, lamellipodia, plasma membrane Options: MutantProtein, CellComponent, Enzyme, Eukaryote, InorganicChemical, Protein, Cell
[ "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "B-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Enzyme", "O", "O", "B-Enzyme", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "B-Enzyme", "O", "B-CellComponent", "O", "O", "B-Cell", "O", "O", "B-Eukaryote", "B-Cell", "I-Cell", "O", "O", "O", "B-Cell", "I-Cell", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "B-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "B-CellComponent", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O" ]
ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. The ARF6 GTPase regulates a novel endosomal-plasma membrane recycling pathway and influences cortical actin remodeling. Here we examined the relationship between ARF6 and Rac1, a Rho family GTPase, implicated in cortical actin rearrangements. Endogenous Rac1 colocalized with ARF6 at the plasma membrane and on the ARF6 recycling endosome in untransfected HeLa and primary human fibroblast cells. In transfected HeLa cells Rac1 and ARF6 also colocalized. Cells expressing wild-type ARF6 or Rac1 formed actin-containing surface protrusions and membrane ruffles, respectively, upon treatment with the G protein activator aluminum fluoride. Aluminum fluoride-treatment of cells transfected with equivalent amounts of plasmid resulted in enhanced membrane ruffling, with protrusions appearing as Rac expression was lowered. Co-expression of the dominant negative, GTP binding-defective ARF6 T27N mutant inhibited the aluminum fluoride-induced ruffling observed in cells expressing Rac1, and the constitutive ruffling observed in cells expressing the activated Rac1 Q61L mutant. In contrast, co-expression of the GTP-binding-defective, T17N mutant of either Rac1 or Cdc42 with ARF6 did not inhibit the aluminum fluoride-induced surface protrusions, nor did inactivation of Rho with C3-transferase. These observations suggest that ARF6, a non-Rho family GTPase, can, by itself, alter cortical actin and can influence the ability of Rac1 to form lamellipodia, in part, by regulating its trafficking to the plasma membrane.
[ "ARF6", "requirement", "for", "Rac", "ruffling", "suggests", "a", "role", "for", "membrane", "trafficking", "in", "cortical", "actin", "rearrangements", ".", "The", "ARF6", "GTPase", "regulates", "a", "novel", "endosomal", "-", "plasma", "membrane", "recycling", "pathway", "and", "influences", "cortical", "actin", "remodeling", ".", "Here", "we", "examined", "the", "relationship", "between", "ARF6", "and", "Rac1", ",", "a", "Rho", "family", "GTPase", ",", "implicated", "in", "cortical", "actin", "rearrangements", ".", "Endogenous", "Rac1", "colocalized", "with", "ARF6", "at", "the", "plasma", "membrane", "and", "on", "the", "ARF6", "recycling", "endosome", "in", "untransfected", "HeLa", "and", "primary", "human", "fibroblast", "cells", ".", "In", "transfected", "HeLa", "cells", "Rac1", "and", "ARF6", "also", "colocalized", ".", "Cells", "expressing", "wild", "-", "type", "ARF6", "or", "Rac1", "formed", "actin", "-", "containing", "surface", "protrusions", "and", "membrane", "ruffles", ",", "respectively", ",", "upon", "treatment", "with", "the", "G", "protein", "activator", "aluminum", "fluoride", ".", "Aluminum", "fluoride", "-", "treatment", "of", "cells", "transfected", "with", "equivalent", "amounts", "of", "plasmid", "resulted", "in", "enhanced", "membrane", "ruffling", ",", "with", "protrusions", "appearing", "as", "Rac", "expression", "was", "lowered", ".", "Co", "-", "expression", "of", "the", "dominant", "negative", ",", "GTP", "binding", "-", "defective", "ARF6", "T27N", "mutant", "inhibited", "the", "aluminum", "fluoride", "-", "induced", "ruffling", "observed", "in", "cells", "expressing", "Rac1", ",", "and", "the", "constitutive", "ruffling", "observed", "in", "cells", "expressing", "the", "activated", "Rac1", "Q61L", "mutant", ".", "In", "contrast", ",", "co", "-", "expression", "of", "the", "GTP", "-", "binding", "-", "defective", ",", "T17N", "mutant", "of", "either", "Rac1", "or", "Cdc42", "with", "ARF6", "did", "not", "inhibit", "the", "aluminum", "fluoride", "-", "induced", "surface", "protrusions", ",", "nor", "did", "inactivation", "of", "Rho", "with", "C3-transferase", ".", "These", "observations", "suggest", "that", "ARF6", ",", "a", "non", "-", "Rho", "family", "GTPase", ",", "can", ",", "by", "itself", ",", "alter", "cortical", "actin", "and", "can", "influence", "the", "ability", "of", "Rac1", "to", "form", "lamellipodia", ",", "in", "part", ",", "by", "regulating", "its", "trafficking", "to", "the", "plasma", "membrane", ".", "\n" ]
[ "MutantProtein", "CellComponent", "InorganicChemical", "Cell", "Protein", "Enzyme", "Eukaryote" ]
ARF6, membrane, cortical actin, ARF6 GTPase, endosomal - plasma membrane, cortical actin, ARF6, Rac1, GTPase, cortical actin, Rac1, ARF6, plasma membrane, ARF6, endosome, HeLa, human, fibroblast cells, HeLa cells, Rac1, ARF6, Cells, ARF6, Rac1, actin - containing surface protrusions, membrane ruffles, G protein, aluminum fluoride, Aluminum fluoride, cells, Rac, GTP binding - defective ARF6 T27N mutant, aluminum fluoride, cells, Rac1, cells, Rac1 Q61L mutant, GTP - binding - defective , T17N mutant, Rac1, Cdc42, ARF6, aluminum fluoride, surface protrusions, Rho, C3-transferase, ARF6, GTPase, cortical actin, Rac1, lamellipodia, plasma membrane
18_task2
Sentence: ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. The ARF6 GTPase regulates a novel endosomal-plasma membrane recycling pathway and influences cortical actin remodeling. Here we examined the relationship between ARF6 and Rac1, a Rho family GTPase, implicated in cortical actin rearrangements. Endogenous Rac1 colocalized with ARF6 at the plasma membrane and on the ARF6 recycling endosome in untransfected HeLa and primary human fibroblast cells. In transfected HeLa cells Rac1 and ARF6 also colocalized. Cells expressing wild-type ARF6 or Rac1 formed actin-containing surface protrusions and membrane ruffles, respectively, upon treatment with the G protein activator aluminum fluoride. Aluminum fluoride-treatment of cells transfected with equivalent amounts of plasmid resulted in enhanced membrane ruffling, with protrusions appearing as Rac expression was lowered. Co-expression of the dominant negative, GTP binding-defective ARF6 T27N mutant inhibited the aluminum fluoride-induced ruffling observed in cells expressing Rac1, and the constitutive ruffling observed in cells expressing the activated Rac1 Q61L mutant. In contrast, co-expression of the GTP-binding-defective, T17N mutant of either Rac1 or Cdc42 with ARF6 did not inhibit the aluminum fluoride-induced surface protrusions, nor did inactivation of Rho with C3-transferase. These observations suggest that ARF6, a non-Rho family GTPase, can, by itself, alter cortical actin and can influence the ability of Rac1 to form lamellipodia, in part, by regulating its trafficking to the plasma membrane. Instructions: please extract entity words from the input sentence
[ "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "B-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Enzyme", "O", "O", "B-Enzyme", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "B-Enzyme", "O", "B-CellComponent", "O", "O", "B-Cell", "O", "O", "B-Eukaryote", "B-Cell", "I-Cell", "O", "O", "O", "B-Cell", "I-Cell", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "B-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "I-CellComponent", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "I-MutantProtein", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "B-InorganicChemical", "I-InorganicChemical", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "O", "O", "O", "B-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "B-CellComponent", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O" ]
ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. The ARF6 GTPase regulates a novel endosomal-plasma membrane recycling pathway and influences cortical actin remodeling. Here we examined the relationship between ARF6 and Rac1, a Rho family GTPase, implicated in cortical actin rearrangements. Endogenous Rac1 colocalized with ARF6 at the plasma membrane and on the ARF6 recycling endosome in untransfected HeLa and primary human fibroblast cells. In transfected HeLa cells Rac1 and ARF6 also colocalized. Cells expressing wild-type ARF6 or Rac1 formed actin-containing surface protrusions and membrane ruffles, respectively, upon treatment with the G protein activator aluminum fluoride. Aluminum fluoride-treatment of cells transfected with equivalent amounts of plasmid resulted in enhanced membrane ruffling, with protrusions appearing as Rac expression was lowered. Co-expression of the dominant negative, GTP binding-defective ARF6 T27N mutant inhibited the aluminum fluoride-induced ruffling observed in cells expressing Rac1, and the constitutive ruffling observed in cells expressing the activated Rac1 Q61L mutant. In contrast, co-expression of the GTP-binding-defective, T17N mutant of either Rac1 or Cdc42 with ARF6 did not inhibit the aluminum fluoride-induced surface protrusions, nor did inactivation of Rho with C3-transferase. These observations suggest that ARF6, a non-Rho family GTPase, can, by itself, alter cortical actin and can influence the ability of Rac1 to form lamellipodia, in part, by regulating its trafficking to the plasma membrane.
[ "ARF6", "requirement", "for", "Rac", "ruffling", "suggests", "a", "role", "for", "membrane", "trafficking", "in", "cortical", "actin", "rearrangements", ".", "The", "ARF6", "GTPase", "regulates", "a", "novel", "endosomal", "-", "plasma", "membrane", "recycling", "pathway", "and", "influences", "cortical", "actin", "remodeling", ".", "Here", "we", "examined", "the", "relationship", "between", "ARF6", "and", "Rac1", ",", "a", "Rho", "family", "GTPase", ",", "implicated", "in", "cortical", "actin", "rearrangements", ".", "Endogenous", "Rac1", "colocalized", "with", "ARF6", "at", "the", "plasma", "membrane", "and", "on", "the", "ARF6", "recycling", "endosome", "in", "untransfected", "HeLa", "and", "primary", "human", "fibroblast", "cells", ".", "In", "transfected", "HeLa", "cells", "Rac1", "and", "ARF6", "also", "colocalized", ".", "Cells", "expressing", "wild", "-", "type", "ARF6", "or", "Rac1", "formed", "actin", "-", "containing", "surface", "protrusions", "and", "membrane", "ruffles", ",", "respectively", ",", "upon", "treatment", "with", "the", "G", "protein", "activator", "aluminum", "fluoride", ".", "Aluminum", "fluoride", "-", "treatment", "of", "cells", "transfected", "with", "equivalent", "amounts", "of", "plasmid", "resulted", "in", "enhanced", "membrane", "ruffling", ",", "with", "protrusions", "appearing", "as", "Rac", "expression", "was", "lowered", ".", "Co", "-", "expression", "of", "the", "dominant", "negative", ",", "GTP", "binding", "-", "defective", "ARF6", "T27N", "mutant", "inhibited", "the", "aluminum", "fluoride", "-", "induced", "ruffling", "observed", "in", "cells", "expressing", "Rac1", ",", "and", "the", "constitutive", "ruffling", "observed", "in", "cells", "expressing", "the", "activated", "Rac1", "Q61L", "mutant", ".", "In", "contrast", ",", "co", "-", "expression", "of", "the", "GTP", "-", "binding", "-", "defective", ",", "T17N", "mutant", "of", "either", "Rac1", "or", "Cdc42", "with", "ARF6", "did", "not", "inhibit", "the", "aluminum", "fluoride", "-", "induced", "surface", "protrusions", ",", "nor", "did", "inactivation", "of", "Rho", "with", "C3-transferase", ".", "These", "observations", "suggest", "that", "ARF6", ",", "a", "non", "-", "Rho", "family", "GTPase", ",", "can", ",", "by", "itself", ",", "alter", "cortical", "actin", "and", "can", "influence", "the", "ability", "of", "Rac1", "to", "form", "lamellipodia", ",", "in", "part", ",", "by", "regulating", "its", "trafficking", "to", "the", "plasma", "membrane", ".", "\n" ]
[ "MutantProtein", "CellComponent", "InorganicChemical", "Cell", "Protein", "Enzyme", "Eukaryote" ]
time required is a Outcome_Other, fluke and worm combination products is a Intervention_Pharmacological, commercial beef cattle at housing . is a Participant_Condition, quantify and compare the time needed to treat commercial beef cattle is a Outcome_Other, three fluke and worm combination products is a Intervention_Pharmacological, Young beef cattle is a Participant_Age, 270 is a Participant_Sample-size, ivermectin + clorsulon injection is a Intervention_Pharmacological, ivermectin + closantel injection is a Intervention_Pharmacological, levamisole + triclabendazole oral drench is a Intervention_Pharmacological, mean time needed is a Outcome_Other, ivermectin + clorsulon ( single injection ) is a Intervention_Pharmacological, planning is a Outcome_Other, selection is a Outcome_Other
35483_task0
Sentence: Comparison of the time required to administer three different fluke and worm combination products to commercial beef cattle at housing . Larger livestock units , a decline in the farm labor force , animal welfare concerns , and a trend toward more selective use of drugs have increased the focus on animal handling , time management , convenience , and compliance in administering veterinary therapeutics . This study was undertaken to quantify and compare the time needed to treat commercial beef cattle with three fluke and worm combination products with different administration profiles . Young beef cattle ( n = 270 ) weighing approximately 400 kg were allocated to batches of five , which were randomly assigned to receive ivermectin + clorsulon injection , ivermectin + closantel injection , or levamisole + triclabendazole oral drench . The mean time needed to administer ivermectin + clorsulon ( single injection ) to five cattle was 31 seconds , which was significantly less than the 100 seconds needed for ivermectin + closantel ( two injections ) and the 126 seconds needed for levamisole + triclabendazole ( P < .001 ) . Such quantitative data can allow for better planning and selection of parasiticide treatment approaches at the farm level . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Comparison of the time required to administer three different fluke and worm combination products to commercial beef cattle at housing . Larger livestock units , a decline in the farm labor force , animal welfare concerns , and a trend toward more selective use of drugs have increased the focus on animal handling , time management , convenience , and compliance in administering veterinary therapeutics . This study was undertaken to quantify and compare the time needed to treat commercial beef cattle with three fluke and worm combination products with different administration profiles . Young beef cattle ( n = 270 ) weighing approximately 400 kg were allocated to batches of five , which were randomly assigned to receive ivermectin + clorsulon injection , ivermectin + closantel injection , or levamisole + triclabendazole oral drench . The mean time needed to administer ivermectin + clorsulon ( single injection ) to five cattle was 31 seconds , which was significantly less than the 100 seconds needed for ivermectin + closantel ( two injections ) and the 126 seconds needed for levamisole + triclabendazole ( P < .001 ) . Such quantitative data can allow for better planning and selection of parasiticide treatment approaches at the farm level .
[ "Comparison", "of", "the", "time", "required", "to", "administer", "three", "different", "fluke", "and", "worm", "combination", "products", "to", "commercial", "beef", "cattle", "at", "housing", ".", "Larger", "livestock", "units", ",", "a", "decline", "in", "the", "farm", "labor", "force", ",", "animal", "welfare", "concerns", ",", "and", "a", "trend", "toward", "more", "selective", "use", "of", "drugs", "have", "increased", "the", "focus", "on", "animal", "handling", ",", "time", "management", ",", "convenience", ",", "and", "compliance", "in", "administering", "veterinary", "therapeutics", ".", "This", "study", "was", "undertaken", "to", "quantify", "and", "compare", "the", "time", "needed", "to", "treat", "commercial", "beef", "cattle", "with", "three", "fluke", "and", "worm", "combination", "products", "with", "different", "administration", "profiles", ".", "Young", "beef", "cattle", "(", "n", "=", "270", ")", "weighing", "approximately", "400", "kg", "were", "allocated", "to", "batches", "of", "five", ",", "which", "were", "randomly", "assigned", "to", "receive", "ivermectin", "+", "clorsulon", "injection", ",", "ivermectin", "+", "closantel", "injection", ",", "or", "levamisole", "+", "triclabendazole", "oral", "drench", ".", "The", "mean", "time", "needed", "to", "administer", "ivermectin", "+", "clorsulon", "(", "single", "injection", ")", "to", "five", "cattle", "was", "31", "seconds", ",", "which", "was", "significantly", "less", "than", "the", "100", "seconds", "needed", "for", "ivermectin", "+", "closantel", "(", "two", "injections", ")", "and", "the", "126", "seconds", "needed", "for", "levamisole", "+", "triclabendazole", "(", "P", "<", ".001", ")", ".", "Such", "quantitative", "data", "can", "allow", "for", "better", "planning", "and", "selection", "of", "parasiticide", "treatment", "approaches", "at", "the", "farm", "level", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
time required is a Outcome_Other, fluke and worm combination products is a Intervention_Pharmacological, commercial beef cattle at housing . is a Participant_Condition, quantify and compare the time needed to treat commercial beef cattle is a Outcome_Other, three fluke and worm combination products is a Intervention_Pharmacological, Young beef cattle is a Participant_Age, 270 is a Participant_Sample-size, ivermectin + clorsulon injection is a Intervention_Pharmacological, ivermectin + closantel injection is a Intervention_Pharmacological, levamisole + triclabendazole oral drench is a Intervention_Pharmacological, mean time needed is a Outcome_Other, ivermectin + clorsulon ( single injection ) is a Intervention_Pharmacological, planning is a Outcome_Other, selection is a Outcome_Other
35483_task1
Sentence: Comparison of the time required to administer three different fluke and worm combination products to commercial beef cattle at housing . Larger livestock units , a decline in the farm labor force , animal welfare concerns , and a trend toward more selective use of drugs have increased the focus on animal handling , time management , convenience , and compliance in administering veterinary therapeutics . This study was undertaken to quantify and compare the time needed to treat commercial beef cattle with three fluke and worm combination products with different administration profiles . Young beef cattle ( n = 270 ) weighing approximately 400 kg were allocated to batches of five , which were randomly assigned to receive ivermectin + clorsulon injection , ivermectin + closantel injection , or levamisole + triclabendazole oral drench . The mean time needed to administer ivermectin + clorsulon ( single injection ) to five cattle was 31 seconds , which was significantly less than the 100 seconds needed for ivermectin + closantel ( two injections ) and the 126 seconds needed for levamisole + triclabendazole ( P < .001 ) . Such quantitative data can allow for better planning and selection of parasiticide treatment approaches at the farm level . Instructions: please typing these entity words according to sentence: time required, fluke and worm combination products, commercial beef cattle at housing ., quantify and compare the time needed to treat commercial beef cattle, three fluke and worm combination products, Young beef cattle, 270, ivermectin + clorsulon injection, ivermectin + closantel injection, levamisole + triclabendazole oral drench, mean time needed, ivermectin + clorsulon ( single injection ), planning, selection Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Comparison of the time required to administer three different fluke and worm combination products to commercial beef cattle at housing . Larger livestock units , a decline in the farm labor force , animal welfare concerns , and a trend toward more selective use of drugs have increased the focus on animal handling , time management , convenience , and compliance in administering veterinary therapeutics . This study was undertaken to quantify and compare the time needed to treat commercial beef cattle with three fluke and worm combination products with different administration profiles . Young beef cattle ( n = 270 ) weighing approximately 400 kg were allocated to batches of five , which were randomly assigned to receive ivermectin + clorsulon injection , ivermectin + closantel injection , or levamisole + triclabendazole oral drench . The mean time needed to administer ivermectin + clorsulon ( single injection ) to five cattle was 31 seconds , which was significantly less than the 100 seconds needed for ivermectin + closantel ( two injections ) and the 126 seconds needed for levamisole + triclabendazole ( P < .001 ) . Such quantitative data can allow for better planning and selection of parasiticide treatment approaches at the farm level .
[ "Comparison", "of", "the", "time", "required", "to", "administer", "three", "different", "fluke", "and", "worm", "combination", "products", "to", "commercial", "beef", "cattle", "at", "housing", ".", "Larger", "livestock", "units", ",", "a", "decline", "in", "the", "farm", "labor", "force", ",", "animal", "welfare", "concerns", ",", "and", "a", "trend", "toward", "more", "selective", "use", "of", "drugs", "have", "increased", "the", "focus", "on", "animal", "handling", ",", "time", "management", ",", "convenience", ",", "and", "compliance", "in", "administering", "veterinary", "therapeutics", ".", "This", "study", "was", "undertaken", "to", "quantify", "and", "compare", "the", "time", "needed", "to", "treat", "commercial", "beef", "cattle", "with", "three", "fluke", "and", "worm", "combination", "products", "with", "different", "administration", "profiles", ".", "Young", "beef", "cattle", "(", "n", "=", "270", ")", "weighing", "approximately", "400", "kg", "were", "allocated", "to", "batches", "of", "five", ",", "which", "were", "randomly", "assigned", "to", "receive", "ivermectin", "+", "clorsulon", "injection", ",", "ivermectin", "+", "closantel", "injection", ",", "or", "levamisole", "+", "triclabendazole", "oral", "drench", ".", "The", "mean", "time", "needed", "to", "administer", "ivermectin", "+", "clorsulon", "(", "single", "injection", ")", "to", "five", "cattle", "was", "31", "seconds", ",", "which", "was", "significantly", "less", "than", "the", "100", "seconds", "needed", "for", "ivermectin", "+", "closantel", "(", "two", "injections", ")", "and", "the", "126", "seconds", "needed", "for", "levamisole", "+", "triclabendazole", "(", "P", "<", ".001", ")", ".", "Such", "quantitative", "data", "can", "allow", "for", "better", "planning", "and", "selection", "of", "parasiticide", "treatment", "approaches", "at", "the", "farm", "level", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
time required, fluke and worm combination products, commercial beef cattle at housing ., quantify and compare the time needed to treat commercial beef cattle, three fluke and worm combination products, Young beef cattle, 270, ivermectin + clorsulon injection, ivermectin + closantel injection, levamisole + triclabendazole oral drench, mean time needed, ivermectin + clorsulon ( single injection ), planning, selection
35483_task2
Sentence: Comparison of the time required to administer three different fluke and worm combination products to commercial beef cattle at housing . Larger livestock units , a decline in the farm labor force , animal welfare concerns , and a trend toward more selective use of drugs have increased the focus on animal handling , time management , convenience , and compliance in administering veterinary therapeutics . This study was undertaken to quantify and compare the time needed to treat commercial beef cattle with three fluke and worm combination products with different administration profiles . Young beef cattle ( n = 270 ) weighing approximately 400 kg were allocated to batches of five , which were randomly assigned to receive ivermectin + clorsulon injection , ivermectin + closantel injection , or levamisole + triclabendazole oral drench . The mean time needed to administer ivermectin + clorsulon ( single injection ) to five cattle was 31 seconds , which was significantly less than the 100 seconds needed for ivermectin + closantel ( two injections ) and the 126 seconds needed for levamisole + triclabendazole ( P < .001 ) . Such quantitative data can allow for better planning and selection of parasiticide treatment approaches at the farm level . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Comparison of the time required to administer three different fluke and worm combination products to commercial beef cattle at housing . Larger livestock units , a decline in the farm labor force , animal welfare concerns , and a trend toward more selective use of drugs have increased the focus on animal handling , time management , convenience , and compliance in administering veterinary therapeutics . This study was undertaken to quantify and compare the time needed to treat commercial beef cattle with three fluke and worm combination products with different administration profiles . Young beef cattle ( n = 270 ) weighing approximately 400 kg were allocated to batches of five , which were randomly assigned to receive ivermectin + clorsulon injection , ivermectin + closantel injection , or levamisole + triclabendazole oral drench . The mean time needed to administer ivermectin + clorsulon ( single injection ) to five cattle was 31 seconds , which was significantly less than the 100 seconds needed for ivermectin + closantel ( two injections ) and the 126 seconds needed for levamisole + triclabendazole ( P < .001 ) . Such quantitative data can allow for better planning and selection of parasiticide treatment approaches at the farm level .
[ "Comparison", "of", "the", "time", "required", "to", "administer", "three", "different", "fluke", "and", "worm", "combination", "products", "to", "commercial", "beef", "cattle", "at", "housing", ".", "Larger", "livestock", "units", ",", "a", "decline", "in", "the", "farm", "labor", "force", ",", "animal", "welfare", "concerns", ",", "and", "a", "trend", "toward", "more", "selective", "use", "of", "drugs", "have", "increased", "the", "focus", "on", "animal", "handling", ",", "time", "management", ",", "convenience", ",", "and", "compliance", "in", "administering", "veterinary", "therapeutics", ".", "This", "study", "was", "undertaken", "to", "quantify", "and", "compare", "the", "time", "needed", "to", "treat", "commercial", "beef", "cattle", "with", "three", "fluke", "and", "worm", "combination", "products", "with", "different", "administration", "profiles", ".", "Young", "beef", "cattle", "(", "n", "=", "270", ")", "weighing", "approximately", "400", "kg", "were", "allocated", "to", "batches", "of", "five", ",", "which", "were", "randomly", "assigned", "to", "receive", "ivermectin", "+", "clorsulon", "injection", ",", "ivermectin", "+", "closantel", "injection", ",", "or", "levamisole", "+", "triclabendazole", "oral", "drench", ".", "The", "mean", "time", "needed", "to", "administer", "ivermectin", "+", "clorsulon", "(", "single", "injection", ")", "to", "five", "cattle", "was", "31", "seconds", ",", "which", "was", "significantly", "less", "than", "the", "100", "seconds", "needed", "for", "ivermectin", "+", "closantel", "(", "two", "injections", ")", "and", "the", "126", "seconds", "needed", "for", "levamisole", "+", "triclabendazole", "(", "P", "<", ".001", ")", ".", "Such", "quantitative", "data", "can", "allow", "for", "better", "planning", "and", "selection", "of", "parasiticide", "treatment", "approaches", "at", "the", "farm", "level", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
Verdachtsdiagnose is an umlsterm, Punktmutationen is an umlsterm, DNA is an umlsterm
DerOpthalmologe.80950549.ger.abstr_task0
Sentence: Fragestellung : Die klinische Verdachtsdiagnose Lebersche Optikusneuropathie ( LHON ) kann durch molekulargenetische Untersuchungen gesichert werden . LHON wird assoziiert mit dem Auftreten von Punktmutationen in der mitochondrialen DNA ( mtDNA ) , als sicher gilt die pathogenetische Bedeutung eines Basenaustausches an den Positionen 3460 , 11 778 und 14 484 der Nukleotidabfolge . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Fragestellung : Die klinische Verdachtsdiagnose Lebersche Optikusneuropathie ( LHON ) kann durch molekulargenetische Untersuchungen gesichert werden . LHON wird assoziiert mit dem Auftreten von Punktmutationen in der mitochondrialen DNA ( mtDNA ) , als sicher gilt die pathogenetische Bedeutung eines Basenaustausches an den Positionen 3460 , 11 778 und 14 484 der Nukleotidabfolge .
[ "Fragestellung", ":", "Die", "klinische", "Verdachtsdiagnose", "Lebersche", "Optikusneuropathie", "(", "LHON", ")", "kann", "durch", "molekulargenetische", "Untersuchungen", "gesichert", "werden", ".", "LHON", "wird", "assoziiert", "mit", "dem", "Auftreten", "von", "Punktmutationen", "in", "der", "mitochondrialen", "DNA", "(", "mtDNA", ")", ",", "als", "sicher", "gilt", "die", "pathogenetische", "Bedeutung", "eines", "Basenaustausches", "an", "den", "Positionen", "3460", ",", "11", "778", "und", "14", "484", "der", "Nukleotidabfolge", "." ]
[ "umlsterm" ]
Verdachtsdiagnose is an umlsterm, Punktmutationen is an umlsterm, DNA is an umlsterm
DerOpthalmologe.80950549.ger.abstr_task1
Sentence: Fragestellung : Die klinische Verdachtsdiagnose Lebersche Optikusneuropathie ( LHON ) kann durch molekulargenetische Untersuchungen gesichert werden . LHON wird assoziiert mit dem Auftreten von Punktmutationen in der mitochondrialen DNA ( mtDNA ) , als sicher gilt die pathogenetische Bedeutung eines Basenaustausches an den Positionen 3460 , 11 778 und 14 484 der Nukleotidabfolge . Instructions: please typing these entity words according to sentence: Verdachtsdiagnose, Punktmutationen, DNA Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Fragestellung : Die klinische Verdachtsdiagnose Lebersche Optikusneuropathie ( LHON ) kann durch molekulargenetische Untersuchungen gesichert werden . LHON wird assoziiert mit dem Auftreten von Punktmutationen in der mitochondrialen DNA ( mtDNA ) , als sicher gilt die pathogenetische Bedeutung eines Basenaustausches an den Positionen 3460 , 11 778 und 14 484 der Nukleotidabfolge .
[ "Fragestellung", ":", "Die", "klinische", "Verdachtsdiagnose", "Lebersche", "Optikusneuropathie", "(", "LHON", ")", "kann", "durch", "molekulargenetische", "Untersuchungen", "gesichert", "werden", ".", "LHON", "wird", "assoziiert", "mit", "dem", "Auftreten", "von", "Punktmutationen", "in", "der", "mitochondrialen", "DNA", "(", "mtDNA", ")", ",", "als", "sicher", "gilt", "die", "pathogenetische", "Bedeutung", "eines", "Basenaustausches", "an", "den", "Positionen", "3460", ",", "11", "778", "und", "14", "484", "der", "Nukleotidabfolge", "." ]
[ "umlsterm" ]
Verdachtsdiagnose, Punktmutationen, DNA
DerOpthalmologe.80950549.ger.abstr_task2
Sentence: Fragestellung : Die klinische Verdachtsdiagnose Lebersche Optikusneuropathie ( LHON ) kann durch molekulargenetische Untersuchungen gesichert werden . LHON wird assoziiert mit dem Auftreten von Punktmutationen in der mitochondrialen DNA ( mtDNA ) , als sicher gilt die pathogenetische Bedeutung eines Basenaustausches an den Positionen 3460 , 11 778 und 14 484 der Nukleotidabfolge . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Fragestellung : Die klinische Verdachtsdiagnose Lebersche Optikusneuropathie ( LHON ) kann durch molekulargenetische Untersuchungen gesichert werden . LHON wird assoziiert mit dem Auftreten von Punktmutationen in der mitochondrialen DNA ( mtDNA ) , als sicher gilt die pathogenetische Bedeutung eines Basenaustausches an den Positionen 3460 , 11 778 und 14 484 der Nukleotidabfolge .
[ "Fragestellung", ":", "Die", "klinische", "Verdachtsdiagnose", "Lebersche", "Optikusneuropathie", "(", "LHON", ")", "kann", "durch", "molekulargenetische", "Untersuchungen", "gesichert", "werden", ".", "LHON", "wird", "assoziiert", "mit", "dem", "Auftreten", "von", "Punktmutationen", "in", "der", "mitochondrialen", "DNA", "(", "mtDNA", ")", ",", "als", "sicher", "gilt", "die", "pathogenetische", "Bedeutung", "eines", "Basenaustausches", "an", "den", "Positionen", "3460", ",", "11", "778", "und", "14", "484", "der", "Nukleotidabfolge", "." ]
[ "umlsterm" ]
diseases is an umlsterm, pain is an umlsterm, pain is an umlsterm, diagnostic is an umlsterm, pain is an umlsterm, etiology is an umlsterm, pain is an umlsterm
DerSchmerz.00140340.eng.abstr_task0
Sentence: Background . In paediatrics , numerous diseases present with the leading symptome of muscular , articular , or bone-related pain . The pain as such is seldom diagnostic with regard to pain etiology . Regularly , the significance of inflammatory as well as non-inflammatory pain is underestimated . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Background . In paediatrics , numerous diseases present with the leading symptome of muscular , articular , or bone-related pain . The pain as such is seldom diagnostic with regard to pain etiology . Regularly , the significance of inflammatory as well as non-inflammatory pain is underestimated .
[ "Background", ".", "In", "paediatrics", ",", "numerous", "diseases", "present", "with", "the", "leading", "symptome", "of", "muscular", ",", "articular", ",", "or", "bone", "-", "related", "pain", ".", "The", "pain", "as", "such", "is", "seldom", "diagnostic", "with", "regard", "to", "pain", "etiology", ".", "Regularly", ",", "the", "significance", "of", "inflammatory", "as", "well", "as", "non", "-", "inflammatory", "pain", "is", "underestimated", "." ]
[ "umlsterm" ]
diseases is an umlsterm, pain is an umlsterm, pain is an umlsterm, diagnostic is an umlsterm, pain is an umlsterm, etiology is an umlsterm, pain is an umlsterm
DerSchmerz.00140340.eng.abstr_task1
Sentence: Background . In paediatrics , numerous diseases present with the leading symptome of muscular , articular , or bone-related pain . The pain as such is seldom diagnostic with regard to pain etiology . Regularly , the significance of inflammatory as well as non-inflammatory pain is underestimated . Instructions: please typing these entity words according to sentence: diseases, pain, pain, diagnostic, pain, etiology, pain Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Background . In paediatrics , numerous diseases present with the leading symptome of muscular , articular , or bone-related pain . The pain as such is seldom diagnostic with regard to pain etiology . Regularly , the significance of inflammatory as well as non-inflammatory pain is underestimated .
[ "Background", ".", "In", "paediatrics", ",", "numerous", "diseases", "present", "with", "the", "leading", "symptome", "of", "muscular", ",", "articular", ",", "or", "bone", "-", "related", "pain", ".", "The", "pain", "as", "such", "is", "seldom", "diagnostic", "with", "regard", "to", "pain", "etiology", ".", "Regularly", ",", "the", "significance", "of", "inflammatory", "as", "well", "as", "non", "-", "inflammatory", "pain", "is", "underestimated", "." ]
[ "umlsterm" ]
diseases, pain, pain, diagnostic, pain, etiology, pain
DerSchmerz.00140340.eng.abstr_task2
Sentence: Background . In paediatrics , numerous diseases present with the leading symptome of muscular , articular , or bone-related pain . The pain as such is seldom diagnostic with regard to pain etiology . Regularly , the significance of inflammatory as well as non-inflammatory pain is underestimated . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Background . In paediatrics , numerous diseases present with the leading symptome of muscular , articular , or bone-related pain . The pain as such is seldom diagnostic with regard to pain etiology . Regularly , the significance of inflammatory as well as non-inflammatory pain is underestimated .
[ "Background", ".", "In", "paediatrics", ",", "numerous", "diseases", "present", "with", "the", "leading", "symptome", "of", "muscular", ",", "articular", ",", "or", "bone", "-", "related", "pain", ".", "The", "pain", "as", "such", "is", "seldom", "diagnostic", "with", "regard", "to", "pain", "etiology", ".", "Regularly", ",", "the", "significance", "of", "inflammatory", "as", "well", "as", "non", "-", "inflammatory", "pain", "is", "underestimated", "." ]
[ "umlsterm" ]
Beckenringfraktur is an umlsterm, Spontangeburt is an umlsterm, unfallchirurgischer is an umlsterm, Beckenringfraktur is an umlsterm, Beckenbodens is an umlsterm, Urethra is an umlsterm, Stressinkontinenz is an umlsterm, Urethra is an umlsterm, Zystozele is an umlsterm, unfallchirurgischen is an umlsterm, Kombinationsverletzung is an umlsterm, unfallchirurgische is an umlsterm, Beckenverletzung is an umlsterm, Haematurie is an umlsterm
DerUrologeA.80370079.ger.abstr_task0
Sentence: Wir berichten ueber den Fall einer kompletten Urethralaengsruptur in Verbindung mit einer vorderen Beckenringfraktur und Symphysensprengung unter Spontangeburt . Erst nach unfallchirurgischer Stabilisierung der Beckenringfraktur war eine Adaptation und spannungsfreie primaere schichtweise Naht des Beckenbodens und der Urethra moeglich . Nach Katheterentfernung drei Wochen spaeter bestand eine mittelgradige Stressinkontinenz . Das kosmetische Ergebnis war gut . Ein Jahr spaeter war die Patientin kontinent . Die Urethra stellte sich regelrecht rekonstruiert dar . Es bestand keine Zystozele . Die Zusammenarbeit mit einer unfallchirurgischen Abteilung ist fuer eine erfolgreiche primaere Versorgung dieser seltenen Kombinationsverletzung wesentlich . Es wird ebenfalls die unfallchirurgische Versorgung einer postpartalen Beckenverletzung diskutiert . Bei unklarer postpartaler Haematurie ist umgehend eine urologische Abklaerung einzuleiten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber den Fall einer kompletten Urethralaengsruptur in Verbindung mit einer vorderen Beckenringfraktur und Symphysensprengung unter Spontangeburt . Erst nach unfallchirurgischer Stabilisierung der Beckenringfraktur war eine Adaptation und spannungsfreie primaere schichtweise Naht des Beckenbodens und der Urethra moeglich . Nach Katheterentfernung drei Wochen spaeter bestand eine mittelgradige Stressinkontinenz . Das kosmetische Ergebnis war gut . Ein Jahr spaeter war die Patientin kontinent . Die Urethra stellte sich regelrecht rekonstruiert dar . Es bestand keine Zystozele . Die Zusammenarbeit mit einer unfallchirurgischen Abteilung ist fuer eine erfolgreiche primaere Versorgung dieser seltenen Kombinationsverletzung wesentlich . Es wird ebenfalls die unfallchirurgische Versorgung einer postpartalen Beckenverletzung diskutiert . Bei unklarer postpartaler Haematurie ist umgehend eine urologische Abklaerung einzuleiten .
[ "Wir", "berichten", "ueber", "den", "Fall", "einer", "kompletten", "Urethralaengsruptur", "in", "Verbindung", "mit", "einer", "vorderen", "Beckenringfraktur", "und", "Symphysensprengung", "unter", "Spontangeburt", ".", "Erst", "nach", "unfallchirurgischer", "Stabilisierung", "der", "Beckenringfraktur", "war", "eine", "Adaptation", "und", "spannungsfreie", "primaere", "schichtweise", "Naht", "des", "Beckenbodens", "und", "der", "Urethra", "moeglich", ".", "Nach", "Katheterentfernung", "drei", "Wochen", "spaeter", "bestand", "eine", "mittelgradige", "Stressinkontinenz", ".", "Das", "kosmetische", "Ergebnis", "war", "gut", ".", "Ein", "Jahr", "spaeter", "war", "die", "Patientin", "kontinent", ".", "Die", "Urethra", "stellte", "sich", "regelrecht", "rekonstruiert", "dar", ".", "Es", "bestand", "keine", "Zystozele", ".", "Die", "Zusammenarbeit", "mit", "einer", "unfallchirurgischen", "Abteilung", "ist", "fuer", "eine", "erfolgreiche", "primaere", "Versorgung", "dieser", "seltenen", "Kombinationsverletzung", "wesentlich", ".", "Es", "wird", "ebenfalls", "die", "unfallchirurgische", "Versorgung", "einer", "postpartalen", "Beckenverletzung", "diskutiert", ".", "Bei", "unklarer", "postpartaler", "Haematurie", "ist", "umgehend", "eine", "urologische", "Abklaerung", "einzuleiten", "." ]
[ "umlsterm" ]
Beckenringfraktur is an umlsterm, Spontangeburt is an umlsterm, unfallchirurgischer is an umlsterm, Beckenringfraktur is an umlsterm, Beckenbodens is an umlsterm, Urethra is an umlsterm, Stressinkontinenz is an umlsterm, Urethra is an umlsterm, Zystozele is an umlsterm, unfallchirurgischen is an umlsterm, Kombinationsverletzung is an umlsterm, unfallchirurgische is an umlsterm, Beckenverletzung is an umlsterm, Haematurie is an umlsterm
DerUrologeA.80370079.ger.abstr_task1
Sentence: Wir berichten ueber den Fall einer kompletten Urethralaengsruptur in Verbindung mit einer vorderen Beckenringfraktur und Symphysensprengung unter Spontangeburt . Erst nach unfallchirurgischer Stabilisierung der Beckenringfraktur war eine Adaptation und spannungsfreie primaere schichtweise Naht des Beckenbodens und der Urethra moeglich . Nach Katheterentfernung drei Wochen spaeter bestand eine mittelgradige Stressinkontinenz . Das kosmetische Ergebnis war gut . Ein Jahr spaeter war die Patientin kontinent . Die Urethra stellte sich regelrecht rekonstruiert dar . Es bestand keine Zystozele . Die Zusammenarbeit mit einer unfallchirurgischen Abteilung ist fuer eine erfolgreiche primaere Versorgung dieser seltenen Kombinationsverletzung wesentlich . Es wird ebenfalls die unfallchirurgische Versorgung einer postpartalen Beckenverletzung diskutiert . Bei unklarer postpartaler Haematurie ist umgehend eine urologische Abklaerung einzuleiten . Instructions: please typing these entity words according to sentence: Beckenringfraktur, Spontangeburt, unfallchirurgischer, Beckenringfraktur, Beckenbodens, Urethra, Stressinkontinenz, Urethra, Zystozele, unfallchirurgischen, Kombinationsverletzung, unfallchirurgische, Beckenverletzung, Haematurie Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber den Fall einer kompletten Urethralaengsruptur in Verbindung mit einer vorderen Beckenringfraktur und Symphysensprengung unter Spontangeburt . Erst nach unfallchirurgischer Stabilisierung der Beckenringfraktur war eine Adaptation und spannungsfreie primaere schichtweise Naht des Beckenbodens und der Urethra moeglich . Nach Katheterentfernung drei Wochen spaeter bestand eine mittelgradige Stressinkontinenz . Das kosmetische Ergebnis war gut . Ein Jahr spaeter war die Patientin kontinent . Die Urethra stellte sich regelrecht rekonstruiert dar . Es bestand keine Zystozele . Die Zusammenarbeit mit einer unfallchirurgischen Abteilung ist fuer eine erfolgreiche primaere Versorgung dieser seltenen Kombinationsverletzung wesentlich . Es wird ebenfalls die unfallchirurgische Versorgung einer postpartalen Beckenverletzung diskutiert . Bei unklarer postpartaler Haematurie ist umgehend eine urologische Abklaerung einzuleiten .
[ "Wir", "berichten", "ueber", "den", "Fall", "einer", "kompletten", "Urethralaengsruptur", "in", "Verbindung", "mit", "einer", "vorderen", "Beckenringfraktur", "und", "Symphysensprengung", "unter", "Spontangeburt", ".", "Erst", "nach", "unfallchirurgischer", "Stabilisierung", "der", "Beckenringfraktur", "war", "eine", "Adaptation", "und", "spannungsfreie", "primaere", "schichtweise", "Naht", "des", "Beckenbodens", "und", "der", "Urethra", "moeglich", ".", "Nach", "Katheterentfernung", "drei", "Wochen", "spaeter", "bestand", "eine", "mittelgradige", "Stressinkontinenz", ".", "Das", "kosmetische", "Ergebnis", "war", "gut", ".", "Ein", "Jahr", "spaeter", "war", "die", "Patientin", "kontinent", ".", "Die", "Urethra", "stellte", "sich", "regelrecht", "rekonstruiert", "dar", ".", "Es", "bestand", "keine", "Zystozele", ".", "Die", "Zusammenarbeit", "mit", "einer", "unfallchirurgischen", "Abteilung", "ist", "fuer", "eine", "erfolgreiche", "primaere", "Versorgung", "dieser", "seltenen", "Kombinationsverletzung", "wesentlich", ".", "Es", "wird", "ebenfalls", "die", "unfallchirurgische", "Versorgung", "einer", "postpartalen", "Beckenverletzung", "diskutiert", ".", "Bei", "unklarer", "postpartaler", "Haematurie", "ist", "umgehend", "eine", "urologische", "Abklaerung", "einzuleiten", "." ]
[ "umlsterm" ]
Beckenringfraktur, Spontangeburt, unfallchirurgischer, Beckenringfraktur, Beckenbodens, Urethra, Stressinkontinenz, Urethra, Zystozele, unfallchirurgischen, Kombinationsverletzung, unfallchirurgische, Beckenverletzung, Haematurie
DerUrologeA.80370079.ger.abstr_task2
Sentence: Wir berichten ueber den Fall einer kompletten Urethralaengsruptur in Verbindung mit einer vorderen Beckenringfraktur und Symphysensprengung unter Spontangeburt . Erst nach unfallchirurgischer Stabilisierung der Beckenringfraktur war eine Adaptation und spannungsfreie primaere schichtweise Naht des Beckenbodens und der Urethra moeglich . Nach Katheterentfernung drei Wochen spaeter bestand eine mittelgradige Stressinkontinenz . Das kosmetische Ergebnis war gut . Ein Jahr spaeter war die Patientin kontinent . Die Urethra stellte sich regelrecht rekonstruiert dar . Es bestand keine Zystozele . Die Zusammenarbeit mit einer unfallchirurgischen Abteilung ist fuer eine erfolgreiche primaere Versorgung dieser seltenen Kombinationsverletzung wesentlich . Es wird ebenfalls die unfallchirurgische Versorgung einer postpartalen Beckenverletzung diskutiert . Bei unklarer postpartaler Haematurie ist umgehend eine urologische Abklaerung einzuleiten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Wir berichten ueber den Fall einer kompletten Urethralaengsruptur in Verbindung mit einer vorderen Beckenringfraktur und Symphysensprengung unter Spontangeburt . Erst nach unfallchirurgischer Stabilisierung der Beckenringfraktur war eine Adaptation und spannungsfreie primaere schichtweise Naht des Beckenbodens und der Urethra moeglich . Nach Katheterentfernung drei Wochen spaeter bestand eine mittelgradige Stressinkontinenz . Das kosmetische Ergebnis war gut . Ein Jahr spaeter war die Patientin kontinent . Die Urethra stellte sich regelrecht rekonstruiert dar . Es bestand keine Zystozele . Die Zusammenarbeit mit einer unfallchirurgischen Abteilung ist fuer eine erfolgreiche primaere Versorgung dieser seltenen Kombinationsverletzung wesentlich . Es wird ebenfalls die unfallchirurgische Versorgung einer postpartalen Beckenverletzung diskutiert . Bei unklarer postpartaler Haematurie ist umgehend eine urologische Abklaerung einzuleiten .
[ "Wir", "berichten", "ueber", "den", "Fall", "einer", "kompletten", "Urethralaengsruptur", "in", "Verbindung", "mit", "einer", "vorderen", "Beckenringfraktur", "und", "Symphysensprengung", "unter", "Spontangeburt", ".", "Erst", "nach", "unfallchirurgischer", "Stabilisierung", "der", "Beckenringfraktur", "war", "eine", "Adaptation", "und", "spannungsfreie", "primaere", "schichtweise", "Naht", "des", "Beckenbodens", "und", "der", "Urethra", "moeglich", ".", "Nach", "Katheterentfernung", "drei", "Wochen", "spaeter", "bestand", "eine", "mittelgradige", "Stressinkontinenz", ".", "Das", "kosmetische", "Ergebnis", "war", "gut", ".", "Ein", "Jahr", "spaeter", "war", "die", "Patientin", "kontinent", ".", "Die", "Urethra", "stellte", "sich", "regelrecht", "rekonstruiert", "dar", ".", "Es", "bestand", "keine", "Zystozele", ".", "Die", "Zusammenarbeit", "mit", "einer", "unfallchirurgischen", "Abteilung", "ist", "fuer", "eine", "erfolgreiche", "primaere", "Versorgung", "dieser", "seltenen", "Kombinationsverletzung", "wesentlich", ".", "Es", "wird", "ebenfalls", "die", "unfallchirurgische", "Versorgung", "einer", "postpartalen", "Beckenverletzung", "diskutiert", ".", "Bei", "unklarer", "postpartaler", "Haematurie", "ist", "umgehend", "eine", "urologische", "Abklaerung", "einzuleiten", "." ]
[ "umlsterm" ]
patients is an umlsterm, metastases is an umlsterm, malignant melanoma is an umlsterm, inhalation therapy is an umlsterm, interleukin-2 is an umlsterm, Inhalation therapy is an umlsterm, DTIC is an umlsterm, patients is an umlsterm, disease is an umlsterm, disease is an umlsterm, Therapy is an umlsterm, toxicity is an umlsterm, patients is an umlsterm, cough is an umlsterm, patient is an umlsterm, inhalation therapy is an umlsterm, lung is an umlsterm, metastases is an umlsterm, therapeutic is an umlsterm, arsenal is an umlsterm, malignant melanoma is an umlsterm
DerHautarzt.70480894.eng.abstr_task0
Sentence: Seven patients with pulmonary metastases of malignant melanoma were treated with inhalation therapy with 36 million IU interleukin-2 for six months . Inhalation therapy was combined with four bolus infusions of DTIC at a dose of 850 mg/m2 once every four weeks . Response rates were 71,4% with 2 patients achieving a complete remission ( CR ) , 2 partial remissions ( PR ) , 1 stable disease ( SD ) , and 2 progressing disease ( PD ) . Therapy was well tolerated with low toxicity . Six of the patients developed cough ; one patient was slightly feverish . We conclude that inhalation therapy of lung metastases is a promising addition to the therapeutic arsenal against malignant melanoma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]
Seven patients with pulmonary metastases of malignant melanoma were treated with inhalation therapy with 36 million IU interleukin-2 for six months . Inhalation therapy was combined with four bolus infusions of DTIC at a dose of 850 mg/m2 once every four weeks . Response rates were 71,4% with 2 patients achieving a complete remission ( CR ) , 2 partial remissions ( PR ) , 1 stable disease ( SD ) , and 2 progressing disease ( PD ) . Therapy was well tolerated with low toxicity . Six of the patients developed cough ; one patient was slightly feverish . We conclude that inhalation therapy of lung metastases is a promising addition to the therapeutic arsenal against malignant melanoma .
[ "Seven", "patients", "with", "pulmonary", "metastases", "of", "malignant", "melanoma", "were", "treated", "with", "inhalation", "therapy", "with", "36", "million", "IU", "interleukin-2", "for", "six", "months", ".", "Inhalation", "therapy", "was", "combined", "with", "four", "bolus", "infusions", "of", "DTIC", "at", "a", "dose", "of", "850", "mg", "/", "m2", "once", "every", "four", "weeks", ".", "Response", "rates", "were", "71,4", "%", "with", "2", "patients", "achieving", "a", "complete", "remission", "(", "CR", ")", ",", "2", "partial", "remissions", "(", "PR", ")", ",", "1", "stable", "disease", "(", "SD", ")", ",", "and", "2", "progressing", "disease", "(", "PD", ")", ".", "Therapy", "was", "well", "tolerated", "with", "low", "toxicity", ".", "Six", "of", "the", "patients", "developed", "cough", ";", "one", "patient", "was", "slightly", "feverish", ".", "We", "conclude", "that", "inhalation", "therapy", "of", "lung", "metastases", "is", "a", "promising", "addition", "to", "the", "therapeutic", "arsenal", "against", "malignant", "melanoma", "." ]
[ "umlsterm" ]
patients is an umlsterm, metastases is an umlsterm, malignant melanoma is an umlsterm, inhalation therapy is an umlsterm, interleukin-2 is an umlsterm, Inhalation therapy is an umlsterm, DTIC is an umlsterm, patients is an umlsterm, disease is an umlsterm, disease is an umlsterm, Therapy is an umlsterm, toxicity is an umlsterm, patients is an umlsterm, cough is an umlsterm, patient is an umlsterm, inhalation therapy is an umlsterm, lung is an umlsterm, metastases is an umlsterm, therapeutic is an umlsterm, arsenal is an umlsterm, malignant melanoma is an umlsterm
DerHautarzt.70480894.eng.abstr_task1
Sentence: Seven patients with pulmonary metastases of malignant melanoma were treated with inhalation therapy with 36 million IU interleukin-2 for six months . Inhalation therapy was combined with four bolus infusions of DTIC at a dose of 850 mg/m2 once every four weeks . Response rates were 71,4% with 2 patients achieving a complete remission ( CR ) , 2 partial remissions ( PR ) , 1 stable disease ( SD ) , and 2 progressing disease ( PD ) . Therapy was well tolerated with low toxicity . Six of the patients developed cough ; one patient was slightly feverish . We conclude that inhalation therapy of lung metastases is a promising addition to the therapeutic arsenal against malignant melanoma . Instructions: please typing these entity words according to sentence: patients, metastases, malignant melanoma, inhalation therapy, interleukin-2, Inhalation therapy, DTIC, patients, disease, disease, Therapy, toxicity, patients, cough, patient, inhalation therapy, lung, metastases, therapeutic, arsenal, malignant melanoma Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]
Seven patients with pulmonary metastases of malignant melanoma were treated with inhalation therapy with 36 million IU interleukin-2 for six months . Inhalation therapy was combined with four bolus infusions of DTIC at a dose of 850 mg/m2 once every four weeks . Response rates were 71,4% with 2 patients achieving a complete remission ( CR ) , 2 partial remissions ( PR ) , 1 stable disease ( SD ) , and 2 progressing disease ( PD ) . Therapy was well tolerated with low toxicity . Six of the patients developed cough ; one patient was slightly feverish . We conclude that inhalation therapy of lung metastases is a promising addition to the therapeutic arsenal against malignant melanoma .
[ "Seven", "patients", "with", "pulmonary", "metastases", "of", "malignant", "melanoma", "were", "treated", "with", "inhalation", "therapy", "with", "36", "million", "IU", "interleukin-2", "for", "six", "months", ".", "Inhalation", "therapy", "was", "combined", "with", "four", "bolus", "infusions", "of", "DTIC", "at", "a", "dose", "of", "850", "mg", "/", "m2", "once", "every", "four", "weeks", ".", "Response", "rates", "were", "71,4", "%", "with", "2", "patients", "achieving", "a", "complete", "remission", "(", "CR", ")", ",", "2", "partial", "remissions", "(", "PR", ")", ",", "1", "stable", "disease", "(", "SD", ")", ",", "and", "2", "progressing", "disease", "(", "PD", ")", ".", "Therapy", "was", "well", "tolerated", "with", "low", "toxicity", ".", "Six", "of", "the", "patients", "developed", "cough", ";", "one", "patient", "was", "slightly", "feverish", ".", "We", "conclude", "that", "inhalation", "therapy", "of", "lung", "metastases", "is", "a", "promising", "addition", "to", "the", "therapeutic", "arsenal", "against", "malignant", "melanoma", "." ]
[ "umlsterm" ]
patients, metastases, malignant melanoma, inhalation therapy, interleukin-2, Inhalation therapy, DTIC, patients, disease, disease, Therapy, toxicity, patients, cough, patient, inhalation therapy, lung, metastases, therapeutic, arsenal, malignant melanoma
DerHautarzt.70480894.eng.abstr_task2
Sentence: Seven patients with pulmonary metastases of malignant melanoma were treated with inhalation therapy with 36 million IU interleukin-2 for six months . Inhalation therapy was combined with four bolus infusions of DTIC at a dose of 850 mg/m2 once every four weeks . Response rates were 71,4% with 2 patients achieving a complete remission ( CR ) , 2 partial remissions ( PR ) , 1 stable disease ( SD ) , and 2 progressing disease ( PD ) . Therapy was well tolerated with low toxicity . Six of the patients developed cough ; one patient was slightly feverish . We conclude that inhalation therapy of lung metastases is a promising addition to the therapeutic arsenal against malignant melanoma . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]
Seven patients with pulmonary metastases of malignant melanoma were treated with inhalation therapy with 36 million IU interleukin-2 for six months . Inhalation therapy was combined with four bolus infusions of DTIC at a dose of 850 mg/m2 once every four weeks . Response rates were 71,4% with 2 patients achieving a complete remission ( CR ) , 2 partial remissions ( PR ) , 1 stable disease ( SD ) , and 2 progressing disease ( PD ) . Therapy was well tolerated with low toxicity . Six of the patients developed cough ; one patient was slightly feverish . We conclude that inhalation therapy of lung metastases is a promising addition to the therapeutic arsenal against malignant melanoma .
[ "Seven", "patients", "with", "pulmonary", "metastases", "of", "malignant", "melanoma", "were", "treated", "with", "inhalation", "therapy", "with", "36", "million", "IU", "interleukin-2", "for", "six", "months", ".", "Inhalation", "therapy", "was", "combined", "with", "four", "bolus", "infusions", "of", "DTIC", "at", "a", "dose", "of", "850", "mg", "/", "m2", "once", "every", "four", "weeks", ".", "Response", "rates", "were", "71,4", "%", "with", "2", "patients", "achieving", "a", "complete", "remission", "(", "CR", ")", ",", "2", "partial", "remissions", "(", "PR", ")", ",", "1", "stable", "disease", "(", "SD", ")", ",", "and", "2", "progressing", "disease", "(", "PD", ")", ".", "Therapy", "was", "well", "tolerated", "with", "low", "toxicity", ".", "Six", "of", "the", "patients", "developed", "cough", ";", "one", "patient", "was", "slightly", "feverish", ".", "We", "conclude", "that", "inhalation", "therapy", "of", "lung", "metastases", "is", "a", "promising", "addition", "to", "the", "therapeutic", "arsenal", "against", "malignant", "melanoma", "." ]
[ "umlsterm" ]
Selbstmord is an umlsterm, Selbst is an umlsterm, Selbst is an umlsterm, Aggression is an umlsterm, Selbst is an umlsterm, Dissoziation is an umlsterm, Selbst is an umlsterm, Aggression is an umlsterm, Selbst is an umlsterm, Selbst is an umlsterm
ForumDerPsychoanalyse.80140123.ger.abstr_task0
Sentence: Zusammenfassung . Selbstbeschaedigung und Selbstmord bezeichnen einen ag-gressiven Angriff auf das Selbst , jedoch handelt es sich bei den beiden verschiedenen Formen der Selbstzerstoerung um ein jeweils verschiedenes Selbst : Bei der Suizidalitaet ist es mit dem boesen oder schlechten introjizierten Objekt ( Objektrepraesentanz ) verschmolzen , die Aggression richtet sich gegen ein ungenuegendes Objekt , das sich im Selbst befindet . Die Dynamik des Selbstbeschaedigungsagierens dagegen beruht nicht auf Introjektions- und Verschmelzungsvorgaengen , sondern auf einer Dissoziation des Selbst . Teile von ihm , meist das Koerperselbst , werden vom uebrigen getrennt und so wie ein aeusseres Objekt erlebt und verwendet . Da sich die Aggression nur gegen einen abgespaltenen Teil des Selbst richtet , kann das Selbst als Ganzes erhalten bleiben . Waehrend Selbstbeschaedigungspatienten sich eher autistisch mit ihrem Koerperselbst von dem Objekt zurueckziehen , sind suizidale viel mehr mit ihm verbunden , mit dem Introjekt identifiziert bzw. an dessen projektiven Stellvertreter , das aeussere Objekt , fixiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Selbstbeschaedigung und Selbstmord bezeichnen einen ag-gressiven Angriff auf das Selbst , jedoch handelt es sich bei den beiden verschiedenen Formen der Selbstzerstoerung um ein jeweils verschiedenes Selbst : Bei der Suizidalitaet ist es mit dem boesen oder schlechten introjizierten Objekt ( Objektrepraesentanz ) verschmolzen , die Aggression richtet sich gegen ein ungenuegendes Objekt , das sich im Selbst befindet . Die Dynamik des Selbstbeschaedigungsagierens dagegen beruht nicht auf Introjektions- und Verschmelzungsvorgaengen , sondern auf einer Dissoziation des Selbst . Teile von ihm , meist das Koerperselbst , werden vom uebrigen getrennt und so wie ein aeusseres Objekt erlebt und verwendet . Da sich die Aggression nur gegen einen abgespaltenen Teil des Selbst richtet , kann das Selbst als Ganzes erhalten bleiben . Waehrend Selbstbeschaedigungspatienten sich eher autistisch mit ihrem Koerperselbst von dem Objekt zurueckziehen , sind suizidale viel mehr mit ihm verbunden , mit dem Introjekt identifiziert bzw. an dessen projektiven Stellvertreter , das aeussere Objekt , fixiert .
[ "Zusammenfassung", ".", "Selbstbeschaedigung", "und", "Selbstmord", "bezeichnen", "einen", "ag", "-", "gressiven", "Angriff", "auf", "das", "Selbst", ",", "jedoch", "handelt", "es", "sich", "bei", "den", "beiden", "verschiedenen", "Formen", "der", "Selbstzerstoerung", "um", "ein", "jeweils", "verschiedenes", "Selbst", ":", "Bei", "der", "Suizidalitaet", "ist", "es", "mit", "dem", "boesen", "oder", "schlechten", "introjizierten", "Objekt", "(", "Objektrepraesentanz", ")", "verschmolzen", ",", "die", "Aggression", "richtet", "sich", "gegen", "ein", "ungenuegendes", "Objekt", ",", "das", "sich", "im", "Selbst", "befindet", ".", "Die", "Dynamik", "des", "Selbstbeschaedigungsagierens", "dagegen", "beruht", "nicht", "auf", "Introjektions-", "und", "Verschmelzungsvorgaengen", ",", "sondern", "auf", "einer", "Dissoziation", "des", "Selbst", ".", "Teile", "von", "ihm", ",", "meist", "das", "Koerperselbst", ",", "werden", "vom", "uebrigen", "getrennt", "und", "so", "wie", "ein", "aeusseres", "Objekt", "erlebt", "und", "verwendet", ".", "Da", "sich", "die", "Aggression", "nur", "gegen", "einen", "abgespaltenen", "Teil", "des", "Selbst", "richtet", ",", "kann", "das", "Selbst", "als", "Ganzes", "erhalten", "bleiben", ".", "Waehrend", "Selbstbeschaedigungspatienten", "sich", "eher", "autistisch", "mit", "ihrem", "Koerperselbst", "von", "dem", "Objekt", "zurueckziehen", ",", "sind", "suizidale", "viel", "mehr", "mit", "ihm", "verbunden", ",", "mit", "dem", "Introjekt", "identifiziert", "bzw", ".", "an", "dessen", "projektiven", "Stellvertreter", ",", "das", "aeussere", "Objekt", ",", "fixiert", "." ]
[ "umlsterm" ]
Selbstmord is an umlsterm, Selbst is an umlsterm, Selbst is an umlsterm, Aggression is an umlsterm, Selbst is an umlsterm, Dissoziation is an umlsterm, Selbst is an umlsterm, Aggression is an umlsterm, Selbst is an umlsterm, Selbst is an umlsterm
ForumDerPsychoanalyse.80140123.ger.abstr_task1
Sentence: Zusammenfassung . Selbstbeschaedigung und Selbstmord bezeichnen einen ag-gressiven Angriff auf das Selbst , jedoch handelt es sich bei den beiden verschiedenen Formen der Selbstzerstoerung um ein jeweils verschiedenes Selbst : Bei der Suizidalitaet ist es mit dem boesen oder schlechten introjizierten Objekt ( Objektrepraesentanz ) verschmolzen , die Aggression richtet sich gegen ein ungenuegendes Objekt , das sich im Selbst befindet . Die Dynamik des Selbstbeschaedigungsagierens dagegen beruht nicht auf Introjektions- und Verschmelzungsvorgaengen , sondern auf einer Dissoziation des Selbst . Teile von ihm , meist das Koerperselbst , werden vom uebrigen getrennt und so wie ein aeusseres Objekt erlebt und verwendet . Da sich die Aggression nur gegen einen abgespaltenen Teil des Selbst richtet , kann das Selbst als Ganzes erhalten bleiben . Waehrend Selbstbeschaedigungspatienten sich eher autistisch mit ihrem Koerperselbst von dem Objekt zurueckziehen , sind suizidale viel mehr mit ihm verbunden , mit dem Introjekt identifiziert bzw. an dessen projektiven Stellvertreter , das aeussere Objekt , fixiert . Instructions: please typing these entity words according to sentence: Selbstmord, Selbst, Selbst, Aggression, Selbst, Dissoziation, Selbst, Aggression, Selbst, Selbst Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Selbstbeschaedigung und Selbstmord bezeichnen einen ag-gressiven Angriff auf das Selbst , jedoch handelt es sich bei den beiden verschiedenen Formen der Selbstzerstoerung um ein jeweils verschiedenes Selbst : Bei der Suizidalitaet ist es mit dem boesen oder schlechten introjizierten Objekt ( Objektrepraesentanz ) verschmolzen , die Aggression richtet sich gegen ein ungenuegendes Objekt , das sich im Selbst befindet . Die Dynamik des Selbstbeschaedigungsagierens dagegen beruht nicht auf Introjektions- und Verschmelzungsvorgaengen , sondern auf einer Dissoziation des Selbst . Teile von ihm , meist das Koerperselbst , werden vom uebrigen getrennt und so wie ein aeusseres Objekt erlebt und verwendet . Da sich die Aggression nur gegen einen abgespaltenen Teil des Selbst richtet , kann das Selbst als Ganzes erhalten bleiben . Waehrend Selbstbeschaedigungspatienten sich eher autistisch mit ihrem Koerperselbst von dem Objekt zurueckziehen , sind suizidale viel mehr mit ihm verbunden , mit dem Introjekt identifiziert bzw. an dessen projektiven Stellvertreter , das aeussere Objekt , fixiert .
[ "Zusammenfassung", ".", "Selbstbeschaedigung", "und", "Selbstmord", "bezeichnen", "einen", "ag", "-", "gressiven", "Angriff", "auf", "das", "Selbst", ",", "jedoch", "handelt", "es", "sich", "bei", "den", "beiden", "verschiedenen", "Formen", "der", "Selbstzerstoerung", "um", "ein", "jeweils", "verschiedenes", "Selbst", ":", "Bei", "der", "Suizidalitaet", "ist", "es", "mit", "dem", "boesen", "oder", "schlechten", "introjizierten", "Objekt", "(", "Objektrepraesentanz", ")", "verschmolzen", ",", "die", "Aggression", "richtet", "sich", "gegen", "ein", "ungenuegendes", "Objekt", ",", "das", "sich", "im", "Selbst", "befindet", ".", "Die", "Dynamik", "des", "Selbstbeschaedigungsagierens", "dagegen", "beruht", "nicht", "auf", "Introjektions-", "und", "Verschmelzungsvorgaengen", ",", "sondern", "auf", "einer", "Dissoziation", "des", "Selbst", ".", "Teile", "von", "ihm", ",", "meist", "das", "Koerperselbst", ",", "werden", "vom", "uebrigen", "getrennt", "und", "so", "wie", "ein", "aeusseres", "Objekt", "erlebt", "und", "verwendet", ".", "Da", "sich", "die", "Aggression", "nur", "gegen", "einen", "abgespaltenen", "Teil", "des", "Selbst", "richtet", ",", "kann", "das", "Selbst", "als", "Ganzes", "erhalten", "bleiben", ".", "Waehrend", "Selbstbeschaedigungspatienten", "sich", "eher", "autistisch", "mit", "ihrem", "Koerperselbst", "von", "dem", "Objekt", "zurueckziehen", ",", "sind", "suizidale", "viel", "mehr", "mit", "ihm", "verbunden", ",", "mit", "dem", "Introjekt", "identifiziert", "bzw", ".", "an", "dessen", "projektiven", "Stellvertreter", ",", "das", "aeussere", "Objekt", ",", "fixiert", "." ]
[ "umlsterm" ]
Selbstmord, Selbst, Selbst, Aggression, Selbst, Dissoziation, Selbst, Aggression, Selbst, Selbst
ForumDerPsychoanalyse.80140123.ger.abstr_task2
Sentence: Zusammenfassung . Selbstbeschaedigung und Selbstmord bezeichnen einen ag-gressiven Angriff auf das Selbst , jedoch handelt es sich bei den beiden verschiedenen Formen der Selbstzerstoerung um ein jeweils verschiedenes Selbst : Bei der Suizidalitaet ist es mit dem boesen oder schlechten introjizierten Objekt ( Objektrepraesentanz ) verschmolzen , die Aggression richtet sich gegen ein ungenuegendes Objekt , das sich im Selbst befindet . Die Dynamik des Selbstbeschaedigungsagierens dagegen beruht nicht auf Introjektions- und Verschmelzungsvorgaengen , sondern auf einer Dissoziation des Selbst . Teile von ihm , meist das Koerperselbst , werden vom uebrigen getrennt und so wie ein aeusseres Objekt erlebt und verwendet . Da sich die Aggression nur gegen einen abgespaltenen Teil des Selbst richtet , kann das Selbst als Ganzes erhalten bleiben . Waehrend Selbstbeschaedigungspatienten sich eher autistisch mit ihrem Koerperselbst von dem Objekt zurueckziehen , sind suizidale viel mehr mit ihm verbunden , mit dem Introjekt identifiziert bzw. an dessen projektiven Stellvertreter , das aeussere Objekt , fixiert . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Selbstbeschaedigung und Selbstmord bezeichnen einen ag-gressiven Angriff auf das Selbst , jedoch handelt es sich bei den beiden verschiedenen Formen der Selbstzerstoerung um ein jeweils verschiedenes Selbst : Bei der Suizidalitaet ist es mit dem boesen oder schlechten introjizierten Objekt ( Objektrepraesentanz ) verschmolzen , die Aggression richtet sich gegen ein ungenuegendes Objekt , das sich im Selbst befindet . Die Dynamik des Selbstbeschaedigungsagierens dagegen beruht nicht auf Introjektions- und Verschmelzungsvorgaengen , sondern auf einer Dissoziation des Selbst . Teile von ihm , meist das Koerperselbst , werden vom uebrigen getrennt und so wie ein aeusseres Objekt erlebt und verwendet . Da sich die Aggression nur gegen einen abgespaltenen Teil des Selbst richtet , kann das Selbst als Ganzes erhalten bleiben . Waehrend Selbstbeschaedigungspatienten sich eher autistisch mit ihrem Koerperselbst von dem Objekt zurueckziehen , sind suizidale viel mehr mit ihm verbunden , mit dem Introjekt identifiziert bzw. an dessen projektiven Stellvertreter , das aeussere Objekt , fixiert .
[ "Zusammenfassung", ".", "Selbstbeschaedigung", "und", "Selbstmord", "bezeichnen", "einen", "ag", "-", "gressiven", "Angriff", "auf", "das", "Selbst", ",", "jedoch", "handelt", "es", "sich", "bei", "den", "beiden", "verschiedenen", "Formen", "der", "Selbstzerstoerung", "um", "ein", "jeweils", "verschiedenes", "Selbst", ":", "Bei", "der", "Suizidalitaet", "ist", "es", "mit", "dem", "boesen", "oder", "schlechten", "introjizierten", "Objekt", "(", "Objektrepraesentanz", ")", "verschmolzen", ",", "die", "Aggression", "richtet", "sich", "gegen", "ein", "ungenuegendes", "Objekt", ",", "das", "sich", "im", "Selbst", "befindet", ".", "Die", "Dynamik", "des", "Selbstbeschaedigungsagierens", "dagegen", "beruht", "nicht", "auf", "Introjektions-", "und", "Verschmelzungsvorgaengen", ",", "sondern", "auf", "einer", "Dissoziation", "des", "Selbst", ".", "Teile", "von", "ihm", ",", "meist", "das", "Koerperselbst", ",", "werden", "vom", "uebrigen", "getrennt", "und", "so", "wie", "ein", "aeusseres", "Objekt", "erlebt", "und", "verwendet", ".", "Da", "sich", "die", "Aggression", "nur", "gegen", "einen", "abgespaltenen", "Teil", "des", "Selbst", "richtet", ",", "kann", "das", "Selbst", "als", "Ganzes", "erhalten", "bleiben", ".", "Waehrend", "Selbstbeschaedigungspatienten", "sich", "eher", "autistisch", "mit", "ihrem", "Koerperselbst", "von", "dem", "Objekt", "zurueckziehen", ",", "sind", "suizidale", "viel", "mehr", "mit", "ihm", "verbunden", ",", "mit", "dem", "Introjekt", "identifiziert", "bzw", ".", "an", "dessen", "projektiven", "Stellvertreter", ",", "das", "aeussere", "Objekt", ",", "fixiert", "." ]
[ "umlsterm" ]
angiotensin II is a Protein, angiotensin II is a Protein, angiotensin II is a Protein, angiotensin II is a Protein, angiotensin II is a Protein
505_task0
Sentence: Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues. [1-N-Methylisoasparagine,8-isoleucine]- (I), [1-sarcosine,4-N-methyltyrosine,8-isoleucine]- (II), [1-sarcosine,5-N-methylisoleucine,8-isoleucine]- (III), [1-sarcosine,8-N-methylisoleucine]- (IV), [1-sarcosine8k-N-methylisoleucine,8-N-methylisoleucine]- (V), [1-sarcosine,8-O-methylthreonine]- (VI), [1-sarcosine,8-methionine]- (VII), and [1-sarcosine,8-serine]angiotensin II (VIII), synthesized by Merrifield's solid-phase procedure, possess respectively 0.8, 0.3, 0.5, 1.0, 0.0, 0.5, 3.7, and 0.7% pressor activity of angiotensin II (vagotomized, ganglion-blocked rats). They caused an initial rise in blood pressure (30 min of infusion, 250 ng/kg/min in vagotomized, ganglion-blocked rats) of 16.57, 9.80, 22.80, 32.00, 7.00, 15.06, 32.50, and 11.42 mmHg and showed secretory activity (isolated cat adrenal medulla) of 1.0, 0.1, 0.01, 0.1, less than 0.01, 0.1, less than 0.01, and 0.05% of angiotensin II. On isolated organs pA2 values (rabbit aortic strips) of 8.74, 7.44, 7.64, 7.85, 7.89, 8.76, 8.63, and 8.08, and pA2 values (cat adrenal medulla of 8.16, 9.16, 9.31, 8.00, 8.00, 7.00, 9.16, and 9.33 were obtained. Dose ratios (ratio of ED20 of angiotensin II during infusion of the antagonist and before infusion of the antagonist) in vagotomized, ganglion-blocked rats, infused at 250 ng/kg/min, were 33.43, 2.14, 3.26, 2.99, 0.62, 62.52, incalculable, and 11.15, respectively. The results obtained suggest that (a) analogs I and VI are potent antagonists of the pressor response of angiotensin II in normal rat, VI being the most potent antagonist thus far synthesized; (b) replacement of position 4 (Tyr) with MeTyr or position 5 and/or 8 (Ile) with Melle in [1-sarcosine,8-isoleucine]angiotensin II reduced the antagonist activity of this peptide (rabbit aortic strips and rats), indicating that steric hindrance imposed due to N-methylation in positions 4, 5, or 8 was not favorable in eliminating the initial pressor activity or prolonging the duration of action of [Sar1, Ile8]angiotensin II without reducing its antagonistic properties; (c) except II, none of the analogs showed any enhanced duration of action, suggesting that N-methylation in positions 5 or 8 did not afford protection against proteolytic enzymes; and (d) perfusion studies in cat adrenals indicated that all of these analogs are only very weak secretagogues. With the exception of [Sar1,Thr(ObetaMe)8]angiotensin II, which gave lower antagonistic properties, all other analogs had either similar antagonistic properties or were better antagonists in adrenal medulla than in smooth muscle. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues. [1-N-Methylisoasparagine,8-isoleucine]- (I), [1-sarcosine,4-N-methyltyrosine,8-isoleucine]- (II), [1-sarcosine,5-N-methylisoleucine,8-isoleucine]- (III), [1-sarcosine,8-N-methylisoleucine]- (IV), [1-sarcosine8k-N-methylisoleucine,8-N-methylisoleucine]- (V), [1-sarcosine,8-O-methylthreonine]- (VI), [1-sarcosine,8-methionine]- (VII), and [1-sarcosine,8-serine]angiotensin II (VIII), synthesized by Merrifield's solid-phase procedure, possess respectively 0.8, 0.3, 0.5, 1.0, 0.0, 0.5, 3.7, and 0.7% pressor activity of angiotensin II (vagotomized, ganglion-blocked rats). They caused an initial rise in blood pressure (30 min of infusion, 250 ng/kg/min in vagotomized, ganglion-blocked rats) of 16.57, 9.80, 22.80, 32.00, 7.00, 15.06, 32.50, and 11.42 mmHg and showed secretory activity (isolated cat adrenal medulla) of 1.0, 0.1, 0.01, 0.1, less than 0.01, 0.1, less than 0.01, and 0.05% of angiotensin II. On isolated organs pA2 values (rabbit aortic strips) of 8.74, 7.44, 7.64, 7.85, 7.89, 8.76, 8.63, and 8.08, and pA2 values (cat adrenal medulla of 8.16, 9.16, 9.31, 8.00, 8.00, 7.00, 9.16, and 9.33 were obtained. Dose ratios (ratio of ED20 of angiotensin II during infusion of the antagonist and before infusion of the antagonist) in vagotomized, ganglion-blocked rats, infused at 250 ng/kg/min, were 33.43, 2.14, 3.26, 2.99, 0.62, 62.52, incalculable, and 11.15, respectively. The results obtained suggest that (a) analogs I and VI are potent antagonists of the pressor response of angiotensin II in normal rat, VI being the most potent antagonist thus far synthesized; (b) replacement of position 4 (Tyr) with MeTyr or position 5 and/or 8 (Ile) with Melle in [1-sarcosine,8-isoleucine]angiotensin II reduced the antagonist activity of this peptide (rabbit aortic strips and rats), indicating that steric hindrance imposed due to N-methylation in positions 4, 5, or 8 was not favorable in eliminating the initial pressor activity or prolonging the duration of action of [Sar1, Ile8]angiotensin II without reducing its antagonistic properties; (c) except II, none of the analogs showed any enhanced duration of action, suggesting that N-methylation in positions 5 or 8 did not afford protection against proteolytic enzymes; and (d) perfusion studies in cat adrenals indicated that all of these analogs are only very weak secretagogues. With the exception of [Sar1,Thr(ObetaMe)8]angiotensin II, which gave lower antagonistic properties, all other analogs had either similar antagonistic properties or were better antagonists in adrenal medulla than in smooth muscle.
[ "Synthesis", "of", "angiotensin", "II", "antagonists", "containing", "N-", "and", "O", "-", "methylated", "and", "other", "amino", "acid", "residues", ".", "\n", "[", "1-N", "-", "Methylisoasparagine,8-isoleucine]-", "(", "I", ")", ",", "[", "1-sarcosine,4-N", "-", "methyltyrosine,8-isoleucine]-", "(", "II", ")", ",", "[", "1-sarcosine,5-N", "-", "methylisoleucine,8-isoleucine]-", "(", "III", ")", ",", "[", "1-sarcosine,8-N", "-", "methylisoleucine]-", "(", "IV", ")", ",", "[", "1-sarcosine8k", "-", "N", "-", "methylisoleucine,8-N", "-", "methylisoleucine]-", "(", "V", ")", ",", "[", "1-sarcosine,8-O", "-", "methylthreonine]-", "(", "VI", ")", ",", "[", "1-sarcosine,8-methionine]-", "(", "VII", ")", ",", "and", "[", "1-sarcosine,8-serine]angiotensin", "II", "(", "VIII", ")", ",", "synthesized", "by", "Merrifield", "'s", "solid", "-", "phase", "procedure", ",", "possess", "respectively", "0.8", ",", "0.3", ",", "0.5", ",", "1.0", ",", "0.0", ",", "0.5", ",", "3.7", ",", "and", "0.7", "%", "pressor", "activity", "of", "angiotensin", "II", "(", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ")", ".", "They", "caused", "an", "initial", "rise", "in", "blood", "pressure", "(", "30", "min", "of", "infusion", ",", "250", "ng", "/", "kg", "/", "min", "in", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ")", "of", "16.57", ",", "9.80", ",", "22.80", ",", "32.00", ",", "7.00", ",", "15.06", ",", "32.50", ",", "and", "11.42", "mmHg", "and", "showed", "secretory", "activity", "(", "isolated", "cat", "adrenal", "medulla", ")", "of", "1.0", ",", "0.1", ",", "0.01", ",", "0.1", ",", "less", "than", "0.01", ",", "0.1", ",", "less", "than", "0.01", ",", "and", "0.05", "%", "of", "angiotensin", "II", ".", "On", "isolated", "organs", "pA2", "values", "(", "rabbit", "aortic", "strips", ")", "of", "8.74", ",", "7.44", ",", "7.64", ",", "7.85", ",", "7.89", ",", "8.76", ",", "8.63", ",", "and", "8.08", ",", "and", "pA2", "values", "(", "cat", "adrenal", "medulla", "of", "8.16", ",", "9.16", ",", "9.31", ",", "8.00", ",", "8.00", ",", "7.00", ",", "9.16", ",", "and", "9.33", "were", "obtained", ".", "Dose", "ratios", "(", "ratio", "of", "ED20", "of", "angiotensin", "II", "during", "infusion", "of", "the", "antagonist", "and", "before", "infusion", "of", "the", "antagonist", ")", "in", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ",", "infused", "at", "250", "ng", "/", "kg", "/", "min", ",", "were", "33.43", ",", "2.14", ",", "3.26", ",", "2.99", ",", "0.62", ",", "62.52", ",", "incalculable", ",", "and", "11.15", ",", "respectively", ".", "The", "results", "obtained", "suggest", "that", "(", "a", ")", "analogs", "I", "and", "VI", "are", "potent", "antagonists", "of", "the", "pressor", "response", "of", "angiotensin", "II", "in", "normal", "rat", ",", "VI", "being", "the", "most", "potent", "antagonist", "thus", "far", "synthesized", ";", "(", "b", ")", "replacement", "of", "position", "4", "(", "Tyr", ")", "with", "MeTyr", "or", "position", "5", "and", "/", "or", "8", "(", "Ile", ")", "with", "Melle", "in", "[", "1-sarcosine,8-isoleucine]angiotensin", "II", "reduced", "the", "antagonist", "activity", "of", "this", "peptide", "(", "rabbit", "aortic", "strips", "and", "rats", ")", ",", "indicating", "that", "steric", "hindrance", "imposed", "due", "to", "N", "-", "methylation", "in", "positions", "4", ",", "5", ",", "or", "8", "was", "not", "favorable", "in", "eliminating", "the", "initial", "pressor", "activity", "or", "prolonging", "the", "duration", "of", "action", "of", "[", "Sar1", ",", "Ile8]angiotensin", "II", "without", "reducing", "its", "antagonistic", "properties", ";", "(", "c", ")", "except", "II", ",", "none", "of", "the", "analogs", "showed", "any", "enhanced", "duration", "of", "action", ",", "suggesting", "that", "N", "-", "methylation", "in", "positions", "5", "or", "8", "did", "not", "afford", "protection", "against", "proteolytic", "enzymes", ";", "and", "(", "d", ")", "perfusion", "studies", "in", "cat", "adrenals", "indicated", "that", "all", "of", "these", "analogs", "are", "only", "very", "weak", "secretagogues", ".", "With", "the", "exception", "of", "[", "Sar1,Thr(ObetaMe)8]angiotensin", "II", ",", "which", "gave", "lower", "antagonistic", "properties", ",", "all", "other", "analogs", "had", "either", "similar", "antagonistic", "properties", "or", "were", "better", "antagonists", "in", "adrenal", "medulla", "than", "in", "smooth", "muscle", ".", "\n" ]
[ "Protein" ]
angiotensin II is a Protein, angiotensin II is a Protein, angiotensin II is a Protein, angiotensin II is a Protein, angiotensin II is a Protein
505_task1
Sentence: Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues. [1-N-Methylisoasparagine,8-isoleucine]- (I), [1-sarcosine,4-N-methyltyrosine,8-isoleucine]- (II), [1-sarcosine,5-N-methylisoleucine,8-isoleucine]- (III), [1-sarcosine,8-N-methylisoleucine]- (IV), [1-sarcosine8k-N-methylisoleucine,8-N-methylisoleucine]- (V), [1-sarcosine,8-O-methylthreonine]- (VI), [1-sarcosine,8-methionine]- (VII), and [1-sarcosine,8-serine]angiotensin II (VIII), synthesized by Merrifield's solid-phase procedure, possess respectively 0.8, 0.3, 0.5, 1.0, 0.0, 0.5, 3.7, and 0.7% pressor activity of angiotensin II (vagotomized, ganglion-blocked rats). They caused an initial rise in blood pressure (30 min of infusion, 250 ng/kg/min in vagotomized, ganglion-blocked rats) of 16.57, 9.80, 22.80, 32.00, 7.00, 15.06, 32.50, and 11.42 mmHg and showed secretory activity (isolated cat adrenal medulla) of 1.0, 0.1, 0.01, 0.1, less than 0.01, 0.1, less than 0.01, and 0.05% of angiotensin II. On isolated organs pA2 values (rabbit aortic strips) of 8.74, 7.44, 7.64, 7.85, 7.89, 8.76, 8.63, and 8.08, and pA2 values (cat adrenal medulla of 8.16, 9.16, 9.31, 8.00, 8.00, 7.00, 9.16, and 9.33 were obtained. Dose ratios (ratio of ED20 of angiotensin II during infusion of the antagonist and before infusion of the antagonist) in vagotomized, ganglion-blocked rats, infused at 250 ng/kg/min, were 33.43, 2.14, 3.26, 2.99, 0.62, 62.52, incalculable, and 11.15, respectively. The results obtained suggest that (a) analogs I and VI are potent antagonists of the pressor response of angiotensin II in normal rat, VI being the most potent antagonist thus far synthesized; (b) replacement of position 4 (Tyr) with MeTyr or position 5 and/or 8 (Ile) with Melle in [1-sarcosine,8-isoleucine]angiotensin II reduced the antagonist activity of this peptide (rabbit aortic strips and rats), indicating that steric hindrance imposed due to N-methylation in positions 4, 5, or 8 was not favorable in eliminating the initial pressor activity or prolonging the duration of action of [Sar1, Ile8]angiotensin II without reducing its antagonistic properties; (c) except II, none of the analogs showed any enhanced duration of action, suggesting that N-methylation in positions 5 or 8 did not afford protection against proteolytic enzymes; and (d) perfusion studies in cat adrenals indicated that all of these analogs are only very weak secretagogues. With the exception of [Sar1,Thr(ObetaMe)8]angiotensin II, which gave lower antagonistic properties, all other analogs had either similar antagonistic properties or were better antagonists in adrenal medulla than in smooth muscle. Instructions: please typing these entity words according to sentence: angiotensin II, angiotensin II, angiotensin II, angiotensin II, angiotensin II Options: Protein
[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues. [1-N-Methylisoasparagine,8-isoleucine]- (I), [1-sarcosine,4-N-methyltyrosine,8-isoleucine]- (II), [1-sarcosine,5-N-methylisoleucine,8-isoleucine]- (III), [1-sarcosine,8-N-methylisoleucine]- (IV), [1-sarcosine8k-N-methylisoleucine,8-N-methylisoleucine]- (V), [1-sarcosine,8-O-methylthreonine]- (VI), [1-sarcosine,8-methionine]- (VII), and [1-sarcosine,8-serine]angiotensin II (VIII), synthesized by Merrifield's solid-phase procedure, possess respectively 0.8, 0.3, 0.5, 1.0, 0.0, 0.5, 3.7, and 0.7% pressor activity of angiotensin II (vagotomized, ganglion-blocked rats). They caused an initial rise in blood pressure (30 min of infusion, 250 ng/kg/min in vagotomized, ganglion-blocked rats) of 16.57, 9.80, 22.80, 32.00, 7.00, 15.06, 32.50, and 11.42 mmHg and showed secretory activity (isolated cat adrenal medulla) of 1.0, 0.1, 0.01, 0.1, less than 0.01, 0.1, less than 0.01, and 0.05% of angiotensin II. On isolated organs pA2 values (rabbit aortic strips) of 8.74, 7.44, 7.64, 7.85, 7.89, 8.76, 8.63, and 8.08, and pA2 values (cat adrenal medulla of 8.16, 9.16, 9.31, 8.00, 8.00, 7.00, 9.16, and 9.33 were obtained. Dose ratios (ratio of ED20 of angiotensin II during infusion of the antagonist and before infusion of the antagonist) in vagotomized, ganglion-blocked rats, infused at 250 ng/kg/min, were 33.43, 2.14, 3.26, 2.99, 0.62, 62.52, incalculable, and 11.15, respectively. The results obtained suggest that (a) analogs I and VI are potent antagonists of the pressor response of angiotensin II in normal rat, VI being the most potent antagonist thus far synthesized; (b) replacement of position 4 (Tyr) with MeTyr or position 5 and/or 8 (Ile) with Melle in [1-sarcosine,8-isoleucine]angiotensin II reduced the antagonist activity of this peptide (rabbit aortic strips and rats), indicating that steric hindrance imposed due to N-methylation in positions 4, 5, or 8 was not favorable in eliminating the initial pressor activity or prolonging the duration of action of [Sar1, Ile8]angiotensin II without reducing its antagonistic properties; (c) except II, none of the analogs showed any enhanced duration of action, suggesting that N-methylation in positions 5 or 8 did not afford protection against proteolytic enzymes; and (d) perfusion studies in cat adrenals indicated that all of these analogs are only very weak secretagogues. With the exception of [Sar1,Thr(ObetaMe)8]angiotensin II, which gave lower antagonistic properties, all other analogs had either similar antagonistic properties or were better antagonists in adrenal medulla than in smooth muscle.
[ "Synthesis", "of", "angiotensin", "II", "antagonists", "containing", "N-", "and", "O", "-", "methylated", "and", "other", "amino", "acid", "residues", ".", "\n", "[", "1-N", "-", "Methylisoasparagine,8-isoleucine]-", "(", "I", ")", ",", "[", "1-sarcosine,4-N", "-", "methyltyrosine,8-isoleucine]-", "(", "II", ")", ",", "[", "1-sarcosine,5-N", "-", "methylisoleucine,8-isoleucine]-", "(", "III", ")", ",", "[", "1-sarcosine,8-N", "-", "methylisoleucine]-", "(", "IV", ")", ",", "[", "1-sarcosine8k", "-", "N", "-", "methylisoleucine,8-N", "-", "methylisoleucine]-", "(", "V", ")", ",", "[", "1-sarcosine,8-O", "-", "methylthreonine]-", "(", "VI", ")", ",", "[", "1-sarcosine,8-methionine]-", "(", "VII", ")", ",", "and", "[", "1-sarcosine,8-serine]angiotensin", "II", "(", "VIII", ")", ",", "synthesized", "by", "Merrifield", "'s", "solid", "-", "phase", "procedure", ",", "possess", "respectively", "0.8", ",", "0.3", ",", "0.5", ",", "1.0", ",", "0.0", ",", "0.5", ",", "3.7", ",", "and", "0.7", "%", "pressor", "activity", "of", "angiotensin", "II", "(", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ")", ".", "They", "caused", "an", "initial", "rise", "in", "blood", "pressure", "(", "30", "min", "of", "infusion", ",", "250", "ng", "/", "kg", "/", "min", "in", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ")", "of", "16.57", ",", "9.80", ",", "22.80", ",", "32.00", ",", "7.00", ",", "15.06", ",", "32.50", ",", "and", "11.42", "mmHg", "and", "showed", "secretory", "activity", "(", "isolated", "cat", "adrenal", "medulla", ")", "of", "1.0", ",", "0.1", ",", "0.01", ",", "0.1", ",", "less", "than", "0.01", ",", "0.1", ",", "less", "than", "0.01", ",", "and", "0.05", "%", "of", "angiotensin", "II", ".", "On", "isolated", "organs", "pA2", "values", "(", "rabbit", "aortic", "strips", ")", "of", "8.74", ",", "7.44", ",", "7.64", ",", "7.85", ",", "7.89", ",", "8.76", ",", "8.63", ",", "and", "8.08", ",", "and", "pA2", "values", "(", "cat", "adrenal", "medulla", "of", "8.16", ",", "9.16", ",", "9.31", ",", "8.00", ",", "8.00", ",", "7.00", ",", "9.16", ",", "and", "9.33", "were", "obtained", ".", "Dose", "ratios", "(", "ratio", "of", "ED20", "of", "angiotensin", "II", "during", "infusion", "of", "the", "antagonist", "and", "before", "infusion", "of", "the", "antagonist", ")", "in", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ",", "infused", "at", "250", "ng", "/", "kg", "/", "min", ",", "were", "33.43", ",", "2.14", ",", "3.26", ",", "2.99", ",", "0.62", ",", "62.52", ",", "incalculable", ",", "and", "11.15", ",", "respectively", ".", "The", "results", "obtained", "suggest", "that", "(", "a", ")", "analogs", "I", "and", "VI", "are", "potent", "antagonists", "of", "the", "pressor", "response", "of", "angiotensin", "II", "in", "normal", "rat", ",", "VI", "being", "the", "most", "potent", "antagonist", "thus", "far", "synthesized", ";", "(", "b", ")", "replacement", "of", "position", "4", "(", "Tyr", ")", "with", "MeTyr", "or", "position", "5", "and", "/", "or", "8", "(", "Ile", ")", "with", "Melle", "in", "[", "1-sarcosine,8-isoleucine]angiotensin", "II", "reduced", "the", "antagonist", "activity", "of", "this", "peptide", "(", "rabbit", "aortic", "strips", "and", "rats", ")", ",", "indicating", "that", "steric", "hindrance", "imposed", "due", "to", "N", "-", "methylation", "in", "positions", "4", ",", "5", ",", "or", "8", "was", "not", "favorable", "in", "eliminating", "the", "initial", "pressor", "activity", "or", "prolonging", "the", "duration", "of", "action", "of", "[", "Sar1", ",", "Ile8]angiotensin", "II", "without", "reducing", "its", "antagonistic", "properties", ";", "(", "c", ")", "except", "II", ",", "none", "of", "the", "analogs", "showed", "any", "enhanced", "duration", "of", "action", ",", "suggesting", "that", "N", "-", "methylation", "in", "positions", "5", "or", "8", "did", "not", "afford", "protection", "against", "proteolytic", "enzymes", ";", "and", "(", "d", ")", "perfusion", "studies", "in", "cat", "adrenals", "indicated", "that", "all", "of", "these", "analogs", "are", "only", "very", "weak", "secretagogues", ".", "With", "the", "exception", "of", "[", "Sar1,Thr(ObetaMe)8]angiotensin", "II", ",", "which", "gave", "lower", "antagonistic", "properties", ",", "all", "other", "analogs", "had", "either", "similar", "antagonistic", "properties", "or", "were", "better", "antagonists", "in", "adrenal", "medulla", "than", "in", "smooth", "muscle", ".", "\n" ]
[ "Protein" ]
angiotensin II, angiotensin II, angiotensin II, angiotensin II, angiotensin II
505_task2
Sentence: Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues. [1-N-Methylisoasparagine,8-isoleucine]- (I), [1-sarcosine,4-N-methyltyrosine,8-isoleucine]- (II), [1-sarcosine,5-N-methylisoleucine,8-isoleucine]- (III), [1-sarcosine,8-N-methylisoleucine]- (IV), [1-sarcosine8k-N-methylisoleucine,8-N-methylisoleucine]- (V), [1-sarcosine,8-O-methylthreonine]- (VI), [1-sarcosine,8-methionine]- (VII), and [1-sarcosine,8-serine]angiotensin II (VIII), synthesized by Merrifield's solid-phase procedure, possess respectively 0.8, 0.3, 0.5, 1.0, 0.0, 0.5, 3.7, and 0.7% pressor activity of angiotensin II (vagotomized, ganglion-blocked rats). They caused an initial rise in blood pressure (30 min of infusion, 250 ng/kg/min in vagotomized, ganglion-blocked rats) of 16.57, 9.80, 22.80, 32.00, 7.00, 15.06, 32.50, and 11.42 mmHg and showed secretory activity (isolated cat adrenal medulla) of 1.0, 0.1, 0.01, 0.1, less than 0.01, 0.1, less than 0.01, and 0.05% of angiotensin II. On isolated organs pA2 values (rabbit aortic strips) of 8.74, 7.44, 7.64, 7.85, 7.89, 8.76, 8.63, and 8.08, and pA2 values (cat adrenal medulla of 8.16, 9.16, 9.31, 8.00, 8.00, 7.00, 9.16, and 9.33 were obtained. Dose ratios (ratio of ED20 of angiotensin II during infusion of the antagonist and before infusion of the antagonist) in vagotomized, ganglion-blocked rats, infused at 250 ng/kg/min, were 33.43, 2.14, 3.26, 2.99, 0.62, 62.52, incalculable, and 11.15, respectively. The results obtained suggest that (a) analogs I and VI are potent antagonists of the pressor response of angiotensin II in normal rat, VI being the most potent antagonist thus far synthesized; (b) replacement of position 4 (Tyr) with MeTyr or position 5 and/or 8 (Ile) with Melle in [1-sarcosine,8-isoleucine]angiotensin II reduced the antagonist activity of this peptide (rabbit aortic strips and rats), indicating that steric hindrance imposed due to N-methylation in positions 4, 5, or 8 was not favorable in eliminating the initial pressor activity or prolonging the duration of action of [Sar1, Ile8]angiotensin II without reducing its antagonistic properties; (c) except II, none of the analogs showed any enhanced duration of action, suggesting that N-methylation in positions 5 or 8 did not afford protection against proteolytic enzymes; and (d) perfusion studies in cat adrenals indicated that all of these analogs are only very weak secretagogues. With the exception of [Sar1,Thr(ObetaMe)8]angiotensin II, which gave lower antagonistic properties, all other analogs had either similar antagonistic properties or were better antagonists in adrenal medulla than in smooth muscle. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues. [1-N-Methylisoasparagine,8-isoleucine]- (I), [1-sarcosine,4-N-methyltyrosine,8-isoleucine]- (II), [1-sarcosine,5-N-methylisoleucine,8-isoleucine]- (III), [1-sarcosine,8-N-methylisoleucine]- (IV), [1-sarcosine8k-N-methylisoleucine,8-N-methylisoleucine]- (V), [1-sarcosine,8-O-methylthreonine]- (VI), [1-sarcosine,8-methionine]- (VII), and [1-sarcosine,8-serine]angiotensin II (VIII), synthesized by Merrifield's solid-phase procedure, possess respectively 0.8, 0.3, 0.5, 1.0, 0.0, 0.5, 3.7, and 0.7% pressor activity of angiotensin II (vagotomized, ganglion-blocked rats). They caused an initial rise in blood pressure (30 min of infusion, 250 ng/kg/min in vagotomized, ganglion-blocked rats) of 16.57, 9.80, 22.80, 32.00, 7.00, 15.06, 32.50, and 11.42 mmHg and showed secretory activity (isolated cat adrenal medulla) of 1.0, 0.1, 0.01, 0.1, less than 0.01, 0.1, less than 0.01, and 0.05% of angiotensin II. On isolated organs pA2 values (rabbit aortic strips) of 8.74, 7.44, 7.64, 7.85, 7.89, 8.76, 8.63, and 8.08, and pA2 values (cat adrenal medulla of 8.16, 9.16, 9.31, 8.00, 8.00, 7.00, 9.16, and 9.33 were obtained. Dose ratios (ratio of ED20 of angiotensin II during infusion of the antagonist and before infusion of the antagonist) in vagotomized, ganglion-blocked rats, infused at 250 ng/kg/min, were 33.43, 2.14, 3.26, 2.99, 0.62, 62.52, incalculable, and 11.15, respectively. The results obtained suggest that (a) analogs I and VI are potent antagonists of the pressor response of angiotensin II in normal rat, VI being the most potent antagonist thus far synthesized; (b) replacement of position 4 (Tyr) with MeTyr or position 5 and/or 8 (Ile) with Melle in [1-sarcosine,8-isoleucine]angiotensin II reduced the antagonist activity of this peptide (rabbit aortic strips and rats), indicating that steric hindrance imposed due to N-methylation in positions 4, 5, or 8 was not favorable in eliminating the initial pressor activity or prolonging the duration of action of [Sar1, Ile8]angiotensin II without reducing its antagonistic properties; (c) except II, none of the analogs showed any enhanced duration of action, suggesting that N-methylation in positions 5 or 8 did not afford protection against proteolytic enzymes; and (d) perfusion studies in cat adrenals indicated that all of these analogs are only very weak secretagogues. With the exception of [Sar1,Thr(ObetaMe)8]angiotensin II, which gave lower antagonistic properties, all other analogs had either similar antagonistic properties or were better antagonists in adrenal medulla than in smooth muscle.
[ "Synthesis", "of", "angiotensin", "II", "antagonists", "containing", "N-", "and", "O", "-", "methylated", "and", "other", "amino", "acid", "residues", ".", "\n", "[", "1-N", "-", "Methylisoasparagine,8-isoleucine]-", "(", "I", ")", ",", "[", "1-sarcosine,4-N", "-", "methyltyrosine,8-isoleucine]-", "(", "II", ")", ",", "[", "1-sarcosine,5-N", "-", "methylisoleucine,8-isoleucine]-", "(", "III", ")", ",", "[", "1-sarcosine,8-N", "-", "methylisoleucine]-", "(", "IV", ")", ",", "[", "1-sarcosine8k", "-", "N", "-", "methylisoleucine,8-N", "-", "methylisoleucine]-", "(", "V", ")", ",", "[", "1-sarcosine,8-O", "-", "methylthreonine]-", "(", "VI", ")", ",", "[", "1-sarcosine,8-methionine]-", "(", "VII", ")", ",", "and", "[", "1-sarcosine,8-serine]angiotensin", "II", "(", "VIII", ")", ",", "synthesized", "by", "Merrifield", "'s", "solid", "-", "phase", "procedure", ",", "possess", "respectively", "0.8", ",", "0.3", ",", "0.5", ",", "1.0", ",", "0.0", ",", "0.5", ",", "3.7", ",", "and", "0.7", "%", "pressor", "activity", "of", "angiotensin", "II", "(", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ")", ".", "They", "caused", "an", "initial", "rise", "in", "blood", "pressure", "(", "30", "min", "of", "infusion", ",", "250", "ng", "/", "kg", "/", "min", "in", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ")", "of", "16.57", ",", "9.80", ",", "22.80", ",", "32.00", ",", "7.00", ",", "15.06", ",", "32.50", ",", "and", "11.42", "mmHg", "and", "showed", "secretory", "activity", "(", "isolated", "cat", "adrenal", "medulla", ")", "of", "1.0", ",", "0.1", ",", "0.01", ",", "0.1", ",", "less", "than", "0.01", ",", "0.1", ",", "less", "than", "0.01", ",", "and", "0.05", "%", "of", "angiotensin", "II", ".", "On", "isolated", "organs", "pA2", "values", "(", "rabbit", "aortic", "strips", ")", "of", "8.74", ",", "7.44", ",", "7.64", ",", "7.85", ",", "7.89", ",", "8.76", ",", "8.63", ",", "and", "8.08", ",", "and", "pA2", "values", "(", "cat", "adrenal", "medulla", "of", "8.16", ",", "9.16", ",", "9.31", ",", "8.00", ",", "8.00", ",", "7.00", ",", "9.16", ",", "and", "9.33", "were", "obtained", ".", "Dose", "ratios", "(", "ratio", "of", "ED20", "of", "angiotensin", "II", "during", "infusion", "of", "the", "antagonist", "and", "before", "infusion", "of", "the", "antagonist", ")", "in", "vagotomized", ",", "ganglion", "-", "blocked", "rats", ",", "infused", "at", "250", "ng", "/", "kg", "/", "min", ",", "were", "33.43", ",", "2.14", ",", "3.26", ",", "2.99", ",", "0.62", ",", "62.52", ",", "incalculable", ",", "and", "11.15", ",", "respectively", ".", "The", "results", "obtained", "suggest", "that", "(", "a", ")", "analogs", "I", "and", "VI", "are", "potent", "antagonists", "of", "the", "pressor", "response", "of", "angiotensin", "II", "in", "normal", "rat", ",", "VI", "being", "the", "most", "potent", "antagonist", "thus", "far", "synthesized", ";", "(", "b", ")", "replacement", "of", "position", "4", "(", "Tyr", ")", "with", "MeTyr", "or", "position", "5", "and", "/", "or", "8", "(", "Ile", ")", "with", "Melle", "in", "[", "1-sarcosine,8-isoleucine]angiotensin", "II", "reduced", "the", "antagonist", "activity", "of", "this", "peptide", "(", "rabbit", "aortic", "strips", "and", "rats", ")", ",", "indicating", "that", "steric", "hindrance", "imposed", "due", "to", "N", "-", "methylation", "in", "positions", "4", ",", "5", ",", "or", "8", "was", "not", "favorable", "in", "eliminating", "the", "initial", "pressor", "activity", "or", "prolonging", "the", "duration", "of", "action", "of", "[", "Sar1", ",", "Ile8]angiotensin", "II", "without", "reducing", "its", "antagonistic", "properties", ";", "(", "c", ")", "except", "II", ",", "none", "of", "the", "analogs", "showed", "any", "enhanced", "duration", "of", "action", ",", "suggesting", "that", "N", "-", "methylation", "in", "positions", "5", "or", "8", "did", "not", "afford", "protection", "against", "proteolytic", "enzymes", ";", "and", "(", "d", ")", "perfusion", "studies", "in", "cat", "adrenals", "indicated", "that", "all", "of", "these", "analogs", "are", "only", "very", "weak", "secretagogues", ".", "With", "the", "exception", "of", "[", "Sar1,Thr(ObetaMe)8]angiotensin", "II", ",", "which", "gave", "lower", "antagonistic", "properties", ",", "all", "other", "analogs", "had", "either", "similar", "antagonistic", "properties", "or", "were", "better", "antagonists", "in", "adrenal", "medulla", "than", "in", "smooth", "muscle", ".", "\n" ]
[ "Protein" ]